[go: up one dir, main page]

WO2025049708A1 - Human neutralizing antibodies against hiv env - Google Patents

Human neutralizing antibodies against hiv env Download PDF

Info

Publication number
WO2025049708A1
WO2025049708A1 PCT/US2024/044375 US2024044375W WO2025049708A1 WO 2025049708 A1 WO2025049708 A1 WO 2025049708A1 US 2024044375 W US2024044375 W US 2024044375W WO 2025049708 A1 WO2025049708 A1 WO 2025049708A1
Authority
WO
WIPO (PCT)
Prior art keywords
cdr3
cdr2
cdr1
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/044375
Other languages
French (fr)
Inventor
Elise LANDAIS
Devin Sok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International AIDS Vaccine Initiative Inc
Original Assignee
International AIDS Vaccine Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International AIDS Vaccine Initiative Inc filed Critical International AIDS Vaccine Initiative Inc
Publication of WO2025049708A1 publication Critical patent/WO2025049708A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Previously identified bnAbs predominantly target 7 main conserved neutralizing epitopes on Env termed, the CD4 (receptor) binding site (CD4bs), the V2 apex, N332 glycan site, gp120-gp41 interface, fusion peptide (FP), silent face, and the membrane proximal external region (MPER). Sok et al., Nature Immunology 2018, 19 (11), 1179. Soluble recombinant Env trimers with stabilized native-like conformations display neutralizing epitopes while occluding non-neutralizing epitopes, and are excellent tools to selectively isolate neutralizing antibodies from donors.
  • CD4bs functions to mediate viral entry into host cells (Gallo et al., Biochimica et Biophysica Acta (BBA) - Biomembranes 2003, 1614 (1), 36), this region must be conserved and can only mutate at the cost of viral fitness (Dingens et al., Immunity 2019, 50 (2), 520).
  • CD4bs directed bnAbs mimic and block the interaction between CD4 and the CD4bs (Wu et al., Science 2010, 329 (5993), 856) and tend to have broader coverage than bnAbs to other neutralizing epitopes (Sok et al., Nature Immunology 2018, 19 (11), 1179).
  • CD4bs bnAbs tend to be highly mutated and take longer to develop within an individual, because antibodies of this class evolve to accommodate or avoid shielding glycans to increase neutralization breadth.
  • variable loops 1, 2 and 5 V1, V2, V5 can restrict access to this epitope as well and rapid sequence alteration of these loops under immune pressure such as increasing N-linked glycosylation sites (PNGS), can lead to virus escape.
  • PNGS N-linked glycosylation sites
  • bnAbs target 7 distinct sites on the HIV-1 envelope glycoprotein (Env) spike, including the CD4-binding site (CD4bs), V2 apex, N332/V3 base supersite (also referred to as high-mannose patch epitope), silent face, gp120-gp41 interface, fusion peptide, and membrane-proximal external region (MPER).
  • CD4bs CD4-binding site
  • V2 apex V2 apex
  • N332/V3 base supersite also referred to as high-mannose patch epitope
  • silent face gp120-gp41 interface
  • fusion peptide fusion peptide
  • MPER membrane-proximal external region
  • an isolated monoclonal antibody or antigen-binding fragment thereof that binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with VRC01 for binding to the HIV Env trimer, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof which binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B,
  • the reference antibody is the PC68-L31_54Q antibody.
  • an isolated monoclonal antibody or antigen-binding fragment thereof which binds to the same epitope of an HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43C, PC68-L31_43
  • the reference antibody is the PC68-L31_54Q antibody.
  • the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively; and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262), (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263), and (c) a VL CDR2 comprising
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the VH CDR1 of an antibody described herein (e.g., PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_
  • the antibody comprises the PC68- L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • VH heavy chain variable region
  • the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38A, PC68-L31_38B, PC68-L31_38A, PC68-L31_38B, PC68-L31_38
  • the antibody comprises the PC68- L31_54Q VH and VL.
  • pharmaceutical compositions comprising a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein.
  • a polynucleotide e.g., mRNA
  • isolated polynucleotides e.g., mRNA
  • methods of producing a monoclonal antibody or antigen- binding fragment thereof described herein are provided herein.
  • provided herein are methods of neutralizing an HIV virus, comprising contacting the virus with a monoclonal antibody or antigen-binding fragment thereof described herein.
  • methods of reducing the likelihood of HIV infection in a subject exposed to HIV comprising administering to the subject a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein.
  • provided herein are methods of treating HIV/AIDS comprising administering to a subject in need thereof a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein.
  • methods of reducing viral load comprising administering to a subject in need thereof a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein.
  • FIG. 1 In one aspect, provided herein are methods of producing an engineered variant of a monoclonal antibody or antigen-binding fragment thereof described herein.
  • FIG. 1 PC68 bnAb Lineage 31 characterization. Confirmation of neutralization breadth and potency.
  • Figure 2. PC68-L31 bnAb lineage (lineage #31) shows bnAb activity, high SHM and a defining CDRH2 insertion feature.
  • Figure 3. PC68-L31 targets an epitope that is distinct but overlaps with previously reported CD4bs bnAbs. Competition BLI of PC68 mAbs with other bnAbs of known epitopes.
  • PC68-L31 targets an epitope that is distinct but overlaps with previously reported CD4bs bnAbs.
  • Figure 5. PC68-L31 bnAbs neutralization breadth and potency are similar to VRC01 on Seaman Panel. Breadth as a function of neutralization potency on a large 118 pseudovirus panel shown.
  • Figure 6. PC68-L31 bnAbs do not depend on glycans. Fold change in neutralization following single point mutation.
  • human immunodeficiency virus refer generally to a retrovirus that is the causative agent for acquired immunodeficiency syndrome (AIDS), variants thereof (e.g., simian acquired immunodeficiency syndrome, SAIDS), and diseases, conditions, or opportunistic infections associated with AIDS or its variants, and includes HIV-Type 1 (HIV-1) and HIV-Type 2 (HIV-2) of any clade or strain therein, related retroviruses (e.g., simian immunodeficiency virus (SIV)), and variants thereof (e.g., engineered retroviruses, e.g., chimeric HIV viruses, e.g., simian-human immunodeficiency viruses (SHIVs)).
  • AIDS acquired immunodeficiency syndrome
  • SAIDS simian acquired immunodeficiency syndrome
  • SHIVs simian-human immunodeficiency viruses
  • an HIV virus is an HIV-Type-1 virus.
  • Previous names for HIV include human T-lymphotropic virus- III (HTLV-III), lymphadenopathy-associated virus (LAV), and AIDS-associated retrovirus (ARV).
  • HTLV-III human T-lymphotropic virus- III
  • LAV lymphadenopathy-associated virus
  • ARV AIDS-associated retrovirus
  • clade refers to related human immunodeficiency viruses (HIVs) classified according to their degree of genetic similarity.
  • M, N, O, and P There are currently four known groups of HIV-1 isolates: M, N, O, and P.
  • Group M (major strains) viruses are responsible for the majority of the global HIV epidemic. The other three groups, i.e., N, O and P are quite uncommon and only occur in Cameroon, Gabon and Equatorial Guinea.
  • an HIV virus is a Group M HIV virus.
  • group M there are known to be at least nine genetically distinct subtypes or clades of HIV-1: subtypes or clades A, B, C, D, F, G, H, J and K. Additionally, different subtypes can combine genetic material to form a hybrid virus, known as a 'circulating recombinant form' (CRFs).
  • Subtype/clade B is the dominant HIV subtype in the Americas, Western Europe and Australasia.
  • Subtype/clade C is very common in the high AIDS prevalence countries of Southern Africa, as well as in the horn of Africa and India. Just under half of all people living with HIV have subtype C.
  • methods described herein can be used to treat a subject (e.g., a human) infected with HIV (e.g., HIV-1) or to block or prevent HIV (e.g., HIV-1) infection in subject (e.g., a human) at risk of HIV transmission.
  • HIV e.g., HIV-1
  • the HIV may be of two, three, four, five, six, seven, eight, nine, ten, or more clades and/or two or more groups of HIV.
  • AIDS Acquired immune deficiency syndrome
  • HIV is a disease caused by the human immunodeficiency virus, or HIV.
  • envelope glycoprotein refers to the glycoprotein that is expressed on the surface of the envelope of HIV virions and the surface of the plasma membrane of HIV infected cells.
  • envelope glycoprotein or “Env” encompass, but are not limited to, native Env, an isoform of Env, or a variant of Env (e.g., well-ordered trimer variant) derived from an HIV isolate, for example, BG505.
  • Env is a MD-39 variant Env (Steichen et al, 2016), repaired and stabilized (RnS) variant Env (Rutten et al, 2018), DS variant Env (Kwon et al, 2015), NFL-TD variant Env (Guenaga et al, 2016), or DS-BG505-chimera variant Env (Joyce et al, 2018).
  • Env is the sole virally encoded gene product on the surface of the virus and, as such, is the only target of neutralizing antibodies.
  • Env is a trimer of heterodimers composed of two non- covalently associated subunits: the receptor-binding gp120 and the gp41 containing the fusion machinery.
  • Each subunit is derived from a gp160 precursor glycoprotein following cleavage by cellular furins.
  • HIV-1 gp120 binds the CD4 molecule on the surface of human target T cells to initiate the viral entry process, and following co-receptor engagement, fusion is mediated by gp41.
  • the gp41 domain comprises the fusion peptide, fusion peptide proximal region, heptad repeats 1 and 2 (HR1, HR2), the membrane proximal external region (MPER), the transmembrane domain (TM) and the cytoplasmic tail (CT).
  • gp140 env is the uncleaved ectodomain of gp160.
  • well-ordered Env trimer or "well-ordered trimer” as used herein refers to an envelope glycoprotein trimer comprising three cleaved gp140 polypeptides that closely mimic the quaternary structure of the Env ectodomain on the surface of the envelope of HIV or SIV virions and the surface of the plasma membrane of HIV or SIV infected cells.
  • the gp120 and gp41 ectodomain is linked by a covalent linkage, for example, a disulfide bond.
  • the gp140 polypeptide comprises one or more mutations to promote trimer formation.
  • the gp140 polypeptide comprises one or more Cys substitutions to promote disulfide formation.
  • the well-ordered trimer is a SOSIP gp140 trimer.
  • Well-ordered SOSIP trimers have been disclosed in US Patent Appl. Pub. No. 2014/0212458, and Sanders, R. W. et al., PLoS Pathog. 9, e1003618 (2013), each of which is incorporated by reference herein in its entirety.
  • the well-ordered trimer is a MD-39 trimer (Steichen et al, 2016), repaired and stabilized (RnS) trimer (Rutten et al, 2018), DS trimer (Kwon et al, 2015), NFL-TD trimer (Guenaga et al, 2016), or DS-BG505-chimera trimer (Joyce et al, 2018).
  • a well-ordered trimer is formed from a clade A Env.
  • a well-ordered trimer is formed from a clade B Env.
  • a well-ordered trimer is formed from a clade C Env.
  • a well-ordered trimer is formed from a circulating recombinant form Env, wherein 'circulating recombinant form' (CRF) refers to a hybrid virus comprising a combination of genetic material from different subtypes.
  • a well-ordered Env trimer is a native flexibly linked (NFL) trimer as described in Sharna, et al., Cell Reports, 11(4):539-50 (2015).
  • a well ordered trimer is BG505 SOSIP.
  • a well ordered trimer is BG505 SOSIP.664.
  • BG505 SOSIP.664 comprises the amino acid sequence of SEQ ID NO: 1270.
  • a nascent BG505 SOSIP.664 further comprises a leader sequence, wherein the nascent BG505 SOSIP.664 comprises the amino acid sequence of SEQ ID NO: 1271.
  • a well-ordered Env trimer is a DS-SOSIP as described in Chuang GY, et al., J. Virology, 91(10). pii: e02268-16 (2017).
  • a well-ordered trimer is formed from an SIV Env.
  • a well-ordered trimer is an SIV Env SOSIP.
  • the gp120 and gp41 ectodomain is linked by a peptide linker, for example, a Gly- Ser linker, as described in Georgiev IS, et al., J. Virology 89(10): 5318-5329 (2015).
  • the well-ordered Env trimer is stable.
  • antibody means an immunoglobulin molecule (or a group of immunoglobulin molecules) that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
  • a target such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
  • the terms “antibody” and “antibodies” are terms of art and can be used interchangeably herein and refer to a molecule with an antigen-binding site that specifically binds an antigen.
  • Antibodies can include, for example, monoclonal antibodies, recombinantly produced antibodies, human antibodies, humanized antibodies, resurfaced antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain- antibody heavy chain pair, intrabodies, heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), affybodies, Fab fragments, F(ab') 2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti- Id antibodies), bispecific antibodies, and multi-specific antibodies.
  • monoclonal antibodies recombinantly produced antibodies
  • human antibodies humanized antibodies, resurfaced antibodies
  • chimeric antibodies immunoglobulins
  • antibodies described herein refer to polyclonal antibody populations.
  • Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , or IgA 2 ), or any subclasses (isotypes) thereof (e.g.
  • immunoglobulin molecule based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively.
  • the different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations.
  • Antibodies can be naked or conjugated or fused to other molecules such as toxins, radioisotopes, other polypeptides etc.
  • the terms "antigen-binding domain,” “antigen-binding region,” “antigen- binding site,” and similar terms refer to the portion of antibody molecules, which comprises the amino acid residues that confer on the antibody molecule its specificity for the antigen (e.g., HIV Env).
  • the antigen-binding region can be derived from any animal species, such as mouse and humans.
  • the terms “variable region” or “variable domain” are used interchangeably and are common in the art. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR).
  • the variable region comprises 3 CDRs (CDR1, CDR2, and CDR3) and 4 framework regions (FR1, FR2, FR3, and FR4) in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3- FR4 from the N terminus to the C terminus.
  • the variable region is a human variable region.
  • the variable region comprises human CDRs and human framework regions (FRs).
  • variable region comprises CDRs and framework regions (FRs) wherein one or more of the CDRs were modified by a substitution, deletion, or insertion relative to the CDRs of a parental antibody.
  • variable region comprises CDRs and framework regions (FRs) wherein one or more of the FRs were modified by a substitution, deletion, or insertion relative to the FRs of a parental antibody.
  • variable region comprises CDRs and framework regions (FRs) wherein one or more of the CDRs and one or more of the FRs were modified by a substitution, deletion, or insertion relative to the CDRs and FRs of a parental antibody.
  • variable region comprises human CDRs and primate (e.g., non-human primate) framework regions (FRs).
  • primate e.g., non-human primate
  • FRs framework regions
  • the CDR sequences are identified according to Kabat. In some embodiments, the CDR sequences are identified according to Chothia. In some embodiments, the CDR sequences are identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003). It is understood that the identification of CDRs in a variable region also identifies the FRs as the sequences flanking the CDRs.
  • the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat EA, et al., Sequences of Immunological Interest. (5th Ed., 1991, National Institutes of Health, Bethesda, Md.) ("Kabat").
  • Kabat EA et al.
  • Sequences of Immunological Interest. 5th Ed., 1991, National Institutes of Health, Bethesda, Md.
  • a heavy chain variable domain can include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82.
  • the Kabat numbering of residues can be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.
  • Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)).
  • the end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34).
  • the AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software, available, for example, at bioinf.org.uk/abs/software.
  • the CDR sequences are identified according to Kabat.
  • the CDR sequences are identified according to Chothia.
  • the CDR sequences are identified according to AbM.
  • the CDR sequences are identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003).
  • the VH CDR3 sequence is identified according to Kabat.
  • the VH CDR3 sequence is identified according to Chothia. In some embodiments, the VH CDR3 sequence is identified according to AbM. In some embodiments, the VH CDR sequence is identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003).
  • the terms "VL” and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody.
  • VH and VH domain are used interchangeably to refer to the heavy chain variable region of an antibody.
  • antibody fragment refers to a portion of an intact antibody.
  • an "antigen-binding fragment” refers to a portion of an intact antibody that binds to an antigen.
  • An antigen-binding fragment can contain the antigenic determining variable regions of an intact antibody. Examples of antibody fragments include, but are not limited to Fab, Fab', F(ab') 2 , and Fv fragments, linear antibodies, and single chain antibodies.
  • a "monoclonal” antibody or antigen-binding fragment thereof refers to a homogeneous antibody or antigen-binding fragment population involved in the highly specific recognition and binding of a single antigenic determinant, or epitope. This is in contrast to polyclonal antibodies that typically include different antibodies directed against different antigenic determinants.
  • the term "monoclonal” antibody or antigen-binding fragment thereof encompasses both intact and full- length monoclonal antibodies as well as antibody fragments (such as Fab, Fab', F(ab') 2 , Fv), single chain (scFv) mutants, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site.
  • “monoclonal” antibody or antigen-binding fragment thereof refers to such antibodies and antigen-binding fragments thereof made in any number of manners including but not limited to by hybridoma, phage selection, recombinant expression, and transgenic animals.
  • polyclonal antibody describes a composition of different (diverse) antibody molecules, which are capable of binding to or reacting with several different specific antigenic determinants on the same or on different antigens. Usually, the variability of a polyclonal antibody is primarily located in the so-called variable regions of the polyclonal antibody, in particular in the CDR regions.
  • a mixture of two or more polyclonal antibodies is produced in one mixture from a polyclonal polycomposition cell line, which is produced from two or more parental polyclonal cell lines each expressing antibody molecules, which are capable of binding to a distinct target, but it may also be a mixture of two or more polyclonal antibodies produced separately.
  • chimeric antibodies or antigen-binding fragments thereof refers to antibodies or antigen-binding fragments thereof wherein the amino acid sequence is derived from two or more species.
  • the variable region of both light and heavy chains corresponds to the variable region of antibodies or antigen-binding fragments thereof derived from one species of mammals (e.g., mouse) with the desired specificity, affinity, and capability, while the constant regions are homologous to the sequences in antibodies or antigen-binding fragments thereof derived from another (usually human) to avoid eliciting an immune response in that species.
  • epitopes or "antigenic determinant” are used interchangeably herein and refer to that portion of an antigen capable of being recognized and specifically bound by a particular antibody.
  • the antigen is a polypeptide
  • epitopes can be formed both from contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon protein denaturing, whereas epitopes formed by tertiary folding are typically lost upon protein denaturing.
  • An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.
  • Binding affinity generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured by common methods known in the art, including those described herein.
  • an anti-HIV antibody described herein binds to HIV Env trimer (e.g., BG505 SOSIP ) with a K D of at least about 0.1 ⁇ M or less, at least about 0.01 ⁇ M or less, at least about 1 nM or less, or at least about 0.1 nM or less.
  • HIV Env trimer e.g., BG505 SOSIP
  • an anti-HIV antibody described herein binds to HIV Env trimer with a K D of at least about 0.01 ⁇ M or less.
  • the HIV Env trimer is BG505 SOSIP.
  • an anti-HIV antibody described herein is capable of binding to cells that express functional, well- ordered HIV-1 membrane Env trimers.
  • an anti-HIV antibody described herein is capable of binding to HIV Env trimer in biolayer interferometry (BLI) assay.
  • an anti-HIV antibody described herein is capable of binding to HIV Env trimer in ELISA.
  • an anti-HIV antibody described herein is capable of binding Env trimers from detergent-solubilized HIV-1 virions in an ELISA assay.
  • the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions in a BN-PAGE gel mobility-shift assay.
  • binding affinity refers to a stronger binding between a molecule and its binding partner.
  • Or better when used herein refers to a stronger binding, represented by a smaller numerical K D value.
  • an antibody which has an affinity for an antigen of "0.6 nM or better"
  • the antibody's affinity for the antigen is ⁇ 0.6 nM, i.e.
  • immunospecifically binds As used herein, the terms “immunospecifically binds,” “immunospecifically recognizes,” “specifically binds,” and “specifically recognizes” are analogous terms in the context of antibodies and refer to molecules that bind to an antigen (e.g., epitope or immune complex) as such binding is understood by one skilled in the art.
  • an antigen e.g., epitope or immune complex
  • a molecule that specifically binds to an antigen can bind to other peptides or polypeptides, generally with lower affinity as determined by, e.g., immunoassays, BIAcore ® , KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), ELISA, biolayer interferometry (BLI), flow cytometry or other assays known in the art.
  • molecules that immunospecifically bind to an antigen bind to the antigen with a K D that is at least 2 logs, 2.5 logs, 3 logs, or 4 logs lower than the K D when the molecules bind non- specifically to another antigen.
  • the antibody may specifically bind to cells that express functional, well-ordered HIV-1 membrane Env trimers. In one example, the antibody may specifically bind to the HIV Env trimer. In one example, the antibody may specifically bind to the HIV Env trimer (e.g., Bg505 SOSIP) in biolayer interferometry (BLI) assay. In one example, the antibody may specifically bind to the HIV Env trimer in ELISA assay. In one example, the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions. In one example, the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions in an ELISA assay.
  • the HIV Env trimer e.g., Bg505 SOSIP
  • Bg505 SOSIP biolayer interferometry
  • the antibody may specifically bind to the HIV Env trimer in ELISA assay.
  • the antibody may specifically bind to Env trimers from detergent-solubilized HIV
  • the antibody may specifically bind to Env trimers from detergent- solubilized HIV-1 virions in a BN-PAGE gel mobility-shift assay.
  • the antibody may bind to HIV Env trimer with a K D at least 2 logs, 2.5 logs, 3 logs, or 4 logs lower than K D of binding to other viral or non-viral polypeptides.
  • An antibody that specifically binds to Env trimer encompass, but are not limited to, antibodies that specifically bind to native Env, an isoform of Env, or a variant of Env derived from an HIV isolate.
  • preferentially binds it is meant that the antibody specifically binds to an epitope more readily than it would bind to a related, similar, homologous, or analogous epitope.
  • an antibody, which "preferentially binds" to a given epitope would more likely bind to that epitope than to a related epitope, even though such an antibody may cross-react with the related epitope.
  • An antibody is said to "competitively inhibit" binding of a reference antibody to a given epitope if it preferentially binds to that epitope or an overlapping epitope to the extent that it blocks, to some degree, binding of the reference antibody to the epitope.
  • bnAb narrowly neutralizing antibody
  • HIV e.g., HIV-1
  • bnAb an antibody that recognizes HIV Env of more than one isolate or strain of HIV and inhibits or prevents receptor binding of target cells as evaluated in an in vitro neutralization assay.
  • a broadly neutralizing antibody inhibits infection of a susceptible target cell by HIV.
  • a neutralizing (e.g., broadly neutralizing) antibody specifically binds an HIV Env and inhibits infection of a susceptible target cell (e.g., TZM-bl) by an HIV pseudovirus comprising an Env polypeptide.
  • HIV pseudovirus neutralization assays have been disclosed in the art, for example, in Walker L.M., et al., Nature 477, 466–470 (2011), Li M., et al., J. Virol. 79:10108-10125 (2005), each of which is incorporated herein by reference in its entirety for all purposes.
  • a broadly neutralizing antibody neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses.
  • a broadly neutralizing antibody neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses that belong to the same or different clades.
  • a broadly neutralizing antibody is capable of neutralizing HIV strains or pseudoviruses from at least two different clades.
  • a broadly neutralizing antibody is capable of neutralizing at least one clade B strain or pseudovirus and one clade C strain or pseudovirus.
  • a broadly neutralizing antibody is capable of neutralizing more than one clade B strain or pseudovirus and more than one clade C strain or pseudovirus.
  • a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten clades.
  • a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, or all sixteen clades selected from the group consisting of clades A, A (T/F), AC, ACD, B, B (T/F), BC, C, C (T/F), CD, CRF01_AE, CRF01_AE (T/F), CRF02_AG, D, D (T/F) and G.
  • a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or all eleven clades selected from the group consisting of clades A, AC, ACD, AE, AG, B, BC, C, CD, D, D (T/F), and G.
  • the breadth of neutralization is tested on an indicator virus panel comprising cross-clade HIV isolates.
  • the virus panel comprises the 13 cross- clade isolates listed in Figure 1.
  • a broadly neutralizing antibody is capable of neutralizing at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 50% of cross-clade HIV isolates in the 13-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 70% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 90% of cross-clade HIV isolates in the 13-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 13- member indicator virus panel with a median IC 50 equal to or less than about 2 ⁇ g/ml, about 1.5 ⁇ g/ml, about 1 ⁇ g/ml, about 0.75 ⁇ g/ml, about 0.5 ⁇ g/ml, about 0.25 ⁇ g/ml, about 0.1 ⁇ g/ml, 0.07 ⁇ g/ml, 0.06 ⁇ g/ml, 0.05 ⁇ g/ml, 0.025 ⁇ g/ml, 0.01 ⁇ g/ml or 0.005 ⁇ g/ml.
  • a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC 50 equal to or less than 0.75 ⁇ g/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC 50 equal to or less than 0.5 ⁇ g/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC 50 equal to or less than 0.25 ⁇ g/ml.
  • the breadth of neutralization is tested on an indicator virus panel comprising cross-clade HIV isolates.
  • the virus panel comprises the 119 cross-clade isolates listed in Table 4.
  • a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or 100% of cross- clade HIV isolates in the 119-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 50% of cross-clade HIV isolates in the 119-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 70% of cross- clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 90% of cross-clade HIV isolates in the 119-member indicator virus panel.
  • a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 119- member indicator virus panel with a median IC 50 equal to or less than about 2 ⁇ g/ml, about 1.5 ⁇ g/ml, about 1 ⁇ g/ml, about 0.75 ⁇ g/ml, about 0.5 ⁇ g/ml, about 0.25 ⁇ g/ml, about 0.1 ⁇ g/ml, 0.07 ⁇ g/ml, 0.06 ⁇ g/ml, 0.05 ⁇ g/ml, 0.025 ⁇ g/ml, 0.01 ⁇ g/ml or 0.005 ⁇ g/ml.
  • a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than 0.1 ⁇ g/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than 0.75 ⁇ g/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than 0.5 ⁇ g/ml.
  • a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119- member indicator virus panel with a median IC 50 equal to or less than 0.25 ⁇ g/ml.
  • IC 50 refers to the half maximal inhibitory concentration of an inhibitor, e.g., a broadly neutralizing antibody.
  • IC 50 is the concentration of an inhibitor, e.g., a broadly neutralizing antibody, where the response, e.g., infection by pseudovirus, is reduced by half.
  • IC 80 refers to the concentration of an inhibitor, e.g., a broadly neutralizing antibody, where the response, e.g., infection by pseudovirus, is reduced by 80%.
  • the phrase “substantially similar,” or “substantially the same”, as used herein, denotes a sufficiently high degree of similarity between two numeric values (generally one associated with an antibody described herein and the other associated with a reference/comparator antibody) such that one of skill in the art would consider the difference between the two values to be of little or no biological and/or statistical significance within the context of the biological characteristic measured by said values (e.g., K D values).
  • a polypeptide, antibody, polynucleotide, vector, cell, or composition, which is "isolated” is a polypeptide, antibody, polynucleotide, vector, cell, or composition, which is in a form not found in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cell or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature.
  • an antibody, polynucleotide, vector, cell, or composition, which is isolated is substantially pure.
  • substantially pure refers to material, which is at least 50% pure (i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.
  • polypeptide polypeptide
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • the polypeptides described herein are based upon antibodies, in certain embodiments, the polypeptides can occur as single chains or associated chains.
  • nucleic acids or polypeptides refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity.
  • the percent identity can be measured using sequence comparison software or algorithms or by visual inspection.
  • sequence comparison software or algorithms or by visual inspection.
  • Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences.
  • One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin S., et al, Proc. Natl. Acad.
  • Gapped BLAST can be used as described in Altschul SF, et al., Nucleic Acids Res. 25:3389-3402 (1997).
  • BLAST-2 Altschul SF, et al., Methods in Enzymology, 266:460-480 (1996)), ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or Megalign (DNASTAR) are additional publicly available software programs that can be used to align sequences.
  • the percent identity between two nucleotide sequences is determined using the GAP program in GCG software (e.g., using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 90 and a length weight of 1, 2, 3, 4, 5, or 6).
  • the GAP program in the GCG software package which incorporates the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) can be used to determine the percent identity between two amino acid sequences (e.g., using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5).
  • the percent identity between nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS, 4:11-17 (1989)).
  • the percent identity can be determined using the ALIGN program (version 2.0) and using a PAM120 with residue table, a gap length penalty of 12 and a gap penalty of 4.
  • Appropriate parameters for maximal alignment by particular alignment software can be determined by one skilled in the art.
  • the default parameters of the alignment software are used.
  • the percentage identity "X" of a first amino acid sequence to a second sequence amino acid is calculated as 100 x (Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence.
  • the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence.
  • whether any particular polynucleotide has a certain percentage sequence identity e.g., is at least 80% identical, at least 85% identical, at least 90% identical, and in some embodiments, at least 95%, 96%, 97%, 98%, or 99% identical
  • a reference sequence can, in certain embodiments, be determined using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711).
  • Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2: 482 489 (1981)) to find the best segment of homology between two sequences.
  • Bestfit or any other sequence alignment program uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2: 482 489 (1981)) to find the best segment of homology between two sequences.
  • the parameters are set such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in identity of up to 5% of the total number of nucleotides in the reference sequence are allowed.
  • two nucleic acids or polypeptides described herein are substantially identical, meaning they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in some embodiments at least 95%, 96%, 97%, 98%, 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection.
  • Identity can exist over a region of the sequences that is at least about 10, about 20, about 40-60 residues in length or any integral value there between, and can be over a longer region than 60-80 residues, for example, at least about 90-100 residues, and in some embodiments, the sequences are substantially identical over the full length of the sequences being compared, such as the coding region of a nucleotide sequence for example.
  • a "conservative amino acid substitution" is one in which one amino acid residue is replaced with another amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
  • basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • substitution of a phenylalanine for a tyrosine is a conservative substitution.
  • conservative substitutions in the sequences of the polypeptides and antibodies described herein do not abrogate the binding of the polypeptide or antibody containing the amino acid sequence, to the antigen(s).
  • Methods of identifying nucleotide and amino acid conservative substitutions, which do not eliminate antigen binding are well-known in the art (see, e.g., Brummell DA, et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks EA, et al., Proc. Natl. Acad. Sci.
  • treatment refers to treatment of an infected person.
  • treating includes alleviating or reducing at least one adverse or negative effect or symptom of a condition, disease or disorder. This condition, disease or disorder can be HIV infection.
  • Terms such as “treating” or “treatment” or “to treat” or “alleviating” or “to alleviate” refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder, such as HIV or AIDS.
  • those in need of treatment include those already diagnosed with or suspected of having the disorder.
  • a subject is successfully "treated” for the disorder according to the methods described herein if the patient shows one or more of the following: a reduction in the number of or complete absence of viral load; a reduction in the viral burden; inhibition of or an absence of the virus into peripheral organs; relief of one or more symptoms associated with the disorder; reduced morbidity and mortality; improvement in quality of life; increased progression-free survival (PFS), disease-free survival (DFS), or overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), a decrease in progressive disease (PD), a reduced time to progression (TTP), or any combination thereof.
  • PFS progression-free survival
  • DFS disease-free survival
  • OS overall survival
  • C complete response
  • PR partial response
  • SD stable disease
  • PD progressive disease
  • TTP time to progression
  • prevention refers to preventing a subject from becoming infected with, or reducing the risk of a subject from becoming infected with, or halting transmission of, or the reducing the risk of transmission of a virus.
  • Prophylactic or preventative measures refer to measures that prevent and/or slow the development of a targeted pathological condition or disorder.
  • those in need of prophylactic or preventative measures include those prone to have the disorder and those in whom the disorder is to be prevented.
  • prevention encompasses passive immunization of a subject in need thereof comprising administering an effective amount of an antibody described herein.
  • an “effective amount” refers to an amount effective, at dosages, and for periods of time necessary, to achieve the desired result with respect to the treatment of the relevant disorder, condition, or side effect.
  • An “effective amount” can be determined empirically and in a routine manner, in relation to the stated purpose.
  • the effective amount of components of the present invention will vary from patient to patient not only with the particular vaccine, component or composition selected, the route of administration, and the ability of the components to elicit a desired result in the individual, but also with factors such as the disease state or severity of the condition to be alleviated, hormone levels, age, sex, weight of the individual, the state of being of the patient, and the severity of the pathological condition being treated, concurrent medication or special diets then being followed by the particular patient, and other factors, which those skilled in the art will recognize, with the appropriate dosage being at the discretion of the attending physician. Dosage regimes may be adjusted to provide an improved therapeutic response. An effective amount is also one in which any toxic or detrimental effects of the components are outweighed by the therapeutically beneficial effects.
  • the term "therapeutically effective amount” refers to an amount of an antibody, recombinant virus, immunoconjugate, or other drug effective to "treat” a disease or disorder in a subject or mammal. To the extent an antibody can prevent growth and/or kill existing cells, it can be cytostatic and/or cytotoxic.
  • a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • the terms "subject,” “individual,” and “patient” are used interchangeably herein, and refer to an animal, for example a human, to whom treatment, including prophylactic treatment, with the antibody or pharmaceutical composition according to the present disclosure, is provided.
  • the subject, individual, or patient has been infected with HIV.
  • the subject, individual, or patient suffers from AIDS.
  • the subject, individual, or patient has been exposed to HIV.
  • the subject, individual, or patient is at risk of being exposed to HIV.
  • Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) or consecutive administration in any order.
  • composition refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable” or “pharmaceutical formulation” refers to a preparation, which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components, which are unacceptably toxic to a subject to which the formulation would be administered.
  • the formulation can be sterile.
  • ART antiretroviral therapy
  • NRTIs nucleoside reverse transcriptase inhibitors
  • NRTIs non-nucleoside reverse transcriptase inhibitors
  • PIs protease inhibitors
  • fusion inhibitors entry inhibitors, maturation inhibitors, cellular inhibitors, integrase strand transfer inhibitors, and multi-class combinations.
  • Such drugs include, but are not limited to, lamivudine and zidovudine, emtricitabine (FTC), zidovudine (ZDV), azidothymidine (AZT), lamivudine (3TC), zalcitabine, dideoxycytidine (ddC), tenofovir disoproxil fumarate (TDF), didanosine (ddl), stavudine (d4T), abacavir sulfate (ABC), etravirine (ETR), delavirdine (DLV), efavirenz (EFV), nevirapine (NVP), amprenavir (APV), tipranavir (TPV), indinavir (IDV), saquinavir, saquinavir mesylate (SQV), lopinavir (LPV), ritonavir (RTV), fosamprenavir calcium (FOS-APV), ritona
  • ART drugs can also include antibodies that target HIV proteins or cellular proteins associated with disease progression. Also included are immune-based therapies, such as IL-2, IL-12, and alpha- epibromide. Each of these drugs can be administered alone or in combination with any other ART drug or any HIV-specific neutralizing antibody, such as a broadly neutralizing antibody, which is incorporated by reference herein in its entirety for all purposes.
  • a reservoir activator comprises a histone deacytelase (HDAC) inhibitor (e.g., romidepsin, vorinostat, and panobinostat), immunologic activator (e.g., cytokines and TLR agonists), or a dedicated small molecule drug.
  • HDAC histone deacytelase
  • immunomodulator refers to an agent, such as an antibody or peptide, which is capable of increasing, inducing, or extending an immune response (e.g., a cell- mediated immune response and/or a humoral immune response) when administered to a subject (e.g., a human, e.g., a human infected with HIV or at risk of an HIV infection or transmission).
  • Immunomodulators include, but are not limited to immune checkpoint inhibitors, for example, a PD-1, PD-L1, LAG-3, or TIGIT antagonist.
  • an immunomodulator used in the methods described herein comprises an anti-PD-1 antibody, anti-PD-L1 antibody, anti-LAG3 antibody, or an anti-TIGIT antibody.
  • An immunomodulator can be administered in conjunction with (e.g., prior to, concurrently with, or subsequent to, or within the context of a treatment regimen that includes the administration of a broadly neutralizing antibody described herein.
  • the terms "VRC01,” and “VRC01 antibody” are used interchangeably herein to refer to an antibody with the same binding specificity as the VRC01 antibody disclosed by Wu et al., Science, 329(5993):856–61 (2010).
  • the VRC01 antibody comprises the VH and VL of SEQ ID NO: 1272 and 1273, respectively.
  • Anti-HIV antibodies In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with VRC01 for binding to the HIV Env trimer.
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen- binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262).
  • the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263).
  • the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264).
  • the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR2 comprising
  • an isolated monoclonal antibody or antigen-binding fragment thereof which binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B,
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is PC68-L31_54Q, i.e., a monoclonal antibody comprising the PC68-L31_54Q VH and VL.
  • the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262).
  • the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263).
  • the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264).
  • the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR2 comprising
  • an isolated monoclonal antibody or antigen-binding fragment thereof which binds to the same epitope of an HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F,
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is PC68-L31_54Q, i.e., a monoclonal antibody comprising the PC68-L31_54Q VH and VL.
  • the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
  • the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262).
  • the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263).
  • the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264).
  • the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR2 comprising
  • an antibody or antibody fragment described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences shown in Table 1.
  • an antibody or antibody fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequence shown in Table 1. Table 1. Example VH and VL CDR sequences.
  • Examp q .
  • an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of a VH or VL shown in Table 2.
  • an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2 and VH CDR3 of a single VH shown in Table 2. and a VL CDR1, VL CDR2, and VL CDR3 of a single VL shown in Table 2.
  • an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a single VH and its corresponding VL shown in Table 2.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is as shown in Table 1.
  • an antibody or antibody fragment described herein comprises a VH and VL having at least about 80% sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, at least about 96% sequence identity, at least about 97% sequence identity, at least about 98% sequence identity, or at least about 99% sequence identity to a VH, a VL, or a VH and corresponding VL as shown in Table 2.
  • an antibody or antibody fragment described herein comprises a VH, a VL, or a VH and corresponding VL as shown in Table 2.
  • the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43A,
  • the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43A,
  • the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K
  • the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
  • the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68
  • the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K
  • the VL CDR3 comprises the PC68-L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VL CDR3 comprises the PC68-L31_54Q VL CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
  • the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 selected independently from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises (i) the VH CDR1, VH CDR2, and VH CDR3 of a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a VH/VL pair selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_43J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
  • the antibody or antigen-binding fragment described herein comprises a VH and a VL, wherein (a) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_31_
  • the VH and VL comprises a VH/VL pair selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-68-L
  • the antibody or antigen-binding fragment described herein comprises a VH and a VL, wherein (i) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH, and (ii) the VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VL.
  • the antibody or antigen-binding fragment described herein comprises a VH and a VL comprising an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH and VL, respectively.
  • the antibody or antigen-binding fragment described herein comprises the PC68-L31_54Q VH and VL, respectively.
  • an isolated monoclonal antibody described herein comprises a VH CDR3 sequence shown in Table 1.
  • an isolated monoclonal antibody described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences shown in Table 1. In some embodiments, an isolated monoclonal antibody described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequence shown in Table 1. In some embodiments, an isolated monoclonal antibody described herein comprises a VH CDR3 sequence of a VH shown in Table 2.
  • an isolated monoclonal antibody described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of a VH and VL shown in Table 2.
  • an isolated monoclonal antibody described herein comprises the VH CDR1, VH CDR2, and VH CDR3 sequences of a VH shown in Table 2 and the VL CDR1, VL CDR2, and VL CDR3 sequences of a VL shown in Table 2.
  • an isolated monoclonal antibody described herein comprises the VH CDR1, VH CDR2, and VH CDR3 sequences of a VH shown in Table 2 and the VL CDR1, VL CDR2, and VL CDR3 sequences of the corresponding VL shown in Table 2.
  • the CDR sequences are according to Kabat.
  • an isolated monoclonal antibody described herein comprises a VH, a VL, or a VH and VL as shown in Table 2.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68
  • the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K
  • the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K
  • the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3. In some embodiments, the VH CDR3 is according to Kabat. In some embodiments, the VH CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43
  • the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_32K, PC68-
  • the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_32K, PC68-
  • the VH CDR1 comprises the PC68-L31_54Q VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions
  • the VH CDR2 comprises the PC68-L31_54Q VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions
  • the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions.
  • the VH CDR1 comprises the PC68-L31_54Q VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions
  • the VH CDR2 comprises the PC68- L31_54Q VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions
  • the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
  • the VH CDR1 comprises the PC68-L31_54Q VH CDR1;
  • the VH CDR2 comprises the PC68-L31_54Q VH CDR2; and/or
  • the VH CDR3 comprises the PC68-L31_54Q VH CDR3.
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_32_32F
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_32_32F
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_32_32F
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively.
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively.
  • the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3, respectively.
  • the VH CDR1, VH CDR2, and/or VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and/or VH CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env.
  • the VL CDR1 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L
  • the VL CDR1 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_32K, PC68-
  • the VL CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_32K, PC68-
  • the VL CDR1 comprises the PC68-L31_54Q VL CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions
  • the VL CDR2 comprises the PC68-L31_54Q VL CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions
  • the VL CDR3 comprises the PC68-L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions.
  • the VL CDR1 comprises the PC68-L31_54Q VL CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions
  • the VL CDR2 comprises the PC68-L31_54Q VL CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions
  • the VL CDR3 comprises the PC68- L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
  • the VL CDR1 comprises the PC68-L31_54Q VL CDR1;
  • the VL CDR2 comprises the PC68-L31_54Q VL CDR2; and/or
  • the VL CDR3 comprises the PC68-L31_54Q VL CDR3.
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_32_32F
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_32_32F
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_32_32F
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions, respectively.
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, respectively.
  • the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3, respectively.
  • the VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Table 1.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H,
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H,
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68- L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Table 1.
  • the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B,
  • the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31
  • the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31
  • the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_54Q VH FW1, VH FW2, VH FW3 and VH FW4.
  • VH FW1, VH FW2, VH FW3 and/or VH FW4 are according to Table 2.
  • VH FW1, VH FW2, VH FW3 and VH FW4 are according to Table 2.
  • the VL FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31
  • the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC
  • the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively.
  • the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68- L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively.
  • the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4, respectively.
  • the VL FW1, VL FW2, VL FW3 and/or VL FW4 are according to Table 2.
  • the VL FW1, VL FW2, VL FW3 and VL FW4 are according to Table 2.
  • the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43A, PC68-L31_43B, PC68-L31_43
  • the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-
  • the VH and VL comprise the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K
  • the VH comprises an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VH.
  • the VH comprises an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is identical to the PC68-L31_54Q VH. In some embodiments, the VL comprises an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VL.
  • the VL comprises an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is identical to the PC68-L31_54Q VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH and VL.
  • the VH and VL comprise an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise the PC68-L31_54Q VH and VL.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L
  • the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH.
  • the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43
  • VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3.
  • the VH CDR1, VH CDR2, and/or VH CDR3 is according to Kabat.
  • the VH CDR1, VH CDR2, and/or VH CDR3 is according to Table 1.
  • the VH CDR1, VH CDR2, and VH CDR3 is according to Kabat.
  • the VH CDR1, VH CDR2, and VH CDR3 is according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • the isolated monoclonal antibody or antigen-binding fragment described herein further comprises a light chain variable region (VL), wherein the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-
  • the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL.
  • the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43
  • the VL comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3.
  • the VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat.
  • the VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
  • the VL CDR1, VL CDR2, and VL CDR3 is according to Kabat.
  • the VL CDR1, VL CDR2, and VL CDR3 is according to Table 1.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B
  • the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G,
  • the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3, respectively.
  • the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G,
  • the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3, respectively.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
  • the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A VH.
  • the VH comprises the PC68-L31_32A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A VL.
  • the VL comprises the PC68- L31_32A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_32A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32B.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32B VH.
  • the VH comprises the PC68-L31_32B VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32B VL.
  • the VL comprises the PC68- L31_32B VL CDR1, VL CDR2, and VL CDR3.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32C VH.
  • the VH comprises the PC68-L31_32C VH CDR1, VH CDR2, and VH CDR3.
  • the VL comprises the PC68-L31_32C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32D VH.
  • the VH comprises the PC68-L31_32D VH CDR1, VH CDR2, and VH CDR3.
  • the VL comprises the PC68-L31_32D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32F.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32F VH.
  • the VH comprises the PC68-L31_32F VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32F VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32F VL.
  • the VL comprises the PC68- L31_32F VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_32F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32F VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32F VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32G.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32G VH.
  • the VH comprises the PC68-L31_32G VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32G VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32G VL.
  • the VL comprises the PC68- L31_32G VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_32G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32G VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32G VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32H.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32H VH.
  • the VH comprises the PC68-L31_32H VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32H VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32H VL.
  • the VL comprises the PC68- L31_32H VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_32H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32H VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32H VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32I.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32I VH.
  • the VH comprises the PC68-L31_32I VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32I VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32I VL.
  • the VL comprises the PC68- L31_32I VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_32I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32I VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32I VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32J.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32J VH.
  • the VH comprises the PC68-L31_32J VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32J VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32J VL.
  • the VL comprises the PC68- L31_32J VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_32J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32J VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32J VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32K.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32K VH.
  • the VH comprises the PC68-L31_32K VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_32K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32K VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32K VL.
  • the VL comprises the PC68- L31_32K VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_32K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32K VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_32K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_32K VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38A VH.
  • the VH comprises the PC68-L31_38A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_38A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38A VL.
  • the VL comprises the PC68- L31_38A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_38A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_38A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_38A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38B.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38B VH.
  • the VH comprises the PC68-L31_38B VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_38B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38B VL.
  • the VL comprises the PC68- L31_38B VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_38B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38B VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_38B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_38B VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38C VH.
  • the VH comprises the PC68-L31_38C VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_38C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38C VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38C VL.
  • the VL comprises the PC68- L31_38C VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_38C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_38C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_38C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38D VH.
  • the VH comprises the PC68-L31_38D VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_38D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38D VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38D VL.
  • the VL comprises the PC68- L31_38D VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_38D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_38D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_38D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38E.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38E VH.
  • the VH comprises the PC68-L31_38E VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_38E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38E VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38E VL.
  • the VL comprises the PC68- L31_38E VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_38E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38E VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_38E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_38E VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43A VH.
  • the VH comprises the PC68-L31_43A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43A VL.
  • the VL comprises the PC68- L31_43A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • the VH comprises the PC68-L31_43B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43B VL.
  • the VL comprises the PC68- L31_43B VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43B VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43B VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43C VH.
  • the VH comprises the PC68-L31_43C VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43C VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43C VL.
  • the VL comprises the PC68- L31_43C VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43D VH.
  • the VH comprises the PC68-L31_43D VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43D VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43D VL.
  • the VL comprises the PC68- L31_43D VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43E.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43E VH.
  • the VH comprises the PC68-L31_43E VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43E VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43E VL.
  • the VL comprises the PC68- L31_43E VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43E VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43E VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43F.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43F VH.
  • the VH comprises the PC68-L31_43F VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43F VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43F VL.
  • the VL comprises the PC68- L31_43F VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43F VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43F VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43G.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43G VH.
  • the VH comprises the PC68-L31_43G VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43G VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43G VL.
  • the VL comprises the PC68- L31_43G VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43G VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43G VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43H.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43H VH.
  • the VH comprises the PC68-L31_43H VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43H VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43H VL.
  • the VL comprises the PC68- L31_43H VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43H VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43H VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43I.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43I VH.
  • the VH comprises the PC68-L31_43I VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43I VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43I VL.
  • the VL comprises the PC68- L31_43I VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_43I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43I VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43I VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43J.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43J VH.
  • the VH comprises the PC68-L31_43J VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43J VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43J VL.
  • the VL comprises the PC68- L31_43J VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_43J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43J VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43J VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43K.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43K VH.
  • the VH comprises the PC68-L31_43K VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43K VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43K VL.
  • the VL comprises the PC68- L31_43K VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43K VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43K VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43L.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43L VH.
  • the VH comprises the PC68-L31_43L VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43L VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43L VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43L VL.
  • the VL comprises the PC68- L31_43L VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43L VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43L VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43L VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43L VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43M.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43M VH.
  • the VH comprises the PC68-L31_43M VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43M VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43M VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43M VL.
  • the VL comprises the PC68-L31_43M VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43M VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43M VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43M VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43M VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43N.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43N VH.
  • the VH comprises the PC68-L31_43N VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43N VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43N VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43N VL.
  • the VL comprises the PC68- L31_43N VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43N VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43N VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43N VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43N VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43P.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43P VH.
  • the VH comprises the PC68-L31_43P VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43P VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43P VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43P VL.
  • the VL comprises the PC68- L31_43P VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43P VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43P VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43P VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43P VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43Q.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43Q VH.
  • the VH comprises the PC68-L31_43Q VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43Q VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43Q VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43Q VL.
  • the VL comprises the PC68- L31_43Q VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43Q VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43Q VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43Q VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43R.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43R VH.
  • the VH comprises the PC68-L31_43R VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43R VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43R VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43R VL.
  • the VL comprises the PC68- L31_43R VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43R VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43R VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43R VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43R VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43S.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43S VH.
  • the VH comprises the PC68-L31_43S VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_43S VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43S VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43S VL.
  • the VL comprises the PC68- L31_43S VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_43S VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43S VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_43S VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_43S VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49A VH.
  • the VH comprises the PC68-L31_49A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_49A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49A VL.
  • the VL comprises the PC68- L31_49A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_49A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_49A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_49A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49B.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49B VH.
  • the VH comprises the PC68-L31_49B VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_49B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49B VL.
  • the VL comprises the PC68- L31_49B VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_49B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49B VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_49B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_49B VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49C VH.
  • the VH comprises the PC68-L31_49C VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_49C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49C VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49C VL.
  • the VL comprises the PC68- L31_49C VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_49C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_49C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_49C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49D VH.
  • the VH comprises the PC68-L31_49D VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_49D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49D VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49D VL.
  • the VL comprises the PC68- L31_49D VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_49D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_49D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_49D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49E.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49E VH.
  • the VH comprises the PC68-L31_49E VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_49E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49E VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49E VL.
  • the VL comprises the PC68- L31_49E VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_49E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49E VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_49E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_49E VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54A VH.
  • the VH comprises the PC68-L31_54A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54A VL.
  • the VL comprises the PC68- L31_54A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54B.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54B VH.
  • the VH comprises the PC68-L31_54B VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54B VL.
  • the VL comprises the PC68- L31_54B VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54B VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54B VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54C VH.
  • the VH comprises the PC68-L31_54C VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54C VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54C VL.
  • the VL comprises the PC68- L31_54C VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54D VH.
  • the VH comprises the PC68-L31_54D VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54D VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54D VL.
  • the VL comprises the PC68- L31_54D VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54E.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54E VH.
  • the VH comprises the PC68-L31_54E VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54E VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54E VL.
  • the VL comprises the PC68- L31_54E VL CDR1, VL CDR2, and VL CDR3.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54F.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54F VH.
  • the VH comprises the PC68-L31_54F VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54F VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54F VL.
  • the VL comprises the PC68- L31_54F VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54F VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54F VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54G.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54G VH.
  • the VH comprises the PC68-L31_54G VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54G VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54G VL.
  • the VL comprises the PC68- L31_54G VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54G VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54G VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54H.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54H VH.
  • the VH comprises the PC68-L31_54H VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54H VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54H VL.
  • the VL comprises the PC68- L31_54H VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54H VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54H VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54I.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54I VH.
  • the VH comprises the PC68-L31_54I VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54I VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54I VL.
  • the VL comprises the PC68- L31_54I VL CDR1, VL CDR2, and VL CDR3.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54J.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54J VH.
  • the VH comprises the PC68-L31_54J VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54J VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54J VL.
  • the VL comprises the PC68- L31_54J VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_54J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54J VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54J VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54K.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54K VH.
  • the VH comprises the PC68-L31_54K VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54K VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54K VL.
  • the VL comprises the PC68- L31_54K VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54K VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54K VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54L.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54L VH.
  • the VH comprises the PC68-L31_54L VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54L VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54L VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54L VL.
  • the VL comprises the PC68- L31_54L VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54L VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54L VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54L VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54L VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54M.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54M VH.
  • the VH comprises the PC68-L31_54M VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54M VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54M VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54M VL.
  • the VL comprises the PC68-L31_54M VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54M VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54M VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54M VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54M VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54N.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54N VH.
  • the VH comprises the PC68-L31_54N VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54N VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54N VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54N VL.
  • the VL comprises the PC68- L31_54N VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54N VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54N VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54N VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54N VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54P.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54P VH.
  • the VH comprises the PC68-L31_54P VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54P VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54P VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54P VL.
  • the VL comprises the PC68- L31_54P VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54P VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54P VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54P VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54P VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54Q.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH.
  • the VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL.
  • the VL comprises the PC68- L31_54Q VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54Q VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54R.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54R VH.
  • the VH comprises the PC68-L31_54R VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54R VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54R VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54R VL.
  • the VL comprises the PC68- L31_54R VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54R VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54R VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54R VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54R VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54S.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54S VH.
  • the VH comprises the PC68-L31_54S VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_54S VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54S VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54S VL.
  • the VL comprises the PC68- L31_54S VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_54S VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54S VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_54S VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_54S VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59A.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59A VH.
  • the VH comprises the PC68-L31_59A VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59A VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59A VL.
  • the VL comprises the PC68- L31_59A VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59A VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59A VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59B.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59B VH.
  • the VH comprises the PC68-L31_59B VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59B VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59B VL.
  • the VL comprises the PC68- L31_59B VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59B VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59B VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59C.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59C VH.
  • the VH comprises the PC68-L31_59C VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59C VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59C VL.
  • the VL comprises the PC68- L31_59C VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59C VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59C VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59D.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59D VH.
  • the VH comprises the PC68-L31_59D VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59D VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59D VL.
  • the VL comprises the PC68- L31_59D VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59D VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59D VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59E.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59E VH.
  • the VH comprises the PC68-L31_59E VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59E VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59E VL.
  • the VL comprises the PC68- L31_59E VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59E VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59E VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59F.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59F VH.
  • the VH comprises the PC68-L31_59F VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59F VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59F VL.
  • the VL comprises the PC68- L31_59F VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59F VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59F VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59G.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59G VH.
  • the VH comprises the PC68-L31_59G VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59G VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59G VL.
  • the VL comprises the PC68- L31_59G VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59G VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59G VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59H.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59H VH.
  • the VH comprises the PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59H VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59H VL.
  • the VL comprises the PC68- L31_59H VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68-L31_59H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59H VL.
  • the antibody or antigen- binding fragment comprises the PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59H VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59I.
  • the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59I VH.
  • the VH comprises the PC68-L31_59I VH CDR1, VH CDR2, and VH CDR3.
  • the VH comprises the PC68-L31_59I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59I VH.
  • the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59I VL.
  • the VL comprises the PC68- L31_59I VL CDR1, VL CDR2, and VL CDR3.
  • the VL comprises the PC68- L31_59I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59I VL.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
  • the antibody or antigen-binding fragment comprises the PC68-L31_59I VH and VL.
  • the CDRs are according to Kabat.
  • the CDRs are according to Table 1.
  • the HIV Env is BG505 HIV Env.
  • the antibody is not the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68- L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68- L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J,
  • an antibody described herein comprises a VH CDR3 comprising a sequence that is not identical to the VHCDR3 of any of the VH regions shown in Table 2. In some embodiments, an antibody described herein comprises a VH CDR1, VH CDR2, or VH CDR3 comprising an amino acid sequence that is not identical to the amino acid sequence of VH CDR1, VH CDR2, or VH CDR3 of any of the VH regions shown in Table 2.
  • an antibody described herein comprises a VL CDR1, VL CDR2, or VL CDR3 comprising an amino acid sequence that is not identical to the amino acid sequence of VL CDR1, VL CDR2, or VL CDR3 of any of the VL regions shown in Table 2.
  • an antibody described herein comprises a VH comprising an amino acid sequence that is not identical to the amino acid sequence of any VH region shown in Table 2.
  • an antibody described herein comprises a VL comprising an amino acid sequence that is not identical to the amino acid sequence of any VL region shown in Table 2.
  • an antibody described herein comprises a VH that is markedly different from the VH regions shown in Table 2.
  • an antibody described herein comprises a VL that is markedly different from the VL regions shown in Table 2. In some embodiments, an antibody described herein comprises at least one substitution, insertion, or deletion compared to the corresponding amino acid sequence of any of the VH and VL regions shown in Table 2. In some embodiments, the monoclonal antibody or antigen-binding fragment described herein further comprises a heavy and/or light chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a heavy chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a light chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a heavy and light chain constant region.
  • the isolated monoclonal antibody or antigen-binding fragment described herein is a recombinant antibody, a chimeric antibody, a human antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody.
  • the antibody fragment comprises a single-chain Fv (scFv), Fab fragment, F(ab’)2 fragment, or an isolated VH domain.
  • the antibody is a bispecific antibody. In some embodiments, the antibody is a trispecific antibody.
  • the antibody or antigen-binding fragment thereof described herein competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is the PC68-L31_54Q antibody.
  • the antibody or antigen-binding fragment thereof described herein binds to the same epitope of the HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is the PC68-L31_54Q antibody.
  • the HIV Env is BG505 HIV Env.
  • the antibody or antigen-binding fragment is capable of neutralizing at least 6 HIV isolates in the 13-member indicator virus panel.
  • the antibody or antigen-binding fragment is capable of neutralizing at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the HIV isolates in the 119-member indicator virus panel. In some embodiments of the antibody or antigen-binding fragment thereof described herein the antibody or antigen-binding fragment is capable of neutralizing the HIV isolates with a median IC50 equal to or less than about 1 ⁇ g/ml, about 0.8 ⁇ g/ml, 0.5 ⁇ g/ml, or 0.3 ⁇ g/ml.
  • an antibody or antibody fragment described herein neutralizes a pseudovirus produced in the presence of kifunensine better than those with wildtype glycoforms.
  • the antibody has a lowed IC50 value against a pseudovirus produced in the presence of kifunensine than against the corresponding pseudovirus comprising wildtype glycoforms.
  • the antibody has a lowed IC80 value against a pseudovirus produced in the presence of kifunensine than against the corresponding pseudovirus comprising wildtype glycoforms.
  • an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising a single substitution in the Env polypeptide selected from the group consisting of N197A, N234A, N262A, N276A, N301A, N363A, N386A and N462A with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution.
  • an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N197A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution.
  • an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N234A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N262A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N276A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution.
  • an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N301A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N363A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N386A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution.
  • an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N462A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution.
  • an antibody or antibody fragment described herein is capable of neutralizing at least two cross-clade isolates of HIV.
  • the antibody is capable of neutralizing at least one clade B isolate and at least one clade AG isolate.
  • the antibody is capable of neutralizing at least one clade B isolate and at least one clade AC isolate.
  • an antibody or antigen-binding fragment thereof described herein is a broadly neutralizing antibody.
  • an antibody or antigen-binding fragment thereof described herein neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses that belong to the same or different clades.
  • an antibody described herein is capable of neutralizing HIV strains or pseudoviruses from at least two different clades.
  • an antibody described herein is capable of neutralizing at least one clade B strain or pseudovirus and one clade AG strain or pseudovirus.
  • an antibody described herein is capable of neutralizing at least one clade B strain or pseudovirus and one clade AC strain or pseudovirus.
  • an antibody described herein is capable of neutralizing more than one clade B strain or pseudovirus.
  • the antibody is a broadly neutralizing antibody. In some embodiments, the antibody specifically binds an Env trimer of at least one HIV isolate in the 13- member indicator virus panels of Figure 1. In some embodiments, the antibody specifically binds an Env trimer of at least two, at least three, at least four, or at least five HIV isolates in the 13- member indicator virus panel of Figure 1. In some embodiments, the antibody specifically binds an Env trimer of at least one HIV isolate in the 119-member indicator virus panels of Table 4. In some embodiments, the antibody specifically binds an Env trimer of at least 30%, at least 40% or at least 50% of the HIV isolates in the 119-member indicator virus panel of Table 4.
  • an antibody or antigen-binding fragment thereof described herein is a recombinant antibody, a chimeric antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein is a bispecific antibody or a trispecific antibody. In some embodiments, the antibody or antigen-binding fragment thereof is a human antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein is not polyreactive. In some embodiments, an isolated monoclonal antibody described herein further comprises heavy and/or light chain constant regions.
  • an isolated monoclonal antibody described herein further comprises human heavy and/or light chain constant regions.
  • the heavy chain constant region is selected from the group consisting of human immunoglobulins IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
  • the heavy chain constant region comprises a native amino acid sequence.
  • the heavy chain constant region comprises a non-native variant amino acid sequence.
  • an antibody described herein is a recombinant antibody, a chimeric antibody, a bispecific antibody, a trispecific antibody, or a multispecific antibody.
  • the antibody fragment comprises a single-chain Fv (scFv), F(ab) fragment, F(ab’) 2 fragment, or an isolated VH domain.
  • an antibody described herein is a multispecific antibody, e.g. a bispecific antibody.
  • Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In some embodiments, one of the binding specificities is for HIV Env and the other is for any other antigen. In some embodiments, bispecific antibodies bind to two different epitopes of HIV Env. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
  • bispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker A., et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole” engineering (see, e.g., U.S. Patent No. 5,731,168).
  • Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody” technology for making bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci.
  • an antibody described herein also includes a "Dual Acting Fab” or “DAF” comprising an antigen- binding site that binds to different epitopes, e.g., two different HIV Env epitopes (see, US 2008/0069820, for example).
  • an antibody described herein is a multispecific antibody, e.g. a bispecific antibody comprising a first antigen-binding domain comprising a VH domain or VH and VL domains described herein, and a second antigen-binding region capable of binding an HIV Env epitope.
  • the second antigen-binding region binds to an HIV Env epitope region different from the HIV Env epitope region bound by an antibody described herein.
  • the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, N332/V3 base supersite, fusion peptide (FP), silent face, gp120-gp41 interface or membrane-proximal external region (MPER).
  • the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, silent face, fusion peptide (FP), gp120-gp41 interface or membrane-proximal external region (MPER).
  • the second antigen-binding region binds to the CD4 binding site (CD4bs) epitope region.
  • the second antigen-binding region binds to the V2 apex.
  • the second antigen-binding region binds to the N332/V3 base supersite.
  • the second antigen-binding region binds to the gp120-gp41 interface epitope region.
  • the second antigen-binding region binds to the silent face. In some embodiments, the second antigen-binding region binds to fusion peptide (FP). In some embodiments, the second antigen-binding region binds to the membrane-proximal external region (MPER).
  • an antibody described herein comprises a heavy and/or light chain constant region. In some embodiments, an antibody described herein comprises a human heavy and/or light chain constant region. In some embodiments, the heavy chain constant region is human immunoglobulin IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2 constant region. In some embodiments, the heavy chain constant region is human immunoglobulin IgG1 constant region.
  • the heavy chain constant region comprises a native amino acid sequence.
  • an antibody described herein is capable of neutralizing at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or 100% of cross-clade HIV isolates in the 119-member indicator virus panel.
  • an antibody described herein is capable of neutralizing at least about 40%, of cross- clade HIV isolates in the 119-member indicator virus panel.
  • an antibody described herein is capable of neutralizing at least about 50%, of cross-clade HIV isolates in the 119-member indicator virus panel.
  • an antibody described herein is capable of neutralizing at least about 60%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 90%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 95%, of cross-clade HIV isolates in the 119-member indicator virus panel.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 2 ⁇ g/ml, about 1.5 ⁇ g/ml, about 1 ⁇ g/ml, about 0.75 ⁇ g/ml, about 0.5 ⁇ g/ml, about 0.3 ⁇ g/ml, about 0.2 ⁇ g/ml, about 0.1 ⁇ g/ml, about 0.05 ⁇ g/ml, about 0.025 ⁇ g/ml, about 0.01 ⁇ g/ml, or about 0.005 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than 0.5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than 0.25 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 2 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 1.5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross- clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 1 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 2 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 1.5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 50 equal to or less than about 1 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than about 1 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing at least about 80% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than about 1 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than about 0.5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 80% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC 50 equal to or less than about 0.5 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 80 equal to or less than about 7 ⁇ g/ml, about 6 ⁇ g/ml, about 5 ⁇ g/ml, about 4 ⁇ g/ml, about 3 ⁇ g/ml, about 2 ⁇ g/ml, about 1 ⁇ g/ml, or about 0.5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 80 equal to or less than about 7 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates with a median IC 80 equal to or less than about 6 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 80 equal to or less than about 5 ⁇ g/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119- member indicator virus panel with a median IC 80 equal to or less than about 2 ⁇ g/ml.
  • an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC 80 equal to or less than about 1 ⁇ g/ml.
  • antibodies that bind the same or an overlapping epitope of Env as an antibody described herein e.g., PC68-L31_43J.
  • the epitope of an antibody can be determined by, e.g., NMR spectroscopy, X-ray crystallography, negative-stain and cryo-EM (see, e.g., Lin M, et al., J Am Soc Mass Spectrom.5: 961-971 (2016); Rantalainen et al., Cell Rep.23(11); 3249-3261 (2016); Torrents de la Pe ⁇ a A et al., PLoS Pathog.
  • ELISA assays hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo- peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping).
  • mass spectrometry e.g., liquid chromatography electrospray mass spectrometry
  • array-based oligo- peptide scanning assays e.g., site-directed mutagenesis mapping
  • crystallization may be accomplished using any of the known methods in the art (e.g., Giegé R, et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen NE (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303).
  • Antibody:antigen crystals may be studied using well-known X-ray diffraction techniques and may be refined using computer software such as Phenix (Adams et al., Acta Crystallogr Biol Crystallogr D66, 213-221 (2010)) and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne G (1997) Meth. Enzymol. 276A: 361-423, ed Carter CW; Roversi P et al., (2000) Acta Crystallogr. D Biol. Crystallogr.56(Pt 10): 1316-1323). Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art.
  • the epitope of an antibody is determined using alanine scanning mutagenesis studies. Usually, binding to the antigen is reduced or disrupted when a residue within the epitope is substituted to alanine. In some embodiments, the K D of binding to the antigen is increased by about 5-fold, 10-fold, 20-fold, 10-fold or more when a residue within the epitope is substituted for alanine. In some embodiments, binding affinity is determined by ELISA.
  • antibodies that recognize and bind to the same or overlapping epitopes of Env can be identified using routine techniques such as an immunoassay, for example, by showing the ability of one antibody to block the binding of another antibody to a target antigen, i.e., a competitive binding assay.
  • the antibody or antigen-binding fragment thereof described herein competes with a reference antibody for binding to an HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is the PC68-L31_54Q antibody.
  • the antibody or antigen-binding fragment thereof described herein binds to the same epitope of an the HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A,
  • the trimer is an SOSIP trimer.
  • the HIV Env is BG505 HIV Env.
  • the reference antibody is the PC68-L31_54Q antibody.
  • a method of producing an engineered variant of an antibody described herein comprising (a) substituting one or more amino acid residues of the VH; and/or substituting one or more amino acid residues of the VL of the antibody to create an engineered variant antibody, and (b) producing the engineered variant antibody.
  • the antibody is selected from the group consisting of the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_32K,
  • the antibody is the PC68- L31_54Q antibody.
  • a method for producing an engineered variant comprises directed-evolution and yeast display.
  • the method further comprises determining that the engineered variant antibody has improved properties, for example, by determining the engineered variant antibody's binding affinity to target antigen, binding affinity to target antigen at low pH, median neutralization IC 50 potency, or breadth of neutralization compared to the parent antibody. Suitable methods for producing the engineered antibody are disclosed in International Patent Publication Nos. WO 2020023827 and WO 2020/117740, each of which is hereby incorporated by reference herein in its entirety.
  • an engineered antibody possesses one or more improved properties, for example, higher binding affinity to target antigen, higher binding affinity to target antigen at low pH, increased median neutralization IC 50 potency, and increased breadth of neutralization compared to the parent antibody.
  • the affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method well-known in the art, e.g., flow cytometry, enzyme-linked immunoabsorbent assay (ELISA), biolayer interferometry (BLI) assay, radioimmunoassay (RIA), or kinetics (e.g., BIACORETM analysis). Direct binding assays as well as competitive binding assay formats can be readily employed.
  • the measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g., salt concentration, pH, temperature).
  • affinity and other antigen-binding parameters e.g., K D or Kd, K on , K off
  • K D or Kd, K on , K off are made with standardized solutions of antibody and antigen, and a standardized buffer, as known in the art and such as the buffer described herein.
  • an antibody described herein is a monoclonal antibody.
  • Monoclonal antibodies can be made using recombinant DNA methods, for example, as described in U.S. Patent 4,816,567.
  • the polynucleotides encoding a monoclonal antibody can be amplified from a suitable source or chemically synthetized.
  • the isolated polynucleotides encoding the heavy and light chains are then cloned into suitable expression vectors, which when transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, monoclonal antibodies are generated by the host cells.
  • the polynucleotide(s) encoding a monoclonal antibody can be modified in a number of different manners using recombinant DNA technology to generate alternative antibodies.
  • the constant domains of the light and heavy chains can be substituted for a non- immunoglobulin polypeptide to generate a fusion antibody.
  • the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody.
  • Site-directed or high-density mutagenesis of the variable region can be used to optimize specificity, affinity, etc. of a monoclonal antibody.
  • Methods for engineering antibodies can also be used and are well-known in the art.
  • An engineered antibody can have one or more amino acid residues substituted, deleted or inserted.
  • Antibodies can be used to reduce immunogenicity or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art.
  • Antibodies can also be engineered to eliminate development liabilities by altering or eliminating sequence elements targeted for post-translational modification including glycosylation sites, oxidation sites, or deamination sites.
  • the CDR residues are directly and most substantially involved in influencing antibody binding. Accordingly, part or all of the CDR sequences are maintained while the variable framework and constant regions can be engineered by introducing substitutions, insertions, or deletions.
  • Antibodies described herein can also optionally be engineered with retention of high affinity for the antigen and other favorable biological properties.
  • engineered antibodies can be prepared by a process of analysis of the parental sequences and various conceptual engineered products using three-dimensional models of the parental and engineered sequences.
  • Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available, which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • framework (FR) residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • an antibody fragment is provided.
  • Various techniques are known for the production of antibody fragments. Traditionally, these fragments are derived via proteolytic digestion of intact antibodies (for example Morimoto et al., 1993, Journal of Biochemical and Biophysical Methods 24:107-117; Brennan et al., 1985, Science, 229:81).
  • antibody fragments are produced recombinantly. Fab, Fv, and scFv antibody fragments can all be expressed in and secreted from E. coli or other host cells, thus allowing the production of large amounts of these fragments.
  • Such antibody fragments can also be isolated from antibody phage libraries.
  • the antibody fragment can also be linear antibodies as described in U.S.
  • variable domains in both the heavy and light chains are altered by at least partial replacement of one or more CDRs and, if necessary, by partial framework region replacement and sequence changing.
  • the CDRs can be derived from an antibody of the same class or even subclass as the antibody from which the framework regions are derived, it is envisaged that the CDRs may be derived from an antibody of different class and in certain embodiments from an antibody from a different species. It may not be necessary to replace all of the CDRs with the complete CDRs from the donor variable region to transfer the antigen-binding capacity of one variable domain to another.
  • the modified antibodies described herein will comprise antibodies (e.g., full-length antibodies or antigen-binding fragments thereof) in which at least a fraction of one or more of the constant region domains has been deleted or otherwise altered so as to provide desired biochemical characteristics such as increased serum half-life when compared with an antibody of approximately the same antigen-binding activity comprising a native or unaltered constant region.
  • the constant region of the modified antibodies will comprise a human constant region.
  • Modifications to the constant region compatible with this invention comprise additions, deletions or substitutions of one or more amino acids in one or more domains.
  • the modified antibodies described herein can comprise alterations or modifications to one or more of the three heavy chain constant domains (C H 1, C H 2 or C H 3) and/or to the light chain constant domain (C L ).
  • modified constant regions wherein one or more domains are partially or entirely deleted are contemplated.
  • the modified antibodies will comprise domain deleted constructs or variants wherein the entire C H 2 domain has been removed ( ⁇ CH2 constructs).
  • the omitted constant region domain will be replaced by a short amino acid spacer (e.g., 10 residues) that provides some of the molecular flexibility typically imparted by the absent constant region.
  • the modified antibodies can be engineered to fuse the C H 3 domain directly to the hinge region of the respective modified antibodies.
  • compatible constructs could be expressed wherein the C H 2 domain has been deleted and the remaining C H 3 domain (modified or unmodified) is joined to the hinge region with a 5-20 amino acid spacer.
  • Such a spacer can be added, for instance, to ensure that the regulatory elements of the constant domain remain free and accessible or that the hinge region remains flexible.
  • amino acid spacers can, in some cases, prove to be immunogenic and elicit an unwanted immune response against the construct.
  • any spacer added to the construct will be relatively non-immunogenic, or even omitted altogether, so as to maintain the desired biochemical qualities of the modified antibodies.
  • the antibodies described herein can be provided by the partial deletion or substitution of a few or even a single amino acid.
  • Such partial deletions of the constant regions can improve selected characteristics of the antibody (serum half-life) while leaving other desirable functions associated with the subject constant region domain intact.
  • the constant regions of the disclosed antibodies can be modified through the mutation or substitution of one or more amino acids that enhances the profile of the resulting construct.
  • a conserved binding site e.g., Fc binding
  • Certain embodiments can comprise the addition of one or more amino acids to the constant region to enhance desirable characteristics such as decreasing or increasing effector function or provide for more cytotoxin or carbohydrate attachment.
  • it can be desirable to insert or replicate specific sequences derived from selected constant region domains.
  • an antibody described herein comprises a variant IgG Fc region (e.g., variant IgG1 Fc region) comprising the M428L and N434S substitutions to improve the recycling of the antibody via the antibody salvage pathway.
  • a variant IgG Fc region e.g., variant IgG1 Fc region
  • the half-life of an IgG is mediated by its pH-dependent binding to the neonatal receptor FcRn.
  • an antibody described herein comprises a variant Fc region that has been modified to enhance binding to FcRn (see, e.g., Petkova et al., Int. Immunol.
  • an antibody described herein comprises a variant Fc region that has been modified to have a selective affinity for FcRn at pH 6.0, but not pH 7.4.
  • the variant Fc region contains one or more of the following modifications that increase half-life: IgG1-M252Y, S254T, T256E; IgG1-T250Q, M428L; IgG1-M428L and N434S (the "LS" mutation); IgG1-H433K, N434Y; IgG1-N434A; and IgG1-T307A, E380A, N434A; wherein the numbering of the residues is that of the EU index of Kabat et al. (Kabat et al., Sequences of Proteins of Immunological Interest, 1991 Fifth edition, herein incorporated by reference).
  • an antibody described herein comprises a variant Fc region that has been modified to reduce its effector functions.
  • the variant Fc region comprises the L234A, L235A hinge region substitutions, wherein the numbering of the residues is that of the EU index of Kabat et al.
  • an antibody described herein comprises an Fc region having a carbohydrate structure that lacks fucose attached (directly or indirectly) to the Fc region or has a reduced level of fucosylation.
  • a fucosylation variant antibody has improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108; US 2004/0093621, each of which is incorporated by reference herein in its entirety.
  • Examples of publications related to "defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol.336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech.
  • Examples of cell lines capable of producing defucosylated antibodies include Lec 13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1; and WO 2004/056312), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol.
  • an antibody described herein comprises bisected oligosaccharides, in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc.
  • an antibody comprising bisected oligosaccharides has reduced fucosylation and/or improved ADCC function. See, e.g., WO 2003/011878; U.S. Pat. No. 6,602,684; and US 2005/0123546, each of which is incorporated by reference herein in its entirety.
  • an antibody described herein comprises at least one galactose residue in the oligosaccharide attached to the Fc region.
  • Such antibody variants may have improved CDC function. See, e.g., in WO 1997/30087; WO 1998/58964; and WO 1999/22764, each of which is incorporated by reference herein in its entirety.
  • an antibody described herein comprises a variant Fc region comprising a combination of substitutions with increased binding to FcRn and Fc gamma RIIIa. The combinations increase antibody half-life and ADCC.
  • such combination include antibodies with the following amino acid substitution in the Fc region: (1) S239D/I332E and T250Q/M428L; (2) S239D/I332E and M428L/N434S; (3) S239D/I332E and N434A; (4) S239D/I332E and T307A/E380A/N434A; (5) S239D/I332E and M252Y/S254T/T256E; (6) S239D/A330L/I332E and 250Q/M428L; (7) S239D/A330L/I332E and M428L/N434S; (8) S239D/A330L/I332E and N434A; (9) S239D/A330L/I332E and T307A/E380A/N434A; or (10) S239D/A330L/I332E and M252Y/S254T
  • an antibody comprising the variant Fc region is directly cytotoxic to infected cells, or uses natural defenses such as complement, antibody dependent cellular cytotoxicity (ADCC), or phagocytosis by macrophages.
  • the present invention further embraces variants and equivalents, which are substantially homologous to the chimeric, humanized and human antibodies, or antibody fragments thereof, set forth herein. These can contain, for example, conservative substitution mutations, i.e., the substitution of one or more amino acids by similar amino acids. For example, conservative substitution refers to the substitution of an amino acid with another within the same general class such as, for example, one acidic amino acid with another acidic amino acid, one basic amino acid with another basic amino acid or one neutral amino acid by another neutral amino acid.
  • polypeptides provided herein can be recombinant polypeptides, natural polypeptides, or synthetic polypeptides comprising an antibody, or fragment thereof. It will be recognized in the art that some amino acid sequences described herein can be varied without significant effect of the structure or function of the protein.
  • the invention further includes variations of the polypeptides, which show substantial activity or which include regions of an antibody, or fragment thereof, against a human folate receptor protein. Such mutants include deletions, insertions, inversions, repeats, and type substitutions.
  • the polypeptides and analogs can be further modified to contain additional chemical moieties not normally part of the protein.
  • moieties can improve the solubility, the biological half-life or absorption of the protein.
  • the moieties can also reduce or eliminate any desirable side effects of the proteins and the like.
  • An overview for those moieties can be found in REMINGTON'S PHARMACEUTICAL SCIENCES, 21th ed., Mack Publishing Co., Easton, PA (2005). III.
  • polynucleotides comprising a nucleotide sequence or nucleotide sequences encoding an antibody described herein (e.g., a variable light chain and/or variable heavy chain region) or an antigen-binding fragment thereof and vectors, e.g., vectors comprising such polynucleotides.
  • the vectors can be used for recombinant expression of an antibody described herein in host cells (e.g., E. coli and mammalian cells).
  • the vectors can be used for administration of an antibody described herein to a patient in need thereof.
  • the antibody comprises PC68-L31_43J.
  • provided herein are isolated polynucleotides encoding the heavy chain variable region or heavy chain of an antibody described herein. In one aspect, provided herein are isolated polynucleotides encoding the light chain variable region or light chain of an antibody described herein. In one aspect, provided herein are isolated polynucleotides encoding the heavy chain variable region or heavy chain of an antibody described herein and the light chain variable region or light chain of an antibody described herein. In some embodiments, the polynucleotide encodes PC68-L31_43J. In some embodiments, the polynucleotide encodes a VH or VL as referenced in Table 2.
  • the polynucleotide encodes a polypeptide comprising an amino acid sequence referenced in Tables 1 and 2. In some embodiments, the polynucleotide comprises any one of the nucleotide sequences referenced in Table 3. In some embodiments, an isolated polynucleotide described herein encodes an antibody described herein and comprises an mRNA. In some embodiments, the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.
  • the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil ( ⁇ ), N1-methylpseudouracil (m1 ⁇ ), 1-ethylpseudouracil, 2-thiouracil, 4′- thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combination thereof.
  • a modified mRNA encoding an antibody described herein is for administering to a subject to treat or prevent HIV infection.
  • an "isolated" polynucleotide or nucleic acid molecule is one, which is separated from other nucleic acid molecules, which are present in the natural source (e.g., in a mouse or a human) of the nucleic acid molecule.
  • an "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • the language "substantially free” includes preparations of polynucleotide or nucleic acid molecule having less than about 15%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (in particular less than about 10%) of other material, e.g., cellular material, culture medium, other nucleic acid molecules, chemical precursors and/or other chemicals.
  • a nucleic acid molecule(s) encoding an antibody or fusion polypeptide described herein is isolated or purified.
  • polynucleotides comprising nucleotide sequences encoding antibodies described herein, as well as antibodies that compete with such antibodies for binding to HIV, or which binds to the same epitope as that of such antibodies.
  • polynucleotides comprising a nucleotide sequence encoding the light chain or heavy chain of an antibody described herein.
  • the polynucleotides can comprise nucleotide sequences encoding a light chain comprising the VL of antibodies described herein (see, e.g., Table 3).
  • the polynucleotides can comprise nucleotide sequences encoding a heavy chain comprising the VH of antibodies described herein (see, e.g., Table 3).
  • a polynucleotide described herein encodes a VH domain shown in Table 3.
  • a polynucleotide described herein encodes a VL domain shown in Table 3.
  • a polynucleotide described herein encodes PC68-L31_43J.
  • the antibody is a chimeric antibody.
  • polynucleotides comprising a nucleotide sequence encoding an antibody comprising three VL chain CDRs, e.g., containing VL CDR1, VL CDR2, and VL CDR3 of any one of antibodies described herein (e.g., see Table 1).
  • polynucleotides comprising three VH chain CDRs, e.g., containing VH CDR1, VH CDR2, and VH CDR3 of any one of antibodies described herein (e.g., see Table 1).
  • polynucleotides comprising a nucleotide sequence encoding an anti-Env antibody comprising three VL CDRs, e.g., containing VL CDR1, VL CDR2, and VL CDR3 of any one of antibodies described herein (e.g., see Table 1) and three VH chain CDRs, e.g., containing VH CDR1, VH CDR2, and VH CDR3 of any one of antibodies described herein (e.g., see Table 1).
  • a polynucleotide comprising a nucleotide sequence encoding an antibody comprising a light chain and a heavy chain, e.g., a separate light chain and heavy chain.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding a kappa light chain.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding a lambda light chain.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein comprising a human kappa light chain or a human lambda light chain.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody, which immunospecifically binds to Env, wherein the antibody comprises a light chain, and wherein the amino acid sequence of the VL domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the light chain comprises the amino acid sequence of a human kappa light chain constant region.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody, which immunospecifically binds to Env, and comprises a light chain, wherein the amino acid sequence of the VL domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the light chain comprises the amino acid sequence of a human lambda light chain constant region.
  • human constant region sequences can be those described in U.S. Patent No.5,693,780.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein, which immunospecifically binds to Env, wherein the antibody comprises a heavy chain, wherein the amino acid sequence of the VH domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the heavy chain comprises the amino acid sequence of a human alpha or gamma heavy chain constant region.
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein, which immunospecifically binds Env, wherein the antibody comprises a VL domain and a VH domain comprising any amino acid sequences described herein, and wherein the constant regions comprise the amino acid sequences of the constant regions of a human IgA 1 , human IgA 2 , human IgG 1 (e.g., allotype 1, 17, or 3), human IgG 2 , or human IgG 4 .
  • a polynucleotide provided herein comprises a nucleotide sequence encoding an anti-Env antibody or a fragment thereof that are optimized, e.g., by codon/RNA optimization, replacement with heterologous signal sequences, and elimination of mRNA instability elements.
  • Methods to generate optimized nucleic acids encoding an anti-Env antibody or a fragment thereof e.g., light chain, heavy chain, VH domain, or VL domain
  • Methods to generate optimized nucleic acids encoding an anti-Env antibody or a fragment thereof e.g., light chain, heavy chain, VH domain, or VL domain
  • RNA potential splice sites and instability elements (e.g., A/T or A/U rich elements) within the RNA can be mutated without altering the amino acids encoded by the nucleic acid sequences to increase stability of the RNA for recombinant expression.
  • the alterations utilize the degeneracy of the genetic code, e.g., using an alternative codon for an identical amino acid.
  • an optimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof can hybridize to an antisense (e.g., complementary) polynucleotide of an unoptimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof (e.g., VL domain or VH domain).
  • an optimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment hybridizes under high stringency conditions to antisense polynucleotide of an unoptimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof.
  • an optimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof hybridizes under high stringency, intermediate or lower stringency hybridization conditions to an antisense polynucleotide of an unoptimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof.
  • Information regarding hybridization conditions has been described, see, e.g., U.S.
  • Patent Application Publication No. US 2005/0048549 (e.g., paragraphs 72-73), which is incorporated herein by reference.
  • the polynucleotides can be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art.
  • Nucleotide sequences encoding antibodies described herein, and modified versions of these antibodies can be determined using methods well-known in the art, i.e., nucleotide codons known to encode particular amino acids are assembled in such a way to generate a nucleic acid that encodes the antibody.
  • Such a polynucleotide encoding the antibody can be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier G et al., (1994), BioTechniques 17: 242-246), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.
  • chemically synthesized oligonucleotides e.g., as described in Kutmeier G et al., (1994), BioTechniques 17: 242-246
  • a polynucleotide encoding an antibody or fragment thereof described herein can be generated from nucleic acid from a suitable source (e.g., PBMCs) using methods well- known in the art (e.g., PCR and other molecular cloning methods). For example, PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of a known sequence can be performed using genomic DNA obtained from hybridoma cells producing the antibody of interest. Such PCR amplification methods can be used to obtain nucleic acids comprising the sequence encoding the light chain and/or heavy chain of an antibody.
  • a suitable source e.g., PBMCs
  • methods well- known in the art e.g., PCR and other molecular cloning methods.
  • PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of a known sequence can be performed using genomic DNA obtained from hybridoma cells producing the antibody of interest.
  • Such PCR amplification methods
  • Such PCR amplification methods can be used to obtain nucleic acids comprising the sequence encoding the variable light chain region and/or the variable heavy chain region of an antibody.
  • the amplified nucleic acids can be cloned into vectors for expression in host cells and for further cloning, for example, to generate chimeric and humanized antibodies.
  • a nucleic acid encoding the immunoglobulin or fragment can be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody described herein) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody.
  • a suitable source e.g., an antibody cDNA library or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody described herein
  • Amplified nucleic acids generated by PCR can then be cloned into replicable cloning vectors using any method well-known in the art.
  • DNA encoding anti-Env antibodies described herein can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the anti-Env antibodies).
  • PBMCs can serve as a source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as E.
  • the DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains with a coding sequence for a non-immunoglobulin polypeptide, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • polynucleotides that hybridize under high stringency, intermediate or lower stringency hybridization conditions to polynucleotides that encode an antibody described herein.
  • polynucleotides described herein hybridize under high stringency, intermediate or lower stringency hybridization conditions to polynucleotides encoding a VH domain and/or VL domain provided herein. Hybridization conditions have been described in the art and are known to one of skill in the art.
  • hybridization under stringent conditions can involve hybridization to filter- bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65°C; hybridization under highly stringent conditions can involve hybridization to filter-bound nucleic acid in 6xSSC at about 45°C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68°C.
  • Hybridization under other stringent hybridization conditions are known to those of skill in the art and have been described, see, for example, Ausubel FM et al., eds., (1989) Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc.
  • cells e.g., host cells
  • vectors e.g., expression vectors
  • polynucleotides comprising nucleotide sequences encoding anti-Env antibodies or a fragment thereof described herein.
  • the vectors can be used for recombinant expression of an antibody described herein in host cells (e.g., mammalian cells). In some embodiments, the vectors can be used for administration of an antibody described herein to a patient in need thereof. Also provided herein are host cells comprising such vectors for recombinantly expressing anti-Env antibodies described herein. In a particular aspect, provided herein are methods for producing an antibody described herein, comprising expressing such antibody in a host cell. In some embodiments, the antibody comprises the PC68-L31_43J VH and VL. In certain aspects, provided herein is an isolated vector comprising a polynucleotide described herein. In some embodiments, the vector is a viral vector.
  • a recombinant virus comprising a polynucleotide described herein.
  • the recombinant virus encodes an antibody described herein.
  • the recombinant virus encodes a bispecific antibody described herein.
  • the recombinant virus is a replication defective virus. Suitable replication defective viral vectors are known to those skilled in the art, for example, as disclosed in U.S. Pat. Nos. 7198784, 9408905, 9862931, 8067156, U.S. Pat. Appl. Pub. Nos. 20150291935, 20120220492, 20180291351, and 20170175137, each of which is incorporated herein by reference in its entirety.
  • the recombinant virus is a retrovirus or retroviral vector, for example, a lentivirus or lentiviral vector.
  • the recombinant virus is an adenovirus or adenoviral vector, HSV or HSV vector, or influenza virus or viral vector.
  • the recombinant virus is an adeno-associated virus (AAV).
  • the recombinant virus is for administration to a subject to prevent or treat HIV infection.
  • the recombinant virus is an adeno-associated virus (AAV) for administration to a subject to prevent or treat HIV infection.
  • the antibody comprises the PC68-L31_43J VH and VL.
  • a host cell comprising a polynucleotide described herein, or a vector described herein.
  • the vector encodes an antibody described herein.
  • a vector described herein comprises a first vector encoding a VH described herein and a second vector encoding a VL described herein.
  • a vector described herein comprises a first nucleotide sequence encoding a VH described herein and a second nucleotide sequence encoding a VL described herein.
  • the antibody comprises the PC68-L31_43J VH and VL.
  • the host cell is selected from the group consisting of E.
  • the host cell is CHO.
  • a method of producing an antibody that binds to HIV comprising culturing a host cell described herein so that the polynucleotide is expressed and the antibody is produced. In some embodiments, the method further comprises recovering the antibody.
  • the isolated polypeptides i.e., anti-HIV Env antibodies described herein can be produced by any suitable method known in the art. Such methods range from direct protein synthetic methods to constructing a DNA sequence encoding isolated polypeptide sequences and expressing those sequences in a suitable transformed host.
  • a DNA sequence is constructed using recombinant technology by isolating or synthesizing a DNA sequence encoding a wild-type protein of interest.
  • the sequence can be mutagenized by site-specific mutagenesis to provide functional analogs thereof. See, e.g. Zoeller et al., Proc. Nat'l. Acad. Sci. USA 81:5662- 5066 (1984) and U.S. Pat.
  • a DNA sequence encoding a polypeptide of interest would be constructed by chemical synthesis using an oligonucleotide synthesizer.
  • Such oligonucleotides can be designed based on the amino acid sequence of the desired polypeptide and selecting those codons that are favored in the host cell in which the recombinant polypeptide of interest will be produced.
  • Standard methods can be applied to synthesize an isolated polynucleotide sequence encoding an isolated polypeptide of interest. For example, a complete amino acid sequence can be used to construct a back-translated gene. Further, a DNA oligomer containing a nucleotide sequence coding for the particular isolated polypeptide can be synthesized.
  • oligonucleotides coding for portions of the desired polypeptide can be synthesized and then ligated.
  • the individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.
  • the polynucleotide sequences encoding a particular isolated polypeptide of interest will be inserted into an expression vector and operatively linked to an expression control sequence appropriate for expression of the protein in a desired host. Proper assembly can be confirmed by nucleotide sequencing, restriction mapping, and expression of a biologically active polypeptide in a suitable host.
  • recombinant expression vectors are used to amplify and express DNA encoding antibodies or fragments thereof.
  • Recombinant expression vectors are replicable DNA constructs, which have synthetic or cDNA-derived DNA fragments encoding a polypeptide chain of an antibody or fragment thereof operatively linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes.
  • a transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences.
  • a regulatory element can include an operator sequence to control transcription.
  • the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants can additionally be incorporated.
  • DNA regions are operatively linked when they are functionally related to each other.
  • DNA for a signal peptide is operatively linked to DNA for a polypeptide if it is expressed as a precursor, which participates in the secretion of the polypeptide; a promoter is operatively linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operatively linked to a coding sequence if it is positioned so as to permit translation.
  • Structural elements intended for use in yeast expression systems include a leader sequence enabling extracellular secretion of translated protein by a host cell.
  • recombinant protein is expressed without a leader or transport sequence, it can include an N-terminal methionine residue.
  • This residue can optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.
  • expression control sequence and expression vector will depend upon the choice of host.
  • a variety of host-expression vector systems can be utilized to express antibody molecules described herein (see, e.g., U.S. Patent No. 5,807,715).
  • host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells which can, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule described herein in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli and B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems (e.g., green algae such as Chlamydomonas reinhardtii) infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS (e.g., COS1 or COS), CHO, BHK, MDCK, HEK 293, NS0, PER.C6,
  • cells for expressing antibodies described herein are CHO cells, for example CHO cells from the CHO GS SystemTM (Lonza).
  • cells for expressing antibodies described herein are human cells, e.g., human cell lines.
  • a mammalian expression vector is pOptiVECTM or pcDNA3.3.
  • bacterial cells such as E. coli, or eukaryotic cells (e.g., mammalian cells), especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule.
  • mammalian cells such as Chinese hamster ovary (CHO) cells in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking MK & Hofstetter H (1986) Gene 45: 101-105; and Cockett MI et al., (1990) Biotechnology 8: 662-667).
  • antibodies described herein are produced by CHO cells or NS0 cells.
  • the expression of nucleotide sequences encoding antibodies described herein which immunospecifically bind Env is regulated by a constitutive promoter, inducible promoter or tissue specific promoter.
  • the vector is a viral vector.
  • Viral vectors can include poxvirus (vaccinia), including vaccinia Ankara and canarypox; adenoviruses, including adenovirus type 5 (Ad5); rubella; sendai virus; rhabdovirus; alphaviruses; and adeno-associated viruses.
  • the viral vector is an adeno-associated virus.
  • a polynucleotide encoding the antibody could be delivered as DNA or RNA to the subject for in vivo expression of the antibody.
  • Suitable host cells for expression of a polypeptide of interest such as an antibody described herein include prokaryotes, yeast, insect or higher eukaryotic cells under the control of appropriate promoters.
  • Prokaryotes include gram negative or gram-positive organisms, for example E. coli or bacilli.
  • Higher eukaryotic cells include established cell lines of mammalian origin. Cell-free translation systems could also be employed.
  • Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al.
  • suitable mammalian host cell lines include but are not limited to CHO, VERO, BHK, Hela, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, COS (e.g., COS1 or COS), PER.C6, VERO, HsS78Bst, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20, BMT10 and HsS78Bst cells.
  • COS e.g., COS1 or COS
  • PER.C6 VERO, HsS78Bst, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB
  • Mammalian expression vectors can comprise non-transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking non-transcribed sequences, and 5' or 3' non-translated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • non-transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking non-transcribed sequences, and 5' or 3' non-translated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988).
  • the proteins produced by a transformed host can be purified according to any suitable method.
  • Such standard methods include chromatography (e.g., ion exchange, affinity and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification.
  • Affinity tags such as hexahistidine, maltose binding domain, influenza HA peptide sequence and glutathione-S-transferase can be attached to the protein to allow easy purification by passage over an appropriate affinity column.
  • Isolated proteins can also be physically characterized using such techniques as proteolysis, nuclear magnetic resonance and x-ray crystallography.
  • supernatants from systems, which secrete recombinant protein, e.g., an antibody, into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix.
  • a suitable purification matrix for example, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups.
  • the matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
  • a cation exchange step can be employed.
  • Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.
  • one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further an agent.
  • RP-HPLC reversed-phase high performance liquid chromatography
  • Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.
  • Recombinant protein produced in bacterial culture can be isolated, for example, by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps.
  • High performance liquid chromatography can be employed for final purification steps.
  • Microbial cells employed in expression of a recombinant protein can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.
  • Methods known in the art for purifying antibodies and other proteins also include, for example, those described in U.S. Patent Publication Nos. 2008/0312425, 2008/0177048, and 2009/0187005, each of which is hereby incorporated by reference herein in its entirety.
  • an antibody described herein is isolated or purified.
  • an isolated antibody is one that is substantially free of other antibodies with different antigenic specificities than the isolated antibody.
  • a preparation of an antibody described herein is substantially free of cellular material and/or chemical precursors.
  • the language "substantially free of cellular material” includes preparations of an antibody in which the antibody is separated from cellular components of the cells from which it is isolated or recombinantly produced.
  • an antibody that is substantially free of cellular material includes preparations of antibody having less than about 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein”) and/or variants of an antibody, for example, different post-translational modified forms of an antibody.
  • the polypeptide e.g., antibody described herein
  • culture medium represents less than about 20%, 10%, 2%, 1%, 0.5%, or 0.1% of the volume of the protein preparation.
  • the polypeptide e.g., antibody described herein
  • such preparations of the polypeptide have less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.
  • compositions comprising the antibodies or antigen-binding fragments thereof described herein (e.g., PC68-L31_43J) are also provided. Further provided herein are compositions comprising a polynucleotide or polynucleotides encoding the antibodies or antigen-binding fragments thereof described herein.
  • the polynucleotide comprises mRNA.
  • the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.
  • the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil ( ⁇ ), N1-methylpseudouracil (m1 ⁇ ), 1-ethylpseudouracil, 2-thiouracil, 4′-thiouracil, 5-methylcytosine, 5-methyluracil, 5- methoxyuracil, and any combination thereof.
  • the composition is a pharmaceutical composition.
  • the antibody comprises PC68-L31_43J.
  • the composition is a lyophilized composition.
  • the composition is formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration.
  • a pharmaceutical composition comprising an antibody described herein (e.g., PC68-L31_43J) and a pharmaceutically acceptable excipient.
  • the antibody is an intact antibody.
  • the antibody is an antigen- binding antibody fragment.
  • the composition is formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration.
  • the antibody comprises PC68-L31_43J.
  • the disclosure provides a pharmaceutical composition comprising an antibody described herein (e.g., PC68-L31_43J). Such compositions are intended for prevention and treatment of HIV infection.
  • the antibody comprises PC68-L31_43J.
  • a composition comprising the antibody described herein can additionally be combined with other compositions for the treatment of HIV infection or the prevention of HIV transmission.
  • an antibody described herein may be administered within a pharmaceutically acceptable diluent, carrier, or excipient, in unit dose form.
  • Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer to individuals being treated for HIV infection.
  • the administration is prophylactic. Any appropriate route of administration may be employed, for example, administration may be parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal, intranasal, aerosol, suppository, oral administration, vaginal, or anal.
  • compositions described herein are prepared in a manner known per se, for example, by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see for example, in Remington: The Science and Practice of Pharmacy (21st ed.), ed. A.R. Gennaro, 2005, Lippincott Williams & Wilkins, Philadelphia, PA, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 2013, Marcel Dekker, New York, NY).
  • the injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
  • compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, tablets, pills, or capsules.
  • the formulations can be administered to human individuals in therapeutically or prophylactic effective amounts (e.g., amounts which prevent, eliminate, or reduce a pathological condition) to provide therapy for a disease or condition.
  • the preferred dosage of therapeutic agent to be administered is likely to depend on such variables as the type and extent of the disorder, the overall health status of the particular patient, the formulation of the compound excipients, and its route of administration.
  • the compositions described herein can be formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration.
  • the composition may be formulated as a gel, or formulated as a topical cream, ointment, lotion or foam formulation.
  • Useful formulations are known in the art, for example, as disclosed in U.S. Patent Appl. Pub. No. 20130022619, which is incorporated by reference herein in its entirety for all purposes.
  • the composition may further comprise a pharmaceutically acceptable excipient, a lubricant, or an antiviral agent.
  • the topical formulations of the present invention can be used to prevent HIV infection in a human, or to inhibit transmission of the HIV virus from an infected human to another human.
  • the topical formulations of the present invention can inhibit the growth or replication of HIV.
  • the topical formulations are useful in the prophylactic treatment of humans who are at risk for HIV infection.
  • the topical formulations also can be used to treat objects or materials, such as contraceptive devices (for example condoms or intrauterine devices), medical equipment, supplies, or fluids, including biological fluids, such as blood, blood products, and tissues, to prevent or inhibit viral infection of a human.
  • contraceptive devices for example condoms or intrauterine devices
  • Such topical formulations also are useful to prevent transmission, such as sexual transmission of viral infections, e.g., HIV, which is the primary way in which HIV is transmitted globally.
  • the methods of prevention or inhibition or retardation of transmission of viral infection comprise vaginal, rectal, penile or other topical treatment with an antiviral effective amount of a topical preparation of the present invention, alone or in combination with another antiviral compound as described herein.
  • the composition is in the form of a cream, lotion, gel, or foam that is applied to the affected skin or epithelial cavity, and preferably spread over the entire skin or epithelial surface which is at risk of contact with bodily fluids.
  • Such formulations which are suitable for vaginal or rectal administration, may be present as aqueous or oily suspensions, solutions or emulsions (liquid formulations) containing in addition to the active ingredient, such carriers as are known in the art to be appropriate. These formulations are useful to protect not only against sexual transmission of HIV, but also to prevent infection of a baby during passage through the birth canal. Thus the vaginal administration can take place prior to sexual intercourse, during sexual intercourse, and immediately prior to childbirth.
  • the active ingredient may be used in conjunction with a spermicide and may be employed with a condom, diaphragm, sponge or other contraceptive device.
  • spermicides include nonylphenoxypolyoxyethylene glycol (nonoxynol 9), benzethonium chloride, and chlorindanol.
  • the pH of the composition is 4.5 to 8.5.
  • Vaginal compositions preferably have a pH of 4.5 to 6, most preferably about 5.
  • Vaginal formulations include suppositories (for example, gel-covered creams), tablets and films. The suppositories can be administered by insertion with an applicator using methods well- known in the art. Vaginal formulations further include vaginal ring devices formulated for sustained release. See, e.g., Morrow et al., Eur J Pharm Biopharm.
  • compositions used in this invention may also contain a lubricant that facilitates application of the composition to the desired areas of skin and epithelial tissue, and reduces friction during sexual intercourse.
  • a lubricant that facilitates application of the composition to the desired areas of skin and epithelial tissue, and reduces friction during sexual intercourse.
  • the lubricant can be applied to the exterior of the dosage form to facilitate insertion.
  • the topical formulation comprises one or more lubricants.
  • the gels and foams of the present invention optionally can include one or more lubricants.
  • the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of an antibody described herein (e.g., PC68-L31_54Q). In some embodiments, the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV.
  • an antibody e.g., a bispecific antibody
  • the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method of inhibiting transmission of
  • the method comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein.
  • the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV. In some embodiments, the subject at risk of being exposed to HIV is a health care worker, a sexual partner of an HIV infected individual, or a sex worker. In some embodiments, the subject that has been exposed to HIV or is at risk of being exposed to HIV is a newborn.
  • an antibody e.g., PC68-L31_54Q
  • a pharmaceutical composition e.g., an isolated polynucleotide, or a recombinant virus for reducing the risk of a subject becoming infected with HIV.
  • the antibody is PC68-L31_54Q.
  • a method for passively immunizing a subject comprising administering to the subject in need thereof an effective amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein.
  • the method comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein.
  • the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV. In some embodiments, the subject at risk of being exposed to HIV is a health care worker, a sexual partner of an HIV infected individual, or a sex worker. In some embodiments, the subject that has been exposed to HIV or is at risk of being exposed to HIV is a newborn.
  • an antibody e.g., PC68-L31_43J
  • a pharmaceutical composition e.g., an isolated polynucleotide, or a recombinant virus for passively immunizing a subject.
  • the antibody is PC68-L31_43J.
  • a method of neutralizing an HIV virus comprising contacting the virus with an effective amount of an antibody described herein (e.g., PC68-L31_43J).
  • the virus is comprised by a composition, for example, a fluid, including a biological fluid, such as blood or blood product.
  • the method comprises adding an antibody described herein to a composition comprising HIV in a sufficient amount or concentration to neutralize the HIV.
  • the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein.
  • the antibody is PC68- L31_43J.
  • the antibody can be a chimeric antibody, engineered antibody, recombinant antibody, or a monoclonal antibody described herein.
  • the antibody is a full antibody, a Fab fragment, or an F(ab') 2 fragment described herein.
  • the antibody is an engineered monoclonal antibody described herein.
  • the antibody is a recombinant monoclonal antibody described herein. In a specific embodiment, the antibody is a chimeric monoclonal antibody described herein. In a specific embodiment, the antibody is a Fab described herein. In a specific embodiment, the antibody is an F(ab') 2 fragment described herein.
  • a method of preventing HIV infection provided herein comprises administering to a subject in need thereof a therapeutically sufficient amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, the antibody is PC68-L31_43J.
  • a method of treating HIV/AIDS provided herein comprises administering to a subject in need thereof a therapeutically sufficient amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein.
  • a method of treating HIV/AIDS comprises administering an antibody described herein.
  • a method of treating HIV/AIDS comprises administering a pharmaceutical composition described herein.
  • a method of treating HIV/AIDS comprises administering an isolated polynucleotide described herein.
  • a method of treating HIV/AIDS comprises administering a recombinant virus described herein.
  • an antibody described herein is used to reduce the likelihood of vaginal or rectal acquisition of HIV.
  • further administration of ART and/or an immunomodulator and/or a second antibody is contemplated.
  • the ART and/or immunomodulator and/or a second antibody can be administered in conjunction with, prior to, concurrently with, subsequent to, or within the context of a treatment regimen that includes administration of an antibody described herein.
  • An antibody described herein, or a pharmaceutical composition described herein can be delivered to a subject by a variety of routes, such as oral, parenteral, subcutaneous, intravenous, intradermal, transdermal, intranasal, vaginal, or anal.
  • the antibody or pharmaceutical composition is administered intravenously, vaginally, or anally.
  • the amount of an antibody described herein, or a pharmaceutical composition described herein, which will be effective in the treatment and/or prevention of a condition will depend on the nature of the disease, and can be determined by standard clinical techniques.
  • the precise dose to be employed in a pharmaceutical composition will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each subject's circumstances.
  • effective doses may also vary depending upon means of administration, target site, physiological state of the patient (including age, body weight and health), whether the patient is human or an animal, other medications administered, or whether treatment is prophylactic or therapeutic.
  • the patient is a human, but non-human mammals including transgenic mammals can also be treated.
  • Treatment dosages are optimally titrated to optimize safety and efficacy.
  • an in vitro assay is employed to help identify optimal dosage ranges. Effective doses may be extrapolated from dose response curves derived from in vitro or animal model test systems. Detection & Diagnostic Uses
  • An antibody described herein can be used to detect HIV and/or assay HIV levels in a biological sample using classical immunohistological methods known to those of skill in the art, including immunoassays, such as the enzyme linked immunosorbent assay (ELISA), immunoprecipitation, or Western blotting.
  • ELISA enzyme linked immunosorbent assay
  • an antibody described herein can also be used as an imaging agent, for example, a tissue-penetrating imaging agent.
  • an antibody described herein is conjugated with a detectable label.
  • Suitable assay labels include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( 125 I, 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 121 In), and technetium ( 99 Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.
  • enzyme labels such as, glucose oxidase
  • radioisotopes such as iodine ( 125 I, 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 121 In), and technetium ( 99 Tc)
  • luminescent labels such as luminol
  • fluorescent labels such as fluorescein and rho
  • a second antibody that recognizes an antibody described herein can be labeled and used in combination with the antibody described herein to detect HIV levels.
  • biological sample refers to any biological sample obtained from a subject, cell line, tissue, or other source potentially comprising HIV. Methods for obtaining tissue biopsies and body fluids from animals (e.g., humans) are well-known in the art.
  • an antibody described herein can be used to detect levels of HIV, which levels can then be linked to certain disease symptoms.
  • An antibody described herein may carry a detectable or functional label.
  • An antibody described herein can carry a fluorescence label.
  • Exemplary fluorescence labels include, for example, reactive and conjugated probes, e.g., Aminocoumarin, Fluorescein and Texas red, Alexa Fluor dyes, Cy dyes and DyLight dyes.
  • An antibody described herein can carry a radioactive label, such as the isotopes 3 H, 14 C, 32 P, 35 S, 36 Cl, 51 Cr, 57 Co, 58 Co, 59 Fe, 67 Cu, 90 Y, 99 Tc, 111 In, 117 Lu, 121 I, 124 I, 125 I, 131 I, 198 Au, 211 At, 213 Bi, 225 Ac and 186 Re.
  • radioactive labels When radioactive labels are used, currently available counting procedures known in the art may be utilized to identify and quantitate the specific binding of an antibody described herein to HIV.
  • detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques as known in the art. This can be achieved by contacting a sample or a control sample with an antibody described herein under conditions that allow for the formation of a complex between the antibody and HIV. Any complexes formed between the antibody and HIV are detected and compared in the sample and the control.
  • An antibody described herein can also be used to purify HIV via immunoaffinity purification.
  • provided herein are methods for in vitro detecting HIV in a sample, comprising contacting said sample with an antibody described herein.
  • the use of an antibody described herein, for in vitro detecting HIV in a sample comprising contacting said sample with an antibody described herein.
  • provided herein is the use of an antibody described herein, for in vitro detecting HIV in a sample.
  • an antibody or pharmaceutical composition described herein for use in the detection of HIV in a subject.
  • the antibody comprises a detectable label.
  • the subject is a human.
  • the method of detecting HIV in a sample comprises contacting the sample with an antibody described herein.
  • the present disclosure provides methods of purifying HIV from a sample.
  • the method of purifying HIV from a sample comprises contacting the sample with an antibody described herein under conditions that allow the antibody to bind to HIV.
  • the antibody comprises a tag, for example, hexa-histidine tag or FLAG-tag to facilitate the purification of HIV.
  • Kits Provided herein are kits comprising one or more antibodies described herein (e.g., PC68- L31_54Q).
  • a pharmaceutical pack or kit described herein comprises one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein, such as one or more antibodies described herein.
  • a kit contains an antibody described herein or a pharmaceutical composition described herein, and a second prophylactic or therapeutic agent used in the treatment or prevention of HIV.
  • the second agent is an antiretroviral agent.
  • the second agent is a reservoir activator.
  • the second agent is an immunomodulator.
  • the second agent is one or more anti-HIV antibody.
  • the second agent is one or more anti-HIV Env antibody that binds to an HIV Env epitope region different from the HIV Env epitope region bound by an antibody described herein (e.g., PC68- L31_54Q).
  • the second agent is one or more anti-HIV Env antibody that binds to the CD4 (receptor) binding site (CD4bs), the V2 apex, N332 glycan site, gp120-gp41 interface, fusion peptide (FP), silent face, and the membrane proximal external region (MPER).
  • the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, silent face, gp120-gp41 interface or membrane-proximal external region (MPER).
  • a kit contains an antibody described herein or a pharmaceutical composition described herein, and a reagent used in the detection of HIV.
  • the detection reagent comprises DNA primers for the detection of HIV.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the antibody comprises PC68-L31_54Q.
  • a kit described herein comprises an antibody described herein or a pharmaceutical composition described herein and a) a detection reagent, b) an HIV antigen, c) a notice that reflects approval for use or sale for human administration, or d) any combination thereof.
  • Embodiments of the present disclosure can be further defined by reference to the following non-limiting examples, which describe in detail preparation of certain antibodies of the present disclosure and methods for using antibodies of the present disclosure. It will be apparent to those skilled in the art that many modifications, both to materials and methods, can be practiced without departing from the scope of the present disclosure. All documents, patent, and patent applications cited herein are hereby incorporated by reference, and may be employed in the practice described herein. EXAMPLES Example 1.
  • lineage 31 (L31), the most populated lineage with 58 mAbs, was the most broad and potent.
  • Figure 1 Many members neutralized all viruses on the indicator panel with a geometric mean IC 50 of 0.093 ⁇ g/mL. The degree of nucleotide mutations among members in the various lineages were directly associated with pseudovirus neutralization breath and potency.
  • a key characteristic feature of most HIV bnAbs is a high level of somatic hypermutation (SHM), with heavy chain V-region SHM ranging from ⁇ 6-25%.
  • SHM somatic hypermutation
  • L31 antibodies were some of the most mutated of all isolated mAbs, being 17.7%-28.3% mutated from the IGHV3-30 germline gene and 11.5%-22.6% from the IGLV3-21 germline gene.
  • Figure 2. These antibodies have an average human heavy chain complementarity determining region 3 (HCDR3) length of 15 amino acid, in contrast to bnAbs whose neutralization is mediated primarily by glycan recognition via a long HCDR3.
  • HCDR3 human heavy chain complementarity determining region 3
  • all members of lineage 31 monoclonal antibodies featured an acidic 5 amino acid insertion (Figure 2), suggesting a key role by this motif in epitope recognition.
  • PC68-L31_54Q was the best neutralizer with a geometric mean IC 50 of 0.076 ⁇ g/mL and 79% breadth on a 118 multiclade pseudovirus panel (Table 4 and Figure 5).
  • lineage 31 antibodies have features pronounced of other known bnAbs such as large insertions and extensive SHM and are likely a major contributor to Donor 68’s serum neutralization activity.
  • Table 4 Neutralization of 118 multiclade pseudovirus panel.
  • VRCO1 and N6 are positive control antibodies.
  • Den3 is a negative control antibody.
  • N eutralization IC50 (ug/mL) Lineage 31 + - 3 HIV-16845-2.22 C N/D N/D N/D >20 C e1086_B2 C (T/F) 0.013 0.029 >20 0.008 >20 R1166.c01 CRF01_AE 0.132 0.126 0.394 0.089 >20 R 3265.c06 CRF01_AE >20 >20 >20 1.705 >20 235-47 CRF02_AG 0.006 0.026 0.021 0.009 >20 R HPA4259.7 B 0.004 0.053 0.018 0.009 >20 Example 2.
  • HCDRs 1 and 3 facilitated contacts with the main gp120 protomer near the CD4bs, with HCDR3 interacting with several conserved residues within and near the CD4 binding loop. Many of these interactions were side chain mediated.
  • HCDR3 other than the E370 gp120 side chain interaction with the indole amine of W100 HC , a substantial number of hydrogen bonding contacts were made by backbone contacts, such as interactions between F96 HC : D368 gp120 , T98 HC : D368 gp120 side chain, and potentially Y99 HC side chain : R429 gp120 .
  • HCDR1 resides S25 HC and N31 HC seemed to interact with the backbone carbonyls of A281 gp120 and Q428 gp120 respectively.
  • the recognition of the adjacent gp120 (gp120adj) was driven by the 5 AA insertion in the HCDR2 which extends the HCDR2 loop to mediate an extensive network of interactions with the positively charged region at the base of the V3 loop of the adjacent protomer.
  • E53 HC and D54 HC each form salt bridges with R308 gp120adj (35.9% R, 37.1% H) and R304 gp120adj (94.7% conserved) at the base of V3, and D55 HC with K207 gp120adj of a quaternary CD4bs region recently described as CD4bs2 (99.3% conserved).
  • Backbone mediated hydrogen bonding interactions were also observed, including between H52f HC and the backbone carbonyl of G314 gp120adj , and D54 HC backbone amine group with the Y318 gp120 adj.
  • I52e HC side chain further bolsters the interaction by filling the pocket formed between the CD4bs2 and the C-terminus of the a1 helix.
  • the paratope interaction with electropositive residues at the gp120 interprotomer region were reminiscent of the mode of quaternary epitope recognition by several VRC01 antibodies with acidic heavy chain framework region 3 (HFWR3) insertions, including 3BNC117, VRC03, VRC06, antibodies in which these quaternary contacts are not required for binding to the CD4bs but essential for neutralization.
  • HFWR3 acidic heavy chain framework region 3
  • Antibodies such as VRC01 that avoids proximal glycans demonstrate improved neutralization in viruses expressing fully high-mannose glycans.
  • the L31 epitope is heavily surrounded by glycans such as N363, N386, N197, and potentially N301, N276 along with additional glycans in V5 and V2 that are unresolved in our EM reconstruction.
  • the LCDR loops come in close contact with these glycans; LCDR1 is positioned up against N363, and LCDR2 and LCDR3 are both in close proximity to N197 and V2.
  • VRC01 was unable to protect against acquisition of HIV infection when given as a monotherapy.
  • a high potency IC 80 threshold of less than 1 ⁇ g/mL is necessary for protection for a given virus.
  • a cocktail of bnAbs with high neutralization potencies that in concert can complement neutralization of single bnAb resistant viruses would be required for protective efficacy.
  • PC68_L31 mAbs bound the CD4bs in a different manner than VRC01-class bnAbs, the question whether known VRC01-class antibody resistant mutations also influenced sensitivity to L31 mAbs was investigated.
  • clade B coverage was lower for both lineage 31 mAbs, with 73% breadth for PC68-L31_54Q with PC68-L31_43J more adversely impacted with only 20% coverage of clade B.
  • resistance of the clade B AMP viruses to PC68-L31_54Q may be mediated by lack of conservation of proton donor side chains at residue 308.
  • Resistant viruses contained bulky or uncharged residues such as proline, threonine, and serine that could break the salt bridges formed by the extended anionic HCDR2 loop.
  • PC68-L31_54Q neutralizes both clades B and C more broadly and potently at concentrations below 1 ⁇ g/mL which was shown to be more relevant in vivo. Because of their breath and potency, lineage 31 mAbs are suitable as prophylactics in combination with other bnAbs.
  • Recombinant Trimer Production and Purification BG505 SOSIP.664-Avi gp140 and BG505 gp120 were expressed in FreeStyle 293F cells (ThermoFisher) as described previously (Walker et al. 2011) Supernatants were purified by affinity chromatography using a PGT145 column.
  • Pseudovirus Env plasmid was co-transfected with env-deficient backbone plasmid (pSG3 ⁇ Env) in a 1:2 ratio with transfection reagent Fugene in HEK293T cells. Pseudoviruses were harvested after 72 hours by spinning down cell culture supernatants and stored at ⁇ 80°C. Serially diluted monoclonal antibodies were incubated with equal volume of pseudovirus at 37°C for 1 hour and then transferred onto TZM-bl cells seeded into half-area 96-well plates.
  • NEB Q5 High Fidelity Site-Directed Mutagenesis kit
  • BG505 SOSIP and gp120 were added at 1 ⁇ g/mL in 1% BSA for 1h.
  • Antibody samples were diluted to 50 ug/mL in 1% BSA with 5-fold serial dilution. Serially diluted samples were then added in plates and incubated for 1 h at RT. After washing, alkaline phosphatase-conjugated goat anti- human IgG Fcy secondary antibody (Jackson ImmunoResearch, 109-055-008) was added in 1:1000 dilution and incubated for 1h at RT. After final wash, phosphatase substrate (Sigma-Aldrich, S0942-200TAB) was added into each well.
  • EC50 50% maximal binding
  • Biolayer interferometry 100 nm of BG505 SOSIP or gp120 were captured using streptavidin biosensors or anti-penta-HIS biosensors (18-5120, Molecular Devices). After antigen loading for 5 min, a saturating concentration of mAbs at 100 ⁇ g/mL was added for 6 minutes. Competitor mAbs were added at a concentration of 25 ⁇ g/mL for 5 min to measure binding in the presence of saturating antibodies.
  • VGSYGMYWF SEQ ID NO: 54 PC68-L31_54P VH CDR1 VGSYGMYWF SEQ ID NO: 55 PC68-L31_54Q VH CDR1 VASYGMYWF SEQ ID NO: 56 PC68-L31_54R VH CDR1 VGSYGMYWF SEQ ID NO: 57 PC68-L31_54S VH CDR1 VGSYGMYWF SEQ ID NO: 58 PC68-L31_59A VH CDR1 VSNHGMYWF SEQ ID NO: 59 PC68-L31_59B VH CDR1 VSNHGMYWF SEQ ID NO: 60 PC68-L31_59C VH CDR1 VSNHGMYWF SEQ ID NO: 61 PC68-L31_59D VH CDR1 VSNHGMYWF SEQ ID NO: 62 PC68-L31_59E VH CDR1 VANYGMYWF SEQ ID NO: 63 PC68

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to anti-HIV antibodies and their use in the treatment or prevention of HIV/AIDS and in the development of HIV vaccines.

Description

Human neutralizing antibodies against HIV Env GOVERNMENT INTEREST [0001] The invention was made with government support under Cooperative Agreement No. AID- OAA-A-16-00032 awarded by the U.S. Agency for International Development (USAID) and under Grant No. UM1AI144462 awarded by the NIH/NIAID CHAVD. The U.S. government has certain rights in the invention. FIELD OF THE INVENTION [0002] The field of the invention generally relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. CROSS-REFRENCE TO RELATED APPLICATIONS [0003] This application claims the benefit of U.S. application no. 63/535,669, filed August 31, 2023, which is incorporated herein by reference in its entirety. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY [0004] The content of the electronically submitted sequence listing (Name: 6765_1401_Sequence Listing.xml, Size: 1,074,254 bytes, and Date of Creation: August 28, 2024) is herein incorporated by reference in its entirety. BACKGROUND [0005] A successful HIV vaccine candidate should elicit broadly neutralizing antibodies (bnAbs) against the HIV envelope (Env) viral spike protein. Env is not particularly immunogenic due to shielding of conserved regions by N-linked glycans, and exposed epitopes vary widely in viral diversity. Burton et al., Nature Immunology 2015, 16 (6), 571. Therefore, HIV bnAbs that recognize vulnerable neutralizing epitopes on diverse Envs only naturally occur in a fraction of individuals, (Burton et al., Annu Rev Immunol 2016, 34, 635) but it has been demonstrated that sterilizing antibody responses play a key role in preventing viral acquisition in animal models. Pegu et al., Immunological Reviews 2017, 275 (1), 296. Previously identified bnAbs predominantly target 7 main conserved neutralizing epitopes on Env termed, the CD4 (receptor) binding site (CD4bs), the V2 apex, N332 glycan site, gp120-gp41 interface, fusion peptide (FP), silent face, and the membrane proximal external region (MPER). Sok et al., Nature Immunology 2018, 19 (11), 1179. Soluble recombinant Env trimers with stabilized native-like conformations display neutralizing epitopes while occluding non-neutralizing epitopes, and are excellent tools to selectively isolate neutralizing antibodies from donors. Sanders et al., PLOS Pathogens 2013, 9 (9), e1003618; Binley et al., Journal of Virology 2000, 74 (2), 627; and Sanders et al., Immunological Reviews 2017, 275 (1), 161. Using such molecular tools, the repertoire of known bnAbs has expanded in the last decade , aiding in advancing HIV vaccine design as well as the development of HIV antibody therapeutics. van Gils et al., Virology 2013, 435 (1), 46; Steichen et al., Science 2019, 366 (6470); and Pegu et al., Immunological Reviews 2017, 275 (1), 296. [0006] Because the CD4bs functions to mediate viral entry into host cells (Gallo et al., Biochimica et Biophysica Acta (BBA) - Biomembranes 2003, 1614 (1), 36), this region must be conserved and can only mutate at the cost of viral fitness (Dingens et al., Immunity 2019, 50 (2), 520). CD4bs directed bnAbs mimic and block the interaction between CD4 and the CD4bs (Wu et al., Science 2010, 329 (5993), 856) and tend to have broader coverage than bnAbs to other neutralizing epitopes (Sok et al., Nature Immunology 2018, 19 (11), 1179). However, CD4bs bnAbs tend to be highly mutated and take longer to develop within an individual, because antibodies of this class evolve to accommodate or avoid shielding glycans to increase neutralization breadth. Umotoy et al., Immunity 2019, 51 (1), 141; Crooks et al., PLOS Pathogens 2015, 11 (5), e1004932. Additionally, variable loops 1, 2 and 5 (V1, V2, V5) can restrict access to this epitope as well and rapid sequence alteration of these loops under immune pressure such as increasing N-linked glycosylation sites (PNGS), can lead to virus escape. Julien et al., Science 2013, 342 (6165), 1477; Doria-Rose et al., Journal of Virology 2012, 86 (15), 8319; LaBranche et al., PLOS Pathogens 2018, 14 (11), e1007431. [0007] A key goal in HIV vaccine design is to elicit broadly neutralizing antibodies (bnAbs). Burton & Hangartner, Annu Rev Immunol 34, 635-659 (2016). Most bnAbs to HIV-1 have been cloned from elite donors whose plasma shows broad neutralizing activity. These bnAbs target 7 distinct sites on the HIV-1 envelope glycoprotein (Env) spike, including the CD4-binding site (CD4bs), V2 apex, N332/V3 base supersite (also referred to as high-mannose patch epitope), silent face, gp120-gp41 interface, fusion peptide, and membrane-proximal external region (MPER). As bnAbs arise from complex affinity maturation pathways, efforts are underway to dissect the structural and genetic bases of bnAb function to uncover common elements that can simplify vaccine design. Kwong & Mascola, Immunity 48, 855-871 (2018). [0008] Given the absence of an effective vaccine for protection against HIV-1 infection, passive immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block acquisition of HIV-1 are being rigorously pursued in the clinical setting. Walsh & Seaman, Front Immunol.2021; 12: 712122. bnAbs have demonstrated robust protection in preclinical animal models, and several leading bnAb candidates have shown favorable safety and pharmacokinetic profiles when tested individually or in combinations in early phase human clinical trials. However, the currently available bnAbs fail to neutralize all circulating HIV strains. [0009] Thus, there remains a need for the development of neutralizing antibodies that can be used in the treatment or prevention of HIV/AIDS. BRIEF SUMMARY [0010] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with VRC01 for binding to the HIV Env trimer, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env. [0011] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof which binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. [0012] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof which binds to the same epitope of an HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. [0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively; and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262), (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263), and (c) a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). [0014] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the VH CDR1 of an antibody described herein (e.g., PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I) comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, (b) the VH CDR2 comprises the VH CDR2 of an antibody described herein comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, (c) the VH CDR3 comprises the VH CDR3 of an antibody described herein comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, (d) the VL CDR1 comprises the VL CDR1 of an antibody described herein comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, (e) the VL CDR2 comprises the VL CDR2 of an antibody described herein comprising 0, 1, or 2 substitutions, insertions, or deletions, and/or (f) the VL CDR3 comprises the VL CDR3 of an antibody described herein comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, the antibody comprises the PC68- L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. [0015] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH and/or the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL. In some embodiments, the antibody comprises the PC68- L31_54Q VH and VL. [0016] In one aspect, provided herein are pharmaceutical compositions comprising a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein. [0017] In one aspect, provided herein are isolated polynucleotides (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein. [0018] In one aspect, provided herein are methods of producing a monoclonal antibody or antigen- binding fragment thereof described herein. [0019] In one aspect, provided herein are methods of neutralizing an HIV virus, comprising contacting the virus with a monoclonal antibody or antigen-binding fragment thereof described herein. [0020] In one aspect, provided herein are methods of reducing the likelihood of HIV infection in a subject exposed to HIV comprising administering to the subject a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein. [0021] In one aspect, provided herein are methods of treating HIV/AIDS comprising administering to a subject in need thereof a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein. [0022] In one aspect, provided herein are methods of reducing viral load comprising administering to a subject in need thereof a monoclonal antibody or antigen-binding fragment thereof described herein or a polynucleotide (e.g., mRNA) encoding a monoclonal antibody or antigen-binding fragment thereof described herein. [0023] In one aspect, provided herein are methods of producing an engineered variant of a monoclonal antibody or antigen-binding fragment thereof described herein. BRIEF DESCRIPTION OF THE DRAWINGS [0024] Figure 1. PC68 bnAb Lineage 31 characterization. Confirmation of neutralization breadth and potency. [0025] Figure 2. PC68-L31 bnAb lineage (lineage #31) shows bnAb activity, high SHM and a defining CDRH2 insertion feature. [0026] Figure 3. PC68-L31 targets an epitope that is distinct but overlaps with previously reported CD4bs bnAbs. Competition BLI of PC68 mAbs with other bnAbs of known epitopes. VRC01: CD4bs, PGT121: N332 glycan, PGT145: V2 apex, PGT151: gp120gp-41 interface. [0027] Figure 4. PC68-L31 targets an epitope that is distinct but overlaps with previously reported CD4bs bnAbs. [0028] Figure 5. PC68-L31 bnAbs neutralization breadth and potency are similar to VRC01 on Seaman Panel. Breadth as a function of neutralization potency on a large 118 pseudovirus panel shown. [0029] Figure 6. PC68-L31 bnAbs do not depend on glycans. Fold change in neutralization following single point mutation. DETAILED DESCRIPTION [0030] Provided herein is a lineage of highly broad and potent antibodies derived from Protocol C donor 68 that bind a quaternary CD4bs epitope that extends to the V3 region of the adjacent protomer. These antibodies are reminiscent of CD4bs antibodies with FWR3 insertions in combination with V3 specific antibodies and can bind both the conserved CD4bs region with their heavy chains and the conserved base of the V3 region on the adjacent protomer with their light chains. Although the CD4bs and V3 region tend to be heavily shielded by glycans, these antibodies completely avoid contact with the glycans that shield these regions. Because of their breath and potency, lineage 31 mAbs are suitable for use as prophylactics or therapeutics alone or in combination with other bnAbs. I. Definitions [0031] To facilitate an understanding of the present invention, a number of terms and phrases are defined below. [0032] The terms "human immunodeficiency virus" or "HIV," as used herein, refer generally to a retrovirus that is the causative agent for acquired immunodeficiency syndrome (AIDS), variants thereof (e.g., simian acquired immunodeficiency syndrome, SAIDS), and diseases, conditions, or opportunistic infections associated with AIDS or its variants, and includes HIV-Type 1 (HIV-1) and HIV-Type 2 (HIV-2) of any clade or strain therein, related retroviruses (e.g., simian immunodeficiency virus (SIV)), and variants thereof (e.g., engineered retroviruses, e.g., chimeric HIV viruses, e.g., simian-human immunodeficiency viruses (SHIVs)). In some embodiments, an HIV virus is an HIV-Type-1 virus. Previous names for HIV include human T-lymphotropic virus- III (HTLV-III), lymphadenopathy-associated virus (LAV), and AIDS-associated retrovirus (ARV). [0033] As used herein, the term "clade" refers to related human immunodeficiency viruses (HIVs) classified according to their degree of genetic similarity. There are currently four known groups of HIV-1 isolates: M, N, O, and P. Group M (major strains) viruses are responsible for the majority of the global HIV epidemic. The other three groups, i.e., N, O and P are quite uncommon and only occur in Cameroon, Gabon and Equatorial Guinea. In some embodiments, an HIV virus is a Group M HIV virus. Within group M, there are known to be at least nine genetically distinct subtypes or clades of HIV-1: subtypes or clades A, B, C, D, F, G, H, J and K. Additionally, different subtypes can combine genetic material to form a hybrid virus, known as a 'circulating recombinant form' (CRFs). Subtype/clade B is the dominant HIV subtype in the Americas, Western Europe and Australasia. Subtype/clade C is very common in the high AIDS prevalence countries of Southern Africa, as well as in the horn of Africa and India. Just under half of all people living with HIV have subtype C. In certain exemplary embodiments, methods described herein can be used to treat a subject (e.g., a human) infected with HIV (e.g., HIV-1) or to block or prevent HIV (e.g., HIV-1) infection in subject (e.g., a human) at risk of HIV transmission. The HIV may be of two, three, four, five, six, seven, eight, nine, ten, or more clades and/or two or more groups of HIV. [0034] Acquired immune deficiency syndrome ("AIDS") is a disease caused by the human immunodeficiency virus, or HIV. [0035] As used herein, the term "envelope glycoprotein" or "Env" refers to the glycoprotein that is expressed on the surface of the envelope of HIV virions and the surface of the plasma membrane of HIV infected cells. "Envelope glycoprotein" or "Env" encompass, but are not limited to, native Env, an isoform of Env, or a variant of Env (e.g., well-ordered trimer variant) derived from an HIV isolate, for example, BG505. In some embodiments, Env is a MD-39 variant Env (Steichen et al, 2016), repaired and stabilized (RnS) variant Env (Rutten et al, 2018), DS variant Env (Kwon et al, 2015), NFL-TD variant Env (Guenaga et al, 2016), or DS-BG505-chimera variant Env (Joyce et al, 2018). Env is the sole virally encoded gene product on the surface of the virus and, as such, is the only target of neutralizing antibodies. Env is a trimer of heterodimers composed of two non- covalently associated subunits: the receptor-binding gp120 and the gp41 containing the fusion machinery. Each subunit is derived from a gp160 precursor glycoprotein following cleavage by cellular furins. HIV-1 gp120 binds the CD4 molecule on the surface of human target T cells to initiate the viral entry process, and following co-receptor engagement, fusion is mediated by gp41. The gp41 domain comprises the fusion peptide, fusion peptide proximal region, heptad repeats 1 and 2 (HR1, HR2), the membrane proximal external region (MPER), the transmembrane domain (TM) and the cytoplasmic tail (CT). gp140 env is the uncleaved ectodomain of gp160. [0036] The term "well-ordered Env trimer" or "well-ordered trimer" as used herein refers to an envelope glycoprotein trimer comprising three cleaved gp140 polypeptides that closely mimic the quaternary structure of the Env ectodomain on the surface of the envelope of HIV or SIV virions and the surface of the plasma membrane of HIV or SIV infected cells. In some embodiments, the gp120 and gp41 ectodomain is linked by a covalent linkage, for example, a disulfide bond. In some embodiments, the gp140 polypeptide comprises one or more mutations to promote trimer formation. In some embodiments, the gp140 polypeptide comprises one or more Cys substitutions to promote disulfide formation. In some embodiments, the well-ordered trimer is a SOSIP gp140 trimer. Well-ordered SOSIP trimers have been disclosed in US Patent Appl. Pub. No. 2014/0212458, and Sanders, R. W. et al., PLoS Pathog. 9, e1003618 (2013), each of which is incorporated by reference herein in its entirety. In some embodiments, the well-ordered trimer is a MD-39 trimer (Steichen et al, 2016), repaired and stabilized (RnS) trimer (Rutten et al, 2018), DS trimer (Kwon et al, 2015), NFL-TD trimer (Guenaga et al, 2016), or DS-BG505-chimera trimer (Joyce et al, 2018). In some embodiments, a well-ordered trimer is formed from a clade A Env. In some embodiments, a well-ordered trimer is formed from a clade B Env. In some embodiments, a well-ordered trimer is formed from a clade C Env. In some embodiments, a well-ordered trimer is formed from a circulating recombinant form Env, wherein 'circulating recombinant form' (CRF) refers to a hybrid virus comprising a combination of genetic material from different subtypes. In some embodiments, a well-ordered Env trimer is a native flexibly linked (NFL) trimer as described in Sharna, et al., Cell Reports, 11(4):539-50 (2015). In one embodiment, a well ordered trimer is BG505 SOSIP. In one embodiment, a well ordered trimer is BG505 SOSIP.664. In one embodiment, BG505 SOSIP.664 comprises the amino acid sequence of SEQ ID NO: 1270. In one embodiment, a nascent BG505 SOSIP.664 further comprises a leader sequence, wherein the nascent BG505 SOSIP.664 comprises the amino acid sequence of SEQ ID NO: 1271. In some embodiments, a well-ordered Env trimer is a DS-SOSIP as described in Chuang GY, et al., J. Virology, 91(10). pii: e02268-16 (2017). In some embodiments, a well-ordered trimer is formed from an SIV Env. In some embodiments, a well-ordered trimer is an SIV Env SOSIP. In some embodiments, the gp120 and gp41 ectodomain is linked by a peptide linker, for example, a Gly- Ser linker, as described in Georgiev IS, et al., J. Virology 89(10): 5318-5329 (2015). In some embodiments, the well-ordered Env trimer is stable. [0037] The term "antibody" means an immunoglobulin molecule (or a group of immunoglobulin molecules) that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the terms "antibody" and "antibodies" are terms of art and can be used interchangeably herein and refer to a molecule with an antigen-binding site that specifically binds an antigen. [0038] Antibodies can include, for example, monoclonal antibodies, recombinantly produced antibodies, human antibodies, humanized antibodies, resurfaced antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain- antibody heavy chain pair, intrabodies, heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), affybodies, Fab fragments, F(ab')2 fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti- Id antibodies), bispecific antibodies, and multi-specific antibodies. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, or IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2), or any subclasses (isotypes) thereof (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), of immunoglobulin molecule, based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated or fused to other molecules such as toxins, radioisotopes, other polypeptides etc. [0039] As used herein, the terms "antigen-binding domain," "antigen-binding region," "antigen- binding site," and similar terms refer to the portion of antibody molecules, which comprises the amino acid residues that confer on the antibody molecule its specificity for the antigen (e.g., HIV Env). The antigen-binding region can be derived from any animal species, such as mouse and humans. [0040] As used herein, the terms "variable region" or "variable domain" are used interchangeably and are common in the art. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen (e.g., HIV Env). In certain embodiments, the variable region comprises 3 CDRs (CDR1, CDR2, and CDR3) and 4 framework regions (FR1, FR2, FR3, and FR4) in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3- FR4 from the N terminus to the C terminus. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises human CDRs and human framework regions (FRs). In certain embodiments, the variable region comprises CDRs and framework regions (FRs) wherein one or more of the CDRs were modified by a substitution, deletion, or insertion relative to the CDRs of a parental antibody. In certain embodiments, the variable region comprises CDRs and framework regions (FRs) wherein one or more of the FRs were modified by a substitution, deletion, or insertion relative to the FRs of a parental antibody. In certain embodiments, the variable region comprises CDRs and framework regions (FRs) wherein one or more of the CDRs and one or more of the FRs were modified by a substitution, deletion, or insertion relative to the CDRs and FRs of a parental antibody. In certain embodiments, the variable region comprises human CDRs and primate (e.g., non-human primate) framework regions (FRs). [0041] A skilled artisan understands that there are several methods for determining CDRs. One approach is based on cross-species sequence variability (i.e., Kabat EA, et al., Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda Md.) ("Kabat"). Another approach is based on crystallographic studies of antigen-antibody complexes (Al-lazikani B., et al, J. Mol. Biol.273:927-948 (1997)) ("Chothia"). In addition, combinations of these two approaches are sometimes used in the art to determine CDRs. In some embodiments, the CDR sequences are identified according to Kabat. In some embodiments, the CDR sequences are identified according to Chothia. In some embodiments, the CDR sequences are identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003). It is understood that the identification of CDRs in a variable region also identifies the FRs as the sequences flanking the CDRs. [0042] The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat EA, et al., Sequences of Immunological Interest. (5th Ed., 1991, National Institutes of Health, Bethesda, Md.) ("Kabat"). [0043] The amino acid position numbering as in Kabat, refers to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat EA, et al. (Sequences of Immunological Interest. (5th Ed., 1991, National Institutes of Health, Bethesda, Md.), "Kabat"). Using this numbering system, the actual linear amino acid sequence can contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain can include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues can be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence. Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software, available, for example, at bioinf.org.uk/abs/software. In some embodiments, the CDR sequences are identified according to Kabat. In some embodiments, the CDR sequences are identified according to Chothia. In some embodiments, the CDR sequences are identified according to AbM. In some embodiments, the CDR sequences are identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003). In some embodiments, the VH CDR3 sequence is identified according to Kabat. In some embodiments, the VH CDR3 sequence is identified according to Chothia. In some embodiments, the VH CDR3 sequence is identified according to AbM. In some embodiments, the VH CDR sequence is identified according to IMGT. Lefrnac et al., Dev. Comp. Immunol., 27, 55-77 (2003). [0044] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody. [0045] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody. [0046] The term "antibody fragment" refers to a portion of an intact antibody. An "antigen-binding fragment" refers to a portion of an intact antibody that binds to an antigen. An antigen-binding fragment can contain the antigenic determining variable regions of an intact antibody. Examples of antibody fragments include, but are not limited to Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, and single chain antibodies. [0047] A "monoclonal" antibody or antigen-binding fragment thereof refers to a homogeneous antibody or antigen-binding fragment population involved in the highly specific recognition and binding of a single antigenic determinant, or epitope. This is in contrast to polyclonal antibodies that typically include different antibodies directed against different antigenic determinants. The term "monoclonal" antibody or antigen-binding fragment thereof encompasses both intact and full- length monoclonal antibodies as well as antibody fragments (such as Fab, Fab', F(ab')2, Fv), single chain (scFv) mutants, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site. Furthermore, "monoclonal" antibody or antigen-binding fragment thereof refers to such antibodies and antigen-binding fragments thereof made in any number of manners including but not limited to by hybridoma, phage selection, recombinant expression, and transgenic animals. [0048] The term "polyclonal antibody" describes a composition of different (diverse) antibody molecules, which are capable of binding to or reacting with several different specific antigenic determinants on the same or on different antigens. Usually, the variability of a polyclonal antibody is primarily located in the so-called variable regions of the polyclonal antibody, in particular in the CDR regions. In the present disclosure, a mixture of two or more polyclonal antibodies (a polycomposition) is produced in one mixture from a polyclonal polycomposition cell line, which is produced from two or more parental polyclonal cell lines each expressing antibody molecules, which are capable of binding to a distinct target, but it may also be a mixture of two or more polyclonal antibodies produced separately. A mixture of monoclonal antibodies providing the same antigen/epitope coverage as a polyclonal antibody described herein will be considered as an equivalent of a polyclonal antibody. [0049] The term "chimeric" antibodies or antigen-binding fragments thereof refers to antibodies or antigen-binding fragments thereof wherein the amino acid sequence is derived from two or more species. Typically, the variable region of both light and heavy chains corresponds to the variable region of antibodies or antigen-binding fragments thereof derived from one species of mammals (e.g., mouse) with the desired specificity, affinity, and capability, while the constant regions are homologous to the sequences in antibodies or antigen-binding fragments thereof derived from another (usually human) to avoid eliciting an immune response in that species. [0050] The term "epitope" or "antigenic determinant" are used interchangeably herein and refer to that portion of an antigen capable of being recognized and specifically bound by a particular antibody. When the antigen is a polypeptide, epitopes can be formed both from contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon protein denaturing, whereas epitopes formed by tertiary folding are typically lost upon protein denaturing. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. [0051] "Binding affinity" generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present invention. Specific illustrative embodiments are described in the following. In certain embodiments, an anti-HIV antibody described herein binds to HIV Env trimer (e.g., BG505 SOSIP ) with a KD of at least about 0.1 ^M or less, at least about 0.01 ^M or less, at least about 1 nM or less, or at least about 0.1 nM or less. In certain embodiments, an anti-HIV antibody described herein binds to HIV Env trimer with a KD of at least about 0.01 ^M or less. In some embodiments, the HIV Env trimer is BG505 SOSIP. In some embodiments, an anti-HIV antibody described herein is capable of binding to cells that express functional, well- ordered HIV-1 membrane Env trimers. In some embodiments, an anti-HIV antibody described herein is capable of binding to HIV Env trimer in biolayer interferometry (BLI) assay. In some embodiments, an anti-HIV antibody described herein is capable of binding to HIV Env trimer in ELISA. In some embodiments, an anti-HIV antibody described herein is capable of binding Env trimers from detergent-solubilized HIV-1 virions in an ELISA assay. In one example, the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions in a BN-PAGE gel mobility-shift assay. [0052] "Or better" when used herein to refer to binding affinity refers to a stronger binding between a molecule and its binding partner. "Or better" when used herein refers to a stronger binding, represented by a smaller numerical KD value. For example, an antibody, which has an affinity for an antigen of "0.6 nM or better", the antibody's affinity for the antigen is <0.6 nM, i.e. 0.59 nM, 0.58 nM, 0.57 nM etc. or any value less than 0.6 nM. [0053] As used herein, the terms "immunospecifically binds," "immunospecifically recognizes," "specifically binds," and "specifically recognizes" are analogous terms in the context of antibodies and refer to molecules that bind to an antigen (e.g., epitope or immune complex) as such binding is understood by one skilled in the art. For example, a molecule that specifically binds to an antigen can bind to other peptides or polypeptides, generally with lower affinity as determined by, e.g., immunoassays, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), ELISA, biolayer interferometry (BLI), flow cytometry or other assays known in the art. In a specific embodiment, molecules that immunospecifically bind to an antigen bind to the antigen with a KD that is at least 2 logs, 2.5 logs, 3 logs, or 4 logs lower than the KD when the molecules bind non- specifically to another antigen. In one example, the antibody may specifically bind to cells that express functional, well-ordered HIV-1 membrane Env trimers. In one example, the antibody may specifically bind to the HIV Env trimer. In one example, the antibody may specifically bind to the HIV Env trimer (e.g., Bg505 SOSIP) in biolayer interferometry (BLI) assay. In one example, the antibody may specifically bind to the HIV Env trimer in ELISA assay. In one example, the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions. In one example, the antibody may specifically bind to Env trimers from detergent-solubilized HIV-1 virions in an ELISA assay. In one example, the antibody may specifically bind to Env trimers from detergent- solubilized HIV-1 virions in a BN-PAGE gel mobility-shift assay. The antibody may bind to HIV Env trimer with a KD at least 2 logs, 2.5 logs, 3 logs, or 4 logs lower than KD of binding to other viral or non-viral polypeptides. An antibody that specifically binds to Env trimer encompass, but are not limited to, antibodies that specifically bind to native Env, an isoform of Env, or a variant of Env derived from an HIV isolate. [0054] By "preferentially binds," it is meant that the antibody specifically binds to an epitope more readily than it would bind to a related, similar, homologous, or analogous epitope. Thus, an antibody, which "preferentially binds" to a given epitope would more likely bind to that epitope than to a related epitope, even though such an antibody may cross-react with the related epitope. [0055] An antibody is said to "competitively inhibit" binding of a reference antibody to a given epitope if it preferentially binds to that epitope or an overlapping epitope to the extent that it blocks, to some degree, binding of the reference antibody to the epitope. Competitive inhibition may be determined by any method known in the art, for example, competition ELISA assays. An antibody may be said to competitively inhibit binding of the reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%. [0056] The term "broadly neutralizing antibody" or "bnAb," as used herein, with respect to HIV (e.g., HIV-1), refers to an antibody that recognizes HIV Env of more than one isolate or strain of HIV and inhibits or prevents receptor binding of target cells as evaluated in an in vitro neutralization assay. In some embodiments, a broadly neutralizing antibody inhibits infection of a susceptible target cell by HIV. In some embodiments, a neutralizing (e.g., broadly neutralizing) antibody specifically binds an HIV Env and inhibits infection of a susceptible target cell (e.g., TZM-bl) by an HIV pseudovirus comprising an Env polypeptide. HIV pseudovirus neutralization assays have been disclosed in the art, for example, in Walker L.M., et al., Nature 477, 466–470 (2011), Li M., et al., J. Virol. 79:10108-10125 (2005), each of which is incorporated herein by reference in its entirety for all purposes. In some embodiments, a broadly neutralizing antibody neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses. In some embodiments, a broadly neutralizing antibody neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses that belong to the same or different clades. In some embodiments, a broadly neutralizing antibody is capable of neutralizing HIV strains or pseudoviruses from at least two different clades. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least one clade B strain or pseudovirus and one clade C strain or pseudovirus. In some embodiments, a broadly neutralizing antibody is capable of neutralizing more than one clade B strain or pseudovirus and more than one clade C strain or pseudovirus. In some embodiments, a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten clades. In some embodiments, a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, or all sixteen clades selected from the group consisting of clades A, A (T/F), AC, ACD, B, B (T/F), BC, C, C (T/F), CD, CRF01_AE, CRF01_AE (T/F), CRF02_AG, D, D (T/F) and G. In some embodiments, a broadly neutralizing antibody is capable of neutralizing an HIV strain or pseudovirus from at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or all eleven clades selected from the group consisting of clades A, AC, ACD, AE, AG, B, BC, C, CD, D, D (T/F), and G. [0057] In some embodiments, the breadth of neutralization is tested on an indicator virus panel comprising cross-clade HIV isolates. In some embodiments, the virus panel comprises the 13 cross- clade isolates listed in Figure 1. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 50% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 70% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 13-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 90% of cross-clade HIV isolates in the 13-member indicator virus panel. [0058] In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 13- member indicator virus panel with a median IC50 equal to or less than about 2 µg/ml, about 1.5 µg/ml, about 1 µg/ml, about 0.75 µg/ml, about 0.5 µg/ml, about 0.25 µg/ml, about 0.1 µg/ml, 0.07 µg/ml, 0.06 µg/ml, 0.05 µg/ml, 0.025 µg/ml, 0.01 µg/ml or 0.005 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC50 equal to or less than 0.75 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC50 equal to or less than 0.5 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 13-member indicator virus panel with a median IC50 equal to or less than 0.25 µg/ml. [0059] In some embodiments, the breadth of neutralization is tested on an indicator virus panel comprising cross-clade HIV isolates. In some embodiments, the virus panel comprises the 119 cross-clade isolates listed in Table 4. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or 100% of cross- clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 50% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 70% of cross- clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 90% of cross-clade HIV isolates in the 119-member indicator virus panel. [0060] In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cross-clade HIV isolates in the 119- member indicator virus panel with a median IC50 equal to or less than about 2 µg/ml, about 1.5 µg/ml, about 1 µg/ml, about 0.75 µg/ml, about 0.5 µg/ml, about 0.25 µg/ml, about 0.1 µg/ml, 0.07 µg/ml, 0.06 µg/ml, 0.05 µg/ml, 0.025 µg/ml, 0.01 µg/ml or 0.005 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than 0.1 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than 0.75 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than 0.5 µg/ml. In some embodiments, a broadly neutralizing antibody is capable of neutralizing at least about 60% of cross-clade HIV isolates in the 119- member indicator virus panel with a median IC50 equal to or less than 0.25 µg/ml. [0061] The term "IC50" refers to the half maximal inhibitory concentration of an inhibitor, e.g., a broadly neutralizing antibody. For example, IC50 is the concentration of an inhibitor, e.g., a broadly neutralizing antibody, where the response, e.g., infection by pseudovirus, is reduced by half. [0062] The term "IC80" refers to the concentration of an inhibitor, e.g., a broadly neutralizing antibody, where the response, e.g., infection by pseudovirus, is reduced by 80%. [0063] The phrase "substantially similar," or "substantially the same", as used herein, denotes a sufficiently high degree of similarity between two numeric values (generally one associated with an antibody described herein and the other associated with a reference/comparator antibody) such that one of skill in the art would consider the difference between the two values to be of little or no biological and/or statistical significance within the context of the biological characteristic measured by said values (e.g., KD values). The difference between said two values can be less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10% as a function of the value for the reference/comparator antibody. [0064] A polypeptide, antibody, polynucleotide, vector, cell, or composition, which is "isolated" is a polypeptide, antibody, polynucleotide, vector, cell, or composition, which is in a form not found in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cell or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature. In some embodiments, an antibody, polynucleotide, vector, cell, or composition, which is isolated is substantially pure. [0065] As used herein, "substantially pure" refers to material, which is at least 50% pure (i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure. [0066] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that, because the polypeptides described herein are based upon antibodies, in certain embodiments, the polypeptides can occur as single chains or associated chains. [0067] The terms "identical" or percent "identity" in the context of two or more nucleic acids or polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences. One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin S., et al, Proc. Natl. Acad. Sci., 87:2264-2268 (1990), as modified in Karlin S., et al., Proc. Natl. Acad. Sci., 90:5873-5877 (1993), and incorporated into the NBLAST and XBLAST programs (Altschul SF, et al., Nucleic Acids Res., 25:3389-3402 (1991)). In certain embodiments, Gapped BLAST can be used as described in Altschul SF, et al., Nucleic Acids Res. 25:3389-3402 (1997). BLAST-2, WU-BLAST-2 (Altschul SF, et al., Methods in Enzymology, 266:460-480 (1996)), ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or Megalign (DNASTAR) are additional publicly available software programs that can be used to align sequences. In certain embodiments, the percent identity between two nucleotide sequences is determined using the GAP program in GCG software (e.g., using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 90 and a length weight of 1, 2, 3, 4, 5, or 6). In certain alternative embodiments, the GAP program in the GCG software package, which incorporates the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) can be used to determine the percent identity between two amino acid sequences (e.g., using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5). Alternatively, in certain embodiments, the percent identity between nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS, 4:11-17 (1989)). For example, the percent identity can be determined using the ALIGN program (version 2.0) and using a PAM120 with residue table, a gap length penalty of 12 and a gap penalty of 4. Appropriate parameters for maximal alignment by particular alignment software can be determined by one skilled in the art. In certain embodiments, the default parameters of the alignment software are used. In certain embodiments, the percentage identity "X" of a first amino acid sequence to a second sequence amino acid is calculated as 100 x (Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence. [0068] As a non-limiting example, whether any particular polynucleotide has a certain percentage sequence identity (e.g., is at least 80% identical, at least 85% identical, at least 90% identical, and in some embodiments, at least 95%, 96%, 97%, 98%, or 99% identical) to a reference sequence can, in certain embodiments, be determined using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2: 482 489 (1981)) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence described herein, the parameters are set such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in identity of up to 5% of the total number of nucleotides in the reference sequence are allowed. [0069] In some embodiments, two nucleic acids or polypeptides described herein are substantially identical, meaning they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in some embodiments at least 95%, 96%, 97%, 98%, 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection. Identity can exist over a region of the sequences that is at least about 10, about 20, about 40-60 residues in length or any integral value there between, and can be over a longer region than 60-80 residues, for example, at least about 90-100 residues, and in some embodiments, the sequences are substantially identical over the full length of the sequences being compared, such as the coding region of a nucleotide sequence for example. [0070] A "conservative amino acid substitution" is one in which one amino acid residue is replaced with another amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). For example, substitution of a phenylalanine for a tyrosine is a conservative substitution. In some embodiments, conservative substitutions in the sequences of the polypeptides and antibodies described herein do not abrogate the binding of the polypeptide or antibody containing the amino acid sequence, to the antigen(s). Methods of identifying nucleotide and amino acid conservative substitutions, which do not eliminate antigen binding are well-known in the art (see, e.g., Brummell DA, et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10):879-884 (1999); and Burks EA, et al., Proc. Natl. Acad. Sci. USA 94:.412-417 (1997)). [0071] As used herein, the terms "treatment" or "therapy" (as well as different forms thereof, including curative or palliative) refer to treatment of an infected person. As used herein, the term "treating" includes alleviating or reducing at least one adverse or negative effect or symptom of a condition, disease or disorder. This condition, disease or disorder can be HIV infection. [0072] Terms such as "treating" or "treatment" or "to treat" or "alleviating" or "to alleviate" refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder, such as HIV or AIDS. Thus, those in need of treatment include those already diagnosed with or suspected of having the disorder. In certain embodiments, a subject is successfully "treated" for the disorder according to the methods described herein if the patient shows one or more of the following: a reduction in the number of or complete absence of viral load; a reduction in the viral burden; inhibition of or an absence of the virus into peripheral organs; relief of one or more symptoms associated with the disorder; reduced morbidity and mortality; improvement in quality of life; increased progression-free survival (PFS), disease-free survival (DFS), or overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), a decrease in progressive disease (PD), a reduced time to progression (TTP), or any combination thereof. [0073] As used herein, the terms "prevention" or "prophylaxis" refer to preventing a subject from becoming infected with, or reducing the risk of a subject from becoming infected with, or halting transmission of, or the reducing the risk of transmission of a virus. Prophylactic or preventative measures refer to measures that prevent and/or slow the development of a targeted pathological condition or disorder. Thus, those in need of prophylactic or preventative measures include those prone to have the disorder and those in whom the disorder is to be prevented. In some embodiments, prevention encompasses passive immunization of a subject in need thereof comprising administering an effective amount of an antibody described herein. [0074] As employed above and throughout the disclosure the term "effective amount" refers to an amount effective, at dosages, and for periods of time necessary, to achieve the desired result with respect to the treatment of the relevant disorder, condition, or side effect. An "effective amount" can be determined empirically and in a routine manner, in relation to the stated purpose. It will be appreciated that the effective amount of components of the present invention will vary from patient to patient not only with the particular vaccine, component or composition selected, the route of administration, and the ability of the components to elicit a desired result in the individual, but also with factors such as the disease state or severity of the condition to be alleviated, hormone levels, age, sex, weight of the individual, the state of being of the patient, and the severity of the pathological condition being treated, concurrent medication or special diets then being followed by the particular patient, and other factors, which those skilled in the art will recognize, with the appropriate dosage being at the discretion of the attending physician. Dosage regimes may be adjusted to provide an improved therapeutic response. An effective amount is also one in which any toxic or detrimental effects of the components are outweighed by the therapeutically beneficial effects. [0075] The term "therapeutically effective amount" refers to an amount of an antibody, recombinant virus, immunoconjugate, or other drug effective to "treat" a disease or disorder in a subject or mammal. To the extent an antibody can prevent growth and/or kill existing cells, it can be cytostatic and/or cytotoxic. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. [0076] The terms "subject," "individual," and "patient" are used interchangeably herein, and refer to an animal, for example a human, to whom treatment, including prophylactic treatment, with the antibody or pharmaceutical composition according to the present disclosure, is provided. In some embodiments, the subject, individual, or patient has been infected with HIV. In some embodiments, the subject, individual, or patient suffers from AIDS. In some embodiments, the subject, individual, or patient has been exposed to HIV. In some embodiments, the subject, individual, or patient is at risk of being exposed to HIV. [0077] Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) or consecutive administration in any order. [0078] The terms "pharmaceutically composition," "pharmaceutical formulation," "pharmaceutically acceptable formulation," or "pharmaceutically acceptable composition" all of which are used interchangeably, refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio. "Pharmaceutically acceptable" or "pharmaceutical formulation" refers to a preparation, which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components, which are unacceptably toxic to a subject to which the formulation would be administered. The formulation can be sterile. [0079] The term "antiretroviral therapy" or "ART," as used herein, refers to any of the therapies used to manage progression of a retrovirus (e.g., HIV) infection in a subject (e.g., a human), including, for example, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, entry inhibitors, maturation inhibitors, cellular inhibitors, integrase strand transfer inhibitors, and multi-class combinations. Such drugs include, but are not limited to, lamivudine and zidovudine, emtricitabine (FTC), zidovudine (ZDV), azidothymidine (AZT), lamivudine (3TC), zalcitabine, dideoxycytidine (ddC), tenofovir disoproxil fumarate (TDF), didanosine (ddl), stavudine (d4T), abacavir sulfate (ABC), etravirine (ETR), delavirdine (DLV), efavirenz (EFV), nevirapine (NVP), amprenavir (APV), tipranavir (TPV), indinavir (IDV), saquinavir, saquinavir mesylate (SQV), lopinavir (LPV), ritonavir (RTV), fosamprenavir calcium (FOS-APV), ritonavir (RTV), darunavir (DRV), atazanavir sulfate (ATV), nelfinavir mesylate (NFV), enfuvirtide (T-20), maraviroc and raltegravir. ART drugs can also include antibodies that target HIV proteins or cellular proteins associated with disease progression. Also included are immune-based therapies, such as IL-2, IL-12, and alpha- epibromide. Each of these drugs can be administered alone or in combination with any other ART drug or any HIV-specific neutralizing antibody, such as a broadly neutralizing antibody, which is incorporated by reference herein in its entirety for all purposes. [0080] The term "reservoir activator," as used herein, refers to an agent capable of activating a viral reservoir (e.g., an HIV reservoir). In some embodiments, a reservoir activator comprises a histone deacytelase (HDAC) inhibitor (e.g., romidepsin, vorinostat, and panobinostat), immunologic activator (e.g., cytokines and TLR agonists), or a dedicated small molecule drug. [0081] The term "immunomodulator," as used herein, refers to an agent, such as an antibody or peptide, which is capable of increasing, inducing, or extending an immune response (e.g., a cell- mediated immune response and/or a humoral immune response) when administered to a subject (e.g., a human, e.g., a human infected with HIV or at risk of an HIV infection or transmission). Immunomodulators include, but are not limited to immune checkpoint inhibitors, for example, a PD-1, PD-L1, LAG-3, or TIGIT antagonist. In some embodiments, an immunomodulator used in the methods described herein comprises an anti-PD-1 antibody, anti-PD-L1 antibody, anti-LAG3 antibody, or an anti-TIGIT antibody. An immunomodulator can be administered in conjunction with (e.g., prior to, concurrently with, or subsequent to, or within the context of a treatment regimen that includes the administration of a broadly neutralizing antibody described herein. [0082] The terms "VRC01," and "VRC01 antibody" are used interchangeably herein to refer to an antibody with the same binding specificity as the VRC01 antibody disclosed by Wu et al., Science, 329(5993):856–61 (2010). In some embodiments, the VRC01 antibody comprises the VH and VL of SEQ ID NO: 1272 and 1273, respectively. [0083] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a combination of two or more cells, and the like. [0084] The term "and/or" as used in a phrase such as "A and/or B" herein is intended to include both "A and B," "A or B," "A," and "B." Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). [0085] The term "about" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of up to ±20% from the specified value, as such variations are appropriate to perform the disclosed methods. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. [0086] Notwithstanding that the numerical ranges and parameters setting forth the broad scope described herein are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements. [0087] It is understood that wherever embodiments are described herein with the language "comprising," otherwise analogous embodiments described in terms of "consisting of" and/or "consisting essentially of" are also provided. II. Anti-HIV antibodies [0088] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with VRC01 for binding to the HIV Env trimer. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen- binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262). In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263). In some embodiments, the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). [0089] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof which binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is PC68-L31_54Q, i.e., a monoclonal antibody comprising the PC68-L31_54Q VH and VL. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262). In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263). In some embodiments, the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). [0090] In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof which binds to the same epitope of an HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is PC68-L31_54Q, i.e., a monoclonal antibody comprising the PC68-L31_54Q VH and VL. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH and VL of the VH3-30 VL3-21 lineage, respectively. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively, and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53. In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262). In some embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263). In some embodiments, the antibody or antigen- binding fragment thereof comprises a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/R/G/H) GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264). [0091] In some embodiments, an antibody or antibody fragment described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences shown in Table 1. In some embodiments, an antibody or antibody fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequence shown in Table 1. Table 1. Example VH and VL CDR sequences. VH VH VH VL VL VL 3
Figure imgf000032_0001
PC68-L31_32C 3 73 143 213 283 353 PC68-L31_32D 4 74 144 214 284 354
Figure imgf000033_0001
PC68-L31_54C 42 112 182 252 322 392 PC68-L31_54D 43 113 183 253 323 393 Tabl
Figure imgf000034_0001
e 2. Variable heavy chain (VH) and light chain (VL) domains. VH VH AA VL AA nucl VL nucl
Figure imgf000034_0002
PC68-L31_32K 431 501 571 641 PC68-L31_38A 432 502 572 642
Figure imgf000035_0001
PC68-L31_54K 470 540 610 680 PC68-L31_54L 471 541 611 681 Table 3. Examp
Figure imgf000036_0001
q . VH VH VH VH VL VL VL VL FW1 FW2 FW3 FW4 FW1 FW2 FW3 FW4 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8
Figure imgf000036_0002
PC68-L31_43C 719 789 859 929 999 1069 1139 1209 PC68-L31_43D 720 790 860 930 1000 1070 1140 1210 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7
Figure imgf000037_0001
PC68-L31_59A 758 828 898 968 1038 1108 1178 1248 PC68-L31_59B 759 829 899 969 1039 1109 1179 1249 0 1 2 3 4 5 6 [
Figure imgf000038_0001
one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of a VH or VL shown in Table 2. In some embodiments, an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of a VH or VL shown in Table 2. In some embodiments, an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2 and VH CDR3 of a single VH shown in Table 2. and a VL CDR1, VL CDR2, and VL CDR3 of a single VL shown in Table 2. In some embodiments, an antibody or antibody fragment described herein comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a single VH and its corresponding VL shown in Table 2. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is as shown in Table 1. [0093] In some embodiments, an antibody or antibody fragment described herein comprises a VH and VL having at least about 80% sequence identity, at least about 85% sequence identity, at least about 90% sequence identity, at least about 95% sequence identity, at least about 96% sequence identity, at least about 97% sequence identity, at least about 98% sequence identity, or at least about 99% sequence identity to a VH, a VL, or a VH and corresponding VL as shown in Table 2. [0094] In some embodiments, an antibody or antibody fragment described herein comprises a VH, a VL, or a VH and corresponding VL as shown in Table 2. [0095] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68- L31_59H VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions. [0096] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68- L31_59H VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. [0097] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68- L31_59I VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR3. In some embodiments, the VL CDR3 comprises the PC68-L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, the VL CDR3 comprises the PC68-L31_54Q VL CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. [0098] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 selected independently from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, PC68-L31_59H, and PC68-L31_59I VH CDR1s, VH CDR2s, VH CDR3s, VL CDR1s, VL CDR2s, and VL CDR3s. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises (i) the VH CDR1, VH CDR2, and VH CDR3 of a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, and PC68-L31_59H VHs and (ii) a VL CDR1, VL CDR2, and VL CDR3 of a VL selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, and PC68-L31_59I VLs. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a VH/VL pair selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H VH/VL pairs. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_43J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. [0099] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH and a VL, wherein (a) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, and PC68-L31_59H VHs and (b) the VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to a VL selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, and PC68-L31_59I VLs. In some embodiments, the VH and VL comprises a VH/VL pair selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H VH/VL pairs. [00100] In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH and a VL, wherein (i) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH, and (ii) the VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VL. In some embodiments, the antibody or antigen-binding fragment described herein comprises a VH and a VL comprising an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH and VL, respectively. In some embodiments, the antibody or antigen-binding fragment described herein comprises the PC68-L31_54Q VH and VL, respectively. [00101] In some embodiments, an isolated monoclonal antibody described herein comprises a VH CDR3 sequence shown in Table 1. In some embodiments, an isolated monoclonal antibody described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences shown in Table 1. In some embodiments, an isolated monoclonal antibody described herein comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequence shown in Table 1. In some embodiments, an isolated monoclonal antibody described herein comprises a VH CDR3 sequence of a VH shown in Table 2. In some embodiments, an isolated monoclonal antibody described herein comprises one, two, three, four, five or six of the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of a VH and VL shown in Table 2. In some embodiments, an isolated monoclonal antibody described herein comprises the VH CDR1, VH CDR2, and VH CDR3 sequences of a VH shown in Table 2 and the VL CDR1, VL CDR2, and VL CDR3 sequences of a VL shown in Table 2. In some embodiments, an isolated monoclonal antibody described herein comprises the VH CDR1, VH CDR2, and VH CDR3 sequences of a VH shown in Table 2 and the VL CDR1, VL CDR2, and VL CDR3 sequences of the corresponding VL shown in Table 2. In some embodiments, the CDR sequences are according to Kabat. In some embodiments, an isolated monoclonal antibody described herein comprises a VH, a VL, or a VH and VL as shown in Table 2. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, the VH CDR3 comprises the PC68-L31_54Q VH CDR3. In some embodiments, the VH CDR3 is according to Kabat. In some embodiments, the VH CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect , provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (b) the VH CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; and (c) the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VH CDR2 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (c) the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, (a) the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR1; (b) the VH CDR2 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR2; and (c) the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3. In some embodiments, (a) the VH CDR1 comprises the PC68-L31_54Q VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (b) the VH CDR2 comprises the PC68-L31_54Q VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; and/or (c) the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VH CDR1 comprises the PC68-L31_54Q VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VH CDR2 comprises the PC68- L31_54Q VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and/or (c) the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, (a) the VH CDR1 comprises the PC68-L31_54Q VH CDR1; (b) the VH CDR2 comprises the PC68-L31_54Q VH CDR2; and/or (c) the VH CDR3 comprises the PC68-L31_54Q VH CDR3. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3, respectively. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3, respectively. In some embodiments, the VH CDR1, VH CDR2, and/or VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and/or VH CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments of the isolated monoclonal antibody or antigen-binding fragment thereof described herein, (a) the VL CDR1 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions; (b) the VL CDR2 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR2 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions; and (c) the VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VL CDR1 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1 comprising 0, 1, 2, 3, 4 or 5 substitutions; (b) the VL CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR2 comprising 0, 1, 2, 3, 4 or 5 substitutions; and (c) the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68- L31_59I VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions. In some embodiments, (a) the VL CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1; (b) the VL CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR2; and (c) the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR3. In some embodiments, (a) the VL CDR1 comprises the PC68-L31_54Q VL CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (b) the VL CDR2 comprises the PC68-L31_54Q VL CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; and/or (c) the VL CDR3 comprises the PC68-L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VL CDR1 comprises the PC68-L31_54Q VL CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VL CDR2 comprises the PC68-L31_54Q VL CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and/or (c) the VL CDR3 comprises the PC68- L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, (a) the VL CDR1 comprises the PC68-L31_54Q VL CDR1; (b) the VL CDR2 comprises the PC68-L31_54Q VL CDR2; and/or (c) the VL CDR3 comprises the PC68-L31_54Q VL CDR3. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, respectively. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2 and VL CDR3, respectively. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions, respectively. In some embodiments, the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3, respectively. In some embodiments, the VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Table 1. In some embodiments of the isolated monoclonal antibody or antigen-binding fragment thereof described herein, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68- L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Table 1. In some embodiments of the isolated monoclonal antibody or antigen-binding fragment thereof described herein, the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (b) the VH FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (c) the VH FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; and (d) the VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68- L31_59H VH FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VH FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions; (c) the VH FW3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (d) the VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW1; (b) the VH FW2 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW2; (c) the VH FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW3; and (d) the VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68- L31_59H VH FW4. In some embodiments, the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW1, VH FW2, VH FW3 and VH FW4, respectively. In some embodiments, the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_54Q VH FW1, VH FW2, VH FW3 and VH FW4. In some embodiments, VH FW1, VH FW2, VH FW3 and/or VH FW4 are according to Table 2. In some embodiments, VH FW1, VH FW2, VH FW3 and VH FW4 are according to Table 2. In some embodiments, (a) the VL FW1 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (b) the VL FW2 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; (c) the VL FW3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions; and (d) the VL FW4 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions. In some embodiments, (a) the VL FW1 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VL FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions; (c) the VL FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (d) the VL FW4 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions. In some embodiments, (a) the VL FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I; (b) the VL FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW2; (c) the VL FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW3; and (d) the VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW4. In some embodiments, the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68- L31_59I VL FW1, VL FW2, VL FW3 and VL FW4, respectively. In some embodiments, the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions, or deletions, respectively. In some embodiments, the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68- L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, respectively. In some embodiments, the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4, respectively. In some embodiments, the VL FW1, VL FW2, VL FW3 and/or VL FW4 are according to Table 2. In some embodiments, the VL FW1, VL FW2, VL FW3 and VL FW4 are according to Table 2. In some embodiments of the isolated monoclonal antibody or antigen-binding fragment thereof described herein, the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH. In some embodiments, the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL. In some embodiments, the VH and VL comprise the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH and VL. In some embodiments of the isolated monoclonal antibody or antigen-binding fragment thereof described herein, the VH comprises an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises an amino acid sequence that is identical to the PC68-L31_54Q VH. In some embodiments, the VL comprises an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises an amino acid sequence that is identical to the PC68-L31_54Q VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 80%, about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 80% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 95% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise an amino acid sequence that is at least about 97% identical to the PC68-L31_54Q VH and VL. In some embodiments, the VH and VL comprise the PC68-L31_54Q VH and VL. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH. In some embodiments, the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3, respectively. In some embodiments, VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH CDR1, VH CDR2, and/or VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and/or VH CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, and VH CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment described herein further comprises a light chain variable region (VL), wherein the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL. In some embodiments, the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the VL comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VL CDR1, VL CDR2, and VL CDR3 is according to Table 1. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH and VL. In some embodiments, the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3, respectively. In some embodiments, the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3, respectively. In some embodiments, the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3, respectively. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Kabat. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 is according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding a HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH and VL. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A VH. In some embodiments, the VH comprises the PC68-L31_32A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A VL. In some embodiments, the VL comprises the PC68- L31_32A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32B VH. In some embodiments, the VH comprises the PC68-L31_32B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32B VL. In some embodiments, the VL comprises the PC68- L31_32B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32C VH. In some embodiments, the VH comprises the PC68-L31_32C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32C VL. In some embodiments, the VL comprises the PC68- L31_32C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32D VH. In some embodiments, the VH comprises the PC68-L31_32D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32D VL. In some embodiments, the VL comprises the PC68- L31_32D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32E VH. In some embodiments, the VH comprises the PC68-L31_32E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32E VL. In some embodiments, the VL comprises the PC68- L31_32E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32F. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32F VH. In some embodiments, the VH comprises the PC68-L31_32F VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32F VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32F VL. In some embodiments, the VL comprises the PC68- L31_32F VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32F VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32F VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32G. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32G VH. In some embodiments, the VH comprises the PC68-L31_32G VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32G VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32G VL. In some embodiments, the VL comprises the PC68- L31_32G VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32G VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32G VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32H. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32H VH. In some embodiments, the VH comprises the PC68-L31_32H VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32H VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32H VL. In some embodiments, the VL comprises the PC68- L31_32H VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32H VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32H VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32I. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32I VH. In some embodiments, the VH comprises the PC68-L31_32I VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32I VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32I VL. In some embodiments, the VL comprises the PC68- L31_32I VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_32I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32I VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32I VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32J. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32J VH. In some embodiments, the VH comprises the PC68-L31_32J VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32J VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32J VL. In some embodiments, the VL comprises the PC68- L31_32J VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_32J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32J VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32J VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_32K. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32K VH. In some embodiments, the VH comprises the PC68-L31_32K VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_32K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32K VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32K VL. In some embodiments, the VL comprises the PC68- L31_32K VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_32K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_32K VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_32K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_32K VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38A VH. In some embodiments, the VH comprises the PC68-L31_38A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_38A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38A VL. In some embodiments, the VL comprises the PC68- L31_38A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_38A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_38A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_38A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38B VH. In some embodiments, the VH comprises the PC68-L31_38B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_38B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38B VL. In some embodiments, the VL comprises the PC68- L31_38B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_38B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_38B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_38B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38C VH. In some embodiments, the VH comprises the PC68-L31_38C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_38C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38C VL. In some embodiments, the VL comprises the PC68- L31_38C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_38C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_38C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_38C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38D VH. In some embodiments, the VH comprises the PC68-L31_38D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_38D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38D VL. In some embodiments, the VL comprises the PC68- L31_38D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_38D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_38D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_38D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_38E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38E VH. In some embodiments, the VH comprises the PC68-L31_38E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_38E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_38E VL. In some embodiments, the VL comprises the PC68- L31_38E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_38E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_38E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_38E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_38E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43A VH. In some embodiments, the VH comprises the PC68-L31_43A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43A VL. In some embodiments, the VL comprises the PC68- L31_43A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43B VH. In some embodiments, the VH comprises the PC68-L31_43B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43B VL. In some embodiments, the VL comprises the PC68- L31_43B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43C VH. In some embodiments, the VH comprises the PC68-L31_43C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43C VL. In some embodiments, the VL comprises the PC68- L31_43C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43D VH. In some embodiments, the VH comprises the PC68-L31_43D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43D VL. In some embodiments, the VL comprises the PC68- L31_43D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43E VH. In some embodiments, the VH comprises the PC68-L31_43E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43E VL. In some embodiments, the VL comprises the PC68- L31_43E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43F. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43F VH. In some embodiments, the VH comprises the PC68-L31_43F VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43F VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43F VL. In some embodiments, the VL comprises the PC68- L31_43F VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43F VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43F VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43G. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43G VH. In some embodiments, the VH comprises the PC68-L31_43G VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43G VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43G VL. In some embodiments, the VL comprises the PC68- L31_43G VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43G VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43G VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43H. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43H VH. In some embodiments, the VH comprises the PC68-L31_43H VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43H VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43H VL. In some embodiments, the VL comprises the PC68- L31_43H VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43H VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43H VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43I. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43I VH. In some embodiments, the VH comprises the PC68-L31_43I VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43I VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43I VL. In some embodiments, the VL comprises the PC68- L31_43I VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_43I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43I VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43I VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43J. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43J VH. In some embodiments, the VH comprises the PC68-L31_43J VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43J VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43J VL. In some embodiments, the VL comprises the PC68- L31_43J VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_43J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43J VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43J VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43K. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43K VH. In some embodiments, the VH comprises the PC68-L31_43K VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43K VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43K VL. In some embodiments, the VL comprises the PC68- L31_43K VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43K VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43K VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43L. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43L VH. In some embodiments, the VH comprises the PC68-L31_43L VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43L VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43L VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43L VL. In some embodiments, the VL comprises the PC68- L31_43L VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43L VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43L VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43L VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43L VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43M. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43M VH. In some embodiments, the VH comprises the PC68-L31_43M VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43M VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43M VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43M VL. In some embodiments, the VL comprises the PC68-L31_43M VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43M VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43M VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43M VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43M VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43N. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43N VH. In some embodiments, the VH comprises the PC68-L31_43N VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43N VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43N VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43N VL. In some embodiments, the VL comprises the PC68- L31_43N VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43N VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43N VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43N VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43N VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43P. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43P VH. In some embodiments, the VH comprises the PC68-L31_43P VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43P VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43P VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43P VL. In some embodiments, the VL comprises the PC68- L31_43P VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43P VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43P VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43P VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43P VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43Q. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43Q VH. In some embodiments, the VH comprises the PC68-L31_43Q VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43Q VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43Q VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43Q VL. In some embodiments, the VL comprises the PC68- L31_43Q VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43Q VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43Q VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43Q VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43R. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43R VH. In some embodiments, the VH comprises the PC68-L31_43R VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43R VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43R VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43R VL. In some embodiments, the VL comprises the PC68- L31_43R VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43R VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43R VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43R VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43R VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_43S. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43S VH. In some embodiments, the VH comprises the PC68-L31_43S VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_43S VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43S VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_43S VL. In some embodiments, the VL comprises the PC68- L31_43S VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_43S VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_43S VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_43S VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_43S VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49A VH. In some embodiments, the VH comprises the PC68-L31_49A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_49A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49A VL. In some embodiments, the VL comprises the PC68- L31_49A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_49A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_49A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_49A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49B VH. In some embodiments, the VH comprises the PC68-L31_49B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_49B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49B VL. In some embodiments, the VL comprises the PC68- L31_49B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_49B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_49B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_49B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49C VH. In some embodiments, the VH comprises the PC68-L31_49C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_49C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49C VL. In some embodiments, the VL comprises the PC68- L31_49C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_49C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_49C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_49C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49D VH. In some embodiments, the VH comprises the PC68-L31_49D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_49D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49D VL. In some embodiments, the VL comprises the PC68- L31_49D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_49D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_49D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_49D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_49E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49E VH. In some embodiments, the VH comprises the PC68-L31_49E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_49E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_49E VL. In some embodiments, the VL comprises the PC68- L31_49E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_49E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_49E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_49E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_49E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54A VH. In some embodiments, the VH comprises the PC68-L31_54A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54A VL. In some embodiments, the VL comprises the PC68- L31_54A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54B VH. In some embodiments, the VH comprises the PC68-L31_54B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54B VL. In some embodiments, the VL comprises the PC68- L31_54B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54C VH. In some embodiments, the VH comprises the PC68-L31_54C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54C VL. In some embodiments, the VL comprises the PC68- L31_54C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54D VH. In some embodiments, the VH comprises the PC68-L31_54D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54D VL. In some embodiments, the VL comprises the PC68- L31_54D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54E VH. In some embodiments, the VH comprises the PC68-L31_54E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54E VL. In some embodiments, the VL comprises the PC68- L31_54E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54F. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54F VH. In some embodiments, the VH comprises the PC68-L31_54F VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54F VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54F VL. In some embodiments, the VL comprises the PC68- L31_54F VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54F VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54F VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54G. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54G VH. In some embodiments, the VH comprises the PC68-L31_54G VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54G VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54G VL. In some embodiments, the VL comprises the PC68- L31_54G VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54G VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54G VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54H. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54H VH. In some embodiments, the VH comprises the PC68-L31_54H VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54H VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54H VL. In some embodiments, the VL comprises the PC68- L31_54H VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54H VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54H VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54I. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54I VH. In some embodiments, the VH comprises the PC68-L31_54I VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54I VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54I VL. In some embodiments, the VL comprises the PC68- L31_54I VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_54I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54I VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54I VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54J. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54J VH. In some embodiments, the VH comprises the PC68-L31_54J VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54J VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54J VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54J VL. In some embodiments, the VL comprises the PC68- L31_54J VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_54J VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54J VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54J VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54K. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54K VH. In some embodiments, the VH comprises the PC68-L31_54K VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54K VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54K VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54K VL. In some embodiments, the VL comprises the PC68- L31_54K VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54K VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54K VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54K VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54K VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54L. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54L VH. In some embodiments, the VH comprises the PC68-L31_54L VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54L VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54L VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54L VL. In some embodiments, the VL comprises the PC68- L31_54L VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54L VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54L VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54L VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54L VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54M. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54M VH. In some embodiments, the VH comprises the PC68-L31_54M VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54M VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54M VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54M VL. In some embodiments, the VL comprises the PC68-L31_54M VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54M VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54M VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54M VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54M VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54N. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54N VH. In some embodiments, the VH comprises the PC68-L31_54N VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54N VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54N VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54N VL. In some embodiments, the VL comprises the PC68- L31_54N VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54N VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54N VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54N VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54N VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54P. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54P VH. In some embodiments, the VH comprises the PC68-L31_54P VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54P VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54P VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54P VL. In some embodiments, the VL comprises the PC68- L31_54P VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54P VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54P VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54P VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54P VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54Q. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VH. In some embodiments, the VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54Q VL. In some embodiments, the VL comprises the PC68- L31_54Q VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54Q VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54Q VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54R. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54R VH. In some embodiments, the VH comprises the PC68-L31_54R VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54R VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54R VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54R VL. In some embodiments, the VL comprises the PC68- L31_54R VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54R VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54R VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54R VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54R VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_54S. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54S VH. In some embodiments, the VH comprises the PC68-L31_54S VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_54S VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54S VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_54S VL. In some embodiments, the VL comprises the PC68- L31_54S VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_54S VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_54S VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_54S VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_54S VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59A. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59A VH. In some embodiments, the VH comprises the PC68-L31_59A VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59A VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59A VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59A VL. In some embodiments, the VL comprises the PC68- L31_59A VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59A VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59A VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59A VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59A VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59B. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59B VH. In some embodiments, the VH comprises the PC68-L31_59B VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59B VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59B VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59B VL. In some embodiments, the VL comprises the PC68- L31_59B VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59B VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59B VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59B VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59B VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59C. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59C VH. In some embodiments, the VH comprises the PC68-L31_59C VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59C VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59C VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59C VL. In some embodiments, the VL comprises the PC68- L31_59C VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59C VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59C VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59C VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59C VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59D. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59D VH. In some embodiments, the VH comprises the PC68-L31_59D VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59D VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59D VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59D VL. In some embodiments, the VL comprises the PC68- L31_59D VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59D VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59D VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59D VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59D VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59E. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59E VH. In some embodiments, the VH comprises the PC68-L31_59E VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59E VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59E VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59E VL. In some embodiments, the VL comprises the PC68- L31_59E VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59E VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59E VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59E VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59E VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59F. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59F VH. In some embodiments, the VH comprises the PC68-L31_59F VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59F VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59F VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59F VL. In some embodiments, the VL comprises the PC68- L31_59F VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59F VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59F VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59F VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59F VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59G. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59G VH. In some embodiments, the VH comprises the PC68-L31_59G VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59G VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59G VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59G VL. In some embodiments, the VL comprises the PC68- L31_59G VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59G VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59G VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59G VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59G VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59H. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59H VH. In some embodiments, the VH comprises the PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59H VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59H VL. In some embodiments, the VL comprises the PC68- L31_59H VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68-L31_59H VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59H VL. In some embodiments, the antibody or antigen- binding fragment comprises the PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59H VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In one aspect, provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds an HIV Env trimer and comprises the VH CDR3 of PC68- L31_59I. In some embodiments, the antibody or antigen-binding fragment comprises a VH having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59I VH. In some embodiments, the VH comprises the PC68-L31_59I VH CDR1, VH CDR2, and VH CDR3. In some embodiments, the VH comprises the PC68-L31_59I VH CDR1, VH CDR2, and VH CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59I VH. In some embodiments, the antibody or antigen-binding fragment further comprises a VL having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_59I VL. In some embodiments, the VL comprises the PC68- L31_59I VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the VL comprises the PC68- L31_59I VL CDR1, VL CDR2, and VL CDR3 and an amino acid sequence that is at least about 90% identical to the PC68-L31_59I VL. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59I VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the antibody or antigen-binding fragment comprises the PC68-L31_59I VH and VL. In some embodiments, the CDRs are according to Kabat. In some embodiments, the CDRs are according to Table 1. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments of the isolated monoclonal antibody described herein, the antibody is not the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68- L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68- L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68- L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68- L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H antibody. In some embodiments, the antibody is not PC68-L31_54Q. In some embodiments, an antibody described herein comprises a VH CDR3 comprising a sequence that is not identical to the VHCDR3 of any of the VH regions shown in Table 2. In some embodiments, an antibody described herein comprises a VH CDR1, VH CDR2, or VH CDR3 comprising an amino acid sequence that is not identical to the amino acid sequence of VH CDR1, VH CDR2, or VH CDR3 of any of the VH regions shown in Table 2. In some embodiments, an antibody described herein comprises a VL CDR1, VL CDR2, or VL CDR3 comprising an amino acid sequence that is not identical to the amino acid sequence of VL CDR1, VL CDR2, or VL CDR3 of any of the VL regions shown in Table 2. In some embodiments, an antibody described herein comprises a VH comprising an amino acid sequence that is not identical to the amino acid sequence of any VH region shown in Table 2. In some embodiments, an antibody described herein comprises a VL comprising an amino acid sequence that is not identical to the amino acid sequence of any VL region shown in Table 2. In some embodiments, an antibody described herein comprises a VH that is markedly different from the VH regions shown in Table 2. In some embodiments, an antibody described herein comprises a VL that is markedly different from the VL regions shown in Table 2. In some embodiments, an antibody described herein comprises at least one substitution, insertion, or deletion compared to the corresponding amino acid sequence of any of the VH and VL regions shown in Table 2. In some embodiments, the monoclonal antibody or antigen-binding fragment described herein further comprises a heavy and/or light chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a heavy chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a light chain constant region. In some embodiments, the monoclonal antibody or antigen-binding fragment comprises a heavy and light chain constant region. In some embodiments, the heavy and/or light chain constant region is a human heavy and/or light chain constant region. In some embodiments, the heavy and light chain constant region are a human heavy and light chain constant region. In some embodiments, the heavy chain constant region is selected from the group consisting of a human immunoglobulin IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2 constant region. In some embodiments, the heavy chain constant region comprises a native amino acid sequence. In some embodiments, the heavy chain constant region comprises a non-native variant amino acid sequence. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment described herein is a recombinant antibody, a chimeric antibody, a human antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody. In some embodiments, the antibody fragment comprises a single-chain Fv (scFv), Fab fragment, F(ab’)2 fragment, or an isolated VH domain. In some embodiments, the antibody is a bispecific antibody. In some embodiments, the antibody is a trispecific antibody. In some embodiments, the antibody or antigen-binding fragment thereof described herein competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. In some embodiments, the antibody or antigen-binding fragment thereof described herein binds to the same epitope of the HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. In some embodiments of the antibody or antigen-binding fragment thereof described herein the HIV Env is BG505 HIV Env. In some embodiments of the antibody or antigen-binding fragment thereof described herein the antibody or antigen-binding fragment is capable of neutralizing at least 6 HIV isolates in the 13-member indicator virus panel. In some embodiments of the antibody or antigen-binding fragment thereof described herein the antibody or antigen-binding fragment is capable of neutralizing at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the HIV isolates in the 119-member indicator virus panel. In some embodiments of the antibody or antigen-binding fragment thereof described herein the antibody or antigen-binding fragment is capable of neutralizing the HIV isolates with a median IC50 equal to or less than about 1 µg/ml, about 0.8 µg/ml, 0.5 µg/ml, or 0.3 µg/ml. In some embodiments, an antibody or antibody fragment described herein neutralizes a pseudovirus produced in the presence of kifunensine better than those with wildtype glycoforms. In some embodiments, the antibody has a lowed IC50 value against a pseudovirus produced in the presence of kifunensine than against the corresponding pseudovirus comprising wildtype glycoforms. In some embodiments, the antibody has a lowed IC80 value against a pseudovirus produced in the presence of kifunensine than against the corresponding pseudovirus comprising wildtype glycoforms. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising a single substitution in the Env polypeptide selected from the group consisting of N197A, N234A, N262A, N276A, N301A, N363A, N386A and N462A with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N197A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N234A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N262A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N276A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N301A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N363A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N386A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein can neutralize a pseudovirusvirus comprising the N462A Env substitution with the same or lower IC50 than a corresponding pseudovirus that does not comprise the substitution. In some embodiments, an antibody or antibody fragment described herein is capable of neutralizing at least two cross-clade isolates of HIV. In some embodiments, the antibody is capable of neutralizing at least one clade B isolate and at least one clade AG isolate. In some embodiments, the antibody is capable of neutralizing at least one clade B isolate and at least one clade AC isolate. In some embodiments, an antibody or antigen-binding fragment thereof described herein is a broadly neutralizing antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein neutralizes 2, 3, 4, 5, 6, 7, 8, 9, or more HIV strains or pseudoviruses that belong to the same or different clades. In some embodiments, an antibody described herein is capable of neutralizing HIV strains or pseudoviruses from at least two different clades. In some embodiments, an antibody described herein is capable of neutralizing at least one clade B strain or pseudovirus and one clade AG strain or pseudovirus. In some embodiments, an antibody described herein is capable of neutralizing at least one clade B strain or pseudovirus and one clade AC strain or pseudovirus. In some embodiments, an antibody described herein is capable of neutralizing more than one clade B strain or pseudovirus. In some embodiments, the antibody is a broadly neutralizing antibody. In some embodiments, the antibody specifically binds an Env trimer of at least one HIV isolate in the 13- member indicator virus panels of Figure 1. In some embodiments, the antibody specifically binds an Env trimer of at least two, at least three, at least four, or at least five HIV isolates in the 13- member indicator virus panel of Figure 1. In some embodiments, the antibody specifically binds an Env trimer of at least one HIV isolate in the 119-member indicator virus panels of Table 4. In some embodiments, the antibody specifically binds an Env trimer of at least 30%, at least 40% or at least 50% of the HIV isolates in the 119-member indicator virus panel of Table 4. In some embodiments, an antibody or antigen-binding fragment thereof described herein is a recombinant antibody, a chimeric antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein is a bispecific antibody or a trispecific antibody. In some embodiments, the antibody or antigen-binding fragment thereof is a human antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, an antibody or antigen-binding fragment thereof described herein is not polyreactive. In some embodiments, an isolated monoclonal antibody described herein further comprises heavy and/or light chain constant regions. In some embodiments, an isolated monoclonal antibody described herein further comprises human heavy and/or light chain constant regions. In some embodiments, the heavy chain constant region is selected from the group consisting of human immunoglobulins IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. In some embodiments, the heavy chain constant region comprises a native amino acid sequence. In some embodiments, the heavy chain constant region comprises a non-native variant amino acid sequence. In some embodiments, an antibody described herein is a recombinant antibody, a chimeric antibody, a bispecific antibody, a trispecific antibody, or a multispecific antibody. In some embodiments, the antibody fragment comprises a single-chain Fv (scFv), F(ab) fragment, F(ab’)2 fragment, or an isolated VH domain. In some embodiments, an antibody described herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In some embodiments, one of the binding specificities is for HIV Env and the other is for any other antigen. In some embodiments, bispecific antibodies bind to two different epitopes of HIV Env. Bispecific antibodies can be prepared as full length antibodies or antibody fragments. Techniques for making multispecific antibodies, e.g., bispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker A., et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole" engineering (see, e.g., U.S. Patent No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology for making bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (scFv) dimers (see, e.g. Gruber et al., J. Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. J. Immunol. 147: 60 (1991). Engineered antibodies with three or more functional antigen-binding sites, including "Octopus antibodies" and dual variable domain (DVD) immunoglobulins are also included herein (see, e.g. US 2006/0025576A1 and US Patent 10,093,733). The antibody or fragment described herein also includes a "Dual Acting Fab" or "DAF" comprising an antigen- binding site that binds to different epitopes, e.g., two different HIV Env epitopes (see, US 2008/0069820, for example). In some embodiments, an antibody described herein is a multispecific antibody, e.g. a bispecific antibody comprising a first antigen-binding domain comprising a VH domain or VH and VL domains described herein, and a second antigen-binding region capable of binding an HIV Env epitope. In some embodiments, the second antigen-binding region binds to an HIV Env epitope region different from the HIV Env epitope region bound by an antibody described herein. In some embodiments, the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, N332/V3 base supersite, fusion peptide (FP), silent face, gp120-gp41 interface or membrane-proximal external region (MPER). In some embodiments, the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, silent face, fusion peptide (FP), gp120-gp41 interface or membrane-proximal external region (MPER). In some embodiments, the second antigen-binding region binds to the CD4 binding site (CD4bs) epitope region. In some embodiments, the second antigen-binding region binds to the V2 apex. In some embodiments, the second antigen-binding region binds to the N332/V3 base supersite. In some embodiments, the second antigen-binding region binds to the gp120-gp41 interface epitope region. In some embodiments, the second antigen-binding region binds to the silent face. In some embodiments, the second antigen-binding region binds to fusion peptide (FP). In some embodiments, the second antigen-binding region binds to the membrane-proximal external region (MPER). In some embodiments, an antibody described herein comprises a heavy and/or light chain constant region. In some embodiments, an antibody described herein comprises a human heavy and/or light chain constant region. In some embodiments, the heavy chain constant region is human immunoglobulin IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2 constant region. In some embodiments, the heavy chain constant region is human immunoglobulin IgG1 constant region. In some embodiments, the heavy chain constant region comprises a native amino acid sequence. In some embodiments, an antibody described herein is capable of neutralizing at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or 100% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 40%, of cross- clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 50%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 60%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 80% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 90%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 95%, of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing at least about 98%, of cross- clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing 100% of cross-clade HIV isolates in the 119-member indicator virus panel. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 2 µg/ml, about 1.5 µg/ml, about 1 µg/ml, about 0.75 µg/ml, about 0.5 µg/ml, about 0.3 µg/ml, about 0.2 µg/ml, about 0.1 µg/ml, about 0.05 µg/ml, about 0.025 µg/ml, about 0.01 µg/ml, or about 0.005 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than 0.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 40% of cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than 0.25 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 2 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 1.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross- clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 1 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 2 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 1.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC50 equal to or less than about 1 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than about 1 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 80% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than about 1 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 70% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than about 0.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing at least about 80% cross-clade HIV isolates in the 119-member indicator virus panel with a median IC50 equal to or less than about 0.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC80 equal to or less than about 7 µg/ml, about 6 µg/ml, about 5 µg/ml, about 4 µg/ml, about 3 µg/ml, about 2 µg/ml, about 1 µg/ml, or about 0.5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC80 equal to or less than about 7 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates with a median IC80 equal to or less than about 6 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC80 equal to or less than about 5 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119- member indicator virus panel with a median IC80 equal to or less than about 2 µg/ml. In some embodiments, an antibody described herein is capable of neutralizing the cross-clade HIV isolates of the 119-member indicator virus panel with a median IC80 equal to or less than about 1 µg/ml. In another aspect, provided herein are antibodies that bind the same or an overlapping epitope of Env as an antibody described herein (e.g., PC68-L31_43J). In certain embodiments, the epitope of an antibody can be determined by, e.g., NMR spectroscopy, X-ray crystallography, negative-stain and cryo-EM (see, e.g., Lin M, et al., J Am Soc Mass Spectrom.5: 961-971 (2018); Rantalainen et al., Cell Rep.23(11); 3249-3261 (2018); Torrents de la Peña A et al., PLoS Pathog. 15;15(7):e1007920 (2019)), ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo- peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (e.g., Giegé R, et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen NE (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303). Antibody:antigen crystals may be studied using well-known X-ray diffraction techniques and may be refined using computer software such as Phenix (Adams et al., Acta Crystallogr Biol Crystallogr D66, 213-221 (2010)) and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne G (1997) Meth. Enzymol. 276A: 361-423, ed Carter CW; Roversi P et al., (2000) Acta Crystallogr. D Biol. Crystallogr.56(Pt 10): 1316-1323). Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art. See, e.g., Champe M et al., (1995) supra and Cunningham BC & Wells JA (1989) supra for a description of mutagenesis techniques, including alanine scanning mutagenesis techniques. In a specific embodiment, the epitope of an antibody is determined using alanine scanning mutagenesis studies. Usually, binding to the antigen is reduced or disrupted when a residue within the epitope is substituted to alanine. In some embodiments, the KD of binding to the antigen is increased by about 5-fold, 10-fold, 20-fold, 10-fold or more when a residue within the epitope is substituted for alanine. In some embodiments, binding affinity is determined by ELISA. In addition, antibodies that recognize and bind to the same or overlapping epitopes of Env can be identified using routine techniques such as an immunoassay, for example, by showing the ability of one antibody to block the binding of another antibody to a target antigen, i.e., a competitive binding assay. In some embodiments, the antibody or antigen-binding fragment thereof described herein competes with a reference antibody for binding to an HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. In some embodiments, the antibody or antigen-binding fragment thereof described herein binds to the same epitope of an the HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the trimer is an SOSIP trimer. In some embodiments, the HIV Env is BG505 HIV Env. In some embodiments, the reference antibody is the PC68-L31_54Q antibody. In one aspect, provided herein is a method of producing an engineered variant of an antibody described herein comprising (a) substituting one or more amino acid residues of the VH; and/or substituting one or more amino acid residues of the VL of the antibody to create an engineered variant antibody, and (b) producing the engineered variant antibody. In some embodiments, the antibody is selected from the group consisting of the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody. In some embodiments, the antibody is the PC68- L31_54Q antibody. In some embodiments, a method for producing an engineered variant comprises directed-evolution and yeast display. In some embodiments, the method further comprises determining that the engineered variant antibody has improved properties, for example, by determining the engineered variant antibody's binding affinity to target antigen, binding affinity to target antigen at low pH, median neutralization IC50 potency, or breadth of neutralization compared to the parent antibody. Suitable methods for producing the engineered antibody are disclosed in International Patent Publication Nos. WO 2020023827 and WO 2020/117740, each of which is hereby incorporated by reference herein in its entirety. In some embodiments, an engineered antibody possesses one or more improved properties, for example, higher binding affinity to target antigen, higher binding affinity to target antigen at low pH, increased median neutralization IC50 potency, and increased breadth of neutralization compared to the parent antibody. The affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method well-known in the art, e.g., flow cytometry, enzyme-linked immunoabsorbent assay (ELISA), biolayer interferometry (BLI) assay, radioimmunoassay (RIA), or kinetics (e.g., BIACORE™ analysis). Direct binding assays as well as competitive binding assay formats can be readily employed. (See, for example, Berzofsky, et al., "Antibody-Antigen Interactions," In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, N.Y. (1984); Kuby, Janis Immunology, W. H. Freeman and Company: New York, N.Y. (1992); and methods described herein. The measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g., salt concentration, pH, temperature). Thus, measurements of affinity and other antigen-binding parameters (e.g., KD or Kd, Kon, Koff) are made with standardized solutions of antibody and antigen, and a standardized buffer, as known in the art and such as the buffer described herein. In some embodiments, an antibody described herein is a monoclonal antibody. Monoclonal antibodies can be made using recombinant DNA methods, for example, as described in U.S. Patent 4,816,567. The polynucleotides encoding a monoclonal antibody can be amplified from a suitable source or chemically synthetized. The isolated polynucleotides encoding the heavy and light chains are then cloned into suitable expression vectors, which when transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, monoclonal antibodies are generated by the host cells. The polynucleotide(s) encoding a monoclonal antibody can be modified in a number of different manners using recombinant DNA technology to generate alternative antibodies. In some embodiments, the constant domains of the light and heavy chains can be substituted for a non- immunoglobulin polypeptide to generate a fusion antibody. In some embodiments, the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody. Site-directed or high-density mutagenesis of the variable region can be used to optimize specificity, affinity, etc. of a monoclonal antibody. Methods for engineering antibodies can also be used and are well-known in the art. An engineered antibody can have one or more amino acid residues substituted, deleted or inserted. These sequence modifications can be used to reduce immunogenicity or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art. Antibodies can also be engineered to eliminate development liabilities by altering or eliminating sequence elements targeted for post-translational modification including glycosylation sites, oxidation sites, or deamination sites. In general, the CDR residues are directly and most substantially involved in influencing antibody binding. Accordingly, part or all of the CDR sequences are maintained while the variable framework and constant regions can be engineered by introducing substitutions, insertions, or deletions. Antibodies described herein can also optionally be engineered with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, engineered antibodies can be prepared by a process of analysis of the parental sequences and various conceptual engineered products using three-dimensional models of the parental and engineered sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available, which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, framework (FR) residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In certain embodiments an antibody fragment is provided. Various techniques are known for the production of antibody fragments. Traditionally, these fragments are derived via proteolytic digestion of intact antibodies (for example Morimoto et al., 1993, Journal of Biochemical and Biophysical Methods 24:107-117; Brennan et al., 1985, Science, 229:81). In certain embodiments, antibody fragments are produced recombinantly. Fab, Fv, and scFv antibody fragments can all be expressed in and secreted from E. coli or other host cells, thus allowing the production of large amounts of these fragments. Such antibody fragments can also be isolated from antibody phage libraries. The antibody fragment can also be linear antibodies as described in U.S. Patent 5,641,870, for example, and can be monospecific or bispecific. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. In certain embodiments, the variable domains in both the heavy and light chains are altered by at least partial replacement of one or more CDRs and, if necessary, by partial framework region replacement and sequence changing. Although the CDRs can be derived from an antibody of the same class or even subclass as the antibody from which the framework regions are derived, it is envisaged that the CDRs may be derived from an antibody of different class and in certain embodiments from an antibody from a different species. It may not be necessary to replace all of the CDRs with the complete CDRs from the donor variable region to transfer the antigen-binding capacity of one variable domain to another. Rather, it may only be necessary to transfer those residues that are necessary to maintain the activity of the antigen-binding site. Given the explanations set forth in U.S. Pat. Nos. 5,585,089, 5,693,761 and 5,693,762, it will be well within the competence of those skilled in the art, either by carrying out routine experimentation or by trial and error testing to obtain a functional antibody with reduced immunogenicity. Alterations to the variable region notwithstanding, those skilled in the art will appreciate that the modified antibodies described herein will comprise antibodies (e.g., full-length antibodies or antigen-binding fragments thereof) in which at least a fraction of one or more of the constant region domains has been deleted or otherwise altered so as to provide desired biochemical characteristics such as increased serum half-life when compared with an antibody of approximately the same antigen-binding activity comprising a native or unaltered constant region. In some embodiments, the constant region of the modified antibodies will comprise a human constant region. Modifications to the constant region compatible with this invention comprise additions, deletions or substitutions of one or more amino acids in one or more domains. That is, the modified antibodies described herein can comprise alterations or modifications to one or more of the three heavy chain constant domains (CH1, CH2 or CH3) and/or to the light chain constant domain (CL). In some embodiments, modified constant regions wherein one or more domains are partially or entirely deleted are contemplated. In some embodiments, the modified antibodies will comprise domain deleted constructs or variants wherein the entire CH2 domain has been removed (ΔCH2 constructs). In some embodiments, the omitted constant region domain will be replaced by a short amino acid spacer (e.g., 10 residues) that provides some of the molecular flexibility typically imparted by the absent constant region. It will be noted that in certain embodiments, the modified antibodies can be engineered to fuse the CH3 domain directly to the hinge region of the respective modified antibodies. In other constructs it may be desirable to provide a peptide spacer between the hinge region and the modified CH2 and/or CH3 domains. For example, compatible constructs could be expressed wherein the CH2 domain has been deleted and the remaining CH3 domain (modified or unmodified) is joined to the hinge region with a 5-20 amino acid spacer. Such a spacer can be added, for instance, to ensure that the regulatory elements of the constant domain remain free and accessible or that the hinge region remains flexible. However, it should be noted that amino acid spacers can, in some cases, prove to be immunogenic and elicit an unwanted immune response against the construct. Accordingly, in certain embodiments, any spacer added to the construct will be relatively non-immunogenic, or even omitted altogether, so as to maintain the desired biochemical qualities of the modified antibodies. Besides the deletion of whole constant region domains, it will be appreciated that the antibodies described herein can be provided by the partial deletion or substitution of a few or even a single amino acid. For example, it may be desirable to simply delete that part of one or more constant region domains that control the effector function (e.g., complement C1q binding) to be modulated. Such partial deletions of the constant regions can improve selected characteristics of the antibody (serum half-life) while leaving other desirable functions associated with the subject constant region domain intact. Moreover, as alluded to above, the constant regions of the disclosed antibodies can be modified through the mutation or substitution of one or more amino acids that enhances the profile of the resulting construct. In this respect it may be possible to disrupt the activity provided by a conserved binding site (e.g., Fc binding) while substantially maintaining the configuration and immunogenic profile of the modified antibody. Certain embodiments can comprise the addition of one or more amino acids to the constant region to enhance desirable characteristics such as decreasing or increasing effector function or provide for more cytotoxin or carbohydrate attachment. In such embodiments, it can be desirable to insert or replicate specific sequences derived from selected constant region domains. In further embodiments, an antibody described herein comprises a variant IgG Fc region (e.g., variant IgG1 Fc region) comprising the M428L and N434S substitutions to improve the recycling of the antibody via the antibody salvage pathway. See, e.g., Grevys, et al., J. Immunology, 194:5497-508 (2015). The half-life of an IgG is mediated by its pH-dependent binding to the neonatal receptor FcRn. In some embodiments, an antibody described herein comprises a variant Fc region that has been modified to enhance binding to FcRn (see, e.g., Petkova et al., Int. Immunol. 18: 1759-1769 (2006); Dall'Acqua et al., J. Immunol.169: 5171-5180 (2002); Oganesyan et al., Mol. Immunol.46: 1750-1755 (2009); Dall'Acqua et al., J. Biol. Chem. 281: 23514-23524 (2006), Hinton et al., J. Immunol.176: 346-356 (2006); Datta-Mannan et al., Drug Metab. Dispos.35: 86-94 (2007); Datta- Mannan et al., J. Biol. Chem. 282: 1709-1717 (2007); WO 06/130834; Strohl, Curr. Opin. Biotechnol.20: 685-691 (2009); and Yeung et al., J. Immunol.182: 7663-7671 (2009), the contents of each of which is herein incorporated by reference in its entirety). In some embodiments, an antibody described herein comprises a variant Fc region that has been modified to have a selective affinity for FcRn at pH 6.0, but not pH 7.4. By way of example, the variant Fc region contains one or more of the following modifications that increase half-life: IgG1-M252Y, S254T, T256E; IgG1-T250Q, M428L; IgG1-M428L and N434S (the "LS" mutation); IgG1-H433K, N434Y; IgG1-N434A; and IgG1-T307A, E380A, N434A; wherein the numbering of the residues is that of the EU index of Kabat et al. (Kabat et al., Sequences of Proteins of Immunological Interest, 1991 Fifth edition, herein incorporated by reference). In some embodiments, an antibody described herein comprises a variant Fc region that has been modified to reduce its effector functions. In some embodiments, the variant Fc region comprises the L234A, L235A hinge region substitutions, wherein the numbering of the residues is that of the EU index of Kabat et al. In some embodiments, an antibody described herein comprises an Fc region having a carbohydrate structure that lacks fucose attached (directly or indirectly) to the Fc region or has a reduced level of fucosylation. In some embodiments, a fucosylation variant antibody has improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108; US 2004/0093621, each of which is incorporated by reference herein in its entirety. Examples of publications related to "defucosylated" or "fucose-deficient" antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol.336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng.87: 614 (2004), each of which is incorporated by reference herein in its entirety. Examples of cell lines capable of producing defucosylated antibodies include Lec 13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Pat Appl No US 2003/0157108 A1; and WO 2004/056312), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94:680-688 (2006); and WO2003/085107), each of which is incorporated by reference herein in its entirety. In some embodiments, an antibody described herein comprises bisected oligosaccharides, in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. In some embodiment, an antibody comprising bisected oligosaccharides has reduced fucosylation and/or improved ADCC function. See, e.g., WO 2003/011878; U.S. Pat. No. 6,602,684; and US 2005/0123546, each of which is incorporated by reference herein in its entirety. In some embodiment, an antibody described herein comprises at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. See, e.g., in WO 1997/30087; WO 1998/58964; and WO 1999/22764, each of which is incorporated by reference herein in its entirety. In some embodiments, an antibody described herein comprises a variant Fc region comprising a combination of substitutions with increased binding to FcRn and Fc gamma RIIIa. The combinations increase antibody half-life and ADCC. For example, such combination include antibodies with the following amino acid substitution in the Fc region: (1) S239D/I332E and T250Q/M428L; (2) S239D/I332E and M428L/N434S; (3) S239D/I332E and N434A; (4) S239D/I332E and T307A/E380A/N434A; (5) S239D/I332E and M252Y/S254T/T256E; (6) S239D/A330L/I332E and 250Q/M428L; (7) S239D/A330L/I332E and M428L/N434S; (8) S239D/A330L/I332E and N434A; (9) S239D/A330L/I332E and T307A/E380A/N434A; or (10) S239D/A330L/I332E and M252Y/S254T/T256E, wherein the numbering of the residues is that of the EU index of Kabat et al. In some embodiments, an antibody comprising the variant Fc region is directly cytotoxic to infected cells, or uses natural defenses such as complement, antibody dependent cellular cytotoxicity (ADCC), or phagocytosis by macrophages. The present invention further embraces variants and equivalents, which are substantially homologous to the chimeric, humanized and human antibodies, or antibody fragments thereof, set forth herein. These can contain, for example, conservative substitution mutations, i.e., the substitution of one or more amino acids by similar amino acids. For example, conservative substitution refers to the substitution of an amino acid with another within the same general class such as, for example, one acidic amino acid with another acidic amino acid, one basic amino acid with another basic amino acid or one neutral amino acid by another neutral amino acid. What is intended by a conservative amino acid substitution is well-known in the art. The polypeptides provided herein can be recombinant polypeptides, natural polypeptides, or synthetic polypeptides comprising an antibody, or fragment thereof. It will be recognized in the art that some amino acid sequences described herein can be varied without significant effect of the structure or function of the protein. Thus, the invention further includes variations of the polypeptides, which show substantial activity or which include regions of an antibody, or fragment thereof, against a human folate receptor protein. Such mutants include deletions, insertions, inversions, repeats, and type substitutions. The polypeptides and analogs can be further modified to contain additional chemical moieties not normally part of the protein. Those derivatized moieties can improve the solubility, the biological half-life or absorption of the protein. The moieties can also reduce or eliminate any desirable side effects of the proteins and the like. An overview for those moieties can be found in REMINGTON'S PHARMACEUTICAL SCIENCES, 21th ed., Mack Publishing Co., Easton, PA (2005). III. Polynucleotides In certain aspects, provided herein are polynucleotides comprising a nucleotide sequence or nucleotide sequences encoding an antibody described herein (e.g., a variable light chain and/or variable heavy chain region) or an antigen-binding fragment thereof and vectors, e.g., vectors comprising such polynucleotides. In some embodiments, the vectors can be used for recombinant expression of an antibody described herein in host cells (e.g., E. coli and mammalian cells). In some embodiments, the vectors can be used for administration of an antibody described herein to a patient in need thereof. In some embodiments, the antibody comprises PC68-L31_43J. In one aspect, provided herein are isolated polynucleotides encoding the heavy chain variable region or heavy chain of an antibody described herein. In one aspect, provided herein are isolated polynucleotides encoding the light chain variable region or light chain of an antibody described herein. In one aspect, provided herein are isolated polynucleotides encoding the heavy chain variable region or heavy chain of an antibody described herein and the light chain variable region or light chain of an antibody described herein. In some embodiments, the polynucleotide encodes PC68-L31_43J. In some embodiments, the polynucleotide encodes a VH or VL as referenced in Table 2. In some embodiments, the polynucleotide encodes a polypeptide comprising an amino acid sequence referenced in Tables 1 and 2. In some embodiments, the polynucleotide comprises any one of the nucleotide sequences referenced in Table 3. In some embodiments, an isolated polynucleotide described herein encodes an antibody described herein and comprises an mRNA. In some embodiments, the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof. In some embodiments, the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil (ψ), N1-methylpseudouracil (m1ψ), 1-ethylpseudouracil, 2-thiouracil, 4′- thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, and any combination thereof. In some embodiments, a modified mRNA encoding an antibody described herein is for administering to a subject to treat or prevent HIV infection. As used herein, an "isolated" polynucleotide or nucleic acid molecule is one, which is separated from other nucleic acid molecules, which are present in the natural source (e.g., in a mouse or a human) of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. For example, the language "substantially free" includes preparations of polynucleotide or nucleic acid molecule having less than about 15%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (in particular less than about 10%) of other material, e.g., cellular material, culture medium, other nucleic acid molecules, chemical precursors and/or other chemicals. In a specific embodiment, a nucleic acid molecule(s) encoding an antibody or fusion polypeptide described herein is isolated or purified. In particular aspects, provided herein are polynucleotides comprising nucleotide sequences encoding antibodies described herein, as well as antibodies that compete with such antibodies for binding to HIV, or which binds to the same epitope as that of such antibodies. In certain aspects, provided herein are polynucleotides comprising a nucleotide sequence encoding the light chain or heavy chain of an antibody described herein. The polynucleotides can comprise nucleotide sequences encoding a light chain comprising the VL of antibodies described herein (see, e.g., Table 3). The polynucleotides can comprise nucleotide sequences encoding a heavy chain comprising the VH of antibodies described herein (see, e.g., Table 3). In specific embodiments, a polynucleotide described herein encodes a VH domain shown in Table 3. In specific embodiments, a polynucleotide described herein encodes a VL domain shown in Table 3. In some embodiments, a polynucleotide described herein encodes PC68-L31_43J. In some embodiments, the antibody is a chimeric antibody. In particular embodiments, provided herein are polynucleotides comprising a nucleotide sequence encoding an antibody comprising three VL chain CDRs, e.g., containing VL CDR1, VL CDR2, and VL CDR3 of any one of antibodies described herein (e.g., see Table 1). In specific embodiments, provided herein are polynucleotides comprising three VH chain CDRs, e.g., containing VH CDR1, VH CDR2, and VH CDR3 of any one of antibodies described herein (e.g., see Table 1). In specific embodiments, provided herein are polynucleotides comprising a nucleotide sequence encoding an anti-Env antibody comprising three VL CDRs, e.g., containing VL CDR1, VL CDR2, and VL CDR3 of any one of antibodies described herein (e.g., see Table 1) and three VH chain CDRs, e.g., containing VH CDR1, VH CDR2, and VH CDR3 of any one of antibodies described herein (e.g., see Table 1). In specific aspects, provided herein is a polynucleotide comprising a nucleotide sequence encoding an antibody comprising a light chain and a heavy chain, e.g., a separate light chain and heavy chain. With respect to the light chain, in a specific embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding a kappa light chain. In another specific embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding a lambda light chain. In yet another specific embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein comprising a human kappa light chain or a human lambda light chain. In a particular embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody, which immunospecifically binds to Env, wherein the antibody comprises a light chain, and wherein the amino acid sequence of the VL domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the light chain comprises the amino acid sequence of a human kappa light chain constant region. In another particular embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody, which immunospecifically binds to Env, and comprises a light chain, wherein the amino acid sequence of the VL domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the light chain comprises the amino acid sequence of a human lambda light chain constant region. For example, human constant region sequences can be those described in U.S. Patent No.5,693,780. In a particular embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein, which immunospecifically binds to Env, wherein the antibody comprises a heavy chain, wherein the amino acid sequence of the VH domain can comprise the amino acid sequence set forth in Table 3, and wherein the constant region of the heavy chain comprises the amino acid sequence of a human alpha or gamma heavy chain constant region. In yet another specific embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an antibody described herein, which immunospecifically binds Env, wherein the antibody comprises a VL domain and a VH domain comprising any amino acid sequences described herein, and wherein the constant regions comprise the amino acid sequences of the constant regions of a human IgA1, human IgA2, human IgG1 (e.g., allotype 1, 17, or 3), human IgG2, or human IgG4. In yet another specific embodiment, a polynucleotide provided herein comprises a nucleotide sequence encoding an anti-Env antibody or a fragment thereof that are optimized, e.g., by codon/RNA optimization, replacement with heterologous signal sequences, and elimination of mRNA instability elements. Methods to generate optimized nucleic acids encoding an anti-Env antibody or a fragment thereof (e.g., light chain, heavy chain, VH domain, or VL domain) for recombinant expression by introducing codon changes and/or eliminating inhibitory regions in the mRNA can be carried out by adapting the optimization methods described in, e.g., U.S. Patent Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498, accordingly. For example, potential splice sites and instability elements (e.g., A/T or A/U rich elements) within the RNA can be mutated without altering the amino acids encoded by the nucleic acid sequences to increase stability of the RNA for recombinant expression. The alterations utilize the degeneracy of the genetic code, e.g., using an alternative codon for an identical amino acid. In some embodiments, it can be desirable to alter one or more codons to encode a conservative mutation, e.g., a similar amino acid with similar chemical structure and properties and/or function as the original amino acid. In certain embodiments, an optimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof (e.g., VL domain or VH domain) can hybridize to an antisense (e.g., complementary) polynucleotide of an unoptimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof (e.g., VL domain or VH domain). In specific embodiments, an optimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment hybridizes under high stringency conditions to antisense polynucleotide of an unoptimized polynucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof. In a specific embodiment, an optimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof hybridizes under high stringency, intermediate or lower stringency hybridization conditions to an antisense polynucleotide of an unoptimized nucleotide sequence encoding an anti-Env antibody described herein or a fragment thereof. Information regarding hybridization conditions has been described, see, e.g., U.S. Patent Application Publication No. US 2005/0048549 (e.g., paragraphs 72-73), which is incorporated herein by reference. The polynucleotides can be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. Nucleotide sequences encoding antibodies described herein, and modified versions of these antibodies can be determined using methods well-known in the art, i.e., nucleotide codons known to encode particular amino acids are assembled in such a way to generate a nucleic acid that encodes the antibody. Such a polynucleotide encoding the antibody can be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier G et al., (1994), BioTechniques 17: 242-246), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR. Alternatively, a polynucleotide encoding an antibody or fragment thereof described herein can be generated from nucleic acid from a suitable source (e.g., PBMCs) using methods well- known in the art (e.g., PCR and other molecular cloning methods). For example, PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of a known sequence can be performed using genomic DNA obtained from hybridoma cells producing the antibody of interest. Such PCR amplification methods can be used to obtain nucleic acids comprising the sequence encoding the light chain and/or heavy chain of an antibody. Such PCR amplification methods can be used to obtain nucleic acids comprising the sequence encoding the variable light chain region and/or the variable heavy chain region of an antibody. The amplified nucleic acids can be cloned into vectors for expression in host cells and for further cloning, for example, to generate chimeric and humanized antibodies. If a clone containing a nucleic acid encoding a particular antibody or fragment thereof is not available, but the sequence of the antibody molecule or fragment thereof is known, a nucleic acid encoding the immunoglobulin or fragment can be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody described herein) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR can then be cloned into replicable cloning vectors using any method well-known in the art. DNA encoding anti-Env antibodies described herein can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the anti-Env antibodies). PBMCs can serve as a source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells (e.g., CHO cells from the CHO GS System™ (Lonza)), or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of anti-Env antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains with a coding sequence for a non-immunoglobulin polypeptide, or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Also provided are polynucleotides that hybridize under high stringency, intermediate or lower stringency hybridization conditions to polynucleotides that encode an antibody described herein. In specific embodiments, polynucleotides described herein hybridize under high stringency, intermediate or lower stringency hybridization conditions to polynucleotides encoding a VH domain and/or VL domain provided herein. Hybridization conditions have been described in the art and are known to one of skill in the art. For example, hybridization under stringent conditions can involve hybridization to filter- bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65°C; hybridization under highly stringent conditions can involve hybridization to filter-bound nucleic acid in 6xSSC at about 45°C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68°C. Hybridization under other stringent hybridization conditions are known to those of skill in the art and have been described, see, for example, Ausubel FM et al., eds., (1989) Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and 2.10.3. IV. Vectors, Cells, and Methods of Producing a Broadly Neutralizing Agent In certain aspects, provided herein are cells (e.g., host cells) expressing (e.g., recombinantly) antibodies described herein, which specifically bind to Env and related polynucleotides and expression vectors. Provided herein are vectors (e.g., expression vectors) comprising polynucleotides comprising nucleotide sequences encoding anti-Env antibodies or a fragment thereof described herein. In some embodiments, the vectors can be used for recombinant expression of an antibody described herein in host cells (e.g., mammalian cells). In some embodiments, the vectors can be used for administration of an antibody described herein to a patient in need thereof. Also provided herein are host cells comprising such vectors for recombinantly expressing anti-Env antibodies described herein. In a particular aspect, provided herein are methods for producing an antibody described herein, comprising expressing such antibody in a host cell. In some embodiments, the antibody comprises the PC68-L31_43J VH and VL. In certain aspects, provided herein is an isolated vector comprising a polynucleotide described herein. In some embodiments, the vector is a viral vector. In certain aspects, provided herein is a recombinant virus comprising a polynucleotide described herein. In some embodiments, the recombinant virus encodes an antibody described herein. In some embodiments, the recombinant virus encodes a bispecific antibody described herein. In some embodiments, the recombinant virus is a replication defective virus. Suitable replication defective viral vectors are known to those skilled in the art, for example, as disclosed in U.S. Pat. Nos. 7198784, 9408905, 9862931, 8067156, U.S. Pat. Appl. Pub. Nos. 20150291935, 20120220492, 20180291351, and 20170175137, each of which is incorporated herein by reference in its entirety. In some embodiments, the recombinant virus is a retrovirus or retroviral vector, for example, a lentivirus or lentiviral vector. In some embodiments, the recombinant virus is an adenovirus or adenoviral vector, HSV or HSV vector, or influenza virus or viral vector. In some embodiments, the recombinant virus is an adeno-associated virus (AAV). In some embodiments, the recombinant virus is for administration to a subject to prevent or treat HIV infection. In some embodiments, the recombinant virus is an adeno-associated virus (AAV) for administration to a subject to prevent or treat HIV infection. Recombinant AAV particles encoding an antibody that binds to HIV Env and methods for producing thereof are known to one skilled in the art, for example, as disclosed in US Patent 8,865,881 and US20190031740, each of which is incorporated by reference herein in its entirety for all purposes. See also, Lin and Balazs, Retrovirology 15:66 (2018) and van den Berg et al., Molecular Therapy: Methods & Clinical Development 14:100-112 (2019), each of which is incorporated by reference herein in its entirety for all purposes. In some embodiments, the antibody comprises the PC68-L31_43J VH and VL. In certain aspects, provided herein is a host cell comprising a polynucleotide described herein, or a vector described herein. In some embodiments, the vector encodes an antibody described herein. In some embodiments, a vector described herein comprises a first vector encoding a VH described herein and a second vector encoding a VL described herein. In some embodiments, a vector described herein comprises a first nucleotide sequence encoding a VH described herein and a second nucleotide sequence encoding a VL described herein. In some embodiments, the antibody comprises the PC68-L31_43J VH and VL. In some embodiments, the host cell is selected from the group consisting of E. coli, Pseudomonas, Bacillus, Streptomyces, yeast, CHO, YB/20, NS0, PER-C6, HEK-293T, NIH-3T3, Helga, BHK, Hep G2, SP2/0, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, BMT10 cell, plant cell, insect cell, and human cell in tissue culture. In some embodiments, the host cell is CHO. In certain aspects, provided herein is a method of producing an antibody that binds to HIV comprising culturing a host cell described herein so that the polynucleotide is expressed and the antibody is produced. In some embodiments, the method further comprises recovering the antibody. The isolated polypeptides, i.e., anti-HIV Env antibodies described herein can be produced by any suitable method known in the art. Such methods range from direct protein synthetic methods to constructing a DNA sequence encoding isolated polypeptide sequences and expressing those sequences in a suitable transformed host. In some embodiments, a DNA sequence is constructed using recombinant technology by isolating or synthesizing a DNA sequence encoding a wild-type protein of interest. Optionally, the sequence can be mutagenized by site-specific mutagenesis to provide functional analogs thereof. See, e.g. Zoeller et al., Proc. Nat'l. Acad. Sci. USA 81:5662- 5066 (1984) and U.S. Pat. No.4,588,585. In some embodiments, a DNA sequence encoding a polypeptide of interest would be constructed by chemical synthesis using an oligonucleotide synthesizer. Such oligonucleotides can be designed based on the amino acid sequence of the desired polypeptide and selecting those codons that are favored in the host cell in which the recombinant polypeptide of interest will be produced. Standard methods can be applied to synthesize an isolated polynucleotide sequence encoding an isolated polypeptide of interest. For example, a complete amino acid sequence can be used to construct a back-translated gene. Further, a DNA oligomer containing a nucleotide sequence coding for the particular isolated polypeptide can be synthesized. For example, several small oligonucleotides coding for portions of the desired polypeptide can be synthesized and then ligated. The individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly. Once assembled (by synthesis, site-directed mutagenesis or another method), the polynucleotide sequences encoding a particular isolated polypeptide of interest will be inserted into an expression vector and operatively linked to an expression control sequence appropriate for expression of the protein in a desired host. Proper assembly can be confirmed by nucleotide sequencing, restriction mapping, and expression of a biologically active polypeptide in a suitable host. As is well-known in the art, in order to obtain high expression levels of a transfected gene in a host, the gene must be operatively linked to transcriptional and translational expression control sequences that are functional in the chosen expression host. In certain embodiments, recombinant expression vectors are used to amplify and express DNA encoding antibodies or fragments thereof. Recombinant expression vectors are replicable DNA constructs, which have synthetic or cDNA-derived DNA fragments encoding a polypeptide chain of an antibody or fragment thereof operatively linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences. Such regulatory elements can include an operator sequence to control transcription. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants can additionally be incorporated. DNA regions are operatively linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operatively linked to DNA for a polypeptide if it is expressed as a precursor, which participates in the secretion of the polypeptide; a promoter is operatively linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operatively linked to a coding sequence if it is positioned so as to permit translation. Structural elements intended for use in yeast expression systems include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it can include an N-terminal methionine residue. This residue can optionally be subsequently cleaved from the expressed recombinant protein to provide a final product. The choice of expression control sequence and expression vector will depend upon the choice of host. A variety of host-expression vector systems can be utilized to express antibody molecules described herein (see, e.g., U.S. Patent No. 5,807,715). Such host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells which can, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule described herein in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli and B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems (e.g., green algae such as Chlamydomonas reinhardtii) infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS (e.g., COS1 or COS), CHO, BHK, MDCK, HEK 293, NS0, PER.C6, VERO, CRL7O3O, HsS78Bst, Helga, and NIH 3T3, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20 and BMT10 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). In a specific embodiment, cells for expressing antibodies described herein are CHO cells, for example CHO cells from the CHO GS System™ (Lonza). In a particular embodiment, cells for expressing antibodies described herein are human cells, e.g., human cell lines. In a specific embodiment, a mammalian expression vector is pOptiVEC™ or pcDNA3.3. In a particular embodiment, bacterial cells such as E. coli, or eukaryotic cells (e.g., mammalian cells), especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary (CHO) cells in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking MK & Hofstetter H (1986) Gene 45: 101-105; and Cockett MI et al., (1990) Biotechnology 8: 662-667). In certain embodiments, antibodies described herein are produced by CHO cells or NS0 cells. In a specific embodiment, the expression of nucleotide sequences encoding antibodies described herein which immunospecifically bind Env is regulated by a constitutive promoter, inducible promoter or tissue specific promoter. For applications where it is desired that the antibodies described herein be expressed in vivo, for example in a subject in need of treatment with an antibody described herein, any vector that allows for the expression of the antibodies and is safe for use in vivo may be used. In some embodiments, the vector is a viral vector. Viral vectors can include poxvirus (vaccinia), including vaccinia Ankara and canarypox; adenoviruses, including adenovirus type 5 (Ad5); rubella; sendai virus; rhabdovirus; alphaviruses; and adeno-associated viruses. In some embodiments, the viral vector is an adeno-associated virus. Alternatively, a polynucleotide encoding the antibody could be delivered as DNA or RNA to the subject for in vivo expression of the antibody. Suitable host cells for expression of a polypeptide of interest such as an antibody described herein include prokaryotes, yeast, insect or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram-positive organisms, for example E. coli or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin. Cell-free translation systems could also be employed. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al. (Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., 1985), the relevant disclosure of which is hereby incorporated by reference. Additional information regarding methods of protein production, including antibody production, can be found, e.g., in U.S. Patent Publication No. 2008/0187954, U.S. Patent Nos.6,413,746 and 6,660,501, and International Patent Publication No. WO 04009823, each of which is hereby incorporated by reference herein in its entirety. Various mammalian or insect cell culture systems are also advantageously employed to express a recombinant protein such as an antibody described herein. Expression of recombinant proteins in mammalian cells can be performed because such proteins are generally correctly folded, appropriately modified and completely functional. Examples of suitable mammalian host cell lines include but are not limited to CHO, VERO, BHK, Hela, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, COS (e.g., COS1 or COS), PER.C6, VERO, HsS78Bst, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20, BMT10 and HsS78Bst cells. Mammalian expression vectors can comprise non-transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking non-transcribed sequences, and 5' or 3' non-translated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988). The proteins produced by a transformed host can be purified according to any suitable method. Such standard methods include chromatography (e.g., ion exchange, affinity and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification. Affinity tags such as hexahistidine, maltose binding domain, influenza HA peptide sequence and glutathione-S-transferase can be attached to the protein to allow easy purification by passage over an appropriate affinity column. Isolated proteins can also be physically characterized using such techniques as proteolysis, nuclear magnetic resonance and x-ray crystallography. For example, supernatants from systems, which secrete recombinant protein, e.g., an antibody, into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further an agent. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein. Recombinant protein produced in bacterial culture can be isolated, for example, by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. High performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of a recombinant protein can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Methods known in the art for purifying antibodies and other proteins also include, for example, those described in U.S. Patent Publication Nos. 2008/0312425, 2008/0177048, and 2009/0187005, each of which is hereby incorporated by reference herein in its entirety. In specific embodiments, an antibody described herein is isolated or purified. Generally, an isolated antibody is one that is substantially free of other antibodies with different antigenic specificities than the isolated antibody. For example, in a particular embodiment, a preparation of an antibody described herein is substantially free of cellular material and/or chemical precursors. The language "substantially free of cellular material" includes preparations of an antibody in which the antibody is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, an antibody that is substantially free of cellular material includes preparations of antibody having less than about 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein") and/or variants of an antibody, for example, different post-translational modified forms of an antibody. When the polypeptide (e.g., antibody described herein) is recombinantly produced, it is also generally substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, 2%, 1%, 0.5%, or 0.1% of the volume of the protein preparation. When the polypeptide (e.g., antibody described herein) is produced by chemical synthesis, it is generally substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals, which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide (e.g., antibody described herein) have less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest. In some embodiments, antibodies described herein are isolated or purified. V. Pharmaceutical Compositions Compositions comprising the antibodies or antigen-binding fragments thereof described herein (e.g., PC68-L31_43J) are also provided. Further provided herein are compositions comprising a polynucleotide or polynucleotides encoding the antibodies or antigen-binding fragments thereof described herein. In some embodiments, the polynucleotide comprises mRNA. In some embodiments, the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof. In some embodiments, the at least one chemically modified nucleobase is selected from the group consisting of pseudouracil (ψ), N1-methylpseudouracil (m1ψ), 1-ethylpseudouracil, 2-thiouracil, 4′-thiouracil, 5-methylcytosine, 5-methyluracil, 5- methoxyuracil, and any combination thereof. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the antibody comprises PC68-L31_43J. In some embodiments, the composition is a lyophilized composition. In some embodiments, the composition is formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration. In certain aspects, provided herein is a pharmaceutical composition comprising an antibody described herein (e.g., PC68-L31_43J) and a pharmaceutically acceptable excipient. In some embodiments, the antibody is an intact antibody. In some embodiments, the antibody is an antigen- binding antibody fragment. In some embodiments, the composition is formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration. In some embodiments, the antibody comprises PC68-L31_43J. In another embodiment, the disclosure provides a pharmaceutical composition comprising an antibody described herein (e.g., PC68-L31_43J). Such compositions are intended for prevention and treatment of HIV infection. In some embodiments, the antibody comprises PC68-L31_43J. In further embodiments of the present disclosure, a composition comprising the antibody described herein can additionally be combined with other compositions for the treatment of HIV infection or the prevention of HIV transmission. In some embodiments, an antibody described herein may be administered within a pharmaceutically acceptable diluent, carrier, or excipient, in unit dose form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer to individuals being treated for HIV infection. In some embodiments, the administration is prophylactic. Any appropriate route of administration may be employed, for example, administration may be parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal, intranasal, aerosol, suppository, oral administration, vaginal, or anal. The pharmaceutical compositions described herein are prepared in a manner known per se, for example, by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see for example, in Remington: The Science and Practice of Pharmacy (21st ed.), ed. A.R. Gennaro, 2005, Lippincott Williams & Wilkins, Philadelphia, PA, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 2013, Marcel Dekker, New York, NY). The injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, tablets, pills, or capsules. The formulations can be administered to human individuals in therapeutically or prophylactic effective amounts (e.g., amounts which prevent, eliminate, or reduce a pathological condition) to provide therapy for a disease or condition. The preferred dosage of therapeutic agent to be administered is likely to depend on such variables as the type and extent of the disorder, the overall health status of the particular patient, the formulation of the compound excipients, and its route of administration. In certain embodiments, the compositions described herein can be formulated for topical administration, and in certain embodiments the composition is formulated for vaginal or rectal administration. The composition may be formulated as a gel, or formulated as a topical cream, ointment, lotion or foam formulation. Useful formulations are known in the art, for example, as disclosed in U.S. Patent Appl. Pub. No. 20130022619, which is incorporated by reference herein in its entirety for all purposes. In certain embodiments, the composition may further comprise a pharmaceutically acceptable excipient, a lubricant, or an antiviral agent. The topical formulations of the present invention can be used to prevent HIV infection in a human, or to inhibit transmission of the HIV virus from an infected human to another human. The topical formulations of the present invention can inhibit the growth or replication of HIV. The topical formulations are useful in the prophylactic treatment of humans who are at risk for HIV infection. The topical formulations also can be used to treat objects or materials, such as contraceptive devices (for example condoms or intrauterine devices), medical equipment, supplies, or fluids, including biological fluids, such as blood, blood products, and tissues, to prevent or inhibit viral infection of a human. Such topical formulations also are useful to prevent transmission, such as sexual transmission of viral infections, e.g., HIV, which is the primary way in which HIV is transmitted globally. The methods of prevention or inhibition or retardation of transmission of viral infection, e.g., HIV infection, in accordance with the present invention, comprise vaginal, rectal, penile or other topical treatment with an antiviral effective amount of a topical preparation of the present invention, alone or in combination with another antiviral compound as described herein. In some embodiments, the composition is in the form of a cream, lotion, gel, or foam that is applied to the affected skin or epithelial cavity, and preferably spread over the entire skin or epithelial surface which is at risk of contact with bodily fluids. Such formulations, which are suitable for vaginal or rectal administration, may be present as aqueous or oily suspensions, solutions or emulsions (liquid formulations) containing in addition to the active ingredient, such carriers as are known in the art to be appropriate. These formulations are useful to protect not only against sexual transmission of HIV, but also to prevent infection of a baby during passage through the birth canal. Thus the vaginal administration can take place prior to sexual intercourse, during sexual intercourse, and immediately prior to childbirth. As a vaginal formulation, the active ingredient may be used in conjunction with a spermicide and may be employed with a condom, diaphragm, sponge or other contraceptive device. Examples of suitable spermicides include nonylphenoxypolyoxyethylene glycol (nonoxynol 9), benzethonium chloride, and chlorindanol. Suitably, the pH of the composition is 4.5 to 8.5. Vaginal compositions preferably have a pH of 4.5 to 6, most preferably about 5. Vaginal formulations include suppositories (for example, gel-covered creams), tablets and films. The suppositories can be administered by insertion with an applicator using methods well- known in the art. Vaginal formulations further include vaginal ring devices formulated for sustained release. See, e.g., Morrow et al., Eur J Pharm Biopharm. 77:3-10 (2011), Zhao et al., Antimicrob Agents Chemother.61:pii: e02465-16 (2017). Buccal formulations include creams, ointments, gels, tablets or films that comprise ingredients that are safe when administered via the mouth cavity. Buccal formulations can also comprise a taste-masking or flavoring agent. The present compositions may be associated with a contraceptive device or article, such as a vaginal ring device, an intrauterine device (IUD), vaginal diaphragm, vaginal sponge, pessary, condom, etc. In some embodiments, the compositions described herein are used in conjunction with condoms, to enhance the risk-reducing effectiveness of condoms and provide maximum protection for users. The composition can either be coated onto condoms during manufacture, and enclosed within conventional watertight plastic or foil packages that contain one condom per package, or it can be manually applied by a user to either the inside or the outside of a condom, immediately before use. As used herein, "condom" refers to a barrier device, which is used to provide a watertight physical barrier between male and female genitalia during sexual intercourse, and which is removed after intercourse. This term includes conventional condoms that cover the penis; it also includes so-called "female condoms", which are inserted into the vaginal cavity prior to intercourse. In another embodiment, a composition described herein is in the form of an intra-vaginal pill, an intra-rectal pill, or a suppository. The suppository or pill should be inserted into the vaginal or rectal cavity in a manner that permits the suppository or pill, as it dissolves or erodes, to coat the vaginal or rectal walls with a prophylactic layer of an antibody described herein. In certain embodiments, the composition may further comprise a pharmaceutically acceptable excipient, a lubricant, or an antiviral agent. Compositions used in the methods of this invention may also comprise other active agents, such as another agent to prevent HIV infection, and agents that protect individuals from conception and other sexually transmitted diseases. Thus, in another embodiment the compositions used in this invention further comprise a second anti-HIV agent, a virucide effective against viral infections other than HIV, and/or a spermicide. The compositions used in this invention may also contain a lubricant that facilitates application of the composition to the desired areas of skin and epithelial tissue, and reduces friction during sexual intercourse. In the case of a pill or suppository, the lubricant can be applied to the exterior of the dosage form to facilitate insertion. In the cream or ointment embodiments of the present invention, the topical formulation comprises one or more lubricants. The gels and foams of the present invention optionally can include one or more lubricants. Non-limiting examples of useful lubricants include cetyl esters wax, hydrogenated vegetable oil, magnesium stearate, methyl stearate, mineral oil, polyoxyethylene-polyoxypropylene copolymer, polyethylene glycol, polyvinyl alcohol, sodium lauryl sulfate, white wax, or mixtures of two or more of the above. The gel formulations of the present invention comprise one or more gelling agents. Non- limiting examples of useful gelling agents include carboxylic acid polymers including acrylic acid polymers crosslinked with cross links such as allyl ethers of sucrose (e.g. carbomer brand thickeners), cetostearyl alcohol, hydroxymethyl cellulose, polyoxyethylene-polyoxypropylene copolymer, sodium carboxymethylcellulose, polyvinyl pyrrolidone, or mixtures of two or more thereof. VI. Therapeutic Uses and Methods In one aspect, provided herein is a method of treating HIV or inhibiting transmission of HIV. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of an antibody described herein (e.g., PC68- L31_54Q), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus (e.g., recombinant AAV) described herein. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method of inhibiting transmission of HIV comprises administering to a subject in need thereof an effective amount of an antibody described herein (e.g., PC68-L31_54Q). In some embodiments, the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV. In some embodiments, the subject at risk of being exposed to HIV is a health care worker, a sexual partner of an HIV infected individual, or a sex worker. In some embodiments, the subject that has been exposed to HIV or is at risk of being exposed to HIV is a newborn. In some embodiments, the antibody is PC68-L31_54Q. In one aspect, provided herein is a method of reducing the risk of a subject becoming infected with HIV comprising administering to the subject in need thereof an effective amount of an antibody (e.g., bispecific antibody) described herein (e.g., PC68-L31_54Q), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV. In some embodiments, the subject at risk of being exposed to HIV is a health care worker, a sexual partner of an HIV infected individual, or a sex worker. In some embodiments, the subject that has been exposed to HIV or is at risk of being exposed to HIV is a newborn. In one aspect, provided herein is an antibody (e.g., PC68-L31_54Q), a pharmaceutical composition, an isolated polynucleotide, or a recombinant virus for reducing the risk of a subject becoming infected with HIV. In some embodiments, the antibody is PC68-L31_54Q. In one aspect, provided herein is a method for passively immunizing a subject comprising administering to the subject in need thereof an effective amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the subject has been exposed to HIV. In some embodiments, the subject is at risk of being exposed to HIV. In some embodiments, the subject at risk of being exposed to HIV is a health care worker, a sexual partner of an HIV infected individual, or a sex worker. In some embodiments, the subject that has been exposed to HIV or is at risk of being exposed to HIV is a newborn. In one aspect, provided herein is an antibody (e.g., PC68-L31_43J), a pharmaceutical composition, an isolated polynucleotide, or a recombinant virus for passively immunizing a subject. In some embodiments, the antibody is PC68-L31_43J. Further provided herein is a method of neutralizing an HIV virus comprising contacting the virus with an effective amount of an antibody described herein (e.g., PC68-L31_43J). In some embodiments, the virus is comprised by a composition, for example, a fluid, including a biological fluid, such as blood or blood product. In certain embodiments, the method comprises adding an antibody described herein to a composition comprising HIV in a sufficient amount or concentration to neutralize the HIV. In some embodiments, the antibody is PC68-L31_43J. Further provided herein is a method of reducing viral load comprising administering to a subject in need thereof an effective amount of an antibody (e.g., bispecific antibody) described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a recombinant AAV encoding an antibody (e.g., a bispecific antibody) described herein. In some embodiments, the antibody is PC68- L31_43J. In some embodiments of a method described herein, the antibody can be a chimeric antibody, engineered antibody, recombinant antibody, or a monoclonal antibody described herein. In some embodiments, the antibody is a full antibody, a Fab fragment, or an F(ab')2 fragment described herein. In a specific embodiment, the antibody is an engineered monoclonal antibody described herein. In a specific embodiment, the antibody is a recombinant monoclonal antibody described herein. In a specific embodiment, the antibody is a chimeric monoclonal antibody described herein. In a specific embodiment, the antibody is a Fab described herein. In a specific embodiment, the antibody is an F(ab')2 fragment described herein. In some embodiments, a method of preventing HIV infection provided herein comprises administering to a subject in need thereof a therapeutically sufficient amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, the antibody is PC68-L31_43J. In some embodiments, a method of treating HIV/AIDS provided herein comprises administering to a subject in need thereof a therapeutically sufficient amount of an antibody described herein (e.g., PC68-L31_43J), a pharmaceutical composition described herein, an isolated polynucleotide described herein, or a recombinant virus described herein. In some embodiments, a method of treating HIV/AIDS comprises administering an antibody described herein. In some embodiments, a method of treating HIV/AIDS comprises administering a pharmaceutical composition described herein. In some embodiments, a method of treating HIV/AIDS comprises administering an isolated polynucleotide described herein. In some embodiments, a method of treating HIV/AIDS comprises administering a recombinant virus described herein. In one aspect, provided herein is an antibody, a pharmaceutical composition, an isolated polynucleotide, or a recombinant virus for treating HIV/AIDS. In some embodiments, the antibody is PC68-L31_43J. In some embodiments, the administering to the subject is by at least one mode selected from oral, parenteral, subcutaneous, intramuscular, intravenous, vaginal, rectal, buccal, sublingual, and transdermal In some embodiments, a method of treatment described herein further comprises administering at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent comprises an antiretroviral therapy (ART) agent, a reservoir activator, an immunomodulator, a second antibody, or a second and third antibody. In some embodiments, the additional therapeutic agent comprises a second antibody. In some embodiments, the additional therapeutic agent comprises a second and third antibody. In some embodiments, the additional therapeutic agent comprises a second and optionally third antibody, which is an anti-HIV antibody. In some embodiments, the additional therapeutic agent comprises a second and optionally third antibody, which is an anti-HIV Env antibody. In some embodiments, the additional therapeutic agent comprises a second and optionally third anti-HIV Env antibody, which binds to an HIV Env epitope region different from the HIV Env epitope region bound by an antibody described herein. In some embodiments, the additional therapeutic agent comprises a second and optionally third anti-HIV Env antibody, which binds to the CD4 binding site (CD4bs), V2 apex, N332/V3 base supersite, silent face, gp120-gp41 interface, fusion peptide (FP) or membrane-proximal external region (MPER). In some embodiments, the additional therapeutic agent comprises a second and optionally third anti-HIV Env antibody, which binds to the CD4 binding site (CD4bs), V2 apex, silent face, gp120-gp41 interface or membrane-proximal external region (MPER). In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the CD4 binding site (CD4bs) epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the V2 apex epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the N332/V3 base supersite epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the gp120- gp41 interface epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the silent face epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the fusion peptide (FP) epitope region. In some embodiments, the additional therapeutic agent comprises a second anti-HIV Env antibody, which binds to the membrane-proximal external region (MPER). In certain embodiments, the subject is at risk for exposure to HIV. In some embodiments, the subject is infected with HIV. In some embodiments, the subject is diagnosed with AIDS. In certain embodiments, the subject at risk for exposure to HIV is a health care worker. In certain embodiments, the subject at risk for exposure to HIV is a sex worker. In certain embodiments, the subject at risk for exposure to HIV is a sexual partner of an HIV infected individual. In certain embodiments, the subject at risk for exposure to HIV is a newborn. The invention also features methods of blocking HIV infection in a subject (e.g., a human) at risk of HIV transmission. For example, in one aspect, the subject may be a fetus of an HIV- infected pregnant female and the method includes administering to the HIV-infected pregnant female an antibody described herein (e.g., PC68-L31_43J), thereby blocking the HIV infection in the fetus. In other instances, the subject is a newborn having an HIV-infected mother, a subject at risk of HIV transmission following a needle stick injury, or a subject at risk of HIV transmission following a sexual exposure to an HIV-infected individual. In some embodiments, the antibody is PC68-L31_43J. In instances when the subject is a newborn having an HIV-infected mother, the newborn can be administered an antibody described herein (e.g., PC68-L31_43J) peripartum and/or postpartum, for example, prior to, during, and/or following breastfeeding from the HIV-infected mother, in order to block an HIV infection in the newborn. In some embodiments, the antibody is PC68-L31_43J. In instances when the subject is at risk of HIV transmission following a sexual exposure to an HIV-infected individual, the subject can be administered an antibody described herein (e.g., PC68-L31_43J) following the sexual exposure in order to block an HIV infection in the subject. In some embodiments, the antibody is PC68-L31_43J. In some embodiments, an antibody described herein can be used as a microbicides to prevent mucosal HIV acquisition. In some embodiments, an antibody described herein is used to prevent vaginal or rectal acquisition of HIV. In some embodiments, an antibody described herein can be used as a microbicides to reduce the likelihood of mucosal HIV acquisition. In some embodiments, an antibody described herein is used to reduce the likelihood of vaginal or rectal acquisition of HIV. In any of the methods described above, further administration of ART and/or an immunomodulator and/or a second antibody is contemplated. For example, the ART and/or immunomodulator and/or a second antibody can be administered in conjunction with, prior to, concurrently with, subsequent to, or within the context of a treatment regimen that includes administration of an antibody described herein. An antibody described herein, or a pharmaceutical composition described herein can be delivered to a subject by a variety of routes, such as oral, parenteral, subcutaneous, intravenous, intradermal, transdermal, intranasal, vaginal, or anal. In some embodiments, the antibody or pharmaceutical composition is administered intravenously, vaginally, or anally. The amount of an antibody described herein, or a pharmaceutical composition described herein, which will be effective in the treatment and/or prevention of a condition will depend on the nature of the disease, and can be determined by standard clinical techniques. The precise dose to be employed in a pharmaceutical composition will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each subject's circumstances. For example, effective doses may also vary depending upon means of administration, target site, physiological state of the patient (including age, body weight and health), whether the patient is human or an animal, other medications administered, or whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but non-human mammals including transgenic mammals can also be treated. Treatment dosages are optimally titrated to optimize safety and efficacy. In certain embodiments, an in vitro assay is employed to help identify optimal dosage ranges. Effective doses may be extrapolated from dose response curves derived from in vitro or animal model test systems. Detection & Diagnostic Uses An antibody described herein can be used to detect HIV and/or assay HIV levels in a biological sample using classical immunohistological methods known to those of skill in the art, including immunoassays, such as the enzyme linked immunosorbent assay (ELISA), immunoprecipitation, or Western blotting. An antibody described herein can also be used as an imaging agent, for example, a tissue-penetrating imaging agent. In some embodiments, an antibody described herein is conjugated with a detectable label. Suitable assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (121In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. Such labels can be used to label an antibody or fusion polypeptide described herein. Alternatively, a second antibody that recognizes an antibody described herein can be labeled and used in combination with the antibody described herein to detect HIV levels. As used herein, the term "biological sample" refers to any biological sample obtained from a subject, cell line, tissue, or other source potentially comprising HIV. Methods for obtaining tissue biopsies and body fluids from animals (e.g., humans) are well-known in the art. In another embodiment, an antibody described herein can be used to detect levels of HIV, which levels can then be linked to certain disease symptoms. An antibody described herein may carry a detectable or functional label. An antibody described herein can carry a fluorescence label. Exemplary fluorescence labels include, for example, reactive and conjugated probes, e.g., Aminocoumarin, Fluorescein and Texas red, Alexa Fluor dyes, Cy dyes and DyLight dyes. An antibody described herein can carry a radioactive label, such as the isotopes 3H, 14C, 32P, 35S, 36Cl, 51Cr, 57Co, 58Co, 59Fe, 67Cu, 90Y, 99Tc, 111In, 117Lu, 121I, 124I, 125I, 131I, 198Au, 211At, 213Bi, 225Ac and 186Re. When radioactive labels are used, currently available counting procedures known in the art may be utilized to identify and quantitate the specific binding of an antibody described herein to HIV. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques as known in the art. This can be achieved by contacting a sample or a control sample with an antibody described herein under conditions that allow for the formation of a complex between the antibody and HIV. Any complexes formed between the antibody and HIV are detected and compared in the sample and the control. An antibody described herein can also be used to purify HIV via immunoaffinity purification. In some aspects, provided herein are methods for in vitro detecting HIV in a sample, comprising contacting said sample with an antibody described herein. In some aspects, provided herein is the use of an antibody described herein, for in vitro detecting HIV in a sample. In one aspect, provided herein is an antibody or pharmaceutical composition described herein for use in the detection of HIV in a subject. In one aspect, provided herein is an antibody or pharmaceutical composition described herein for use as a diagnostic. In one preferred embodiment, the antibody comprises a detectable label. In some embodiments, the subject is a human. In some embodiments, the method of detecting HIV in a sample comprises contacting the sample with an antibody described herein. In some embodiments, the present disclosure provides methods of purifying HIV from a sample. In some embodiments, the method of purifying HIV from a sample comprises contacting the sample with an antibody described herein under conditions that allow the antibody to bind to HIV. In some embodiments, the antibody comprises a tag, for example, hexa-histidine tag or FLAG-tag to facilitate the purification of HIV. VII. Kits Provided herein are kits comprising one or more antibodies described herein (e.g., PC68- L31_54Q). In some embodiments, a pharmaceutical pack or kit described herein comprises one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein, such as one or more antibodies described herein. In some embodiments, a kit contains an antibody described herein or a pharmaceutical composition described herein, and a second prophylactic or therapeutic agent used in the treatment or prevention of HIV. In some embodiments, the second agent is an antiretroviral agent. In some embodiments, the second agent is a reservoir activator. In some embodiments, the second agent is an immunomodulator. In some embodiments, the second agent is one or more anti-HIV antibody. In some embodiments, the second agent is one or more anti-HIV Env antibody that binds to an HIV Env epitope region different from the HIV Env epitope region bound by an antibody described herein (e.g., PC68- L31_54Q). In some embodiments, the second agent is one or more anti-HIV Env antibody that binds to the CD4 (receptor) binding site (CD4bs), the V2 apex, N332 glycan site, gp120-gp41 interface, fusion peptide (FP), silent face, and the membrane proximal external region (MPER). In some embodiments, the second agent is one or more anti-HIV Env antibody that binds to the CD4 binding site (CD4bs), V2 apex, silent face, gp120-gp41 interface or membrane-proximal external region (MPER). In some embodiments, a kit contains an antibody described herein or a pharmaceutical composition described herein, and a reagent used in the detection of HIV. In some embodiments, the detection reagent comprises DNA primers for the detection of HIV. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In some embodiments, the antibody comprises PC68-L31_54Q. In some embodiments, a kit described herein comprises an antibody described herein or a pharmaceutical composition described herein and a) a detection reagent, b) an HIV antigen, c) a notice that reflects approval for use or sale for human administration, or d) any combination thereof. Embodiments of the present disclosure can be further defined by reference to the following non-limiting examples, which describe in detail preparation of certain antibodies of the present disclosure and methods for using antibodies of the present disclosure. It will be apparent to those skilled in the art that many modifications, both to materials and methods, can be practiced without departing from the scope of the present disclosure. All documents, patent, and patent applications cited herein are hereby incorporated by reference, and may be employed in the practice described herein. EXAMPLES Example 1. Isolation of a broadly neutralizing antibody lineage Development of several bnAb lineages from IAVI protocol C, a longitudinal cohort of 439 HIV infected individuals from Sub-Saharan Africa have previously described. Landais et al. PLOS Pathogens 2016, 12 (1), e1005369. PC68 was the best neutralizer from this cohort, with 98% neutralization breadth and median ID50 of ~1266 on a 37 pseudovirus panel. However, the serum epitope specificity was ambiguous. Serum antibody depletion by monomeric gp120 adsorption or competition by addition of CD4bs and MPER epitope mimetics did not alter the donor serum neutralization profile. Single or combined amino acid substitutions in known epitopes had no effect on neutralization. Overall, these observations suggested an unknown epitope with trimer dependency. Neutralization was negatively impacted by pseudoviruses treated with kifunensine, suggesting glycan dependency. Due to the ambiguity of the broadly neutralizing epitope specificity in the PC68 donor serum, a broad targeting approach to bnAb isolation was employed as opposed to flow cytometric B cell sorting. B cells isolated from peripheral blood mononuclear cells (PBMC) were activated in bulk, then subjected to a high throughput single cell screen for binding specificity against target antigens. Since previous attempts to map the antibody epitope indicated trimer specificity, native- like soluble SOSIP trimers stabilized with a gp120-gp41 disulfide bond (SOS) and an Ile559Pro (IP) from 4 different virus isolates were screened as antigens. 267 unique monoclonal antibodies (mAbs) representing 52 different lineages that bound between 1 to 4 SOSIPs were identified. MAbs were screened for neutralization against the multiclade 12 pseudovirus global panel. Antibodies from most lineages displayed little to no neutralization suggesting that these lineages did not play a significant role in the serum neutralizing activity. Of the 6 lineages containing members displaying detectable neutralizing activity in the 12 virus panel, lineage 31 (L31), the most populated lineage with 58 mAbs, was the most broad and potent. Figure 1. Many members neutralized all viruses on the indicator panel with a geometric mean IC50 of 0.093 μg/mL. The degree of nucleotide mutations among members in the various lineages were directly associated with pseudovirus neutralization breath and potency. A key characteristic feature of most HIV bnAbs is a high level of somatic hypermutation (SHM), with heavy chain V-region SHM ranging from ~6-25%. L31 antibodies were some of the most mutated of all isolated mAbs, being 17.7%-28.3% mutated from the IGHV3-30 germline gene and 11.5%-22.6% from the IGLV3-21 germline gene. Figure 2. These antibodies have an average human heavy chain complementarity determining region 3 (HCDR3) length of 15 amino acid, in contrast to bnAbs whose neutralization is mediated primarily by glycan recognition via a long HCDR3. Interestingly, all members of lineage 31 monoclonal antibodies featured an acidic 5 amino acid insertion (Figure 2), suggesting a key role by this motif in epitope recognition. Of these antibodies, PC68-L31_54Q was the best neutralizer with a geometric mean IC50 of 0.076 μg/mL and 79% breadth on a 118 multiclade pseudovirus panel (Table 4 and Figure 5). In sum, lineage 31 antibodies have features reminiscent of other known bnAbs such as large insertions and extensive SHM and are likely a major contributor to Donor 68’s serum neutralization activity. Table 4. Neutralization of 118 multiclade pseudovirus panel. VRCO1 and N6 are positive control antibodies. Den3 is a negative control antibody. Neutralization IC50 (ug/mL) Lineage 31 + - 3
Figure imgf000158_0001
HIV-16845-2.22 C N/D N/D N/D N/D >20 Ce1086_B2 C (T/F) 0.013 0.029 >20 0.008 >20
Figure imgf000159_0001
R1166.c01 CRF01_AE 0.132 0.126 0.394 0.089 >20 R3265.c06 CRF01_AE >20 >20 >20 1.705 >20
Figure imgf000160_0001
235-47 CRF02_AG 0.006 0.026 0.021 0.009 >20 RHPA4259.7 B 0.004 0.053 0.018 0.009 >20
Figure imgf000161_0001
Example 2. L31 Antibodies bind proximal to the CD4bs The most potent bnAb PC68-L31_54Q antibody and a moderately potent antibody PC68- L31_43J were selected for epitope characterization. HIV Env trimer binding by PC68-L31_54Q and PC68-L31_43J was competed with well-known HIV bnAbs (Figure 3). Wu et al. Science 2010, 329 (5993), 856; Walker et al. Nature 2011, 477 (7365), 466; Falkowska et al. Immunity 2014, 40 (5), 657. Only the CD4bs antibody VRC01 impeded PC68 antibody binding. However, because PC68 serum depleted with a CD4bs mimic designed to bind VRC01 retained neutralization (Landais et al. PLOS Pathogens 2016, 12 (1), e1005369), the observed competition by VRC01 suggested PC68_L31 antibodies bound at or near the CD4bs in a different manner than previously characterized CD4bs antibodies. Using biolayer interferometry, we detected selective binding to BG505 trimer but not gp120 for PC68-L31_54Q (Figure 3), suggesting that PC68-L31_54Q bound a quaternary epitope encompassing the CD4bs. Example 3. A long HCDR2 insertion is central to the quaternary specificity of L31 mAbs To better define the epitope of PC68 lineage 31 antibodies, a 2.9 Å cryoEM structure of PC68-L31_43J complexed with BG505 SOSIP was solved. Figure 4. The model confirmed that PC68-L31_43J bound near the CD4bs with substantial epitope footprint overlap with VRC01, but with extensive contacts between the HCDR2 and the gp120 interprotomer region. PC68-L31_54Q, the more potent member of the family, was homology modeled using the PC68-L31_43J structure to assess key contacts. HCDRs 1 and 3 facilitated contacts with the main gp120 protomer near the CD4bs, with HCDR3 interacting with several conserved residues within and near the CD4 binding loop. Many of these interactions were side chain mediated. In the HCDR3, other than the E370gp120 side chain interaction with the indole amine of W100HC, a substantial number of hydrogen bonding contacts were made by backbone contacts, such as interactions between F96HC : D368gp120, T98HC : D368gp120 side chain, and potentially Y99HC side chain : R429gp120. HCDR1 resides S25HC and N31HC seemed to interact with the backbone carbonyls of A281gp120 and Q428gp120 respectively. The recognition of the adjacent gp120 (gp120adj) was driven by the 5 AA insertion in the HCDR2 which extends the HCDR2 loop to mediate an extensive network of interactions with the positively charged region at the base of the V3 loop of the adjacent protomer. E53HC and D54HC each form salt bridges with R308gp120adj (35.9% R, 37.1% H) and R304gp120adj (94.7% conserved) at the base of V3, and D55HC with K207gp120adj of a quaternary CD4bs region recently described as CD4bs2 (99.3% conserved). Backbone mediated hydrogen bonding interactions were also observed, including between H52fHC and the backbone carbonyl of G314gp120adj, and D54HC backbone amine group with the Y318gp120adj. I52eHC side chain further bolsters the interaction by filling the pocket formed between the CD4bs2 and the C-terminus of the a1 helix. The paratope interaction with electropositive residues at the gp120 interprotomer region were reminiscent of the mode of quaternary epitope recognition by several VRC01 antibodies with acidic heavy chain framework region 3 (HFWR3) insertions, including 3BNC117, VRC03, VRC06, antibodies in which these quaternary contacts are not required for binding to the CD4bs but essential for neutralization. This motif is also shared by the 1-18 bnAb family, a VH1-46 class CD4bs bnAb, which acquires a 6 AA insertion to interact with the adjacent V3 loop in a similar manner. However, compared to these other bnAbs, PC68-L31_43J recognized a much larger contact surface area on the adjacent gp120, consistent with its strong trimer dependence for binding. Example 4. PC68_L31 antibodies evade steric pressures imposed by N-glycans PC68 donor serum was previously observed to neutralize viruses produced in the presence of kifunensine better than those with wildtype glycoforms. Antibodies such as VRC01 that avoids proximal glycans demonstrate improved neutralization in viruses expressing fully high-mannose glycans. Similarly, the L31 epitope is heavily surrounded by glycans such as N363, N386, N197, and potentially N301, N276 along with additional glycans in V5 and V2 that are unresolved in our EM reconstruction. The LCDR loops come in close contact with these glycans; LCDR1 is positioned up against N363, and LCDR2 and LCDR3 are both in close proximity to N197 and V2. Analysis of L31 member LC sequences revealed a high enrichment of Gly, Ser residues and deletions, which confer loop flexibility, analogous mutations and deletions observed in the LCDR1 of VRC01-class antibodies that somatically mature to avoid clashes with the N276 glycan. Singly knocking out the epitope proximal N-linked glycans typically had no impact on or enhanced pseudovirus neutralization IC50 (Figure 6), confirming that the binding of L31 mAbs not dependent on glycan recognition, but avoidance instead. Example 5. Lineage 31 antibodies potently neutralize circulating HIV strains Due to the mutability of HIV, it has been demonstrated that a cocktail of broadly neutralizing antibodies targeting multiple epitopes is required to provide protection and suppress viral rebound. In human efficacy trails, VRC01 was unable to protect against acquisition of HIV infection when given as a monotherapy. Corey et al. New England Journal of Medicine 2021, 384 (11), 1003. These studies revealed that a high potency IC80 threshold of less than 1 μg/mL is necessary for protection for a given virus. Accordingly, a cocktail of bnAbs with high neutralization potencies that in concert can complement neutralization of single bnAb resistant viruses would be required for protective efficacy. Because PC68_L31 mAbs bound the CD4bs in a different manner than VRC01-class bnAbs, the question whether known VRC01-class antibody resistant mutations also influenced sensitivity to L31 mAbs was investigated. Schommers et al. Cell 2020, 180 (3), 471. These mutations occurring around the N276 glycan and in the V5 region minimally affected or even enhanced neutralization against all mutants in the panel, suggesting that potent members of L31 may potently neutralize circulating VRC01-resistant strains. PC68-L31_54Q and PC68-L31_43J neutralization of pseudotyped breakthrough strains from clades B and C from the AMP trial was assessed. PC68-L31_54Q neutralized 92% of the clade C panel with a geomean IC50 of 0.114 μg/mL compared to VRC01 which neutralized these strains with a geomean IC50 of 0.783 μg/mL. However, clade B coverage was lower for both lineage 31 mAbs, with 73% breadth for PC68-L31_54Q with PC68-L31_43J more adversely impacted with only 20% coverage of clade B. Without being bound by any theory, resistance of the clade B AMP viruses to PC68-L31_54Q may be mediated by lack of conservation of proton donor side chains at residue 308. Resistant viruses contained bulky or uncharged residues such as proline, threonine, and serine that could break the salt bridges formed by the extended anionic HCDR2 loop. It has been previously demonstrated that other quaternary specific bnAbs such as V2 apex antibody PGDM1400 are less broad and potent against clade B isolates, and had been suggested that the prevalence of an additional positively charged residue at the apex may enhance the sampling speed between the open and closed states. Consistent with this prediction, the breadth and geomean IC50 of PC68_L31 mAbs and PGDM1400 fared worse against clade B strains in this panel, whereas the geomean IC50 and IC80 of VRC01 were relatively unchanged between clade B and C strains. However, PC68-L31_54Q neutralizes both clades B and C more broadly and potently at concentrations below 1 μg/mL which was shown to be more relevant in vivo. Because of their breath and potency, lineage 31 mAbs are suitable as prophylactics in combination with other bnAbs. Recombinant Trimer Production and Purification. BG505 SOSIP.664-Avi gp140 and BG505 gp120 were expressed in FreeStyle 293F cells (ThermoFisher) as described previously (Walker et al. 2011) Supernatants were purified by affinity chromatography using a PGT145 column. Constructs with AviTags were biotinylated by co-transfection with BirA plasmid and addition of biotin. The affinity-purified trimers were purified by size exclusion using a Superdex 300 column. Antibody Production and Purification. Antibody heavy and light chains were co- transfected at a 1:2.5 ratio with transfection reagent fectopro in expi293F cells. After 5 to 6 days of transfection, cells were harvested and spun down and supernatants were collected, and sterile filtered (0.22 µm) Antibodies were purified with Protein A Sepharose resin (Cytiva) as previously described. (Sok et al.2013). Env Mutation, Pseudovirus Production, and Neutralization Assays. Mutation was introduced to the envelope plasmid using the Q5 High Fidelity Site-Directed Mutagenesis kit (NEB). Pseudovirus Env plasmid was co-transfected with env-deficient backbone plasmid (pSG3ΔEnv) in a 1:2 ratio with transfection reagent Fugene in HEK293T cells. Pseudoviruses were harvested after 72 hours by spinning down cell culture supernatants and stored at −80°C. Serially diluted monoclonal antibodies were incubated with equal volume of pseudovirus at 37°C for 1 hour and then transferred onto TZM-bl cells seeded into half-area 96-well plates. After incubation for 48 hours at 37°C, supernatant was aspirated, and cells were lysed. Luciferase activity was measured by adding BrightGlo (Promega) according to manufacturer’s instructions. Neutralization IC50 was calculated using “One-Site Fit LogIC50” in GraphPad Prism. Antigen Binding ELISA.6x-His tag monoclonal antibody or streptavidin were coated onto 96-well half-area high-binding ELISA plates (Corning, 3690) at 2 µg/mL in PBS overnight at 4°C. After washing, plates were blocked with PBS/3% BSA for 1h at RT. After tapping plates dry, BG505 SOSIP and gp120 were added at 1 µg/mL in 1% BSA for 1h. Antibody samples were diluted to 50 ug/mL in 1% BSA with 5-fold serial dilution. Serially diluted samples were then added in plates and incubated for 1 h at RT. After washing, alkaline phosphatase-conjugated goat anti- human IgG Fcy secondary antibody (Jackson ImmunoResearch, 109-055-008) was added in 1:1000 dilution and incubated for 1h at RT. After final wash, phosphatase substrate (Sigma-Aldrich, S0942-200TAB) was added into each well. Absorption was measured at 405 nm and the 50% maximal binding (EC50) was calculated as the antibody concentration that reached half maximal signal. Biolayer interferometry. 100 nm of BG505 SOSIP or gp120 were captured using streptavidin biosensors or anti-penta-HIS biosensors (18-5120, Molecular Devices). After antigen loading for 5 min, a saturating concentration of mAbs at 100 µg/mL was added for 6 minutes. Competitor mAbs were added at a concentration of 25 µg/mL for 5 min to measure binding in the presence of saturating antibodies. While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. All publications, patents, patent applications, internet sites, and accession numbers/database sequences including both polynucleotide and polypeptide sequences cited herein are hereby incorporated by reference herein in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, internet site, or accession number/database sequence were specifically and individually indicated to be so incorporated by reference. SEQUENCES SEQ ID NO: 1 PC68-L31_32A VH CDR1 VTNYGMHWV SEQ ID NO: 2 PC68-L31_32B VH CDR1 IGSYGMYWV SEQ ID NO: 3 PC68-L31_32C VH CDR1 ISSYGMYWV SEQ ID NO: 4 PC68-L31_32D VH CDR1 VTNHGMYWF SEQ ID NO: 5 PC68-L31_32E VH CDR1 ISSYGMYWV SEQ ID NO: 6 PC68-L31_32F VH CDR1 IGSYGMYWV SEQ ID NO: 7 PC68-L31_32G VH CDR1 VSYYTMHWV SEQ ID NO: 8 PC68-L31_32H VH CDR1 VSNYGMYWV SEQ ID NO: 9 PC68-L31_32I VH CDR1 IGSYGMYWF SEQ ID NO: 10 PC68-L31_32J VH CDR1 ISYYTIHWV SEQ ID NO: 11 PC68-L31_32K VH CDR1 VSYYTIHWV SEQ ID NO: 12 PC68-L31_38A VH CDR1 VSNYGMYWV SEQ ID NO: 13 PC68-L31_38B VH CDR1 VSNYGMYWV SEQ ID NO: 14 PC68-L31_38C VH CDR1 VTNHGMYWF SEQ ID NO: 15 PC68-L31_38D VH CDR1 VSNYGMYWV SEQ ID NO: 16 PC68-L31_38E VH CDR1 VSYYTMHWV SEQ ID NO: 17 PC68-L31_43A VH CDR1 VANHGMYWF SEQ ID NO: 18 PC68-L31_43B VH CDR1 VTNHGMYWF SEQ ID NO: 19 PC68-L31_43C VH CDR1 VTNHGMYWF SEQ ID NO: 20 PC68-L31_43D VH CDR1 VTNHGMYWF SEQ ID NO: 21 PC68-L31_43E VH CDR1 VTNHGMYWF SEQ ID NO: 22 PC68-L31_43F VH CDR1 VTNHGMYWF SEQ ID NO: 23 PC68-L31_43G VH CDR1 VSNYGMYWA SEQ ID NO: 24 PC68-L31_43H VH CDR1 VTNHGMYWF SEQ ID NO: 25 PC68-L31_43I VH CDR1 VTNHGMYWF SEQ ID NO: 26 PC68-L31_43J VH CDR1 VTNHGMYWF SEQ ID NO: 27 PC68-L31_43K VH CDR1 VGSYGMYWF
VGSYGMYWF SEQ ID NO: 54 PC68-L31_54P VH CDR1 VGSYGMYWF SEQ ID NO: 55 PC68-L31_54Q VH CDR1 VASYGMYWF SEQ ID NO: 56 PC68-L31_54R VH CDR1 VGSYGMYWF SEQ ID NO: 57 PC68-L31_54S VH CDR1 VGSYGMYWF SEQ ID NO: 58 PC68-L31_59A VH CDR1 VSNHGMYWF SEQ ID NO: 59 PC68-L31_59B VH CDR1 VSNHGMYWF SEQ ID NO: 60 PC68-L31_59C VH CDR1 VSNHGMYWF SEQ ID NO: 61 PC68-L31_59D VH CDR1 VSNHGMYWF SEQ ID NO: 62 PC68-L31_59E VH CDR1 VANYGMYWF SEQ ID NO: 63 PC68-L31_59F VH CDR1 VANYGMYWF SEQ ID NO: 64 PC68-L31_59G VH CDR1 VASYGMYWF SEQ ID NO: 65 PC68-L31_59H VH CDR1 VGSYGMYWF SEQ ID NO: 66 intentionally left open SEQ ID NO: 67 intentionally left open SEQ ID NO: 68 intentionally left open SEQ ID NO: 69 intentionally left open SEQ ID NO: 70 intentionally left open SEQ ID NO: 71 PC68-L31_32A VH CDR2 DVGIHEEDIKG SEQ ID NO: 72 PC68-L31_32B VH CDR2 DAGLHEDDIIH SEQ ID NO: 73 PC68-L31_32C VH CDR2 DAGIHEDDTIY SEQ ID NO: 74 PC68-L31_32D VH CDR2 DAGIHEDDIKY SEQ ID NO: 75 PC68-L31_32E VH CDR2 DAGIHEDDTIY SEQ ID NO: 76 PC68-L31_32F VH CDR2 DAGLHEDDIIH SEQ ID NO: 77 PC68-L31_32G VH CDR2 DMGPQEEDTEY SEQ ID NO: 78 PC68-L31_32H VH CDR2 DAGIHEDDIKH SEQ ID NO: 79 PC68-L31_32I VH CDR2 DAGIHEDDIKQ SEQ ID NO: 80 PC68-L31_32J VH CDR2 DMGPQEEDAEY SEQ ID NO: 81 PC68-L31_32K VH CDR2 DMGPQEEDAEY SEQ ID NO: 82 PC68-L31_38A VH CDR2 DAGIHEDDTKY SEQ ID NO: 83 PC68-L31_38B VH CDR2 DAGIHEDDTKY SEQ ID NO: 84 PC68-L31_38C VH CDR2 DAGIHEDDIKY SEQ ID NO: 85 PC68-L31_38D VH CDR2 DAGIHEDDTKH SEQ ID NO: 86 PC68-L31_38E VH CDR2 DMGPQEYDTEY SEQ ID NO: 87 PC68-L31_43A VH CDR2 DAGIHEYDLIH SEQ ID NO: 88 PC68-L31_43B VH CDR2 DAGIQEDDLIH SEQ ID NO: 89 PC68-L31_43C VH CDR2 DGGLHEYDTIH SEQ ID NO: 90 PC68-L31_43D VH CDR2 DAGIHEDDIIH SEQ ID NO: 91 PC68-L31_43E VH CDR2 DGGLHEYDTIH SEQ ID NO: 92 PC68-L31_43F VH CDR2 DAGIHEYDVIH SEQ ID NO: 93 PC68-L31_43G VH CDR2 DAGIHEHDTKH SEQ ID NO: 94 PC68-L31_43H VH CDR2 DAGIHEDDVKH SEQ ID NO: 95 PC68-L31_43I VH CDR2 DAGIHEDDIKH SEQ ID NO: 96 PC68-L31_43J VH CDR2 DAGIHEDDTKH SEQ ID NO: 97 PC68-L31_43K VH CDR2 DVGVHEDDIKH SEQ ID NO: 98 PC68-L31_43L VH CDR2 DVGVHEDDVKH SEQ ID NO: 99 PC68-L31_43M VH CDR2 DVGVHEDDVKH SEQ ID NO: 100 PC68-L31_43N VH CDR2 DVGVHEYDVKH SEQ ID NO: 101 PC68-L31_43P VH CDR2 DVGVHEDDVKH SEQ ID NO: 102 PC68-L31_43Q VH CDR2 DVGVHEDDVKH SEQ ID NO: 103 PC68-L31_43R VH CDR2 DVGVHEEDVKH SEQ ID NO: 104 PC68-L31_43S VH CDR2 DVGVHEDDVKY SEQ ID NO: 105 PC68-L31_49A VH CDR2 DAGIHEYDLIH SEQ ID NO: 106 PC68-L31_49B VH CDR2 DGGLHEYDTIH SEQ ID NO: 107 PC68-L31_49C VH CDR2 DVGVHEDDVKH SEQ ID NO: 108 PC68-L31_49D VH CDR2 DGGVNEYDVKH SEQ ID NO: 109 PC68-L31_49E VH CDR2 DGGVHEYDVKH SEQ ID NO: 110 PC68-L31_54A VH CDR2 DAGIHEYDTIH SEQ ID NO: 111 PC68-L31_54B VH CDR2 DAGIHEYDTIH SEQ ID NO: 112 PC68-L31_54C VH CDR2 DAGIQEDDIKH SEQ ID NO: 113 PC68-L31_54D VH CDR2 DGGVNEYDVKH SEQ ID NO: 114 PC68-L31_54E VH CDR2 DGGVNEYDTKH SEQ ID NO: 115 PC68-L31_54F VH CDR2 DGGVNEYDVKH SEQ ID NO: 116 PC68-L31_54G VH CDR2 DGGVNEYDVKH SEQ ID NO: 117 PC68-L31_54H VH CDR2 DGGVNEYDVKH SEQ ID NO: 118 PC68-L31_54I VH CDR2 DGGVNDYDVKH SEQ ID NO: 119 PC68-L31_54J VH CDR2 DGGVNEYDVKH SEQ ID NO: 120 PC68-L31_54K VH CDR2 DGGVNEYDVKH SEQ ID NO: 121 PC68-L31_54L VH CDR2 DGGVNEYDVKH SEQ ID NO: 122 PC68-L31_54M VH CDR2 DGGVNEYDVKH SEQ ID NO: 123 PC68-L31_54N VH CDR2 DGGVNEYDVKH SEQ ID NO: 124 PC68-L31_54P VH CDR2 DGGVNEYDVKH SEQ ID NO: 125 PC68-L31_54Q VH CDR2 DGGVNEYDVKH SEQ ID NO: 126 PC68-L31_54R VH CDR2 DGGVNEYDVKH SEQ ID NO: 127 PC68-L31_54S VH CDR2 DGGVNEYDVKH SEQ ID NO: 128 PC68-L31_59A VH CDR2 DAGIHDDDIIH SEQ ID NO: 129 PC68-L31_59B VH CDR2 DAGIHDEDIIH SEQ ID NO: 130 PC68-L31_59C VH CDR2 DAGIHDEDIIH SEQ ID NO: 131 PC68-L31_59D VH CDR2 DAGIHDEDIIH SEQ ID NO: 132 PC68-L31_59E VH CDR2 DGGVNDYDLKY SEQ ID NO: 133 PC68-L31_59F VH CDR2 DGGVNDYDLKY SEQ ID NO: 134 PC68-L31_59G VH CDR2 DGGVNEYDVKH SEQ ID NO: 135 PC68-L31_59H VH CDR2 HVGVHEXDVKY SEQ ID NO: 136 intentionally left open SEQ ID NO: 137 intentionally left open SEQ ID NO: 138 intentionally left open SEQ ID NO: 139 intentionally left open SEQ ID NO: 140 intentionally left open SEQ ID NO: 141 PC68-L31_32A VH CDR3 AKDRVAYYGYGGPDV SEQ ID NO: 142 PC68-L31_32B VH CDR3 AKDLVPYYGYSGPEI SEQ ID NO: 143 PC68-L31_32C VH CDR3 AKDLVPYYGYSGPEI SEQ ID NO: 144 PC68-L31_32D VH CDR3 AKDFVTYWGYSGPYV SEQ ID NO: 145 PC68-L31_32E VH CDR3 AKDLVPYYGYSGPEI SEQ ID NO: 146 PC68-L31_32F VH CDR3 AKDLVAYYGYSGPEI SEQ ID NO: 147 PC68-L31_32G VH CDR3 AKDLVGLYDTRGPDI SEQ ID NO: 148 PC68-L31_32H VH CDR3 AKDSFAYYGYNGPQT SEQ ID NO: 149 PC68-L31_32I VH CDR3 GKDFVPYYGYNGPHI SEQ ID NO: 150 PC68-L31_32J VH CDR3 AKDLVGFYDTRGPDI SEQ ID NO: 151 PC68-L31_32K VH CDR3 AKDLVGFYDTRGPDI SEQ ID NO: 152 PC68-L31_38A VH CDR3 AKDVVAYYGYSGPHT SEQ ID NO: 153 PC68-L31_38B VH CDR3 AKDVVAYYGYSGPHT SEQ ID NO: 154 PC68-L31_38C VH CDR3 AKDFVTYWGYSGPYV SEQ ID NO: 155 PC68-L31_38D VH CDR3 AKDSFAYYGYNGPQT SEQ ID NO: 156 PC68-L31_38E VH CDR3 AKDIVGFYATKGPDI SEQ ID NO: 157 PC68-L31_43A VH CDR3 AKDYVTYYGYSGPYV SEQ ID NO: 158 PC68-L31_43B VH CDR3 AKDYVTYYGYSGPYV SEQ ID NO: 159 PC68-L31_43C VH CDR3 AKDFVTYWGYNGPYV SEQ ID NO: 160 PC68-L31_43D VH CDR3 AKDFVTYYGYSGPYV SEQ ID NO: 161 PC68-L31_43E VH CDR3 AKDYVTYYGYNGPYV SEQ ID NO: 162 PC68-L31_43F VH CDR3 AKDFVTYYGYSGPYV SEQ ID NO: 163 PC68-L31_43G VH CDR3 GKDSFAYYGYNGPET SEQ ID NO: 164 PC68-L31_43H VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 165 PC68-L31_43I VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 166 PC68-L31_43J VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 167 PC68-L31_43K VH CDR3 AKDIFAYYGYKGPHI SEQ ID NO: 168 PC68-L31_43L VH CDR3 GKDIFAYYGYKGPHI SEQ ID NO: 169 PC68-L31_43M VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 170 PC68-L31_43N VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 171 PC68-L31_43P VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 172 PC68-L31_43Q VH CDR3 GKDIFAYYGYKGPHI SEQ ID NO: 173 PC68-L31_43R VH CDR3 AKDSFAYYGYHGPHI SEQ ID NO: 174 PC68-L31_43S VH CDR3 AKDSFAYYGYKGPHS SEQ ID NO: 175 PC68-L31_49A VH CDR3 AKDYVTYYGYSGPYV SEQ ID NO: 176 PC68-L31_49B VH CDR3 AKDFVTYWGYNGPYV SEQ ID NO: 177 PC68-L31_49C VH CDR3 GKDIFAYYGYKGPHI SEQ ID NO: 178 PC68-L31_49D VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 179 PC68-L31_49E VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 180 PC68-L31_54A VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 181 PC68-L31_54B VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 182 PC68-L31_54C VH CDR3 AKDFVTYWSYSGPYV SEQ ID NO: 183 PC68-L31_54D VH CDR3 AKDSFAYYGYKGPHS SEQ ID NO: 184 PC68-L31_54E VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 185 PC68-L31_54F VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 186 PC68-L31_54G VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 187 PC68-L31_54H VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 188 PC68-L31_54I VH CDR3 AKDSRAYYGYNGPHS SEQ ID NO: 189 PC68-L31_54J VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 190 PC68-L31_54K VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 191 PC68-L31_54L VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 192 PC68-L31_54M VH CDR3 AKDSFAYYGYKGPHS SEQ ID NO: 193 PC68-L31_54N VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 194 PC68-L31_54P VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 195 PC68-L31_54Q VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 196 PC68-L31_54R VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 197 PC68-L31_54S VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 198 PC68-L31_59A VH CDR3 AKDYITYRGYSGPYV SEQ ID NO: 199 PC68-L31_59B VH CDR3 AKDYITYHGYSGPYV SEQ ID NO: 200 PC68-L31_59C VH CDR3 AKDYITYHGYSGPYV SEQ ID NO: 201 PC68-L31_59D VH CDR3 AKDYITYHGYSGPYV SEQ ID NO: 202 PC68-L31_59E VH CDR3 AKDSFAYYGYKGPHS SEQ ID NO: 203 PC68-L31_59F VH CDR3 AKDSFAYYGYKGPHS SEQ ID NO: 204 PC68-L31_59G VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 205 PC68-L31_59H VH CDR3 AKDSFAYYGYNGPHS SEQ ID NO: 206 Intentionally left open SEQ ID NO: 207 Intentionally left open SEQ ID NO: 208 Intentionally left open SEQ ID NO: 209 Intentionally left open SEQ ID NO: 210 Intentionally left open SEQ ID NO: 211 PC68-L31_32A VL CDR1 DRTNLGGR SEQ ID NO: 212 PC68-L31_32B VL CDR1 VGNNIGGR SEQ ID NO: 213 PC68-L31_32C VL CDR1 EGKNIGGR SEQ ID NO: 214 PC68-L31_32D VL CDR1 DGSNLGGR SEQ ID NO: 215 PC68-L31_32E VL CDR1 EGKNIGGR SEQ ID NO: 216 PC68-L31_32F VL CDR1 IGNNIGGR SEQ ID NO: 217 PC68-L31_32G VL CDR1 GDSRVGSK SEQ ID NO: 218 PC68-L31_32H VL CDR1 YGNSLGGR SEQ ID NO: 219 PC68-L31_32I VL CDR1 DGKNLGGR SEQ ID NO: 220 PC68-L31_32J VL CDR1 GDSGVGSK SEQ ID NO: 221 PC68-L31_32K VL CDR1 GDSRVGSK SEQ ID NO: 222 PC68-L31_38A VL CDR1 DGNGLGGR SEQ ID NO: 223 PC68-L31_38B VL CDR1 DGNGLGGR SEQ ID NO: 224 PC68-L31_38C VL CDR1 DGSNLGGR SEQ ID NO: 225 PC68-L31_38D VL CDR1 DGNSLRGR SEQ ID NO: 226 PC68-L31_38E VL CDR1 GDKKIGS SEQ ID NO: 227 PC68-L31_43A VL CDR1 DGSNLGGR SEQ ID NO: 228 PC68-L31_43B VL CDR1 DGSNLGGR SEQ ID NO: 229 PC68-L31_43C VL CDR1 DGNLGGR SEQ ID NO: 230 PC68-L31_43D VL CDR1 VGNNLGGR SEQ ID NO: 231 PC68-L31_43E VL CDR1 DGSNLGGR SEQ ID NO: 232 PC68-L31_43F VL CDR1 VGNNLGGR SEQ ID NO: 233 PC68-L31_43G VL CDR1 DGYGLGAR SEQ ID NO: 234 PC68-L31_43H VL CDR1 DGSSIGGS SEQ ID NO: 235 PC68-L31_43I VL CDR1 DGSNIGGR SEQ ID NO: 236 PC68-L31_43J VL CDR1 DGNNIGGR SEQ ID NO: 237 PC68-L31_43K VL CDR1 DGKSLGGR SEQ ID NO: 238 PC68-L31_43L VL CDR1 DGNTLGGR SEQ ID NO: 239 PC68-L31_43M VL CDR1 DGNGVGGR SEQ ID NO: 240 PC68-L31_43N VL CDR1 DGNGVGGR SEQ ID NO: 241 PC68-L31_43P VL CDR1 DGNGVGGR SEQ ID NO: 242 PC68-L31_43Q VL CDR1 DGNSLGGR SEQ ID NO: 243 PC68-L31_43R VL CDR1 DGNSVGGR SEQ ID NO: 244 PC68-L31_43S VL CDR1 DGNSLGGR SEQ ID NO: 245 PC68-L31_49A VL CDR1 DGSNLGGR SEQ ID NO: 246 PC68-L31_49B VL CDR1 DGNLGGR SEQ ID NO: 247 PC68-L31_49C VL CDR1 DGNSLGGR SEQ ID NO: 248 PC68-L31_49D VL CDR1 DGNGVGGL SEQ ID NO: 249 PC68-L31_49E VL CDR1 DGNGVGGL SEQ ID NO: 250 PC68-L31_54A VL CDR1 AGNNIGGR SEQ ID NO: 251 PC68-L31_54B VL CDR1
SEQ ID NO: 278 Intentionally left open SEQ ID NO: 279 Intentionally left open SEQ ID NO: 280 Intentionally left open SEQ ID NO: 281 PC68-L31_32A VL CDR2 DRP SEQ ID NO: 282 PC68-L31_32B VL CDR2 ERS SEQ ID NO: 283 PC68-L31_32C VL CDR2 ERS SEQ ID NO: 284 PC68-L31_32D VL CDR2 DRA SEQ ID NO: 285 PC68-L31_32E VL CDR2 ERS SEQ ID NO: 286 PC68-L31_32F VL CDR2 ERS SEQ ID NO: 287 PC68-L31_32G VL CDR2 DRA SEQ ID NO: 288 PC68-L31_32H VL CDR2 ERP SEQ ID NO: 289 PC68-L31_32I VL CDR2 ERP SEQ ID NO: 290 PC68-L31_32J VL CDR2 DRA SEQ ID NO: 291 PC68-L31_32K VL CDR2 DRA SEQ ID NO: 292 PC68-L31_38A VL CDR2 ERP SEQ ID NO: 293 PC68-L31_38B VL CDR2 ERP SEQ ID NO: 294 PC68-L31_38C VL CDR2 DRA SEQ ID NO: 295 PC68-L31_38D VL CDR2 ERP SEQ ID NO: 296 PC68-L31_38E VL CDR2 DRA SEQ ID NO: 297 PC68-L31_43A VL CDR2 DRA SEQ ID NO: 298 PC68-L31_43B VL CDR2 DRA SEQ ID NO: 299 PC68-L31_43C VL CDR2 DRA SEQ ID NO: 300 PC68-L31_43D VL CDR2 ERT SEQ ID NO: 301 PC68-L31_43E VL CDR2 DRA SEQ ID NO: 302 PC68-L31_43F VL CDR2 ERT SEQ ID NO: 303 PC68-L31_43G VL CDR2 ERP SEQ ID NO: 304 PC68-L31_43H VL CDR2 DR SEQ ID NO: 305 PC68-L31_43I VL CDR2 DR SEQ ID NO: 306 PC68-L31_43J VL CDR2 DR SEQ ID NO: 307 PC68-L31_43K VL CDR2 ERP SEQ ID NO: 308 PC68-L31_43L VL CDR2 ERP SEQ ID NO: 309 PC68-L31_43M VL CDR2 ERP SEQ ID NO: 310 PC68-L31_43N VL CDR2 ERP SEQ ID NO: 311 PC68-L31_43P VL CDR2 ERP SEQ ID NO: 312 PC68-L31_43Q VL CDR2 ERP SEQ ID NO: 313 PC68-L31_43R VL CDR2 ERP SEQ ID NO: 314 PC68-L31_43S VL CDR2 ERP SEQ ID NO: 315 PC68-L31_49A VL CDR2 DRA SEQ ID NO: 316 PC68-L31_49B VL CDR2 DRA SEQ ID NO: 317 PC68-L31_49C VL CDR2 ERP SEQ ID NO: 318 PC68-L31_49D VL CDR2 ERP SEQ ID NO: 319 PC68-L31_49E VL CDR2 ERP SEQ ID NO: 320 PC68-L31_54A VL CDR2 DW SEQ ID NO: 321 PC68-L31_54B VL CDR2 DW SEQ ID NO: 322 PC68-L31_54C VL CDR2 DR SEQ ID NO: 323 PC68-L31_54D VL CDR2 ERP SEQ ID NO: 324 PC68-L31_54E VL CDR2 ERP SEQ ID NO: 325 PC68-L31_54F VL CDR2 ERP SEQ ID NO: 326 PC68-L31_54G VL CDR2 ERP SEQ ID NO: 327 PC68-L31_54H VL CDR2 ERP SEQ ID NO: 328 PC68-L31_54I VL CDR2 ERP SEQ ID NO: 329 PC68-L31_54J VL CDR2 ERP SEQ ID NO: 330 PC68-L31_54K VL CDR2 ERP SEQ ID NO: 331 PC68-L31_54L VL CDR2 ERP SEQ ID NO: 332 PC68-L31_54M VL CDR2 ERP SEQ ID NO: 333 PC68-L31_54N VL CDR2 ERP SEQ ID NO: 334 PC68-L31_54P VL CDR2 ERP SEQ ID NO: 335 PC68-L31_54Q VL CDR2 ERP SEQ ID NO: 336 PC68-L31_54R VL CDR2 ERP SEQ ID NO: 337 PC68-L31_54S VL CDR2 ERP SEQ ID NO: 338 PC68-L31_59A VL CDR2 DRA SEQ ID NO: 339 PC68-L31_59B VL CDR2 DRA SEQ ID NO: 340 PC68-L31_59C VL CDR2 DRA SEQ ID NO: 341 PC68-L31_59D VL CDR2 DRA SEQ ID NO: 342 PC68-L31_59E VL CDR2 ERP SEQ ID NO: 343 PC68-L31_59F VL CDR2 ERP SEQ ID NO: 344 Intentionally left open SEQ ID NO: 345 PC68-L31_59H VL CDR2 ERP SEQ ID NO: 346 PC68-L31_59I VL CDR2 ERP SEQ ID NO: 347 Intentionally left open SEQ ID NO: 348 Intentionally left open SEQ ID NO: 349 Intentionally left open SEQ ID NO: 350 Intentionally left open SEQ ID NO: 351 PC68-L31_32A VL CDR3 QVWDGSRVR SEQ ID NO: 352 PC68-L31_32B VL CDR3 QMWDGSGAR SEQ ID NO: 353 PC68-L31_32C VL CDR3 QMWDGSGAR SEQ ID NO: 354 PC68-L31_32D VL CDR3 HMWDGSGVR SEQ ID NO: 355 PC68-L31_32E VL CDR3 QMWDGRGAR SEQ ID NO: 356 PC68-L31_32F VL CDR3 QMWDGSGAR SEQ ID NO: 357 PC68-L31_32G VL CDR3 HVWHGSGAH SEQ ID NO: 358 PC68-L31_32H VL CDR3 QMWDGSGVR SEQ ID NO: 359 PC68-L31_32I VL CDR3 YMWDGSGAR SEQ ID NO: 360 PC68-L31_32J VL CDR3 HVWHGSGAR SEQ ID NO: 361 PC68-L31_32K VL CDR3 HVWHGSGAR SEQ ID NO: 362 PC68-L31_38A VL CDR3 QMWDGRGAR SEQ ID NO: 363 PC68-L31_38B VL CDR3 QMWDGRGAR SEQ ID NO: 364 PC68-L31_38C VL CDR3 HMWDGSGVR SEQ ID NO: 365 PC68-L31_38D VL CDR3 YMWDGSGAR SEQ ID NO: 366 PC68-L31_38E VL CDR3 HVWHGSGAR SEQ ID NO: 367 PC68-L31_43A VL CDR3 HMWDGSIPR SEQ ID NO: 368 PC68-L31_43B VL CDR3 HMWDGSGAR SEQ ID NO: 369 PC68-L31_43C VL CDR3 HMWDGSIPR SEQ ID NO: 370 PC68-L31_43D VL CDR3 HMWDGSGSR SEQ ID NO: 371 PC68-L31_43E VL CDR3 HMWDGSIPR SEQ ID NO: 372 PC68-L31_43F VL CDR3 HMWDGSGSR SEQ ID NO: 373 PC68-L31_43G VL CDR3 QMWDGSGLR SEQ ID NO: 374 PC68-L31_43H VL CDR3 YIWDGSGVR SEQ ID NO: 375 PC68-L31_43I VL CDR3 YIWDGSGVR SEQ ID NO: 376 PC68-L31_43J VL CDR3 YIWDGSGVR SEQ ID NO: 377 PC68-L31_43K VL CDR3 YMWDGSGAR SEQ ID NO: 378 PC68-L31_43L VL CDR3 YMWHGSGVR SEQ ID NO: 379 PC68-L31_43M VL CDR3 YMWHGSGVR SEQ ID NO: 380 PC68-L31_43N VL CDR3 YMWDGSGVR SEQ ID NO: 381 PC68-L31_43P VL CDR3 YMWHGSGVG SEQ ID NO: 382 PC68-L31_43Q VL CDR3 YMWHGSGVR SEQ ID NO: 383 PC68-L31_43R VL CDR3 YMWDGSGAR SEQ ID NO: 384 PC68-L31_43S VL CDR3 YMWHGSGVR SEQ ID NO: 385 PC68-L31_49A VL CDR3 HMWDGSGAR SEQ ID NO: 386 PC68-L31_49B VL CDR3 HMWDGSIPR SEQ ID NO: 387 PC68-L31_49C VL CDR3 YMWHGSGVR SEQ ID NO: 388 PC68-L31_49D VL CDR3 YMWHGSGVR SEQ ID NO: 389 PC68-L31_49E VL CDR3 YMWHGSGVH SEQ ID NO: 390 PC68-L31_54A VL CDR3 YIWDGSGVR SEQ ID NO: 391 PC68-L31_54B VL CDR3 YIWDGSGVR SEQ ID NO: 392 PC68-L31_54C VL CDR3 FIWDGSGVR SEQ ID NO: 393 PC68-L31_54D VL CDR3 YMWHGSGVH SEQ ID NO: 394 PC68-L31_54E VL CDR3 YMWHGSGVH SEQ ID NO: 395 PC68-L31_54F VL CDR3 YMWHGSGVH SEQ ID NO: 396 PC68-L31_54G VL CDR3 YMWHGSGVH SEQ ID NO: 397 PC68-L31_54H VL CDR3 YMWHGSGVH SEQ ID NO: 398 PC68-L31_54I VL CDR3 YMWHGSGVH SEQ ID NO: 399 PC68-L31_54J VL CDR3 YMWHGSGVH SEQ ID NO: 400 PC68-L31_54K VL CDR3 YMWHGSGVH SEQ ID NO: 401 PC68-L31_54L VL CDR3 YMWHGSGVH SEQ ID NO: 402 PC68-L31_54M VL CDR3 YMWHGSGVH SEQ ID NO: 403 PC68-L31_54N VL CDR3 YMWHGSGVH SEQ ID NO: 404 PC68-L31_54P VL CDR3 YMWHGSGVH SEQ ID NO: 405 PC68-L31_54Q VL CDR3 YMWHGSGVH SEQ ID NO: 406 PC68-L31_54R VL CDR3 YMWHGSGVH SEQ ID NO: 407 PC68-L31_54S VL CDR3 YMWHGSGVH SEQ ID NO: 408 PC68-L31_59A VL CDR3 HMWDGSLPR SEQ ID NO: 409 PC68-L31_59B VL CDR3 HVWDGSLPR SEQ ID NO: 410 PC68-L31_59C VL CDR3 HMWDGSLPR SEQ ID NO: 411 PC68-L31_59D VL CDR3 HMWDGSLPR SEQ ID NO: 412 PC68-L31_59E VL CDR3 YMWHGSGVH SEQ ID NO: 413 PC68-L31_59F VL CDR3 YMWHGSGVH SEQ ID NO: 414 Intentionally left open SEQ ID NO: 415 PC68-L31_59H VL CDR3 YMWHGSGVR SEQ ID NO: 416 PC68-L31_59I VL CDR3 YIWHGSGVH SEQ ID NO: 417 Intentionally left open SEQ ID NO: 418 Intentionally left open SEQ ID NO: 419 Intentionally left open SEQ ID NO: 420 Intentionally left open SEQ ID NO: 421 PC68-L31_32A VH QVHLVESGGGVVQRGGSLRLSCTAYGIRVTNYGMHWVRQAPGKGLEWVGFIGVDVGIHEEDIKGYGDSVWG RSTITRDPAENTVYLQMNSLRIEDTAIYFCAKDRVAYYGYGGPDVWGRGTTVTVTS SEQ ID NO: 422 PC68-L31_32B VH QVHLVESGGGVVQRGGSLRLSCAASGFRIGSYGMYWVRQAPGKGLEWLAFIGVDAGLHEDDIIHYGDSAWG RFTISRDTGRNTLYLQMSRLTPGDTAVYFCAKDLVPYYGYSGPEIWGRGTPVTVSL SEQ ID NO: 423 PC68-L31_32C VH QVHLVESGGGVVQRGESLRLSCTAYGFRISSYGMYWVRHAPGKGLEWLAFIGIDAGIHEDDTIYYGDSAWG RFTISRDTGKNTLYLQMNRLTPGDTAVYFCAKDLVPYYGYSGPEIWGRGTPVTVSS SEQ ID NO: 424 PC68-L31_32D VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQAPGKGLEWLAFIGIDAGIHEDDIKYYGDSAWG RFTISRDGGKNTLYLQMDRLTPGDTAAYFCAKDFVTYWGYSGPYVWGRGTPVTVSA SEQ ID NO: 425 PC68-L31_32E VH QVHLVESGGGVVQRGESLRLSCAAYGFRISSYGMYWVRHAPGKGLEWLAFIGIDAGIHEDDTIYYGDSAWG RFSISRDTGKNTLYLQMNRLTPGDTAVYFCAKDLVPYYGYSGPEIWGRGTPVTVSS SEQ ID NO: 426 PC68-L31_32F VH QVHLVESGGGVVQRGGSLRLSCEVSGFRIGSYGMYWVRQAPGKGLEWLAFIGVDAGLHEDDIIHYGDSAWG RFTISRDTGRNTLYLQMNRLTPGDTAVYFCAKDLVAYYGYSGPEIWGRGTPVRVSL SEQ ID NO: 427 PC68-L31_32G VH QVHLVESGGGVVQRGGSLRLSCEAFGIRVSYYTMHWVRQAPGKGLEWVASLGPDMGPQEEDTEYYGDSMWG RVTFSRDSSRNTLHLQMNSLRPEDTAVYYCAKDLVGLYDTRGPDIWGHGTLVTVSA SEQ ID NO: 428 PC68-L31_32H VH QVHLVESGGGEVQRGGSLRLSCTAYGFRVSNYGMYWVRQTPVRGLEWLAFIGIDAGIHEDDIKHYGDSAWG RFTISRDTGKNTVNLQMNGLTPHDTGLYFCAKDSFAYYGYNGPQTWGRGTPVTVSS SEQ ID NO: 429 PC68-L31_32I VH QVHLVESGGGVVQRGGSLRLSCEASGFRIGSYGMYWFRQTPARGLEWLAFIGVDAGIHEDDIKQYGDSAWG RFPISRDTAKNILYLQMNSLTPGDTGVYFCGKDFVPYYGYNGPHIWGRGTPVTVSS SEQ ID NO: 430 PC68-L31_32J VH QVHLVESGGGVVQRGGSLRLSCEAFGIRISYYTIHWVRQTPGKGLEWVASLGPDMGPQEEDAEYYGDSMWG RVTFARDNSRNTLHLQMSSLRPGDTGIYYCAKDLVGFYDTRGPDIWGHGTLVTVSA SEQ ID NO: 431 PC68-L31_32K VH QVHLVESGGGVVQRGGSLRLSCEAFGIRVSYYTIHWVRQTPGKGLEWVASLGPDMGPQEEDAEYYGDSMWG RVTFSRDNSRNTLHLQMSSLRPGDTGIYYCAKDLVGFYDTRGPDIWGHGTLVTVSA SEQ ID NO: 432 PC68-L31_38A VH QVQLVESGGGEVQRGGSLRLSCAAYGFRVSNYGMYWVRQTPVRGLEWLAFIGIDAGIHEDDTKYYGDSAWG RFTISRDTGKNTVYLQMSSLTPHDTGLYFCAKDVVAYYGYSGPHTWGRGTPVTVSS SEQ ID NO: 433 PC68-L31_38B VH QVQLVESGGGEVQRGGSLRLSCTAYGFRVSNYGMYWVRQTSVRGLEWLAFIGIDAGIHEDDTKYYGDSAWG RFTISRDTGKNTVYLQMDRLTPHDTGLYFCAKDVVAYYGYSGPHTWGRGTPVTVSS SEQ ID NO: 434 PC68-L31_38C VH QLVQEESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQAPGKGLEWLAFIGIDAGIHEDDIKYYGDSAWG RFTISRDGGKNTLYLQMDRLTPGDTAAYFCAKDFVTYWGYSGPYVWGRGTPVTVSS SEQ ID NO: 435 PC68-L31_38D VH QVQLVESGGGEVQRGGSLRLSCTAYGFRVSNYGMYWVRQTPVRGLEWLAFIGIDAGIHEDDTKHYGDSAWG RFTISRDTGENTVNLQMNGLTPHDTGLYFCAKDSFAYYGYNGPQTWGRGTPVTVSS SEQ ID NO: 436 PC68-L31_38E VH EVQLVESGGAVVQRGGSLRLSCAAFGFKVSYYTMHWVRQAPGKGLEWVASLGPDMGPQEYDTEYYADSVRG RVSFSRDNSVNTLHMRLSDLRPDDTATYYCAKDIVGFYATKGPDIWGHGTLVTVSS SEQ ID NO: 437 PC68-L31_43A VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVANHGMYWFRQAPGKGLEWLAFIGIDAGIHEYDLIHYGDSAWG RFTISRDSGKNTLYLQLDRLTPGDTAAYFCAKDYVTYYGYSGPYVWGRGTPVTVSS SEQ ID NO: 438 PC68-L31_43B VH QVHLVESGGGVVQRGGSLRLSCEVAGFRVTNHGMYWFRQVPGKGLEWLAFIGIDAGIQEDDLIHYGDSAWG RFRISRDSGKNTLYLQMDRLTPGDTAAYFCAKDYVTYYGYSGPYVWGRGTRVTVSS SEQ ID NO: 439 PC68-L31_43C VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQTAGKGLEWLAFIGIDGGLHEYDTIHYGDSAWG RFTISRDSRKNTLYLQMDRLTPGDTGAYFCAKDFVTYWGYNGPYVWGRGTPVTVSS SEQ ID NO: 440 PC68-L31_43D VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQTTARGLEWLAFIGIDAGIHEDDIIHYGDSAWG RFTISRSSVKNTLYLQLDRLTPGDTGAYFCAKDFVTYYGYSGPYVWGRGTPVTVVS SEQ ID NO: 441 PC68-L31_43E VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRHTAGRGLEWLAFIGIDGGLHEYDTIHYGDSAWG RFTISRDSRKNTLYLQMDRLTPGDTGAYFCAKDYVTYYGYNGPYVWGRGTPVTVFS SEQ ID NO: 442 PC68-L31_43F VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQTTARGLEWLAFIGIDAGIHEYDVIHYGDSAWG RFTISRSSVKNTLYLQLDRLTPGDTGAYFCAKDFVTYYGYSGPYVWGRGTPVTVVS SEQ ID NO: 443 PC68-L31_43G VH QVHLVESGGGEVQRGGSLTLSCAAYGFRVSNYGMYWARQTPVRGLEWLAFIGIDAGIHEHDTKHYGDSAWG RFTISRDSGKNTVNLQMNGLTPHDTGLYFCGKDSFAYYGYNGPETWGRGTPVTVSS SEQ ID NO: 444 PC68-L31_43H VH QVHLVESGGGVVHRGESLRLSCEVSGFRVTNHGMYWFRHTPGRGLEWLAFIGIDAGIHEDDVKHYGDSAWG RFSISRDGGKNTLFLQMDRLTPGDTGTYFCAKDFVTYWSYSGPYVWGRGTPVSVSA SEQ ID NO: 445 PC68-L31_43I VH QVHLVESGGGVVHRGESLRLSCEVSGFRVTNHGMYWFRQTPGKGLEWLAFIGIDAGIHEDDIKHYGDSAWG RFSISRDGGKNTLFLQMDRLTPGDTGTYFCAKDFVTYWSYSGPYVWGRGTPVSVSA SEQ ID NO: 446 PC68-L31_43J VH QVHLVESGGGVVRRGESLRLSCEVSGFRVTNHGMYWFRQTPGKGLEWLAFIGIDAGIHEDDTKHYGDSAWG RFSISRDGGKNTLFLQMDRLTPGDTGTYFCAKDFVTYWSYSGPYVWGRGTPVTVTA SEQ ID NO: 447 PC68-L31_43K VH QVHLVESGGGVVQRGGSLRLSCTAYGFRVGSYGMYWFRHTPARGLEWLAFIGVDVGVHEDDIKHYGDSAWG RWPISRDTGKNIVYLQLNGLTFSDTGVYFCAKDIFAYYGYKGPHIWGRGTPVTVSS SEQ ID NO: 448 PC68-L31_43L VH QVHLVESGGGVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGVDVGVHEDDVKHYGDSAWG RWPISRDTAKNTVYLELSGLTFSDTGLYFCGKDIFAYYGYKGPHIWGRGTPVTVSS SEQ ID NO: 449 PC68-L31_43M VH QVHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGVDVGVHEDDVKHYGDSAWG RWPISRDTAKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTPVTVSS SEQ ID NO: 450 PC68-L31_43N VH QVHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGVDVGVHEYDVKHYGDSAWG RWPISRDTAKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTPVTVSS SEQ ID NO: 451 PC68-L31_43P VH QVHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGVDVGVHEDDVKHYGDSAWG RWPISRDTAKNIVYLELSGLAPSDTGDYFCAKDSFAYYGYNGPHSWGRGTPVTVSS SEQ ID NO: 452 PC68-L31_43Q VH QVHLVESGGGVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGVDVGVHEDDVKHYGDSAWG RWPISRDTAKNIVYLELSGLTFSDTGLYFCGKDIFAYYGYKGPHIWGRGTPVTVSS SEQ ID NO: 453 PC68-L31_43R VH QVHLVESGGGVVQRGESLRLSCSAYGFRVGSYGMYWFRHTPARGLEWLAFIGVDVGVHEEDVKHYGDSAWG RWPISRDTAKNIVYLELSGLTFSDTGVYFCAKDSFAYYGYHGPHIWGRGTSVTVSS SEQ ID NO: 454 PC68-L31_43S VH QVHLVESGGGVVQRGESLRLSCSAYGFRVGSYGMYWFRHTPVRGLEWLAFIGVDVGVHEDDVKYYGDSAWG RWPISRDTAKNIVYLELSGLTFSDTGVYFCAKDSFAYYGYKGPHSWGRGTAVTVSA SEQ ID NO: 455 PC68-L31_49A VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQAPGKGLEWLAFIGIDAGIHEYDLIHYGDSAWG RFTISRDSGKNTLYLQMDRLTPGDTAAYFCAKDYVTYYGYSGPYVWGRGTPVIVSS SEQ ID NO: 456 PC68-L31_49B VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVTNHGMYWFRQTAGKGLEWLAFIGIDGGLHEYDTIHYGDSAWG RFTISRDSRKNTLDLQMDRLTPGDTGAYFCAKDFVTYWGYNGPYVWGRGTPVTVSS SEQ ID NO: 457 PC68-L31_49C VH QVHLVESGGGVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPVRGLEWLAFIGVDVGVHEDDVKHYGDSAWG RWPISRDTAKNIVYLELSGLTFSDTGLYFCGKDIFAYYGYKGPHIWGRGTPVTVSS SEQ ID NO: 458 PC68-L31_49D VH QIHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 459 PC68-L31_49E VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVHEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 460 PC68-L31_54A VH QVHLVESGGGVVRRGESLRLSCEVSGFRVTNHGMYWLRQTAGRGLEWLAFIGIDAGIHEYDTIHYGDSAWG RFTISRDVGKNTLFLQMDRLTPGDTGIYFCAKDFVTYWSYSGPYVWGRGTPVTVSA SEQ ID NO: 461 PC68-L31_54B VH QVHLVESGGGVVRRGESLRLSCEVSGFRVTNHGMYWLRHTAGRGLEWLAFIGIDAGIHEYDTIHYGDSAWG RFTISRDVGKNTLFLQMDRLTPGDTGIYFCAKDFVTYWSYSGPYVWGRGTPVTVSA SEQ ID NO: 462 PC68-L31_54C VH QVHLVESGGGVVHRGESLRLSCEVYGFRVINHGMYWFRHTPARGLEWLAFIGIDAGIQEDDIKHYGDSAWA RFSISRDGGKNTVFLQMDRLTPGDTGTYFCAKDFVTYWSYSGPYVWGRGTAVSVSA SEQ ID NO: 463 PC68-L31_54D VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYKGPHSWGRGTSVTVFS SEQ ID NO: 464 PC68-L31_54E VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDTKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 465 PC68-L31_54F VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 466 PC68-L31_54G VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 467 PC68-L31_54H VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTPVTVFS SEQ ID NO: 468 PC68-L31_54I VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNDYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSRAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 469 PC68-L31_54J VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTAVTVFS SEQ ID NO: 470 PC68-L31_54K VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTDKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 471 PC68-L31_54L VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 472 PC68-L31_54M VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNVVYLELSGLAPSDTGVYFCAKDSFAYYGYKGPHSWGRGTSVTVFS SEQ ID NO: 473 PC68-L31_54N VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 474 PC68-L31_54P VH QIHLVESGGDVVQRGGSLRLSCAAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGRNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVFS SEQ ID NO: 475 PC68-L31_54Q VH QIHLVESGGDVVQRGGSLRLSCTAYGFRVASYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTVKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 476 PC68-L31_54R VH QIHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 477 PC68-L31_54S VH QIHLVESGGDVVQRGGSLRLSCTAYGFRVGSYGMYWFRQTPVRGLEWLAFIGIDGGVNEYDVKHYGDSAWG RWPISRDTGKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 478 PC68-L31_59A VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVSNHGMYWFRHVPDKGLEWLAFMGIDAGIHDDDIIHYGDSAWG RFRISRDSRKNTLYLQMDRLTPGDTGTYFCAKDYITYRGYSGPYVWGRGTAVTVSA SEQ ID NO: 479 PC68-L31_59B VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVSNHGMYWFRHVPDKGLEWLAFMGIDAGIHDEDIIHYGDSAWG RFRISRDSRKNTLYLQMDRLTPGDTGTYFCAKDYITYHGYSGPYVWGRGTAVTVSA SEQ ID NO: 480 PC68-L31_59C VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVSNHGMYWFRHVPDKGLEWLAFMGIDAGIHDEDIIHYGDSAWG RFRISRDSRKNTLYLQMDRLTPGDTGTYFCAKDYITYHGYSGPYVWGRGTAVTVSA SEQ ID NO: 481 PC68-L31_59D VH QVHLVESGGGVVQRGGSLRLSCEVSGFRVSNHGMYWFRHVSDKGLEWLAFMGIDAGIHDEDIIHYGDSAWG RFRISRDSRKNTLYLQMDRLTPGDTGTYFCAKDYITYHGYSGPYVWGRGTAVTVSA SEQ ID NO: 482 PC68-L31_59E VH QIHLVESGGDVVQRGGSLRLSCSAYGFRVANYGMYWFRQTPARGLEWLAFMGIDGGVNDYDLKYYGDSAWG RWPISRDTGKNIIYLELSGLAPSDTGVYFCAKDSFAYYGYKGPHSWGRGTSVTVSS SEQ ID NO: 483 PC68-L31_59F VH QIHLVESGGDVVQRGGSLRLFCSAYGFRVANYGMYWFRQTPARGLEWLAFMGIDGGVNDYDLKYYGDSAWG RWPISRDTGKNIIYLELSGLAPSDTGVYFCAKDSFAYYGYKGPHSWGRGTSVTVSS SEQ ID NO: 484 PC68-L31_59G VH EVQLVESGGDVVQRGSLQLSCTAYGFRVASYGMYWFRQTPARGLEWLAFIGIDGGVNEYDVKHYGDSAWGR WPISRDTVKNIVYLELSGLAPSDTGVYFCAKDSFAYYGYNGPHSWGRGTSVTVSS SEQ ID NO: 485 PC68-L31_59H VH EVQLVESGGGVVQRGESLKLSCSAYGFRVGSYGMYWFRHTPARGLEWLAXIGIHVGVHEXDVKYYGDSAWG RWPISRDTXXNIVYLELNGLTFSDTGVYVCAKDSFAYYGYNGPHSWGRXTPVTVSS SEQ ID NO: 486 Intentionally left open SEQ ID NO: 487 Intentionally left open SEQ ID NO: 488 Intentionally left open SEQ ID NO: 489 Intentionally left open SEQ ID NO: 490 Intentionally left open SEQ ID NO: 491 PC68-L31_32A VL SSVLTQPPSVSVAPGKTATITCDRTNLGGRIISWYRQRPGQAPVVVAYDDRDRPSGISERFSGSRSGNTAT LTISRVEDGDEGNYICQVWDGSRVRFGGGTTLTVL SEQ ID NO: 492 PC68-L31_32B VL SSVLTQPPSVSVAPEQTTTITCVGNNIGGRRVHWYRQRPGQAPMLVVYNDRERSSGIPERFSGSKSGNTAT LTISRVEAGDEADYYCQMWDGSGARFGGGTKVTVL SEQ ID NO: 493 PC68-L31_32C VL SSVLTQPPSVSVAPEQTARITCEGKNIGGRRVHWYRQRPGEAPMLVVYNDRERSSGIPDRFSGSKSGNTAT LTISRVEAGDEADYYCQMWDGSGARFGGGTKVTVL SEQ ID NO: 494 PC68-L31_32D VL SSALTQPPSVSVAPGETATITCDGSNLGGRSVHWCRQRPGQAPVSVVYNDRDRASGIPERFSGSKSGNTAT LTISRVEVGDEANYYCHMWDGSGVRLGGGTKVTVL SEQ ID NO: 495 PC68-L31_32E VL SSVLTQPPSVSVAPEQTARITCEGKNIGGRRVHWYRQRPGEAPILVVYNDRERSSGIPDRFSGSKSGNTAT LTISRVEAGDEADYHCQMWDGRGARFGGGTKVTVL SEQ ID NO: 496 PC68-L31_32F VL SSVLTQPPSVSVAPEQTTTITCIGNNIGGRRVHWYRQRPGQAPMLVVYNDRERSSGIPERFSGSKSGNTAT LTISRVEAGDEADYYCQMWDGSGARFGGGTKVTVL SEQ ID NO: 497 PC68-L31_32G VL SYVLAQPPSVSVAPGETATITCGDSRVGSKGFHWYRQRPGQAPVLVIHDNTDRASGIPYRFSGSKSGNTAT LTISRVEAGDEADYFCHVWHGSGAHFGGGTKLTVL SEQ ID NO: 498 PC68-L31_32H VL SSLLTQPPSVAVAPEETATITCYGNSLGGRSIHWYRQRPGQAPLLVVYNDRERPSGIPERFSGSKSGNTAT LTISRVEAGDEANYYCQMWDGSGVRFGGGTKVTVL SEQ ID NO: 499 PC68-L31_32I VL SSVLTQPPSVSVAPGKSATITCDGKNLGGRSLHWCRQRPGQAPVLVMYNDRERPSGIPERFSGSKSGNTAT LTISRVEAGDEADYYCYMWDGSGARFGGGTKLTVL SEQ ID NO: 500 PC68-L31_32J VL SYVLAQPPSVSVAPGETATITCGDSGVGSKGFHWYRQKPGQAPVLVIHDNTDRASGIPYRFSGSKSGNTAT LTISGVEAGDEADYFCHVWHGSGARFGGGTKLTVL SEQ ID NO: 501 PC68-L31_32K VL SYVLAQPPSVSVAPGETATITCGDSRVGSKGFHWYRQKPGQAPVLVIHDNTDRASGIPYRFSGSKSGNTAT LTISTVEAGDEADYFCHVWHGSGARFGGGTKLTVL SEQ ID NO: 502 PC68-L31_38A VL SYELTQPPSVSVAPEKTATLTCDGNGLGGRSVHWYRQRPGQAPLLVVYNDRERPSGIPERFSGSKSGNTAT LTISRVEAGDEANYYCQMWDGRGARFGGGTMVTVL SEQ ID NO: 503 PC68-L31_38B VL SYELTQPPSVSVAPEKTATLTCDGNGLGGRSVHWYRQRPGQAPLLVVYNDRERPSGIPERFSGSKSGNTAT LTISRLEAGDEATYYCQMWDGRGARFGGGTMVTVL SEQ ID NO: 504 PC68-L31_38C VL SYVLTQPPSVSVAPGETATITCDGSNLGGRSVHWCRQRPGQAPVSVVYNDRDRASGIPERFSGSKSGNTAT LTISRVEVGDEANYYCHMWDGSGVRLGGGTKVTVL SEQ ID NO: 505 PC68-L31_38D VL SYVLTQPPSVSVAPGKTATITCDGNSLRGRSLHWCRQRPGQAPVLVIYNDRERPSEIPERFSGSKTGNTAT LTISRVEAGDEAEYYCYMWDGSGARFGGGTKLTVL SEQ ID NO: 506 PC68-L31_38E VL SYELTQPPSVSVAPGETATITCGDKKIGSVHWYRQRPGQAPVLVIHDNTDRASGIPYRFSGSKSGDTATLT ISRVEAGDEADYFCHVWHGSGARFGGGTRLIVL SEQ ID NO: 507 PC68-L31_43A VL SSVLTQALSVSVAPGETATITCDGSNLGGRSVHWCRQRSGQAPVSVVYYGHDRAPEIPERFSASKSGNTAT LTISRVEVGDEATYYCHMWDGSIPRFGGGTKVTVL SEQ ID NO: 508 PC68-L31_43B VL SSVLTQAPSVSVAPGETATITCDGSNLGGRSVHWCRQRPGQAPVSVVYYGHDRAPEIPVRFSASKSGNTAT LTISRVEVGDEATYYCHMWDGSGARFGGGTQVNVL SEQ ID NO: 509 PC68-L31_43C VL SSVLTQPPSVSVAPGETATITCDGNLGGRNVHWCRQRPGQAPVSVVYNGDRASGIPERFSGSKSGNAATLT ISRVEVGDEANYYCHMWDGSIPRFGGGTKVTVL SEQ ID NO: 510 PC68-L31_43D VL SSTLTQPPSVSVAPGETATITCVGNNLGGRSVHWCRQKPGQAPVSVVYNDRERTSGIPERFSDSRSGNTAT LTIARVEVGDEATFYCHMWDGSGSRFGGGTKLTVL SEQ ID NO: 511 PC68-L31_43E VL SSVLTQPPSVSVAPGETATITCDGSNLGGRNVHWCRQRAGQAPVSVVFNGDRASGIPERFSGSKSGSTATL TISRVEVGDEANYYCHMWDGSIPRFGGGTKVTVL SEQ ID NO: 512 PC68-L31_43F VL SSTLTQPPSVSVAPGETATITCVGNNLGGRSVHWCRQKPGQAPVSVVYNDRERTSGIPERFSDSRSGNTAT LTIARVEVGDEATFYCHMWDGSGSRFGGGTKLTVL SEQ ID NO: 513 PC68-L31_43G VL SAGLTQPPSVAVAPEKTATVTCDGYGLGARSVNWYRLRPGQAPLLVLYNDRERPSGIPERFSGSKSGNTAT LTISRVEAGDEDNYYCQMWDGSGLRFGGGTKVTVL SEQ ID NO: 514 PC68-L31_43H VL SSALTQPPSVSVAPGETATITCDGSSIGGSGVHWCRQGPGQAPVSVVYNGGDRPIPARFSASRSGNTATLT ISRVEVGDEASYYCYIWDGSGVRLGGGTKVTVL SEQ ID NO: 515 PC68-L31_43I VL SSALTQPPSVSVAPGETATITCDGSNIGGRGVHWCRQRPGQAPVPVVYSGGDRPIPARFSASRSGTTATLT ISRAEVGDEDTYYCYIWDGSGVRLGGGTKVTVL SEQ ID NO: 516 PC68-L31_43J VL SSALTQPPSVSVAPGETATITCDGNNIGGRGVHWCRQRPGQAPVSVVYNGGDRPIPARFSASRSGNTATLT ISRVEVGDEANYYCYIWDGSGVRLGGGTKVTVL SEQ ID NO: 517 PC68-L31_43K VL SSVITQPPSVSVAPGETATITCDGKSLGGRSLHWCRQRPGQAPVLVMYNDRERPSEIPERFSGSKSGNTAT LTISRAEAGDEAEYYCYMWDGSGARLGGGTKLTVL SEQ ID NO: 518 PC68-L31_43L VL SSVLAQPPSVSVAPGKTATITCDGNTLGGRSLHWCRQRPGQAPVLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 519 PC68-L31_43M VL SSVLTQPPSVSVAPGKTATITCDGNGVGGRSLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 520 PC68-L31_43N VL SSVLTQPPSVSVAPGKTATITCDGNGVGGRSLHWCRRRPGQAPLLLIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWDGSGVRLGGGTKLTVL SEQ ID NO: 521 PC68-L31_43P VL SSVLTQPPSVSVAPGKTVTITCDGNGVGGRSLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVGLGGGTKLTVL SEQ ID NO: 522 PC68-L31_43Q VL SSVLAQPPSVSVAPGKTATITCDGNSLGGRSLHWCRQRPGQAPVLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 523 PC68-L31_43R VL SSVLAQPPSVSVAPGKAATITCDGNSVGGRSLHWCRQRPGQAPVQVIYNDRERPSDIPERFSASKSGNTAT LTISRVEAGDEAEYYCYMWDGSGARFGGGTKLTVL SEQ ID NO: 524 PC68-L31_43S VL SSVLAQPPSVSVAPGETATITCDGNSLGGRSLHWCRQRPGRAPLLVIYNDRERPSDIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 525 PC68-L31_49A VL SSVLTQPPSVSVAPGETATITCDGSNLGGRSVHWCRQRPGQAPVSVVYYGHDRAPEIPERFSASKSVNTAT LTISRVEVGDEATFYCHMWDGSGARFGGGTKLIVL SEQ ID NO: 526 PC68-L31_49B VL ASVLTQPPSVSVAPGETATITCDGNLGGRNVHWCRQRPGQAPVSVVYNGDRASGIPERFSGSKSGNAATLT ISRVEVGDEANYYCHMWDGSIPRFGGGTKVTVL SEQ ID NO: 527 PC68-L31_49C VL SSVLAQPPSVSVAPGKTATITCDGNSLGGRSLHWCRQRPGQAPVLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 528 PC68-L31_49D VL SSVLTQPPSVSVAPGKTATITCDGNGVGGLLLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRLGGGTKLTVL SEQ ID NO: 529 PC68-L31_49E VL SSVLTQPPSVSVAPGKTATITCDGNGVGGLILHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHLGGGTKLTVL SEQ ID NO: 530 PC68-L31_54A VL SSALTQPPSVSVAPGETATIPCAGNNIGGRGVHWCRQRPGQAPVLVVYSGGDWPVPARFSASRSGNTATLT ISRVEVGDEDTYYCYIWDGSGVRLGGGTKVTVL SEQ ID NO: 531 PC68-L31_54B VL SAALTQPPSVSVAPGETATIPCDGNNIGGRGVHWCRQRPGQAPVLVVYSGGDWPVPARFSASRSGNTATLT ISRVEVGDEDTYYCYIWDGSGVRLGGGTKVTVL SEQ ID NO: 532 PC68-L31_54C VL SSTLTQPPSVSVAPGETATITCAGSNIGGRGVHWCRLRPGQAPVPVVFSGGDRPIPARFSASKSGTTATLT ISRAEVGDEDTYYCFIWDGSGVRLGGGTKVTVL SEQ ID NO: 533 PC68-L31_54D VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 534 PC68-L31_54E VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSDIPERFSGSKSGNTAT LTISRVEAGDEGDYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 535 PC68-L31_54F VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 536 PC68-L31_54G VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLKVHWCRQRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYNCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 537 PC68-L31_54H VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLKLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 538 PC68-L31_54I VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 539 PC68-L31_54J VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSEIPDRFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 540 PC68-L31_54K VL PSVVTQPPSVSVAPGTTATITCGGNGIGGLNLHWCRKRPGQAPLLVIYNDRERPSDIPERFSGSKSGNTAT LTISRVEAGDEGEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 541 PC68-L31_54L VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLKLHWCRERPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEGVYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 542 PC68-L31_54M VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLNLHWCRRRPGQAPLLVIYNDRERPSDIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 543 PC68-L31_54N VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLKLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 544 PC68-L31_54P VL PSVVTQPPSVSVAPGKTATITCGGNGIGGLKLHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 545 PC68-L31_54Q VL SSVLTQPPSVSVAPGKTATITCGGNGVGGLLVHWCRERPGQAPLLVIYNDRERPSEIPQRFSGSKSGNTAT LTISRVEVGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 546 PC68-L31_54R VL SSVLTQPPSVSVAPGKTATITCGGNGVGGLLLHWCRKRPGQAPLLVIYNDRERPSEIPERFAGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 547 PC68-L31_54S VL SSVLTQPPSVSVAPGKTATITCDGNAVGKLLLHWCRTRPGQAPLLVIYNDRERPSDIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 548 PC68-L31_59A VL SSVLTQPTSVSVSPGETATITCDGKNIGGRSIHWCRQSPGQAPVTVVYYGYDRAPEIPERFSASTSGNTAT LTISRVEVGDEATFYCHMWDGSLPRFGGGTKLLVL SEQ ID NO: 549 PC68-L31_59B VL SSVLTQPTSVSVSPGDTATITCDGRNIGGRNVHWCRQSPGQAPVTVVYYGYDRAPEIPERFSASTSGNTAT LTISRVEVGDEATFYCHVWDGSLPRFGGGTKLLVL SEQ ID NO: 550 PC68-L31_59C VL SSVLTQPTSVSVSPGETATITCDGKNIGGRNIHWCRQSPGQAPVTVVYYGYDRAPEIPERFSASTSGNRAT LTISRVEVGDEATFYCHMWDGSLPRFGGGTKLLVL SEQ ID NO: 551 PC68-L31_59D VL SSVLTQPTSVSVSPGETATITCDGKNIGGRNIHWCRQSPGQAPVTVVYYGYDRAPEIPERFSASTSGNRAT LTISRVEVGDEATFYCHMWDGSLPRFGGGTKLLVL SEQ ID NO: 552 PC68-L31_59E VL SSVVTQPPSVSVAPGKTATITCDGGGLGGLLVHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEPGDEAEYNCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 553 PC68-L31_59F VL SSVVTQPPSVSVAPGKTATITCDGGGLGGLLVHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEPGDEAEYNCYMWHGSGVHVGGGTKLTVL SEQ ID NO: 554 Intentionally left open SEQ ID NO: 555 PC68-L31_59H VL QSVLTQPPAVSVAPGETASIRCDGNNLGGGGLYWSRQRPGQAPVLVIYNNRERPSDIPGRFSGSRSGNTAT LTISRVEAGDEDEYYCYIWHGSGVHVGGGTKLTVLGQ SEQ ID NO: 556 PC68-L31_59I VL QSALTQPPSVSVAPGKTATITCDGNGVGGLLMHWCRKRPGQAPLLVIYNDRERPSEIPERFSGSKSGNTAT LTISRVEAGDEAEYYCYMWHGSGVRIGGGTKLTVLSQ SEQ ID NO: 557 Intentionally left open 558 Intentionally left open 559 Intentionally left open 560 Intentionally left open 561 PC68-L31_32A VH nucl
Figure imgf000188_0001
CGATCCACCATCACCAGAGACCCTGCCGAGAACACAGTGTATCTGCAAATGAACAGCCTGAGAATTGAGGA CACGGCTATATATTTCTGTGCGAAAGATCGCGTCGCCTATTATGGTTATGGTGGTCCAGATGTCTGGGGCC GAGGGACAACGGTCACCGTCACTTCA SEQ ID NO: 562 PC68-L31_32B VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGCAGC GTCTGGATTCAGAATAGGTAGTTATGGCATGTACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGT TGGCCTTTATAGGAGTTGATGCAGGTCTTCATGAGGATGACATCATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACACTGGCAGGAATACACTGTATCTCCAAATGAGCCGCCTGACACCTGGGGA CACGGCTGTGTATTTCTGTGCGAAAGATCTTGTCCCCTATTATGGTTACAGTGGCCCAGAAATCTGGGGCC GGGGGACACCGGTCACCGTCTCTTTA SEQ ID NO: 563 PC68-L31_32C VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGAGTCCCTGAGACTCTCATGTACAGC GTATGGATTCAGAATAAGCAGTTATGGCATGTACTGGGTCCGCCACGCTCCAGGCAAGGGGCTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGCATTCATGAGGACGACACTATATACTATGGAGACTCCGCGTGGGGC CGATTTACCATCTCCAGAGACACTGGCAAGAATACATTGTATCTTCAAATGAACAGACTGACACCTGGGGA CACGGCTGTATATTTCTGTGCGAAAGATCTTGTCCCCTATTATGGTTATAGTGGCCCAGAAATCTGGGGCC GGGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 564 PC68-L31_32D VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGGATGACATCAAATATTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACGGTGGCAAGAACACACTTTATCTGCAAATGGACAGGCTGACACCTGGGGA CACGGCTGCGTATTTCTGTGCGAAAGATTTTGTCACCTACTGGGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTGCA SEQ ID NO: 565 PC68-L31_32E VH nucl CAGGTGCACTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGAGTCCCTGAGACTCTCATGTGCAGC ATATGGATTCAGAATAAGTAGTTATGGCATGTACTGGGTCCGCCACGCTCCAGGCAAGGGGCTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGCATTCATGAGGACGACACTATATACTATGGAGACTCCGCGTGGGGC CGATTTAGTATCTCCAGAGACACCGGCAAGAATACATTGTATCTTCAAATGAACAGACTGACACCTGGGGA CACGGCTGTATATTTCTGTGCGAAAGATCTTGTCCCCTATTATGGTTATAGTGGCCCAGAAATCTGGGGCC GGGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 566 PC68-L31_32F VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAATAGGCAGTTATGGCATGTACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGT TGGCCTTTATAGGAGTTGATGCAGGTCTTCACGAGGATGACATCATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACACCGGCAGGAATACTCTGTATCTCCAAATGAACAGGCTGACACCTGGGGA CACGGCTGTGTATTTCTGTGCGAAAGATCTTGTCGCCTATTATGGTTACAGTGGCCCAGAAATCTGGGGCC GGGGGACACCGGTCAGAGTCTCTTTA SEQ ID NO: 567 PC68-L31_32G VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCCTGTGAGGC ATTTGGAATCAGAGTTAGTTATTATACCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGG TGGCCTCTCTTGGGCCCGATATGGGGCCCCAAGAAGAAGATACCGAATACTATGGAGACTCTATGTGGGGC CGCGTCACCTTCTCCAGAGACAGTTCCAGAAACACGTTGCATCTGCAAATGAACAGCCTGAGACCTGAGGA CACGGCTGTTTATTACTGTGCGAAGGATCTGGTTGGACTCTATGACACTAGAGGACCAGACATCTGGGGCC ACGGGACACTGGTCACCGTCTCTGCA SEQ ID NO: 568 PC68-L31_32H VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGCACAGC ATATGGATTTAGAGTAAGCAATTATGGCATGTACTGGGTCCGCCAGACTCCAGTCAGGGGGCTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGGATGACATTAAACACTATGGAGACTCCGCGTGGGGC CGCTTCACCATCTCCAGAGACACTGGCAAGAACACAGTGAATCTGCAAATGAATGGCCTGACACCTCACGA CACGGGTCTGTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTACAATGGCCCACAGACTTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 569 PC68-L31_32I VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGC GTCTGGATTCAGAATAGGCAGTTATGGCATGTACTGGTTCCGCCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATCGGCGTTGATGCAGGTATTCATGAGGATGACATTAAACAGTATGGAGACTCCGCGTGGGGC CGGTTTCCCATCTCCAGAGACACTGCCAAGAATATCCTCTATCTACAAATGAACAGCCTGACACCTGGTGA CACGGGTGTCTATTTCTGTGGGAAAGATTTTGTCCCCTATTATGGTTATAATGGCCCACACATCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 570 PC68-L31_32J VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCCTGTGAGGC ATTTGGAATCAGAATTAGTTATTATACGATACACTGGGTCCGCCAGACTCCAGGCAAGGGGCTGGAGTGGG TGGCCTCTCTTGGGCCCGATATGGGGCCCCAAGAAGAAGATGCCGAATACTATGGAGACTCCATGTGGGGC CGCGTCACCTTCGCCAGAGACAATTCCAGGAACACATTGCATCTGCAAATGAGCAGCCTGAGACCTGGGGA CACGGGTATTTATTACTGTGCGAAGGATCTGGTTGGCTTCTATGACACAAGAGGACCAGACATCTGGGGCC ACGGGACACTGGTCACCGTCTCTGCA SEQ ID NO: 571 PC68-L31_32K VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCCTGTGAGGC ATTTGGAATCAGAGTTAGTTATTATACGATACATTGGGTCCGCCAGACTCCAGGCAAGGGGCTGGAGTGGG TGGCCTCTCTGGGGCCCGATATGGGGCCCCAAGAAGAAGATGCCGAATACTATGGAGACTCCATGTGGGGC CGCGTCACCTTCTCCAGAGACAATTCCAGGAACACCTTGCATCTGCAAATGAGCAGCCTGAGACCTGGGGA CACGGGTATTTATTACTGTGCGAAAGATCTGGTTGGCTTCTATGACACTAGAGGACCAGACATCTGGGGCC ACGGGACACTGGTCACCGTCTCTGCA SEQ ID NO: 572 PC68-L31_38A VH nucl CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGCAGC GTATGGATTTAGAGTAAGCAATTATGGCATGTACTGGGTCCGCCAGACTCCAGTCAGGGGGCTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGGACGACACTAAATACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACACTGGCAAGAACACAGTGTATCTGCAAATGAGTAGCCTGACACCTCACGA CACGGGTCTGTATTTCTGTGCGAAAGATGTTGTCGCCTATTATGGATATAGTGGCCCACATACGTGGGGCC GAGGGACACCGGTCACCGTCTCCTCAG SEQ ID NO: 573 PC68-L31_38B VH nucl CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTACAGC GTATGGATTCAGAGTAAGCAATTATGGCATGTATTGGGTCCGCCAGACTTCAGTCAGGGGGCTGGAATGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGGACGACACTAAATACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACACTGGCAAGAACACAGTGTATCTGCAAATGGATAGGCTGACACCTCACGA CACGGGTCTGTATTTCTGTGCGAAGGATGTTGTCGCCTATTATGGTTATAGTGGCCCACATACGTGGGGCC GAGGGACACCGGTCACCGTCTCCTCAG SEQ ID NO: 574 PC68-L31_38C VH nucl CAGCTGGTACAGGAGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGGATGACATCAAATATTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAGACGGTGGCAAGAACACACTTTATCTGCAAATGGACAGGCTGACACCTGGGGA CACGGCTGCGTATTTCTGTGCGAAAGATTTTGTCACCTACTGGGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCCTCAG SEQ ID NO: 575 PC68-L31_38D VH nucl CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGCACAGC ATATGGATTTAGAGTGAGCAATTATGGCATGTACTGGGTCCGCCAGACTCCAGTCAGGGGGCTGGAGTGGT TGGCCTTTATAGGCATCGATGCAGGCATCCATGAGGATGACACTAAACACTATGGAGACTCCGCGTGGGGC CGGTTCACCATCTCCAGAGACACTGGCGAGAACACAGTGAATCTGCAAATGAATGGCCTGACACCTCACGA CACGGGTCTGTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTACAATGGCCCACAGACTTGGGGCC GAGGGACACCGGTCACCGTCTCCTCAG SEQ ID NO: 576 PC68-L31_38E VH nucl GAGGTGCAGCTGGTGGAGTCTGGGGGAGCCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCCTGTGCAGC GTTTGGATTCAAAGTCAGTTATTATACTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGG TGGCATCTCTTGGGCCCGATATGGGGCCCCAAGAATATGATACCGAATACTATGCAGACTCCGTGAGGGGC CGCGTCAGTTTCTCTAGAGACAATTCCGTGAACACCTTACATATGCGACTGAGCGACCTGAGACCTGACGA CACGGCCACTTACTACTGTGCGAAAGACATCGTGGGCTTCTATGCCACTAAAGGCCCAGACATCTGGGGCC ACGGGACGCTGGTCACCGTCTCCTCAG SEQ ID NO: 577 PC68-L31_43A VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCGCCAACCATGGCATGTACTGGTTCCGCCAGGCTCCAGGCAAGGGACTGGAATGGT TGGCCTTTATAGGCATTGATGCAGGTATTCATGAGTATGACCTTATACACTATGGAGACTCCGCCTGGGGC CGATTCACAATCTCCAGAGACAGTGGCAAGAACACACTGTATCTGCAGCTGGACAGGCTGACACCTGGGGA CACGGCTGCGTATTTCTGTGCGAAAGATTATGTCACCTATTATGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 578 PC68-L31_43B VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GGCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTTCGCCAGGTTCCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGTATTCAAGAGGATGACCTTATACATTATGGAGACTCCGCCTGGGGC CGATTCAGAATCTCAAGAGACAGTGGCAAGAACACACTGTATCTGCAGATGGACAGGCTGACACCTGGGGA CACGGCTGCGTATTTCTGTGCGAAAGATTATGTCACCTATTATGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACGGGTCACCGTCTCTTCA SEQ ID NO: 579 PC68-L31_43C VH nucl CAGGTGCACCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGACTGCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGGGGGTCTTCATGAATATGACACTATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGGGACAGCCGGAAGAACACTCTGTATCTGCAGATGGACAGACTGACACCCGGGGA CACGGGCGCGTATTTCTGTGCGAAAGACTTCGTCACTTATTGGGGCTACAATGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCC SEQ ID NO: 580 PC68-L31_43D VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGACTACAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATAGATGCAGGTATTCATGAGGATGACATTATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAAGCAGTGTCAAGAACACACTGTATCTGCAATTGGACAGACTGACACCTGGAGA CACGGGTGCGTACTTCTGTGCGAAAGACTTTGTCACCTATTACGGTTATAGTGGCCCATACGTCTGGGGCC GAGGGACACCGGTCACCGTCGTTTCA SEQ ID NO: 581 PC68-L31_43E VH nucl CAGGTGCACCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCATACTGCAGGCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGGGGGTCTTCATGAATATGACACTATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGGGACAGCCGGAAGAACACACTGTATCTGCAGATGGACAGACTGACACCTGGGGA CACGGGCGCGTATTTCTGTGCGAAAGATTACGTCACTTATTATGGTTATAATGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTTTTCT SEQ ID NO: 582 PC68-L31_43F VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGACTACAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATAGATGCAGGTATTCATGAGTATGACGTTATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGAAGCAGTGTCAAGAACACACTGTATCTGCAATTGGACAGACTGACACCTGGAGA CACGGGTGCGTACTTCTGTGCGAAAGACTTTGTCACCTATTACGGTTATAGTGGCCCATACGTCTGGGGCC GAGGGACACCGGTCACCGTCGTTTCA SEQ ID NO: 583 PC68-L31_43G VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGAGGTCCAGCGGGGGGGGTCCCTGACACTCTCATGCGCAGC ATATGGATTTAGAGTAAGTAATTATGGCATGTATTGGGCCCGGCAGACTCCAGTCAGGGGGCTGGAGTGGT TGGCCTTTATAGGCATCGATGCAGGGATTCATGAACATGACACTAAACACTATGGAGACTCCGCGTGGGGC CGCTTCACTATCTCCAGAGACTCTGGCAAGAACACAGTGAATCTGCAAATGAATGGCCTGACACCTCACGA CACGGGTCTGTATTTCTGTGGAAAAGATTCTTTCGCCTATTATGGTTACAATGGCCCAGAGACTTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 584 PC68-L31_43H VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCACCGGGGGGAGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTATTGGTTCCGCCACACTCCAGGCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGGATACATGAAGATGATGTCAAACATTATGGAGACTCCGCGTGGGGC CGATTTAGCATCTCCAGAGACGGTGGCAAGAACACACTGTTTCTGCAAATGGACAGGCTGACACCTGGGGA CACGGGAACATACTTCTGTGCGAAGGACTTTGTTACCTACTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCAGCGTCTCTGCA SEQ ID NO: 585 PC68-L31_43I VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCACCGGGGGGAGTCCCTGAGACTCTCATGTGAAGT GTCTGGGTTCAGAGTCACCAACCATGGCATGTATTGGTTCCGCCAGACTCCAGGAAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGGATACATGAAGATGATATCAAACATTATGGAGACTCCGCGTGGGGC CGATTCAGTATCTCCAGAGACGGTGGTAAGAACACACTGTTTCTGCAAATGGACAGGCTGACACCTGGGGA CACGGGAACATACTTCTGTGCGAAGGATTTTGTCACCTACTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCAGCGTCTCTGCA SEQ ID NO: 586 PC68-L31_43J VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCGCCGGGGGGAGTCTCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTATTGGTTCCGCCAGACTCCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCGGGGATACATGAAGATGATACCAAACATTATGGAGACTCCGCGTGGGGC CGATTTAGCATCTCCAGAGACGGCGGCAAGAACACACTGTTTCTGCAAATGGACAGGCTGACACCTGGGGA CACGGGAACATACTTCTGTGCGAAGGATTTTGTCACCTACTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCACTGCA SEQ ID NO: 587 PC68-L31_43K VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTACGGC GTATGGATTTAGAGTGGGCAGTTATGGCATGTACTGGTTTCGCCACACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTAGGTGTTCATGAAGATGACATAAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGGCAAGAATATAGTGTATCTGCAGTTGAATGGCCTGACATTTAGTGA CACGGGTGTCTACTTCTGTGCGAAAGATATTTTCGCCTATTATGGTTATAAAGGCCCACACATCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 588 PC68-L31_43L VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCTCTGAGACTCTCATGTACAGC GTATGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGCCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTCGGTGTTCATGAAGATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATACAGTGTATCTGGAATTGAGTGGCCTCACATTTAGTGA CACGGGTCTCTATTTCTGTGGGAAAGATATTTTCGCCTATTATGGTTATAAAGGCCCACACATCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 589 PC68-L31_43M VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTAGGTGTTCATGAGGATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 590 PC68-L31_43N VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTAGGTGTTCATGAGTATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 591 PC68-L31_43P VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTAGGTGTTCATGAGGATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGACTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 592 PC68-L31_43Q VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCTCTGAGACTCTCATGTACAGC GTATGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGCCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTCGGTGTTCATGAAGATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTACCTGGAATTGAGTGGCCTCACATTTAGTGA CACGGGTCTCTATTTTTGTGGGAAAGATATTTTCGCCTATTATGGTTATAAAGGCCCACACATCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 593 PC68-L31_43R VH nucl CAGGTACACTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGAGTCCCTGAGACTCTCATGTTCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGCCACACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTAGGTGTTCATGAAGAAGACGTGAAACATTATGGAGACTCCGCGTGGGGC CGCTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGACATTTAGTGA CACGGGTGTCTACTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATCATGGCCCACACATCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 594 PC68-L31_43S VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGAGTCCCTGAGACTCTCATGTTCAGC GTACGGATTTAGAGTTGGCAGTTATGGCATGTACTGGTTTCGCCACACTCCAGTCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTGGGTGTTCATGAAGATGACGTGAAATACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATTTGGAGTTGAGTGGCCTGACATTTAGTGA CACGGGTGTCTATTTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATAAGGGTCCACACAGCTGGGGCC GAGGGACAGCGGTCACCGTCTCTGCA SEQ ID NO: 595 PC68-L31_49A VH nucl CAGGTGCATCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGGCTCCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGAATTCATGAATATGACCTTATACACTATGGAGACTCCGCCTGGGGC CGATTCACAATCTCCAGAGACAGTGGCAAGAACACACTGTATCTGCAGATGGACAGGCTGACACCTGGGGA CACGGCTGCGTATTTCTGTGCGAAAGATTATGTCACCTATTATGGGTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCATCGTCTCTTCA SEQ ID NO: 596 PC68-L31_49B VH nucl CAGGTGCACCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTACTGGTTCCGCCAGACTGCAGGCAAGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGGGGGTCTTCATGAATATGACACTATACACTATGGAGACTCCGCGTGGGGC CGATTCACCATCTCCAGGGACAGCCGGAAGAACACTCTGGATCTGCAGATGGACAGACTGACACCCGGGGA CACGGGCGCGTATTTCTGTGCGAAAGACTTCGTCACTTACTGGGGCTACAATGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCC SEQ ID NO: 597 PC68-L31_49C VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGGGTCTCTGAGACTCTCATGTACAGC GTATGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGCCAGACTCCAGTCAGGGGACTGGAGTGGT TGGCCTTTATAGGCGTCGACGTCGGTGTTCATGAAGATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCCAGAGACACTGCCAAGAATATAGTGTATCTGGAATTGAGTGGCCTCACATTTAGTGA CACGGGTCTCTATTTCTGTGGGAAAGATATTTTCGCCTATTATGGTTATAAAGGCCCACACATCTGGGGCC GAGGGACACCGGTCACCGTCTCTTCA SEQ ID NO: 598 PC68-L31_49D VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 599 PC68-L31_49E VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTCATGAGTATGACGTGAAACATTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 600 PC68-L31_54A VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCGCCGGGGGGAGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTATTGGTTACGCCAGACTGCAGGCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCGGGGATACATGAATATGATACCATACACTATGGAGACTCCGCGTGGGGC CGATTTACCATCTCCAGAGACGTCGGCAAGAACACACTGTTTCTGCAAATGGACAGACTGACACCTGGGGA CACGGGAATTTACTTCTGTGCGAAGGATTTTGTCACCTACTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTGCA SEQ ID NO: 601 PC68-L31_54B VH nucl CAGGTACACCTGGTGGAGTCTGGGGGAGGCGTGGTCCGCCGGGGGGAGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCACCAACCATGGCATGTATTGGTTACGCCACACTGCAGGCAGAGGACTGGAGTGGT TGGCCTTTATAGGCATTGATGCGGGGATACATGAATATGATACCATACACTATGGAGACTCCGCGTGGGGC CGATTTACCATCTCCAGAGACGTCGGCAAGAACACACTGTTTCTGCAAATGGACAGACTGACACCTGGGGA CACGGGAATTTACTTCTGTGCGAAGGATTTTGTCACCTACTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACACCGGTCACCGTCTCTGCA SEQ ID NO: 602 PC68-L31_54C VH nucl CAGGTGCACCTGGTGGAGTCTGGGGGAGGCGTGGTCCACCGGGGGGAGTCCCTGAGACTCTCATGTGAAGT GTATGGGTTCAGAGTCATAAATCATGGCATGTATTGGTTCCGTCACACTCCAGCCAGGGGCCTGGAGTGGT TGGCCTTTATAGGCATTGATGCAGGAATACAAGAAGATGATATCAAACATTATGGAGACTCCGCGTGGGCC CGATTCAGCATCTCCAGAGACGGTGGCAAGAACACTGTGTTTCTGCAAATGGACAGGCTGACACCTGGGGA CACGGGAACATATTTCTGCGCGAAGGATTTTGTCACCTATTGGAGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACAGCGGTCAGCGTCTCTGCA SEQ ID NO: 603 PC68-L31_54D VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAAAGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 604 PC68-L31_54E VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTATGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTCATAGGCATCGACGGAGGTGTTAATGAGTATGATACGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGGAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCATATTATGGTTATAATGGGCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 605 PC68-L31_54F VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 606 PC68-L31_54G VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCTTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 607 PC68-L31_54H VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACACCGGTCACCGTGTTTTCA SEQ ID NO: 608 PC68-L31_54I VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGC TGGCCTTCATAGGCATTGACGGAGGTGTTAATGATTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATTTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTCGCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 609 PC68-L31_54J VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGATCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACAGCGGTCACCGTTTTTTCA SEQ ID NO: 610 PC68-L31_54K VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAATATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGACAAGAATATAGTGTATCTAGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 611 PC68-L31_54L VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTTTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 612 PC68-L31_54M VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATGTAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAAAGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 613 PC68-L31_54N VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGAATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATTTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 614 PC68-L31_54P VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTGCAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGATGTGAAGCACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAGGAATATAGTGTATCTGGAATTGAGCGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTTTTTTCA SEQ ID NO: 615 PC68-L31_54Q VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTACAGC GTACGGATTCAGAGTTGCTAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGACGTGAAACACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGTCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCAAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGTTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 616 PC68-L31_54R VH nucl CAGATACATCTGGTGGAGTCGGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGTACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGACGTGAAACATTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 617 PC68-L31_54S VH nucl CAGATACACCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCATGCACAGC GTACGGATTCAGAGTTGGCAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGTCAGGGGACTGGAGTGGT TGGCCTTTATAGGCATCGACGGAGGCGTTAATGAGTATGACGTGAAACATTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGGAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 618 PC68-L31_59A VH nucl CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCTCCAACCATGGCATGTACTGGTTCCGCCACGTTCCAGACAAGGGACTGGAGTGGT TGGCCTTTATGGGCATTGATGCAGGGATTCATGACGATGACATTATACACTATGGAGACTCCGCCTGGGGC CGATTCAGAATCTCCCGAGACAGTCGCAAGAACACACTGTATCTACAAATGGACAGGCTGACACCTGGGGA CACGGGAACATATTTCTGTGCGAAGGACTATATCACCTATCGTGGTTATAGTGGCCCTTATGTCTGGGGCC GAGGGACAGCGGTCACCGTCTCTGCA SEQ ID NO: 619 PC68-L31_59B VH nucl CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCTCCAACCATGGCATGTACTGGTTCCGCCACGTTCCAGACAAGGGACTGGAGTGGT TGGCCTTTATGGGCATTGATGCAGGGATTCATGACGAAGACATTATACACTATGGAGACTCCGCCTGGGGC CGATTCAGAATCTCCCGAGACAGTCGCAAGAACACACTGTATCTACAGATGGACAGGCTGACACCTGGGGA CACGGGAACATATTTCTGTGCGAAGGACTATATCACCTATCATGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACAGCGGTCACCGTCTCTGCA SEQ ID NO: 620 PC68-L31_59C VH nucl CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCTCCAACCATGGCATGTACTGGTTCCGCCACGTTCCAGACAAGGGACTGGAGTGGT TGGCCTTTATGGGCATTGATGCTGGGATTCATGACGAAGACATTATACATTATGGAGACTCCGCCTGGGGC CGATTCAGAATCTCCCGAGACAGTCGCAAGAACACACTGTATCTACAGATGGACAGGCTGACACCTGGGGA CACGGGAACATATTTCTGTGCGAAGGACTATATCACCTATCATGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACTGCGGTCACCGTCTCTGCA SEQ ID NO: 621 PC68-L31_59D VH nucl CAGGTGCATCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCGGGGGGGGTCCCTGAGACTCTCATGTGAAGT GTCTGGATTCAGAGTCTCCAACCATGGCATGTACTGGTTCCGCCACGTTTCAGACAAGGGACTGGAGTGGT TGGCCTTTATGGGCATTGATGCTGGGATTCATGACGAAGACATTATACATTATGGAGACTCCGCCTGGGGC CGATTCAGAATCTCCCGAGACAGTCGCAAGAACACACTGTATCTACAGATGGACAGGCTGACACCTGGGGA CACGGGAACATATTTCTGTGCGAAGGACTATATCACCTATCATGGTTATAGTGGCCCATATGTCTGGGGCC GAGGGACTGCGGTCACCGTCTCTGCA SEQ ID NO: 622 PC68-L31_59E VH nucl CAGATACACCTGGTGGAGTCGGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTCTTGTTCAGC GTACGGATTCAGAGTTGCCAACTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATGGGCATCGACGGAGGTGTTAATGACTATGATTTGAAATATTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAATTTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTGTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGCTATAAAGGGCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 623 PC68-L31_59F VH nucl CAGATACACCTGGTGGAGTCGGGGGGAGACGTGGTCCAGCGGGGGGGGTCCCTGCGACTCTTTTGTTCAGC GTACGGATTCAGAGTTGCCAACTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTTATGGGCATCGACGGAGGTGTTAATGACTATGATTTGAAATATTATGGAGACTCCGCGTGGGGC CGGTGGCCCATTTCCAGAGACACTGGCAAGAATATAATTTATCTGGAATTGAGTGGCCTGGCACCTAGTGA CACGGGTGTGTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGCTATAAAGGGCCACACAGCTGGGGCC GAGGGACATCGGTCACCGTCTCTTCA SEQ ID NO: 624 PC68-L31_59G VH nucl GAGGTGCAGCTGGTGGAGTCTGGGGGAGACGTGGTCCAGCGGGGGTCCCTGCAACTCTCATGTACAGCGTA CGGATTCAGAGTTGCTAGTTATGGCATGTACTGGTTTCGGCAGACTCCAGCCAGGGGACTGGAGTGGTTGG CCTTTATAGGCATCGACGGAGGTGTTAATGAGTATGACGTGAAACACTATGGAGACTCCGCGTGGGGCCGG TGGCCCATTTCCAGAGACACTGTCAAGAATATAGTGTATCTGGAATTGAGTGGCCTGGCACCAAGTGACAC GGGTGTCTATTTCTGTGCCAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGTTGGGGCCGAG GGACATCGGTCACCGTCTCCTCA SEQ ID NO: 625 PC68-L31_59H VH nucl GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCGGGGGGAGTCCCTGAAACTCTCATGTTCAGC GTACGGATTTAGAGTTGGCAGTTACGGCATGTACTGGTTCCGCCACACTCCAGCCAGGGGACTGGAGTGGT TGGCCTTNATAGGCATCCACGTGGGTGTTCATGAANATGACGTGAAATACTATGGAGACTCCGCGTGGGGC CGGTGGCCCATCTCAAGAGACACTGNCNAGAATATAGTGTATCTGGAATTGAATGGCCTGACATTTAGTGA CACNGGTGTCTATGTCTGTGCGAAAGATTCTTTCGCCTATTATGGTTATAATGGCCCACACAGCTGGGGCC GANGGACACCGGTCACCGTCTCCTCA SEQ ID NO: 626 Intentionally left open SEQ ID NO: 627 Intentionally left open SEQ ID NO: 628 Intentionally left open SEQ ID NO: 629 Intentionally left open SEQ ID NO: 630 Intentionally left open SEQ ID NO: 631 PC68-L31_32A VL nucl TCCTCTGTGTTGACTCAGCCACCCTCGGTGTCGGTGGCCCCAGGAAAGACGGCCACAATTACCTGTGACAG AACAAATCTTGGAGGCAGAATTATATCCTGGTATCGCCAGAGGCCAGGCCAGGCCCCTGTGGTGGTCGCCT ATGATGACCGTGACCGGCCCTCAGGGATCTCTGAGCGATTCTCTGGCTCCAGATCGGGAAACACGGCCACC CTGACCATAAGTCGGGTCGAAGACGGGGATGAGGGCAACTATATCTGTCAGGTGTGGGATGGAAGTCGTGT TCGATTCGGCGGGGGGACCACGCTGACCGTCCTC SEQ ID NO: 632 PC68-L31_32B VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGAACAGACGACCACGATTACCTGTGTAGG AAACAACATTGGAGGCAGACGTGTACACTGGTACCGGCAGAGGCCAGGCCAGGCCCCTATGTTGGTCGTCT ATAATGACCGTGAACGGTCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACTATAAGTCGGGTCGAGGCCGGGGATGAGGCCGATTATTACTGTCAGATGTGGGATGGAAGTGGTGC TCGATTCGGCGGTGGGACCAAGGTGACCGTCCTA SEQ ID NO: 633 PC68-L31_32C VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGAACAGACGGCCAGGATTACCTGTGAGGG AAAGAACATTGGAGGCAGAAGGGTACACTGGTACCGGCAGAGGCCAGGCGAGGCCCCTATGTTGGTCGTCT ATAATGACCGTGAGCGGTCCTCAGGGATCCCTGACCGATTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGCGTCGAGGCCGGGGATGAGGCCGATTATTACTGTCAGATGTGGGATGGAAGTGGTGC TCGATTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 634 PC68-L31_32D VL nucl TCCTCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAGTGTACACTGGTGCCGGCAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATAATGACCGTGACCGGGCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGAAATACGGCCACC CTGACCATAAGTCGGGTCGAAGTCGGGGATGAGGCCAACTATTACTGTCACATGTGGGATGGAAGTGGTGT ACGACTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 635 PC68-L31_32E VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGAACAGACGGCCAGGATTACCTGTGAGGG AAAGAACATTGGAGGCAGAAGGGTCCACTGGTACCGGCAGAGGCCAGGCGAGGCCCCTATATTGGTCGTCT ATAATGACCGTGAACGGTCCTCAGGGATCCCTGACCGATTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGCGTCGAGGCCGGGGATGAGGCCGATTATCACTGTCAGATGTGGGATGGACGCGGTGC TCGATTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 636 PC68-L31_32F VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGAACAGACGACCACGATTACCTGTATAGG AAACAACATTGGTGGCAGACGGGTTCACTGGTACCGGCAGCGGCCAGGCCAGGCCCCTATGTTGGTCGTCT ATAATGACCGTGAACGGTCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAGGCCGGGGATGAGGCCGATTATTACTGTCAGATGTGGGATGGAAGTGGTGC TCGATTCGGCGGTGGGACCAAGGTGACCGTCCTA SEQ ID NO: 637 PC68-L31_32G VL nucl TCCTATGTGCTGGCTCAGCCACCCTCGGTGTCAGTGGCCCCGGGAGAGACGGCCACCATTACCTGTGGGGA CAGCAGAGTTGGCAGTAAAGGTTTTCACTGGTACCGGCAGAGGCCAGGCCAGGCCCCTGTCTTGGTCATTC ATGATAATACCGACCGGGCCTCAGGGATCCCTTATCGATTCTCTGGCTCCAAGTCTGGGAACACAGCCACC CTGACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTTCTGTCACGTGTGGCATGGGAGTGGTGC GCACTTCGGCGGGGGGACGAAGCTGACCGTCCTA SEQ ID NO: 638 PC68-L31_32H VL nucl TCCTCTTTGCTGACTCAGCCACCCTCGGTGGCAGTGGCCCCAGAAGAGACGGCCACAATTACCTGTTACGG AAACAGCCTTGGCGGCAGAAGTATACACTGGTACCGGCAGAGGCCAGGCCAGGCCCCTCTGTTGGTCGTCT ATAATGACCGTGAGCGGCCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATCAGTCGGGTCGAGGCCGGGGATGAGGCCAATTATTACTGTCAGATGTGGGATGGAAGTGGTGT TCGATTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 639 PC68-L31_32I VL nucl TCGTCCGTACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGTCGGCCACGATTACCTGTGACGG AAAGAACCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATGT ATAATGACCGTGAGCGGCCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGATTATTATTGCTACATGTGGGATGGAAGTGGTGC TCGATTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 640 PC68-L31_32J VL nucl TCCTATGTGCTGGCTCAGCCGCCCTCGGTGTCAGTGGCCCCGGGAGAGACGGCCACCATTACCTGTGGGGA CAGCGGGGTTGGAAGTAAAGGTTTTCACTGGTACCGGCAGAAGCCAGGCCAGGCCCCTGTCTTGGTCATTC ATGATAATACCGACCGGGCCTCAGGGATCCCTTATCGATTCTCTGGGTCCAAGTCTGGGAACACAGCCACC CTGACCATCAGCGGGGTCGAAGCCGGGGATGAGGCCGACTATTTCTGTCACGTGTGGCATGGGAGTGGTGC TCGGTTCGGCGGGGGGACGAAGCTGACCGTCCTA SEQ ID NO: 641 PC68-L31_32K VL nucl TCCTATGTGCTGGCTCAGCCGCCCTCGGTGTCAGTGGCCCCGGGAGAGACGGCCACCATTACCTGTGGGGA CAGCAGAGTTGGAAGTAAAGGTTTTCACTGGTACCGGCAGAAGCCAGGCCAGGCCCCTGTCTTGGTCATTC ATGATAATACCGACCGGGCCTCAGGGATCCCTTATCGATTCTCTGGGTCCAAGTCTGGGAACACAGCCACC CTGACCATCAGCACGGTCGAGGCCGGGGATGAGGCCGACTATTTCTGTCACGTGTGGCATGGGAGTGGTGC TCGGTTCGGCGGGGGGACGAAGCTGACCGTCCTA SEQ ID NO: 642 PC68-L31_38A VL nucl TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGAAAAGACGGCCACACTTACCTGTGACGG AAACGGCCTTGGCGGCAGAAGTGTACACTGGTACCGGCAGCGGCCAGGCCAGGCCCCTCTGTTGGTCGTCT ATAATGACCGTGAGCGGCCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCAATTATTACTGTCAGATGTGGGATGGACGTGGTGC TCGATTCGGCGGGGGGACCATGGTGACCGTCCTAG SEQ ID NO: 643 PC68-L31_38B VL nucl TCCTATGAGCTGACNCAGCCACCCTCGGTGTCAGTGGCCCCAGAAAAGACGGCCACACTTACCTGTGACGG AAACGGCCTTGGCGGCAGAAGTGTGCACTGGTATCGGCAGAGGCCAGGCCAGGCCCCTCTGTTGGTCGTCT ATAATGACCGTGAGCGGCCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGACTCGAAGCCGGGGATGAGGCCACTTATTACTGTCAGATGTGGGATGGACGTGGTGC TCGATTCGGCGGGGGGACCATGGTGACCGTCCTA SEQ ID NO: 644 PC68-L31_38C VL nucl TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAGTGTACACTGGTGCCGGCAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATAATGACCGTGACCGGGCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGAAATACGGCCACC CTGACCATAAGTCGGGTCGAAGTCGGGGATGAGGCCAACTATTACTGTCACATGTGGGATGGAAGTGGTGT ACGACTCGGCGGGGGGACCAAGGTGACCGTCCTAG SEQ ID NO: 645 PC68-L31_38D VL nucl TCCTATGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACCTGTGACGG AAACAGCCTTCGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAAACTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGTTACATGTGGGATGGAAGTGGTGC TCGATTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 646 PC68-L31_38E VL nucl TCCTATGAGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCGGGAGAGACGGCCACGATTACCTGTGGGGA CAAGAAAATTGGAAGTGTGCACTGGTACCGGCAGAGGCCAGGCCAGGCCCCTGTCTTGGTCATTCATGATA ATACCGACCGGGCCTCAGGGATCCCTTATCGATTCTCTGGCTCCAAGTCTGGGGACACAGCCACCCTGACC ATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTTTTGTCACGTGTGGCATGGGAGTGGTGCTCGGTT CGGCGGGGGGACGAGGCTGATCGTCCTAG SEQ ID NO: 647 PC68-L31_43A VL nucl TCGTCTGTTCTGACTCAGGCACTCTCGGTGTCGGTGGCCCCAGGAGAGACGGCCACCATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAGTGTACACTGGTGCCGTCAGAGGTCAGGCCAGGCCCCTGTTTCGGTCGTCT ATTATGGCCATGACCGGGCCCCAGAGATCCCTGAGCGGTTCTCTGCCTCCAAATCTGGAAATACGGCCACC CTGACCATAAGTCGGGTCGAAGTCGGGGATGAGGCCACCTATTACTGTCACATGTGGGATGGAAGTATTCC TCGATTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 648 PC68-L31_43B VL nucl TCGTCTGTTCTGACTCAGGCACCCTCGGTGTCGGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAGTGTACACTGGTGCCGGCAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATTATGGCCATGACCGGGCCCCAGAGATCCCTGTGCGGTTCTCTGCCTCCAAATCTGGAAACACGGCCACC CTGACCATAAGTCGGGTCGAAGTCGGGGATGAGGCCACCTATTACTGTCACATGTGGGATGGAAGTGGTGC TCGGTTCGGCGGGGGGACGCAGGTGAACGTCCTA SEQ ID NO: 649 PC68-L31_43C VL nucl TCCTCTGTCCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAACCTTGGAGGCAGAAATGTACACTGGTGCCGGCAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCTATA ATGGTGACCGGGCCTCAGGGATCCCTGAGAGGTTCTCTGGCTCCAAATCTGGAAATGCGGCCACCCTGACC ATAAGTCGGGTCGAAGTCGGGGATGAGGCCAATTATTACTGTCACATGTGGGATGGAAGTATTCCTCGATT CGGCGGGGGGACCAAGGTGACCGTCTTA SEQ ID NO: 650 PC68-L31_43D VL nucl TCCTCTACACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACATGTGTCGG AAACAACCTTGGAGGCAGAAGTGTACACTGGTGCCGCCAGAAGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATAATGACCGTGAGCGGACCTCAGGGATCCCTGAGCGGTTCTCTGACTCCAGATCTGGAAATACGGCCACC CTGACCATAGCTCGGGTCGAAGTCGGGGATGAGGCCACCTTTTACTGTCACATGTGGGATGGAAGTGGTTC TCGATTCGGCGGGGGGACCAAGCTGACCGTCCTA SEQ ID NO: 651 PC68-L31_43E VL nucl TCCTCTGTCCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAATGTACACTGGTGCCGGCAGAGGGCAGGCCAGGCCCCTGTTTCGGTCGTCT TTAATGGTGACCGGGCCTCAGGGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGAAGTACGGCCACCCTG ACCATAAGTCGGGTCGAAGTCGGGGATGAGGCCAATTATTACTGTCACATGTGGGATGGAAGTATTCCTCG ATTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 652 PC68-L31_43F VL nucl TCCTCTACACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACATGTGTCGG AAACAACCTTGGAGGCAGAAGTGTACACTGGTGCCGCCAGAAGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATAATGACCGTGAGCGGACCTCAGGGATCCCTGAGCGGTTCTCTGACTCCAGATCTGGAAATACGGCCACC CTGACCATAGCTCGGGTCGAAGTCGGGGATGAGGCCACCTTTTACTGTCACATGTGGGATGGAAGTGGTTC TCGATTCGGCGGGGGGACCAAGCTGACCGTCCTA SEQ ID NO: 653 PC68-L31_43G VL nucl TCTGCTGGCCTGACTCAGCCACCCTCGGTAGCGGTGGCCCCAGAAAAGACGGCCACAGTTACCTGTGACGG ATACGGCCTTGGCGCCAGAAGTGTAAACTGGTACCGCCTGAGGCCAGGCCAGGCCCCTCTGCTGGTCCTCT ATAATGACCGTGAGCGGCCCTCAGGGATCCCTGAACGATTCTCTGGCTCCAAATCTGGAAACACGGCCACC CTGACCATTAGTCGTGTCGAGGCCGGGGATGAGGACAATTATTACTGTCAGATGTGGGATGGAAGTGGTCT TCGCTTCGGCGGGGGGACCAAGGTGACCGTCCTA SEQ ID NO: 654 PC68-L31_43H VL nucl TCCTCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGGGAGACGGCCACGATTACCTGTGACGG GAGCAGCATTGGAGGCAGCGGTGTACACTGGTGCCGGCAGGGGCCAGGTCAGGCCCCTGTTTCGGTCGTCT ATAATGGCGGTGACCGGCCCATCCCTGCGCGATTCTCTGCCTCCAGATCTGGAAATACGGCCACCCTGACC ATAAGCCGGGTCGAGGTCGGGGATGAGGCCAGTTATTACTGTTACATATGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAGGTGACCGTCCTG SEQ ID NO: 655 PC68-L31_43I VL nucl TCCTCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG GAGCAACATTGGAGGCAGAGGTGTACACTGGTGCCGGCAGCGGCCAGGTCAGGCCCCTGTTCCGGTCGTCT ATAGTGGCGGTGACCGGCCCATCCCTGCGCGATTCTCTGCCTCCAGATCTGGAACTACGGCCACCCTGACC ATAAGTCGGGCCGAGGTCGGAGATGAGGACACTTATTACTGTTATATATGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAGGTGACCGTCCTG SEQ ID NO: 656 PC68-L31_43J VL nucl TCCTCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG GAACAACATTGGCGGCAGAGGTGTACACTGGTGCCGGCAGAGGCCAGGTCAGGCCCCTGTTTCGGTCGTCT ATAATGGCGGTGACCGGCCCATCCCTGCGCGATTCTCTGCCTCCAGATCTGGAAATACGGCCACCCTGACC ATAAGTCGGGTCGAAGTCGGGGATGAGGCCAATTATTACTGTTATATATGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAGGTGACCGTCCTG SEQ ID NO: 657 PC68-L31_43K VL nucl TCCTCTGTGATAACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCGAGACGGCCACGATTACCTGTGACGG AAAGAGCCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATGT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGAGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGCCGAAGCCGGGGATGAGGCCGAATATTATTGTTACATGTGGGATGGAAGTGGTGC TCGACTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 658 PC68-L31_43L VL nucl TCCTCTGTACTGGCTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACCTGTGACGG AAACACCCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGTAACACGGCCACC CTGACCATAAGTCGGGTCGAGGCCGGGGATGAGGCCGAATACTATTGTTACATGTGGCATGGAAGTGGTGT GCGACTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 659 PC68-L31_43M VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGGTGTTGGAGGCAGAAGTCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCGACTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 660 PC68-L31_43N VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGGTGTTGGAGGCAGAAGTCTGCACTGGTGCCGTAGGAGGCCAGGCCAGGCCCCTCTGTTGCTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGGATGGAAGTGGTGT TCGACTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 661 PC68-L31_43P VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGTCACGATTACGTGTGACGG AAATGGTGTTGGAGGCAGAAGTCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TGGACTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 662 PC68-L31_43Q VL nucl TCCTCTGTACTGGCTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACCTGTGACGG AAACAGCCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGTAACACGGCCACC CTGACCATAAGTCGGGTCGAGGCCGGGGATGAGGCCGAATACTATTGTTACATGTGGCATGGAAGTGGTGT ACGACTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 663 PC68-L31_43R VL nucl TCCTCTGTGCTGGCTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGGCGGCCACGATTACCTGTGACGG AAACAGCGTCGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTACAGGTCATCT ATAATGACCGTGAGCGGCCCTCAGACATCCCTGAGCGGTTCTCTGCCTCCAAGTCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGTTACATGTGGGATGGCAGTGGTGC TCGATTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 664 PC68-L31_43S VL nucl TCCTCTGTGCTGGCTCAGCCGCCCTCGGTGTCAGTGGCCCCAGGCGAGACGGCCACGATTACCTGTGACGG AAACAGCCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCGGGCCCCTCTATTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGACATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGAGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCGACTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 665 PC68-L31_49A VL nucl TCGTCTGTTCTGACTCAGCCACCCTCGGTGTCGGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAGCAACCTTGGAGGCAGAAGTGTACACTGGTGCCGACAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCT ATTATGGCCATGACCGGGCCCCAGAGATCCCTGAGCGGTTCTCTGCCTCCAAATCTGTAAATACGGCCACC CTGACCATAAGTCGGGTCGAGGTCGGGGATGAGGCCACCTTTTACTGTCACATGTGGGATGGAAGTGGTGC TCGATTCGGCGGGGGGACCAAGTTGATCGTCCTA SEQ ID NO: 666 PC68-L31_49B VL nucl GCCTCTGTCCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGACGG AAACCTTGGAGGCAGAAATGTACACTGGTGCCGGCAGAGGCCAGGCCAGGCCCCTGTTTCGGTCGTCTATA ATGGTGACCGGGCCTCAGGGATCCCTGAGAGGTTCTCTGGCTCCAAATCTGGAAATGCGGCCACCCTGACC ATAAGTCGGGTCGAAGTCGGGGATGAGGCCAATTATTACTGTCACATGTGGGATGGAAGTATTCCTCGATT CGGCGGGGGGACCAAGGTGACCGTCTTA SEQ ID NO: 667 PC68-L31_49C VL nucl TCCTCTGTACTGGCTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACCTGTGACGG AAACAGCCTTGGAGGCAGAAGTCTACACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTGTGTTGGTCATCT ATAATGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGTAACACGGCCACC CTGACCATAAGTCGGGTCGAGGCCGGGGATGAGGCCGAATACTATTGTTACATGTGGCATGGAAGTGGTGT ACGACTCGGCGGGGGGACCAAGTTGACCGTCCTA SEQ ID NO: 668 PC68-L31_49D VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGGTGTTGGAGGCTTACTTCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCGACTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 669 PC68-L31_49E VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGGTGTTGGAGGCTTAATTCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCATCTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 670 PC68-L31_54A VL nucl TCCTCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTCCCTGTGCCGG GAACAACATTGGAGGCAGAGGTGTACACTGGTGCCGGCAGAGGCCAGGTCAGGCCCCTGTTTTGGTCGTCT ATAGTGGCGGTGATTGGCCCGTCCCTGCGCGATTTTCTGCCTCCAGATCTGGAAATACGGCCACCCTGACC ATAAGTCGGGTCGAAGTCGGGGATGAGGACACTTATTACTGTTACATATGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAGGTGACCGTCCTG SEQ ID NO: 671 PC68-L31_54B VL nucl TCCGCTGCACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGAGAGACGGCCACGATTCCCTGTGACGG GAATAACATTGGAGGCAGAGGTGTACACTGGTGCCGGCAGAGGCCAGGTCAGGCCCCTGTTTTGGTCGTCT ATAGTGGCGGTGATTGGCCCGTCCCTGCGCGATTTTCTGCCTCCAGATCTGGAAATACGGCCACCCTGACC ATAAGTCGGGTCGAAGTCGGGGATGAGGACACCTATTACTGTTACATATGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAAGTGACCGTCCTG SEQ ID NO: 672 PC68-L31_54C VL nucl TCCTCTACACTGACTCAGCCACCCTCGGTGTCTGTGGCCCCAGGAGAGACGGCCACGATTACCTGTGCCGG GAGCAACATTGGCGGCAGAGGTGTACACTGGTGCCGGCTGCGGCCAGGTCAGGCCCCTGTTCCGGTCGTCT TTAGTGGCGGTGACCGGCCCATCCCTGCGCGATTCTCTGCCTCCAAATCTGGAACTACGGCCACCCTGACC ATAAGTCGGGCCGAGGTCGGAGATGAGGACACTTATTATTGTTTTATCTGGGATGGAAGTGGTGTCCGACT CGGCGGGGGGACCAAGGTGACCGTCCTG SEQ ID NO: 673 PC68-L31_54D VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 674 PC68-L31_54E VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGACATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGGCGACTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGTGGGACCAAGTTGACCGTCCTC SEQ ID NO: 675 PC68-L31_54F VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 676 PC68-L31_54G VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAAAGTGCACTGGTGCCGTCAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATACAATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 677 PC68-L31_54H VL nucl CCCTCTGTGGTGACTCAGCCACCGTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAAGCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 678 PC68-L31_54I VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGAATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 679 PC68-L31_54J VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGCTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGACCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 680 PC68-L31_54K VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCACGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGACATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGGCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 681 PC68-L31_54L VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAAGCTACACTGGTGCCGTGAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAATACGGCCACC CTGACCATAAGTCGGGTCGAGGCCGGGGATGAGGGCGTCTATTATTGTTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 682 PC68-L31_54M VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAATCTGCACTGGTGCCGTAGGAGGCCGGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGACATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGCGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 683 PC68-L31_54N VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACCTGTGGCGG AAATGGTATTGGAGGCTTAAAGCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 684 PC68-L31_54P VL nucl CCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTATTGGAGGCTTAAAGCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ACAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAGTATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 685 PC68-L31_54Q VL nucl TCCTCTGTACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCGGGCAAGACGGCCACAATTACGTGTGGCGG AAATGGTGTTGGAGGCTTACTTGTGCACTGGTGCCGTGAGAGGCCAGGCCAGGCCCCTCTATTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTCAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACGATAAGTCGAGTCGAAGTCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 686 PC68-L31_54R VL nucl TCCTCTGTACTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACATGTGGCGG AAATGGTGTTGGAGGTTTACTTCTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCGCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCGCTGGCTCCAAATCTGGGAACACGGCCACC CTGACGATAAGTCGAGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACTGTCCTC SEQ ID NO: 687 PC68-L31_54S VL nucl TCCTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGCTGTTGGAAAATTACTTCTGCACTGGTGCCGTACGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGACATCCCTGAGCGCTTCTCTGGCTCCAAATCTGGAAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 688 PC68-L31_59A VL nucl TCGTCTGTTTTGACTCAGCCAACCTCGGTGTCGGTGTCCCCGGGAGAGACGGCCACAATTACCTGTGACGG AAAGAACATTGGCGGCAGAAGTATACACTGGTGCCGACAGAGTCCAGGCCAGGCCCCTGTTACGGTCGTCT ATTATGGTTATGACCGGGCCCCAGAGATCCCTGAGCGCTTCTCTGCCTCCACATCTGGAAATACGGCCACC CTGACCATAAGTCGGGTCGAGGTCGGGGATGAGGCCACATTTTACTGTCACATGTGGGATGGAAGTCTTCC TCGATTCGGCGGGGGGACCAAGCTGCTCGTCTTA SEQ ID NO: 689 PC68-L31_59B VL nucl TCGTCTGTTTTGACTCAGCCAACCTCGGTGTCGGTGTCCCCGGGAGACACGGCCACGATTACCTGTGACGG AAGGAACATTGGAGGCAGAAATGTACACTGGTGCCGGCAGAGTCCAGGCCAGGCCCCTGTTACGGTCGTCT ATTATGGCTATGACCGGGCCCCAGAGATCCCTGAGCGGTTCTCTGCCTCCACATCTGGAAATACGGCCACC CTGACCATAAGTCGGGTCGAGGTCGGGGATGAGGCCACATTTTACTGTCACGTGTGGGATGGAAGTCTTCC TCGATTCGGCGGGGGGACCAAGCTGCTCGTCTTA SEQ ID NO: 690 PC68-L31_59C VL nucl TCGTCTGTTTTGACTCAGCCAACCTCGGTGTCGGTGTCCCCGGGAGAGACGGCCACGATTACCTGTGACGG AAAGAACATTGGAGGCAGAAATATACACTGGTGTCGGCAGAGTCCAGGCCAGGCCCCTGTTACGGTCGTCT ATTATGGTTACGACCGGGCCCCAGAGATCCCTGAGCGGTTCTCTGCCTCCACATCTGGAAATAGGGCCACC CTGACCATAAGTCGGGTCGAGGTCGGGGATGAGGCCACATTTTACTGTCACATGTGGGATGGAAGTCTTCC TCGATTCGGCGGGGGGACCAAACTGCTCGTCTTA SEQ ID NO: 691 PC68-L31_59D VL nucl TCGTCTGTTTTGACTCAGCCAACCTCGGTGTCGGTGTCCCCGGGAGAGACGGCCACGATTACCTGTGACGG AAAGAACATTGGAGGCAGAAATATACACTGGTGTCGGCAGAGTCCAGGCCAGGCCCCTGTTACGGTCGTCT ATTATGGTTACGACCGGGCCCCAGAGATCCCTGAGCGGTTCTCTGCCTCCACATCTGGAAATAGGGCCACC CTGACCATAAGTCGGGTCGAGGTCGGGGATGAGGCCACATTTTACTGTCACATGTGGGATGGAAGTCTTCC TCGATTCGGCGGGGGGACCAAACTGCTCGTCTTA SEQ ID NO: 692 PC68-L31_59E VL nucl TCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AGGTGGTCTTGGAGGCTTACTTGTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAACCCGGGGATGAGGCCGAATACAATTGCTACATGTGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 693 PC68-L31_59F VL nucl TCCTCTGTGGTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AGGTGGTCTTGGAGGCTTACTTGTGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAACCCGGGGATGAGGCCGAATACAACTGCTACATGTGGCATGGGAGTGGTGT TCACGTCGGCGGGGGGACCAAGTTGACCGTCCTC SEQ ID NO: 694 Intentionally left open SEQ ID NO: 695 PC68-L31_59H VL nucl CAGTCTGTGCTGACTCAGCCGCCCGCGGTGTCAGTGGCCCCAGGCGAGACGGCCTCGATTCGCTGTGACGG AAACAACCTTGGAGGCGGAGGTCTATACTGGAGCCGTCAGAGGCCAGGCCAGGCCCCTGTATTAGTCATCT ATAATAACCGTGAGCGGCCCTCAGACATCCCTGGGCGGTTCTCTGGCTCCAGATCCGGTAACACGGCCACC CTGACAATAAGTCGAGTCGAGGCCGGGGATGAGGACGAATATTATTGTTACATATGGCATGGAAGTGGTGT TCACGTCGGCGGGGGGACTAAGTTGACCGTCCTAGGTCAA SEQ ID NO: 696 PC68-L31_59I VL nucl CAGTCTGCCCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGCAAGACGGCCACGATTACGTGTGACGG AAATGGTGTTGGAGGCTTACTTATGCACTGGTGCCGTAAGAGGCCAGGCCAGGCCCCTCTGTTGGTCATCT ATAACGACCGTGAGCGGCCCTCAGAGATCCCTGAGCGGTTCTCTGGCTCCAAATCTGGGAACACGGCCACC CTGACCATAAGTCGGGTCGAAGCCGGGGATGAGGCCGAATATTACTGCTACATGTGGCATGGAAGTGGTGT TCGAATAGGCGGGGGGACCAAGTTGACCGTCCTCAGTCAG SEQ ID NO: 697 Intentionally left open SEQ ID NO: 698 Intentionally left open SEQ ID NO: 699 Intentionally left open SEQ ID NO: 700 Intentionally left open SEQ ID NO: 701 PC68-L31_32A VH FW1 QVHLVESGGGVVQRGGSLRLSCTAYGIR SEQ ID NO: 702 PC68-L31_32B VH FW1 QVHLVESGGGVVQRGGSLRLSCAASGFR SEQ ID NO: 703 PC68-L31_32C VH FW1 QVHLVESGGGVVQRGESLRLSCTAYGFR SEQ ID NO: 704 PC68-L31_32D VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 705 PC68-L31_32E VH FW1 QVHLVESGGGVVQRGESLRLSCAAYGFR SEQ ID NO: 706 PC68-L31_32F VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 707 PC68-L31_32G VH FW1 QVHLVESGGGVVQRGGSLRLSCEAFGIR SEQ ID NO: 708 PC68-L31_32H VH FW1 QVHLVESGGGEVQRGGSLRLSCTAYGFR SEQ ID NO: 709 PC68-L31_32I VH FW1 QVHLVESGGGVVQRGGSLRLSCEASGFR SEQ ID NO: 710 PC68-L31_32J VH FW1 QVHLVESGGGVVQRGGSLRLSCEAFGIR SEQ ID NO: 711 PC68-L31_32K VH FW1 QVHLVESGGGVVQRGGSLRLSCEAFGIR SEQ ID NO: 712 PC68-L31_38A VH FW1 QVQLVESGGGEVQRGGSLRLSCAAYGFR SEQ ID NO: 713 PC68-L31_38B VH FW1 QVQLVESGGGEVQRGGSLRLSCTAYGFR SEQ ID NO: 714 PC68-L31_38C VH FW1 QLVQEESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 715 PC68-L31_38D VH FW1 QVQLVESGGGEVQRGGSLRLSCTAYGFR SEQ ID NO: 716 PC68-L31_38E VH FW1 EVQLVESGGAVVQRGGSLRLSCAAFGFK SEQ ID NO: 717 PC68-L31_43A VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 718 PC68-L31_43B VH FW1 QVHLVESGGGVVQRGGSLRLSCEVAGFR SEQ ID NO: 719 PC68-L31_43C VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 720 PC68-L31_43D VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 721 PC68-L31_43E VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 722 PC68-L31_43F VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 723 PC68-L31_43G VH FW1 QVHLVESGGGEVQRGGSLTLSCAAYGFR SEQ ID NO: 724 PC68-L31_43H VH FW1 QVHLVESGGGVVHRGESLRLSCEVSGFR SEQ ID NO: 725 PC68-L31_43I VH FW1 QVHLVESGGGVVHRGESLRLSCEVSGFR SEQ ID NO: 726 PC68-L31_43J VH FW1 QVHLVESGGGVVRRGESLRLSCEVSGFR SEQ ID NO: 727 PC68-L31_43K VH FW1 QVHLVESGGGVVQRGGSLRLSCTAYGFR SEQ ID NO: 728 PC68-L31_43L VH FW1 QVHLVESGGGVVQRGGSLRLSCTAYGFR SEQ ID NO: 729 PC68-L31_43M VH FW1 QVHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 730 PC68-L31_43N VH FW1 QVHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 731 PC68-L31_43P VH FW1 QVHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 732 PC68-L31_43Q VH FW1 QVHLVESGGGVVQRGGSLRLSCTAYGFR SEQ ID NO: 733 PC68-L31_43R VH FW1 QVHLVESGGGVVQRGESLRLSCSAYGFR SEQ ID NO: 734 PC68-L31_43S VH FW1 QVHLVESGGGVVQRGESLRLSCSAYGFR SEQ ID NO: 735 PC68-L31_49A VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 736 PC68-L31_49B VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 737 PC68-L31_49C VH FW1 QVHLVESGGGVVQRGGSLRLSCTAYGFR SEQ ID NO: 738 PC68-L31_49D VH FW1 QIHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 739 PC68-L31_49E VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 740 PC68-L31_54A VH FW1 QVHLVESGGGVVRRGESLRLSCEVSGFR SEQ ID NO: 741 PC68-L31_54B VH FW1 QVHLVESGGGVVRRGESLRLSCEVSGFR SEQ ID NO: 742 PC68-L31_54C VH FW1 QVHLVESGGGVVHRGESLRLSCEVYGFR SEQ ID NO: 743 PC68-L31_54D VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 744 PC68-L31_54E VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 745 PC68-L31_54F VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 746 PC68-L31_54G VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 747 PC68-L31_54H VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 748 PC68-L31_54I VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 749 PC68-L31_54J VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 750 PC68-L31_54K VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 751 PC68-L31_54L VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 752 PC68-L31_54M VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 753 PC68-L31_54N VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 754 PC68-L31_54P VH FW1 QIHLVESGGDVVQRGGSLRLSCAAYGFR SEQ ID NO: 755 PC68-L31_54Q VH FW1 QIHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 756 PC68-L31_54R VH FW1 QIHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 757 PC68-L31_54S VH FW1 QIHLVESGGDVVQRGGSLRLSCTAYGFR SEQ ID NO: 758 PC68-L31_59A VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 759 PC68-L31_59B VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 760 PC68-L31_59C VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 761 PC68-L31_59D VH FW1 QVHLVESGGGVVQRGGSLRLSCEVSGFR SEQ ID NO: 762 PC68-L31_59E VH FW1 QIHLVESGGDVVQRGGSLRLSCSAYGFR SEQ ID NO: 763 PC68-L31_59F VH FW1 QIHLVESGGDVVQRGGSLRLFCSAYGFR SEQ ID NO: 764 PC68-L31_59G VH FW1 EVQLVESGGDVVQRG-SLQLSCTAYGFR SEQ ID NO: 765 PC68-L31_59H VH FW1 EVQLVESGGGVVQRGESLKLSCSAYGFR SEQ ID NO: 766 Intentionally left open SEQ ID NO: 767 Intentionally left open SEQ ID NO: 768 Intentionally left open SEQ ID NO: 769 Intentionally left open SEQ ID NO: 770 Intentionally left open SEQ ID NO: 771 PC68-L31_32A VH FW2 VRQAPGKGLEWVGFIGV SEQ ID NO: 772 PC68-L31_32B VH FW2 VRQAPGKGLEWLAFIGV SEQ ID NO: 773 PC68-L31_32C VH FW2 VRHAPGKGLEWLAFIGI SEQ ID NO: 774 PC68-L31_32D VH FW2 FRQAPGKGLEWLAFIGI SEQ ID NO: 775 PC68-L31_32E VH FW2 VRHAPGKGLEWLAFIGI SEQ ID NO: 776 PC68-L31_32F VH FW2 VRQAPGKGLEWLAFIGV SEQ ID NO: 777 PC68-L31_32G VH FW2 VRQAPGKGLEWVASLGP SEQ ID NO: 778 PC68-L31_32H VH FW2 VRQTPVRGLEWLAFIGI SEQ ID NO: 779 PC68-L31_32I VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 780 PC68-L31_32J VH FW2 VRQTPGKGLEWVASLGP SEQ ID NO: 781 PC68-L31_32K VH FW2 VRQTPGKGLEWVASLGP SEQ ID NO: 782 PC68-L31_38A VH FW2 VRQTPVRGLEWLAFIGI SEQ ID NO: 783 PC68-L31_38B VH FW2 VRQTSVRGLEWLAFIGI SEQ ID NO: 784 PC68-L31_38C VH FW2 FRQAPGKGLEWLAFIGI SEQ ID NO: 785 PC68-L31_38D VH FW2 VRQTPVRGLEWLAFIGI SEQ ID NO: 786 PC68-L31_38E VH FW2 VRQAPGKGLEWVASLGP SEQ ID NO: 787 PC68-L31_43A VH FW2 FRQAPGKGLEWLAFIGI SEQ ID NO: 788 PC68-L31_43B VH FW2 FRQVPGKGLEWLAFIGI SEQ ID NO: 789 PC68-L31_43C VH FW2 FRQTAGKGLEWLAFIGI SEQ ID NO: 790 PC68-L31_43D VH FW2 FRQTTARGLEWLAFIGI SEQ ID NO: 791 PC68-L31_43E VH FW2 FRHTAGRGLEWLAFIGI SEQ ID NO: 792 PC68-L31_43F VH FW2 FRQTTARGLEWLAFIGI SEQ ID NO: 793 PC68-L31_43G VH FW2 ARQTPVRGLEWLAFIGI SEQ ID NO: 794 PC68-L31_43H VH FW2 FRHTPGRGLEWLAFIGI SEQ ID NO: 795 PC68-L31_43I VH FW2 FRQTPGKGLEWLAFIGI SEQ ID NO: 796 PC68-L31_43J VH FW2 FRQTPGKGLEWLAFIGI SEQ ID NO: 797 PC68-L31_43K VH FW2 FRHTPARGLEWLAFIGV SEQ ID NO: 798 PC68-L31_43L VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 799 PC68-L31_43M VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 800 PC68-L31_43N VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 801 PC68-L31_43P VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 802 PC68-L31_43Q VH FW2 FRQTPARGLEWLAFIGV SEQ ID NO: 803 PC68-L31_43R VH FW2 FRHTPARGLEWLAFIGV SEQ ID NO: 804 PC68-L31_43S VH FW2 FRHTPVRGLEWLAFIGV SEQ ID NO: 805 PC68-L31_49A VH FW2 FRQAPGKGLEWLAFIGI SEQ ID NO: 806 PC68-L31_49B VH FW2 FRQTAGKGLEWLAFIGI SEQ ID NO: 807 PC68-L31_49C VH FW2 FRQTPVRGLEWLAFIGV SEQ ID NO: 808 PC68-L31_49D VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 809 PC68-L31_49E VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 810 PC68-L31_54A VH FW2 LRQTAGRGLEWLAFIGI SEQ ID NO: 811 PC68-L31_54B VH FW2 LRHTAGRGLEWLAFIGI SEQ ID NO: 812 PC68-L31_54C VH FW2 FRHTPARGLEWLAFIGI SEQ ID NO: 813 PC68-L31_54D VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 814 PC68-L31_54E VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 815 PC68-L31_54F VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 816 PC68-L31_54G VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 817 PC68-L31_54H VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 818 PC68-L31_54I VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 819 PC68-L31_54J VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 820 PC68-L31_54K VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 821 PC68-L31_54L VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 822 PC68-L31_54M VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 823 PC68-L31_54N VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 824 PC68-L31_54P VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 825 PC68-L31_54Q VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 826 PC68-L31_54R VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 827 PC68-L31_54S VH FW2 FRQTPVRGLEWLAFIGI SEQ ID NO: 828 PC68-L31_59A VH FW2 FRHVPDKGLEWLAFMGI SEQ ID NO: 829 PC68-L31_59B VH FW2 FRHVPDKGLEWLAFMGI SEQ ID NO: 830 PC68-L31_59C VH FW2 FRHVPDKGLEWLAFMGI SEQ ID NO: 831 PC68-L31_59D VH FW2 FRHVSDKGLEWLAFMGI SEQ ID NO: 832 PC68-L31_59E VH FW2 FRQTPARGLEWLAFMGI SEQ ID NO: 833 PC68-L31_59F VH FW2 FRQTPARGLEWLAFMGI SEQ ID NO: 834 PC68-L31_59G VH FW2 FRQTPARGLEWLAFIGI SEQ ID NO: 835 PC68-L31_59H VH FW2 FRHTPARGLEWLAXIGI SEQ ID NO: 836 Intentionally left open SEQ ID NO: 837 Intentionally left open SEQ ID NO: 838 Intentionally left open SEQ ID NO: 839 Intentionally left open SEQ ID NO: 840 Intentionally left open SEQ ID NO: 841 PC68-L31_32A VH FW3 YGDSVWGRSTITRDPAENTVYLQMNSLRIEDTAIYFC SEQ ID NO: 842 PC68-L31_32B VH FW3 YGDSAWGRFTISRDTGRNTLYLQMSRLTPGDTAVYFC SEQ ID NO: 843 PC68-L31_32C VH FW3 YGDSAWGRFTISRDTGKNTLYLQMNRLTPGDTAVYFC SEQ ID NO: 844 PC68-L31_32D VH FW3 YGDSAWGRFTISRDGGKNTLYLQMDRLTPGDTAAYFC SEQ ID NO: 845 PC68-L31_32E VH FW3 YGDSAWGRFSISRDTGKNTLYLQMNRLTPGDTAVYFC SEQ ID NO: 846 PC68-L31_32F VH FW3 YGDSAWGRFTISRDTGRNTLYLQMNRLTPGDTAVYFC SEQ ID NO: 847 PC68-L31_32G VH FW3 YGDSMWGRVTFSRDSSRNTLHLQMNSLRPEDTAVYYC SEQ ID NO: 848 PC68-L31_32H VH FW3 YGDSAWGRFTISRDTGKNTVNLQMNGLTPHDTGLYFC SEQ ID NO: 849 PC68-L31_32I VH FW3 YGDSAWGRFPISRDTAKNILYLQMNSLTPGDTGVYFC SEQ ID NO: 850 PC68-L31_32J VH FW3 YGDSMWGRVTFARDNSRNTLHLQMSSLRPGDTGIYYC SEQ ID NO: 851 PC68-L31_32K VH FW3 YGDSMWGRVTFSRDNSRNTLHLQMSSLRPGDTGIYYC SEQ ID NO: 852 PC68-L31_38A VH FW3 YGDSAWGRFTISRDTGKNTVYLQMSSLTPHDTGLYFC SEQ ID NO: 853 PC68-L31_38B VH FW3 YGDSAWGRFTISRDTGKNTVYLQMDRLTPHDTGLYFC SEQ ID NO: 854 PC68-L31_38C VH FW3 YGDSAWGRFTISRDGGKNTLYLQMDRLTPGDTAAYFC SEQ ID NO: 855 PC68-L31_38D VH FW3 YGDSAWGRFTISRDTGENTVNLQMNGLTPHDTGLYFC SEQ ID NO: 856 PC68-L31_38E VH FW3 YADSVRGRVSFSRDNSVNTLHMRLSDLRPDDTATYYC SEQ ID NO: 857 PC68-L31_43A VH FW3 YGDSAWGRFTISRDSGKNTLYLQLDRLTPGDTAAYFC SEQ ID NO: 858 PC68-L31_43B VH FW3 YGDSAWGRFRISRDSGKNTLYLQMDRLTPGDTAAYFC SEQ ID NO: 859 PC68-L31_43C VH FW3 YGDSAWGRFTISRDSRKNTLYLQMDRLTPGDTGAYFC SEQ ID NO: 860 PC68-L31_43D VH FW3 YGDSAWGRFTISRSSVKNTLYLQLDRLTPGDTGAYFC SEQ ID NO: 861 PC68-L31_43E VH FW3 YGDSAWGRFTISRDSRKNTLYLQMDRLTPGDTGAYFC SEQ ID NO: 862 PC68-L31_43F VH FW3 YGDSAWGRFTISRSSVKNTLYLQLDRLTPGDTGAYFC SEQ ID NO: 863 PC68-L31_43G VH FW3 YGDSAWGRFTISRDSGKNTVNLQMNGLTPHDTGLYFC SEQ ID NO: 864 PC68-L31_43H VH FW3 YGDSAWGRFSISRDGGKNTLFLQMDRLTPGDTGTYFC SEQ ID NO: 865 PC68-L31_43I VH FW3 YGDSAWGRFSISRDGGKNTLFLQMDRLTPGDTGTYFC SEQ ID NO: 866 PC68-L31_43J VH FW3 YGDSAWGRFSISRDGGKNTLFLQMDRLTPGDTGTYFC SEQ ID NO: 867 PC68-L31_43K VH FW3 YGDSAWGRWPISRDTGKNIVYLQLNGLTFSDTGVYFC SEQ ID NO: 868 PC68-L31_43L VH FW3 YGDSAWGRWPISRDTAKNTVYLELSGLTFSDTGLYFC SEQ ID NO: 869 PC68-L31_43M VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 870 PC68-L31_43N VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 871 PC68-L31_43P VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLAPSDTGDYFC SEQ ID NO: 872 PC68-L31_43Q VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLTFSDTGLYFC SEQ ID NO: 873 PC68-L31_43R VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLTFSDTGVYFC SEQ ID NO: 874 PC68-L31_43S VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLTFSDTGVYFC SEQ ID NO: 875 PC68-L31_49A VH FW3 YGDSAWGRFTISRDSGKNTLYLQMDRLTPGDTAAYFC SEQ ID NO: 876 PC68-L31_49B VH FW3 YGDSAWGRFTISRDSRKNTLDLQMDRLTPGDTGAYFC SEQ ID NO: 877 PC68-L31_49C VH FW3 YGDSAWGRWPISRDTAKNIVYLELSGLTFSDTGLYFC SEQ ID NO: 878 PC68-L31_49D VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 879 PC68-L31_49E VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 880 PC68-L31_54A VH FW3 YGDSAWGRFTISRDVGKNTLFLQMDRLTPGDTGIYFC SEQ ID NO: 881 PC68-L31_54B VH FW3 YGDSAWGRFTISRDVGKNTLFLQMDRLTPGDTGIYFC SEQ ID NO: 882 PC68-L31_54C VH FW3 YGDSAWARFSISRDGGKNTVFLQMDRLTPGDTGTYFC SEQ ID NO: 883 PC68-L31_54D VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 884 PC68-L31_54E VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 885 PC68-L31_54F VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 886 PC68-L31_54G VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 887 PC68-L31_54H VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 888 PC68-L31_54I VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 889 PC68-L31_54J VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 890 PC68-L31_54K VH FW3 YGDSAWGRWPISRDTDKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 891 PC68-L31_54L VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 892 PC68-L31_54M VH FW3 YGDSAWGRWPISRDTGKNVVYLELSGLAPSDTGVYFC SEQ ID NO: 893 PC68-L31_54N VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 894 PC68-L31_54P VH FW3 YGDSAWGRWPISRDTGRNIVYLELSGLAPSDTGVYFC SEQ ID NO: 895 PC68-L31_54Q VH FW3 YGDSAWGRWPISRDTVKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 896 PC68-L31_54R VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 897 PC68-L31_54S VH FW3 YGDSAWGRWPISRDTGKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 898 PC68-L31_59A VH FW3 YGDSAWGRFRISRDSRKNTLYLQMDRLTPGDTGTYFC SEQ ID NO: 899 PC68-L31_59B VH FW3 YGDSAWGRFRISRDSRKNTLYLQMDRLTPGDTGTYFC SEQ ID NO: 900 PC68-L31_59C VH FW3 YGDSAWGRFRISRDSRKNTLYLQMDRLTPGDTGTYFC SEQ ID NO: 901 PC68-L31_59D VH FW3 YGDSAWGRFRISRDSRKNTLYLQMDRLTPGDTGTYFC SEQ ID NO: 902 PC68-L31_59E VH FW3 YGDSAWGRWPISRDTGKNIIYLELSGLAPSDTGVYFC SEQ ID NO: 903 PC68-L31_59F VH FW3 YGDSAWGRWPISRDTGKNIIYLELSGLAPSDTGVYFC SEQ ID NO: 904 PC68-L31_59G VH FW3 YGDSAWGRWPISRDTVKNIVYLELSGLAPSDTGVYFC SEQ ID NO: 905 PC68-L31_59H VH FW3 YGDSAWGRWPISRDTXXNIVYLELNGLTFSDTGVYVC SEQ ID NO: 906 Intentionally left open SEQ ID NO: 907 Intentionally left open SEQ ID NO: 908 Intentionally left open SEQ ID NO: 909 Intentionally left open SEQ ID NO: 910 Intentionally left open SEQ ID NO: 911 PC68-L31_32A VH FW4 WGRGTTVTVTS SEQ ID NO: 912 PC68-L31_32B VH FW4 WGRGTPVTVSL SEQ ID NO: 913 PC68-L31_32C VH FW4 WGRGTPVTVSS SEQ ID NO: 914 PC68-L31_32D VH FW4 WGRGTPVTVSA SEQ ID NO: 915 PC68-L31_32E VH FW4 WGRGTPVTVSS SEQ ID NO: 916 PC68-L31_32F VH FW4 WGRGTPVRVSL SEQ ID NO: 917 PC68-L31_32G VH FW4 WGHGTLVTVSA SEQ ID NO: 918 PC68-L31_32H VH FW4 WGRGTPVTVSS SEQ ID NO: 919 PC68-L31_32I VH FW4 WGRGTPVTVSS SEQ ID NO: 920 PC68-L31_32J VH FW4 WGHGTLVTVSA SEQ ID NO: 921 PC68-L31_32K VH FW4 WGHGTLVTVSA SEQ ID NO: 922 PC68-L31_38A VH FW4 WGRGTPVTVSS SEQ ID NO: 923 PC68-L31_38B VH FW4 WGRGTPVTVSS SEQ ID NO: 924 PC68-L31_38C VH FW4 WGRGTPVTVSS SEQ ID NO: 925 PC68-L31_38D VH FW4 WGRGTPVTVSS SEQ ID NO: 926 PC68-L31_38E VH FW4 WGHGTLVTVSS SEQ ID NO: 927 PC68-L31_43A VH FW4 WGRGTPVTVSS SEQ ID NO: 928 PC68-L31_43B VH FW4 WGRGTRVTVSS SEQ ID NO: 929 PC68-L31_43C VH FW4 WGRGTPVTVSS SEQ ID NO: 930 PC68-L31_43D VH FW4 WGRGTPVTVVS SEQ ID NO: 931 PC68-L31_43E VH FW4 WGRGTPVTVFS SEQ ID NO: 932 PC68-L31_43F VH FW4 WGRGTPVTVVS SEQ ID NO: 933 PC68-L31_43G VH FW4 WGRGTPVTVSS SEQ ID NO: 934 PC68-L31_43H VH FW4 WGRGTPVSVSA SEQ ID NO: 935 PC68-L31_43I VH FW4 WGRGTPVSVSA SEQ ID NO: 936 PC68-L31_43J VH FW4 WGRGTPVTVTA SEQ ID NO: 937 PC68-L31_43K VH FW4 WGRGTPVTVSS SEQ ID NO: 938 PC68-L31_43L VH FW4 WGRGTPVTVSS SEQ ID NO: 939 PC68-L31_43M VH FW4 WGRGTPVTVSS SEQ ID NO: 940 PC68-L31_43N VH FW4 WGRGTPVTVSS SEQ ID NO: 941 PC68-L31_43P VH FW4 WGRGTPVTVSS SEQ ID NO: 942 PC68-L31_43Q VH FW4 WGRGTPVTVSS SEQ ID NO: 943 PC68-L31_43R VH FW4 WGRGTSVTVSS SEQ ID NO: 944 PC68-L31_43S VH FW4 WGRGTAVTVSA SEQ ID NO: 945 PC68-L31_49A VH FW4 WGRGTPVIVSS SEQ ID NO: 946 PC68-L31_49B VH FW4 WGRGTPVTVSS SEQ ID NO: 947 PC68-L31_49C VH FW4 WGRGTPVTVSS SEQ ID NO: 948 PC68-L31_49D VH FW4 WGRGTSVTVSS SEQ ID NO: 949 PC68-L31_49E VH FW4 WGRGTSVTVSS SEQ ID NO: 950 PC68-L31_54A VH FW4 WGRGTPVTVSA SEQ ID NO: 951 PC68-L31_54B VH FW4 WGRGTPVTVSA SEQ ID NO: 952 PC68-L31_54C VH FW4 WGRGTAVSVSA SEQ ID NO: 953 PC68-L31_54D VH FW4 WGRGTSVTVFS SEQ ID NO: 954 PC68-L31_54E VH FW4 WGRGTSVTVFS SEQ ID NO: 955 PC68-L31_54F VH FW4 WGRGTSVTVFS SEQ ID NO: 956 PC68-L31_54G VH FW4 WGRGTSVTVFS SEQ ID NO: 957 PC68-L31_54H VH FW4 WGRGTPVTVFS SEQ ID NO: 958 PC68-L31_54I VH FW4 WGRGTSVTVFS SEQ ID NO: 959 PC68-L31_54J VH FW4 WGRGTAVTVFS SEQ ID NO: 960 PC68-L31_54K VH FW4 WGRGTSVTVFS SEQ ID NO: 961 PC68-L31_54L VH FW4 WGRGTSVTVFS SEQ ID NO: 962 PC68-L31_54M VH FW4 WGRGTSVTVFS SEQ ID NO: 963 PC68-L31_54N VH FW4 WGRGTSVTVFS SEQ ID NO: 964 PC68-L31_54P VH FW4 WGRGTSVTVFS SEQ ID NO: 965 PC68-L31_54Q VH FW4 WGRGTSVTVSS SEQ ID NO: 966 PC68-L31_54R VH FW4 WGRGTSVTVSS SEQ ID NO: 967 PC68-L31_54S VH FW4 WGRGTSVTVSS SEQ ID NO: 968 PC68-L31_59A VH FW4 WGRGTAVTVSA SEQ ID NO: 969 PC68-L31_59B VH FW4 WGRGTAVTVSA SEQ ID NO: 970 PC68-L31_59C VH FW4 WGRGTAVTVSA SEQ ID NO: 971 PC68-L31_59D VH FW4 WGRGTAVTVSA SEQ ID NO: 972 PC68-L31_59E VH FW4 WGRGTSVTVSS SEQ ID NO: 973 PC68-L31_59F VH FW4 WGRGTSVTVSS SEQ ID NO: 974 PC68-L31_59G VH FW4 WGRGTSVTVSS SEQ ID NO: 975 PC68-L31_59H VH FW4 WGRXTPVTVSS SEQ ID NO: 976 Intentionally left open SEQ ID NO: 977 Intentionally left open SEQ ID NO: 978 Intentionally left open SEQ ID NO: 979 Intentionally left open SEQ ID NO: 980 Intentionally left open SEQ ID NO: 981 PC68-L31_32A VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 982 PC68-L31_32B VL FW1 SSVLTQPPSVSVAPEQTTTITC SEQ ID NO: 983 PC68-L31_32C VL FW1 SSVLTQPPSVSVAPEQTARITC SEQ ID NO: 984 PC68-L31_32D VL FW1 SSALTQPPSVSVAPGETATITC SEQ ID NO: 985 PC68-L31_32E VL FW1 SSVLTQPPSVSVAPEQTARITC SEQ ID NO: 986 PC68-L31_32F VL FW1 SSVLTQPPSVSVAPEQTTTITC SEQ ID NO: 987 PC68-L31_32G VL FW1 SYVLAQPPSVSVAPGETATITC SEQ ID NO: 988 PC68-L31_32H VL FW1 SSLLTQPPSVAVAPEETATITC SEQ ID NO: 989 PC68-L31_32I VL FW1 SSVLTQPPSVSVAPGKSATITC SEQ ID NO: 990 PC68-L31_32J VL FW1 SYVLAQPPSVSVAPGETATITC SEQ ID NO: 991 PC68-L31_32K VL FW1 SYVLAQPPSVSVAPGETATITC SEQ ID NO: 992 PC68-L31_38A VL FW1 SYELTQPPSVSVAPEKTATLTC SEQ ID NO: 993 PC68-L31_38B VL FW1 SYELTQPPSVSVAPEKTATLTC SEQ ID NO: 994 PC68-L31_38C VL FW1 SYVLTQPPSVSVAPGETATITC SEQ ID NO: 995 PC68-L31_38D VL FW1 SYVLTQPPSVSVAPGKTATITC SEQ ID NO: 996 PC68-L31_38E VL FW1 SYELTQPPSVSVAPGETATITC SEQ ID NO: 997 PC68-L31_43A VL FW1 SSVLTQALSVSVAPGETATITC SEQ ID NO: 998 PC68-L31_43B VL FW1 SSVLTQAPSVSVAPGETATITC SEQ ID NO: 999 PC68-L31_43C VL FW1 SSVLTQPPSVSVAPGETATITC SEQ ID NO: 1000 PC68-L31_43D VL FW1 SSTLTQPPSVSVAPGETATITC SEQ ID NO: 1001 PC68-L31_43E VL FW1 SSVLTQPPSVSVAPGETATITC SEQ ID NO: 1002 PC68-L31_43F VL FW1 SSTLTQPPSVSVAPGETATITC SEQ ID NO: 1003 PC68-L31_43G VL FW1 SAGLTQPPSVAVAPEKTATVTC SEQ ID NO: 1004 PC68-L31_43H VL FW1 SSALTQPPSVSVAPGETATITC SEQ ID NO: 1005 PC68-L31_43I VL FW1 SSALTQPPSVSVAPGETATITC SEQ ID NO: 1006 PC68-L31_43J VL FW1 SSALTQPPSVSVAPGETATITC SEQ ID NO: 1007 PC68-L31_43K VL FW1 SSVITQPPSVSVAPGETATITC SEQ ID NO: 1008 PC68-L31_43L VL FW1 SSVLAQPPSVSVAPGKTATITC SEQ ID NO: 1009 PC68-L31_43M VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1010 PC68-L31_43N VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1011 PC68-L31_43P VL FW1 SSVLTQPPSVSVAPGKTVTITC SEQ ID NO: 1012 PC68-L31_43Q VL FW1 SSVLAQPPSVSVAPGKTATITC SEQ ID NO: 1013 PC68-L31_43R VL FW1 SSVLAQPPSVSVAPGKAATITC SEQ ID NO: 1014 PC68-L31_43S VL FW1 SSVLAQPPSVSVAPGETATITC SEQ ID NO: 1015 PC68-L31_49A VL FW1 SSVLTQPPSVSVAPGETATITC SEQ ID NO: 1016 PC68-L31_49B VL FW1 ASVLTQPPSVSVAPGETATITC SEQ ID NO: 1017 PC68-L31_49C VL FW1 SSVLAQPPSVSVAPGKTATITC SEQ ID NO: 1018 PC68-L31_49D VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1019 PC68-L31_49E VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1020 PC68-L31_54A VL FW1 SSALTQPPSVSVAPGETATIPC SEQ ID NO: 1021 PC68-L31_54B VL FW1 SAALTQPPSVSVAPGETATIPC SEQ ID NO: 1022 PC68-L31_54C VL FW1 SSTLTQPPSVSVAPGETATITC SEQ ID NO: 1023 PC68-L31_54D VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1024 PC68-L31_54E VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1025 PC68-L31_54F VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1026 PC68-L31_54G VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1027 PC68-L31_54H VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1028 PC68-L31_54I VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1029 PC68-L31_54J VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1030 PC68-L31_54K VL FW1 PSVVTQPPSVSVAPGTTATITC SEQ ID NO: 1031 PC68-L31_54L VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1032 PC68-L31_54M VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1033 PC68-L31_54N VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1034 PC68-L31_54P VL FW1 PSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1035 PC68-L31_54Q VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1036 PC68-L31_54R VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1037 PC68-L31_54S VL FW1 SSVLTQPPSVSVAPGKTATITC SEQ ID NO: 1038 PC68-L31_59A VL FW1 SSVLTQPTSVSVSPGETATITC SEQ ID NO: 1039 PC68-L31_59B VL FW1 SSVLTQPTSVSVSPGDTATITC SEQ ID NO: 1040 PC68-L31_59C VL FW1 SSVLTQPTSVSVSPGETATITC SEQ ID NO: 1041 PC68-L31_59D VL FW1 SSVLTQPTSVSVSPGETATITC SEQ ID NO: 1042 PC68-L31_59E VL FW1 SSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1043 PC68-L31_59F VL FW1 SSVVTQPPSVSVAPGKTATITC SEQ ID NO: 1044 Intentionally left open SEQ ID NO: 1045 PC68-L31_59H VL FW1 QSVLTQPPAVSVAPGETASIRC SEQ ID NO: 1046 PC68-L31_59I VL FW1 QSALTQPPSVSVAPGKTATITC SEQ ID NO: 1047 Intentionally left open SEQ ID NO: 1048 Intentionally left open SEQ ID NO: 1049 Intentionally left open SEQ ID NO: 1050 Intentionally left open SEQ ID NO: 1051 PC68-L31_32A VL FW2 IISWYRQRPGQAPVVVAYDDR SEQ ID NO: 1052 PC68-L31_32B VL FW2 RVHWYRQRPGQAPMLVVYNDR SEQ ID NO: 1053 PC68-L31_32C VL FW2 RVHWYRQRPGEAPMLVVYNDR SEQ ID NO: 1054 PC68-L31_32D VL FW2 SVHWCRQRPGQAPVSVVYNDR SEQ ID NO: 1055 PC68-L31_32E VL FW2 RVHWYRQRPGEAPILVVYNDR SEQ ID NO: 1056 PC68-L31_32F VL FW2 RVHWYRQRPGQAPMLVVYNDR SEQ ID NO: 1057 PC68-L31_32G VL FW2 GFHWYRQRPGQAPVLVIHDNT SEQ ID NO: 1058 PC68-L31_32H VL FW2 SIHWYRQRPGQAPLLVVYNDR SEQ ID NO: 1059 PC68-L31_32I VL FW2 SLHWCRQRPGQAPVLVMYNDR SEQ ID NO: 1060 PC68-L31_32J VL FW2 GFHWYRQKPGQAPVLVIHDNT SEQ ID NO: 1061 PC68-L31_32K VL FW2 GFHWYRQKPGQAPVLVIHDNT SEQ ID NO: 1062 PC68-L31_38A VL FW2 SVHWYRQRPGQAPLLVVYNDR SEQ ID NO: 1063 PC68-L31_38B VL FW2 SVHWYRQRPGQAPLLVVYNDR SEQ ID NO: 1064 PC68-L31_38C VL FW2 SVHWCRQRPGQAPVSVVYNDR SEQ ID NO: 1065 PC68-L31_38D VL FW2 SLHWCRQRPGQAPVLVIYNDR SEQ ID NO: 1066 PC68-L31_38E VL FW2 VHWYRQRPGQAPVLVIHDNT SEQ ID NO: 1067 PC68-L31_43A VL FW2 SVHWCRQRSGQAPVSVVYYGH SEQ ID NO: 1068 PC68-L31_43B VL FW2 SVHWCRQRPGQAPVSVVYYGH SEQ ID NO: 1069 PC68-L31_43C VL FW2 NVHWCRQRPGQAPVSVVYNG SEQ ID NO: 1070 PC68-L31_43D VL FW2 SVHWCRQKPGQAPVSVVYNDR SEQ ID NO: 1071 PC68-L31_43E VL FW2 NVHWCRQRAGQAPVSVVFNG SEQ ID NO: 1072 PC68-L31_43F VL FW2 SVHWCRQKPGQAPVSVVYNDR SEQ ID NO: 1073 PC68-L31_43G VL FW2 SVNWYRLRPGQAPLLVLYNDR SEQ ID NO: 1074 PC68-L31_43H VL FW2 GVHWCRQGPGQAPVSVVYNGG SEQ ID NO: 1075 PC68-L31_43I VL FW2 GVHWCRQRPGQAPVPVVYSGG SEQ ID NO: 1076 PC68-L31_43J VL FW2 GVHWCRQRPGQAPVSVVYNGG SEQ ID NO: 1077 PC68-L31_43K VL FW2 SLHWCRQRPGQAPVLVMYNDR SEQ ID NO: 1078 PC68-L31_43L VL FW2 SLHWCRQRPGQAPVLVIYNDR SEQ ID NO: 1079 PC68-L31_43M VL FW2 SLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1080 PC68-L31_43N VL FW2 SLHWCRRRPGQAPLLLIYNDR SEQ ID NO: 1081 PC68-L31_43P VL FW2 SLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1082 PC68-L31_43Q VL FW2 SLHWCRQRPGQAPVLVIYNDR SEQ ID NO: 1083 PC68-L31_43R VL FW2 SLHWCRQRPGQAPVQVIYNDR SEQ ID NO: 1084 PC68-L31_43S VL FW2 SLHWCRQRPGRAPLLVIYNDR SEQ ID NO: 1085 PC68-L31_49A VL FW2 SVHWCRQRPGQAPVSVVYYGH SEQ ID NO: 1086 PC68-L31_49B VL FW2 NVHWCRQRPGQAPVSVVYNG SEQ ID NO: 1087 PC68-L31_49C VL FW2 SLHWCRQRPGQAPVLVIYNDR SEQ ID NO: 1088 PC68-L31_49D VL FW2 LLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1089 PC68-L31_49E VL FW2 ILHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1090 PC68-L31_54A VL FW2 GVHWCRQRPGQAPVLVVYSGG SEQ ID NO: 1091 PC68-L31_54B VL FW2 GVHWCRQRPGQAPVLVVYSGG SEQ ID NO: 1092 PC68-L31_54C VL FW2 GVHWCRLRPGQAPVPVVFSGG SEQ ID NO: 1093 PC68-L31_54D VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1094 PC68-L31_54E VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1095 PC68-L31_54F VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1096 PC68-L31_54G VL FW2 KVHWCRQRPGQAPLLVIYNDR SEQ ID NO: 1097 PC68-L31_54H VL FW2 KLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1098 PC68-L31_54I VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1099 PC68-L31_54J VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1100 PC68-L31_54K VL FW2 NLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1101 PC68-L31_54L VL FW2 KLHWCRERPGQAPLLVIYNDR SEQ ID NO: 1102 PC68-L31_54M VL FW2 NLHWCRRRPGQAPLLVIYNDR SEQ ID NO: 1103 PC68-L31_54N VL FW2 KLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1104 PC68-L31_54P VL FW2 KLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1105 PC68-L31_54Q VL FW2 LVHWCRERPGQAPLLVIYNDR SEQ ID NO: 1106 PC68-L31_54R VL FW2 LLHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1107 PC68-L31_54S VL FW2 LLHWCRTRPGQAPLLVIYNDR SEQ ID NO: 1108 PC68-L31_59A VL FW2 SIHWCRQSPGQAPVTVVYYGY SEQ ID NO: 1109 PC68-L31_59B VL FW2 NVHWCRQSPGQAPVTVVYYGY SEQ ID NO: 1110 PC68-L31_59C VL FW2 NIHWCRQSPGQAPVTVVYYGY SEQ ID NO: 1111 PC68-L31_59D VL FW2 NIHWCRQSPGQAPVTVVYYGY SEQ ID NO: 1112 PC68-L31_59E VL FW2 LVHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1113 PC68-L31_59F VL FW2 LVHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1114 Intentionally left open SEQ ID NO: 1115 PC68-L31_59H VL FW2 GLYWSRQRPGQAPVLVIYNNR SEQ ID NO: 1116 PC68-L31_59I VL FW2 LMHWCRKRPGQAPLLVIYNDR SEQ ID NO: 1117 Intentionally left open SEQ ID NO: 1118 Intentionally left open SEQ ID NO: 1119 Intentionally left open SEQ ID NO: 1120 Intentionally left open SEQ ID NO: 1121 PC68-L31_32A VL FW3 SGISERFSGSRSGNTATLTISRVEDGDEGNYIC SEQ ID NO: 1122 PC68-L31_32B VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEADYYC SEQ ID NO: 1123 PC68-L31_32C VL FW3 SGIPDRFSGSKSGNTATLTISRVEAGDEADYYC SEQ ID NO: 1124 PC68-L31_32D VL FW3 SGIPERFSGSKSGNTATLTISRVEVGDEANYYC SEQ ID NO: 1125 PC68-L31_32E VL FW3 SGIPDRFSGSKSGNTATLTISRVEAGDEADYHC SEQ ID NO: 1126 PC68-L31_32F VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEADYYC SEQ ID NO: 1127 PC68-L31_32G VL FW3 SGIPYRFSGSKSGNTATLTISRVEAGDEADYFC SEQ ID NO: 1128 PC68-L31_32H VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEANYYC SEQ ID NO: 1129 PC68-L31_32I VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEADYYC SEQ ID NO: 1130 PC68-L31_32J VL FW3 SGIPYRFSGSKSGNTATLTISGVEAGDEADYFC SEQ ID NO: 1131 PC68-L31_32K VL FW3 SGIPYRFSGSKSGNTATLTISTVEAGDEADYFC SEQ ID NO: 1132 PC68-L31_38A VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEANYYC SEQ ID NO: 1133 PC68-L31_38B VL FW3 SGIPERFSGSKSGNTATLTISRLEAGDEATYYC SEQ ID NO: 1134 PC68-L31_38C VL FW3 SGIPERFSGSKSGNTATLTISRVEVGDEANYYC SEQ ID NO: 1135 PC68-L31_38D VL FW3 SEIPERFSGSKTGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1136 PC68-L31_38E VL FW3 SGIPYRFSGSKSGDTATLTISRVEAGDEADYFC SEQ ID NO: 1137 PC68-L31_43A VL FW3 PEIPERFSASKSGNTATLTISRVEVGDEATYYC SEQ ID NO: 1138 PC68-L31_43B VL FW3 PEIPVRFSASKSGNTATLTISRVEVGDEATYYC SEQ ID NO: 1139 PC68-L31_43C VL FW3 SGIPERFSGSKSGNAATLTISRVEVGDEANYYC SEQ ID NO: 1140 PC68-L31_43D VL FW3 SGIPERFSDSRSGNTATLTIARVEVGDEATFYC SEQ ID NO: 1141 PC68-L31_43E VL FW3 SGIPERFSGSKSGSTATLTISRVEVGDEANYYC SEQ ID NO: 1142 PC68-L31_43F VL FW3 SGIPERFSDSRSGNTATLTIARVEVGDEATFYC SEQ ID NO: 1143 PC68-L31_43G VL FW3 SGIPERFSGSKSGNTATLTISRVEAGDEDNYYC SEQ ID NO: 1144 PC68-L31_43H VL FW3 PIPARFSASRSGNTATLTISRVEVGDEASYYC ID VL
Figure imgf000220_0001
SEQ ID NO: 1147 PC68-L31_43K VL FW3 SEIPERFSGSKSGNTATLTISRAEAGDEAEYYC SEQ ID NO: 1148 PC68-L31_43L VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1149 PC68-L31_43M VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1150 PC68-L31_43N VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1151 PC68-L31_43P VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1152 PC68-L31_43Q VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1153 PC68-L31_43R VL FW3 SDIPERFSASKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1154 PC68-L31_43S VL FW3 SDIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1155 PC68-L31_49A VL FW3 PEIPERFSASKSVNTATLTISRVEVGDEATFYC SEQ ID NO: 1156 PC68-L31_49B VL FW3 SGIPERFSGSKSGNAATLTISRVEVGDEANYYC SEQ ID NO: 1157 PC68-L31_49C VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1158 PC68-L31_49D VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1159 PC68-L31_49E VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1160 PC68-L31_54A VL FW3 PVPARFSASRSGNTATLTISRVEVGDEDTYYC SEQ ID NO: VL FW3 SEQ ID NO: VL FW3 SEQ ID NO:
Figure imgf000220_0002
VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1164 PC68-L31_54E VL FW3 SDIPERFSGSKSGNTATLTISRVEAGDEGDYYC SEQ ID NO: 1165 PC68-L31_54F VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1166 PC68-L31_54G VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYNC SEQ ID NO: 1167 PC68-L31_54H VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1168 PC68-L31_54I VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1169 PC68-L31_54J VL FW3 SEIPDRFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1170 PC68-L31_54K VL FW3 SDIPERFSGSKSGNTATLTISRVEAGDEGEYYC SEQ ID NO: 1171 PC68-L31_54L VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEGVYYC SEQ ID NO: 1172 PC68-L31_54M VL FW3 SDIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1173 PC68-L31_54N VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1174 PC68-L31_54P VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1175 PC68-L31_54Q VL FW3 SEIPQRFSGSKSGNTATLTISRVEVGDEAEYYC SEQ ID NO: 1176 PC68-L31_54R VL FW3 SEIPERFAGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1177 PC68-L31_54S VL FW3 SDIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1178 PC68-L31_59A VL FW3 PEIPERFSASTSGNTATLTISRVEVGDEATFYC
Figure imgf000221_0001
SEQ ID NO: 1182 PC68-L31_59E VL FW3 SEIPERFSGSKSGNTATLTISRVEPGDEAEYNC SEQ ID NO: 1183 PC68-L31_59F VL FW3 SEIPERFSGSKSGNTATLTISRVEPGDEAEYNC SEQ ID NO: 1184 Intentionally left open SEQ ID NO: 1185 PC68-L31_59H VL FW3 SDIPGRFSGSRSGNTATLTISRVEAGDEDEYYC SEQ ID NO: 1186 PC68-L31_59I VL FW3 SEIPERFSGSKSGNTATLTISRVEAGDEAEYYC SEQ ID NO: 1187 Intentionally left open SEQ ID NO: 1188 Intentionally left open SEQ ID NO: 1189 Intentionally left open SEQ ID NO: 1190 Intentionally left open SEQ ID NO: 1191 PC68-L31_32A VL FW4 FGGGTTLTVL SEQ ID NO: 1192 PC68-L31_32B VL FW4 FGGGTKVTVL SEQ ID NO: 1193 PC68-L31_32C VL FW4 FGGGTKVTVL SEQ ID NO: 1194 PC68-L31_32D VL FW4 LGGGTKVTVL SEQ ID NO: 1195 PC68-L31_32E VL FW4 FGGGTKVTVL SEQ ID NO: 1196 PC68-L31_32F VL FW4 FGGGTKVTVL SEQ ID NO: 1197 PC68-L31_32G VL FW4 FGGGTKLTVL SEQ ID NO: 1198 PC68-L31_32H VL FW4 FGGGTKVTVL SEQ ID NO: 1199 PC68-L31_32I VL FW4 FGGGTKLTVL SEQ ID NO: 1200 PC68-L31_32J VL FW4 FGGGTKLTVL SEQ ID NO: 1201 PC68-L31_32K VL FW4 FGGGTKLTVL SEQ ID NO: 1202 PC68-L31_38A VL FW4 FGGGTMVTVL SEQ ID NO: 1203 PC68-L31_38B VL FW4 FGGGTMVTVL SEQ ID NO: 1204 PC68-L31_38C VL FW4 LGGGTKVTVL SEQ ID NO: 1205 PC68-L31_38D VL FW4 FGGGTKLTVL SEQ ID NO: 1206 PC68-L31_38E VL FW4 FGGGTRLIVL SEQ ID NO: 1207 PC68-L31_43A VL FW4 FGGGTKVTVL SEQ ID NO: 1208 PC68-L31_43B VL FW4 FGGGTQVNVL SEQ ID NO: 1209 PC68-L31_43C VL FW4 FGGGTKVTVL SEQ ID NO: 1210 PC68-L31_43D VL FW4 FGGGTKLTVL SEQ ID NO: 1211 PC68-L31_43E VL FW4 FGGGTKVTVL SEQ ID NO: 1212 PC68-L31_43F VL FW4 FGGGTKLTVL SEQ ID NO: 1213 PC68-L31_43G VL FW4 FGGGTKVTVL SEQ ID NO: 1214 PC68-L31_43H VL FW4 LGGGTKVTVL SEQ ID NO: 1215 PC68-L31_43I VL FW4 LGGGTKVTVL SEQ ID NO: 1216 PC68-L31_43J VL FW4 LGGGTKVTVL SEQ ID NO: 1217 PC68-L31_43K VL FW4 LGGGTKLTVL SEQ ID NO: 1218 PC68-L31_43L VL FW4 LGGGTKLTVL SEQ ID NO: 1219 PC68-L31_43M VL FW4 LGGGTKLTVL SEQ ID NO: 1220 PC68-L31_43N VL FW4 LGGGTKLTVL SEQ ID NO: 1221 PC68-L31_43P VL FW4 LGGGTKLTVL SEQ ID NO: 1222 PC68-L31_43Q VL FW4 LGGGTKLTVL SEQ ID NO: 1223 PC68-L31_43R VL FW4 FGGGTKLTVL SEQ ID NO: 1224 PC68-L31_43S VL FW4 LGGGTKLTVL SEQ ID NO: 1225 PC68-L31_49A VL FW4 FGGGTKLIVL SEQ ID NO: 1226 PC68-L31_49B VL FW4 FGGGTKVTVL SEQ ID NO: 1227 PC68-L31_49C VL FW4 LGGGTKLTVL SEQ ID NO: 1228 PC68-L31_49D VL FW4 LGGGTKLTVL SEQ ID NO: 1229 PC68-L31_49E VL FW4 LGGGTKLTVL SEQ ID NO: 1230 PC68-L31_54A VL FW4 LGGGTKVTVL SEQ ID NO: 1231 PC68-L31_54B VL FW4 LGGGTKVTVL SEQ ID NO: 1232 PC68-L31_54C VL FW4 LGGGTKVTVL SEQ ID NO: 1233 PC68-L31_54D VL FW4 VGGGTKLTVL SEQ ID NO: 1234 PC68-L31_54E VL FW4 VGGGTKLTVL SEQ ID NO: 1235 PC68-L31_54F VL FW4 VGGGTKLTVL SEQ ID NO: 1236 PC68-L31_54G VL FW4 VGGGTKLTVL SEQ ID NO: 1237 PC68-L31_54H VL FW4 VGGGTKLTVL SEQ ID NO: 1238 PC68-L31_54I VL FW4 VGGGTKLTVL SEQ ID NO: 1239 PC68-L31_54J VL FW4 VGGGTKLTVL SEQ ID NO: 1240 PC68-L31_54K VL FW4 VGGGTKLTVL SEQ ID NO: 1241 PC68-L31_54L VL FW4 VGGGTKLTVL SEQ ID NO: 1242 PC68-L31_54M VL FW4 VGGGTKLTVL SEQ ID NO: 1243 PC68-L31_54N VL FW4 VGGGTKLTVL SEQ ID NO: 1244 PC68-L31_54P VL FW4 VGGGTKLTVL SEQ ID NO: 1245 PC68-L31_54Q VL FW4 VGGGTKLTVL SEQ ID NO: 1246 PC68-L31_54R VL FW4 VGGGTKLTVL SEQ ID NO: 1247 PC68-L31_54S VL FW4 VGGGTKLTVL SEQ ID NO: 1248 PC68-L31_59A VL FW4 FGGGTKLLVL SEQ ID NO: 1249 PC68-L31_59B VL FW4 FGGGTKLLVL SEQ ID NO: 1250 PC68-L31_59C VL FW4 FGGGTKLLVL SEQ ID NO: 1251 PC68-L31_59D VL FW4 FGGGTKLLVL SEQ ID NO: 1252 PC68-L31_59E VL FW4 VGGGTKLTVL SEQ ID NO: 1253 PC68-L31_59F VL FW4 VGGGTKLTVL SEQ ID NO: 1254 Intentionally left open SEQ ID NO: 1255 PC68-L31_59H VL FW4 VGGGTKLTVL SEQ ID NO: 1256 PC68-L31_59I VL FW4 IGGGTKLTVL SEQ ID NO: 1257 Intentionally left open SEQ ID NO: 1258 Intentionally left open SEQ ID NO: 1259 Intentionally left open SEQ ID NO: 1260 Intentionally left open SEQ ID NO: 1261 AA insertion in VH CDR2 (V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D SEQ ID NO: 1262 VH CDR2 consensus (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/ Q) SEQ ID NO: 1263 VH CDR3 consensus (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T) (N/S/K/R/G/H)GP(H/Y/E/D/Q)(S/V/I/T) SEQ ID NO: 1264 VL CDR3 consensus (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) SEQ ID NO: 1265 heavy chain constant region ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 1266 light chain constant region RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECG SEQ ID NO: 1267 variant Fc region ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK SEQ ID NO: 1268 BG505.W6M.ENV.C2 MRVMGIQRNCQHLFRWGTMILGMIIICSAAENLWVTVYYGVPVWKDAETTLFCASDAKAYETEKHNVWATH ACVPTDPNPQEIHLENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLQCTNVTNNITDDMR GELKNCSFNMTTELRDKKQKVYSLFYRLDVVQINENQGNRSNNSNKEYRLINCNTSAITQACPKVSFEPIP IHYCAPAGFAILKCKDKKFNGTGPCPSVSTVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSENITNNAKNIL VQFNTPVQINCTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHCTVSKATWNETLGKVVKQLRKHFGNNT IIRFANSSGGDLEVTTHSFNCGGEFFYCNTSGLFNSTWISNTSVQGSNSTGSNDSITLPCRIKQIINMWQR IGQAMYAPPIQGVIRCVSNITGLILTRDGGSTNSTTETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTR AKRRVVGREKRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARNLLSGIVQQQSNLLRAIEAQQHLLKLTVW GIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISNYTQII YGLLEESQNQQEKNEQDLLALDKWASLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVIHRVRQGYS PLSFQTHTPNPRGLDRPERIEEEDGEQDRGRSTRLVSGFLALAWDDLRSLCLFCYHRLRDFILIAARIVEL LGHSSLKGLRLGWEGLKYLWNLLAYWGRELKISAINLFDTIAIAVAEWTDRVIEIGQRLCRAFLHIPRRIR QGLERALL SEQ ID NO: 1269 BG505.W6M.ENV.C2 Env comprising the T330N substitution MRVMGIQRNCQHLFRWGTMILGMIIICSAAENLWVTVYYGVPVWKDAETTLFCASDAKAYETEKHNVWATH ACVPTDPNPQEIHLENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLQCTNVTNNITDDMR GELKNCSFNMTTELRDKKQKVYSLFYRLDVVQINENQGNRSNNSNKEYRLINCNTSAITQACPKVSFEPIP IHYCAPAGFAILKCKDKKFNGTGPCPSVSTVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSENITNNAKNIL VQFNTPVQINCTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHCNVSKATWNETLGKVVKQLRKHFGNNT IIRFANSSGGDLEVTTHSFNCGGEFFYCNTSGLFNSTWISNTSVQGSNSTGSNDSITLPCRIKQIINMWQR IGQAMYAPPIQGVIRCVSNITGLILTRDGGSTNSTTETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTR AKRRVVGREKRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARNLLSGIVQQQSNLLRAIEAQQHLLKLTVW GIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISNYTQII YGLLEESQNQQEKNEQDLLALDKWASLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVIHRVRQGYS PLSFQTHTPNPRGLDRPERIEEEDGEQDRGRSTRLVSGFLALAWDDLRSLCLFCYHRLRDFILIAARIVEL LGHSSLKGLRLGWEGLKYLWNLLAYWGRELKISAINLFDTIAIAVAEWTDRVIEIGQRLCRAFLHIPRRIR QGLERALL SEQ ID NO: 1270 BG505 SOSIP.664 AENLWVTVYYGVPVWKDAETTLFCASDAKAYETEKHNVWATHACVPTDPNPQEIHLENVTEEFNMWKNNMV EQMHTDIISLWDQSLKPCVKLTPLCVTLQCTNVTNNITDDMRGELKNCSFNMTTELRDKKQKVYSLFYRLD VVQINENQGNRSNNSNKEYRLINCNTSAITQACPKVSFEPIPIHYCAPAGFAILKCKDKKFNGTGPCPSVS TVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSENITNNAKNILVQFNTPVQINCTRPNNNTRKSIRIGPGQA FYATGDIIGDIRQAHCNVSKATWNETLGKVVKQLRKHFGNNTIIRFANSSGGDLEVTTHSFNCGGEFFYCN TSGLFNSTWISNTSVQGSNSTGSNDSITLPCRIKQIINMWQRIGQAMYAPPIQGVIRCVSNITGLILTRDG GSTNSTTETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTRCKRRVVGRRRRRRAVGIGAVFLGFLGAAG STMGAASMTLTVQARNLLSGIVQQQSNLLRAPEAQQHLLKLTVWGIKQLQARVLAVERYLRDQQLLGIWGC SGKLICCTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISNYTQIIYGLLEESQNQQEKNEQDLLALD SEQ ID NO: 1271 BG505 SOSIP.664 with leader sequence MDAMKRGLCCVLLLCGAVFVSPSOEIHARFRRAENLWVTVYYGVPVWKDAETTLFCASDAKAYETEKHNVW ATHACVPTDPNPQEIHLENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLQCTNVTNNITD DMRGELKNCSFNMTTELRDKKQKVYSLFYRLDVVQINENQGNRSNNSNKEYRLINCNTSAITQACPKVSFE PIPIHYCAPAGFAILKCKDKKFNGTGPCPSVSTVQCTHGIKPVVSTQLLLNGSLAEEEVMIRSENITNNAK NILVQFNTPVQINCTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHCNVSKATWNETLGKVVKQLRKHFG NNTIIRFANSSGGDLEVTTHSFNCGGEFFYCNTSGLFNSTWISNTSVQGSNSTGSNDSITLPCRIKQIINM WQRIGQAMYAPPIQGVIRCVSNITGLILTRDGGSTNSTTETFRPGGGDMRDNWRSELYKYKVVKIEPLGVA PTRCKRRVVGRRRRRRAVGIGAVFLGFLGAAGSTMGAASMTLTVQARNLLSGIVQQQSNLLRAPEAQQHLL KLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICCTNVPWNSSWSNRNLSEIWDNMTWLQWDKEISN YTQIIYGLLEESQNQQEKNEQDLLALD SEQ ID NO: 1272 VRC01 VH QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMT RDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSS SEQ ID NO: 1273 VRC01 VL EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNL TISNLESGDFGVYYCQQYEFFGQGTKVQVDIK

Claims

CLAIMS What is claimed is: 1. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with VRC01 for binding to the HIV Env trimer, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
2. An isolated monoclonal antibody or antigen-binding fragment thereof which binds to an HIV Env trimer, does not bind to the corresponding monomeric gp120 polypeptide of the HIV Env and competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
3. The antibody or antigen-binding fragment of claim 2, wherein the reference antibody is the PC68- L31_54Q antibody.
4. An isolated monoclonal antibody or antigen-binding fragment thereof which binds to the same epitope of an HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
5. The antibody or antigen-binding fragment of claim 4, wherein the reference antibody is the PC68- L31_54Q antibody.
6. The antibody or antigen-binding fragment of any one of claims 1 to 5, which neutralizes a pseudovirus produced in the presence of kifunensine better than those with wildtype glycoforms.
7. The antibody or antigen-binding fragment of any one of claims 1 to 6, which neutralizes a pseudovirusvirus comprising a single mutation in the Env polypeptide selected from the group consisting of N197A, N234A, N262A, N276A, N301A, N363A, N386A and N462A with the same or lower IC50 than a corresponding pseudovirus that does not comprise the mutation.
8. The antibody or antigen-binding fragment of any one of claims 1 to 7 which comprises (a) a VH and VL of the VH3-30 VL3-21 lineage, respectively; and (b) a VH CDR2 comprising a 5 amino acid insertion comprising the sequence of (V/I/L/P)(H/N/Q)(E/D)(Y/D/E)D (SEQ ID NO: 1261), wherein the insertion is between Kabat position 52 and 53.
9. The antibody or antigen-binding fragment of any one of claims 1 to 7 which comprises (a) a VH CDR2 comprising the amino acid sequence of (D/H)(A/G/V/M)G(V/I/L/P)(H/N/Q)(E/D)(Y/D/E/H)D(V/T/I/L/A)(K/I/E)(H/Y/G/Q) (SEQ ID NO: 1262); (b) a VH CDR3 comprising the amino acid sequence of (A/G)KD(S/F/Y/L/I/V/R)(F/V/I/R)(A/T/P/G)(Y/F/L)(Y/W/H/R)(G/S/D/A)(Y/T)(N/S/K/ R/G/H)GP(H/Y/E/D/Q)(S/V/I/T) (SEQ ID NO: 1263); and (c) a VL CDR3 comprising the amino acid sequence of (Y/H/Q/F)(M/I/V)W(D/H)G(S/R)(G/I/L/R)(V/A/P/S/L)(R/H/G) (SEQ ID NO: 1264)
10. The antibody or antigen-binding fragment of any one of claims 1 to 9 comprising a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions.
11. The antibody or antigen-binding fragment of claim 10, wherein the VH CDR3 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3.
12. The antibody or antigen-binding fragment of claim 10, wherein the VH CDR3 comprises the PC68- L31_54Q VH CDR3.
13. The antibody or antigen-binding fragment of any one of claims 1 to 12 comprising a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions.
14. The antibody or antigen-binding fragment of claim 13, wherein the VL CDR3 comprises the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR3.
15. The antibody or antigen-binding fragment of claim 13, wherein the VL CDR3 comprises the PC68- L31_54Q VL CDR3.
16. The antibody or antigen-binding fragment of any one of claims 1 to 15 comprising a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 selected independently from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, PC68-L31_59H, and PC68-L31_59I VH CDR1s, VH CDR2s, VH CDR3s, VL CDR1s, VL CDR2s, and VL CDR3s.
17. The antibody or antigen-binding fragment of claim 16, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises (i) the VH CDR1, VH CDR2, and VH CDR3 of a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68- L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68- L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68- L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68- L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68- L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, and PC68-L31_59H VHs and (ii) a VL CDR1, VL CDR2, and VL CDR3 of a VL selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, and PC68-L31_59I VLs.
18. The antibody or antigen-binding fragment of claim 17, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of a VH/VL pair selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H VH/VL pairs.
19. The antibody or antigen-binding fragment of claim 18, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
20. The antibody or antigen-binding fragment of claim 18, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_43J VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
21. The antibody or antigen-binding fragment of any one of claims 1 to 20, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Kabat.
22. The antibody or antigen-binding fragment of any one of claims 1 to 20, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 is according to Table 1.
23. The antibody or antigen-binding fragment of any one of claims 1 to 22 comprising a VH and a VL, wherein (a) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to a VH selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, and PC68-L31_59H VHs and (b) the VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to a VL selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, and PC68-L31_59I VLs.
24. The antibody or antigen-binding fragment of claim 23, wherein the VH and VL comprises a VH/VL pair selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68- L31_59H VH/VL pairs.
25. The antibody or antigen-binding fragment of any one of claims 1 to 22 comprising a VH and a VL, wherein (i) the VH comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH, and (ii) the VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VL.
26. The antibody or antigen-binding fragment of any one of claims 1 to 22 comprising a VH and a VL, wherein the VH and VL comprises an amino acid sequence having at least about 90%, 95%, 97%, 98%, 99% or 100% identity to the PC68-L31_54Q VH and VL, respectively.
27. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding HIV Env and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
28. The isolated monoclonal antibody or antigen-binding fragment of claim 27, wherein the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR3.
29. The isolated monoclonal antibody or antigen-binding fragment of claim 27 or claim 28, wherein the VH CDR3 is according to Kabat.
30. The isolated monoclonal antibody or antigen-binding fragment of claim 27 or claim 28, wherein the VH CDR3 is according to Table 1.
31. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VH CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (c) the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
32. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR1; (b) the VH CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR2; and (c) the VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH CDR3.
33. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein. (a) the VH CDR1 comprises the PC68-L31_54Q VH CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VH CDR2 comprises the PC68-L31_54Q VH CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (c) the VH CDR3 comprises the PC68-L31_54Q VH CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
34. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein (a) the VH CDR1 comprises the PC68-L31_54Q VH CDR1; (b) the VH CDR2 comprises the PC68-L31_54Q VH CDR2; and (c) the VH CDR3 comprises the PC68-L31_54Q VH CDR3.
35. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68- L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68- L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68- L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68- L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68- L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions.
36. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68- L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68- L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68- L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68- L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68- L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3.
37. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions.
38. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3.
39. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 31 to 38, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Kabat.
40. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 31 to 38, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Table 1.
41. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein (a) the VL CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR1 comprising 0, 1, 2, 3, 4 or 5 substitutions; (b) the VL CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR2 comprising 0, 1, 2, 3, 4 or 5 substitutions; and (c) the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR3 comprising 0, 1, 2, 3, 4 or 5 substitutions.
42. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein (a) the VL CDR1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR1; (b) the VL CDR2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR2; and (c) the VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL CDR3.
43. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein (a) the VL CDR1 comprises the PC68-L31_54Q VL CDR1 comprising 0, 1, 2, 3, 4, or 5 substitutions; (b) the VL CDR2 comprises the PC68-L31_54Q VL CDR2 comprising 0, 1, 2, 3, 4, or 5 substitutions; and (c) the VL CDR3 comprises the PC68-L31_54Q VL CDR3 comprising 0, 1, 2, 3, 4, or 5 substitutions.
44. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein (a) the VL CDR1 comprises the PC68-L31_54Q VL CDR1; (b) the VL CDR2 comprises the PC68-L31_54Q VL CDR2; and (c) the VL CDR3 comprises the PC68-L31_54Q VL CDR3.
45. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions.
46. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2 and VL CDR3.
47. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3 independently comprising 0, 1, 2, 3, 4 or 5 substitutions.
48. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 31 to 40, wherein the VL CDR1, VL CDR2 and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2 and VL CDR3.
49. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 41 to 48, wherein the VL CDR1, VL CDR2, and VL CDR3 are according to Kabat.
50. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 41 to 48, wherein the VL CDR1, VL CDR2, and VL CDR3 are according to Table 1.
51. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions.
52. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
53. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 independently comprising 0, 1, 2, 3, 4, or 5 substitutions.
54. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3.
55. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 51 to 54, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are according to Kabat.
56. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 51 to 54, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are according to Table 1.
57. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 56, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; (b) the VH FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; (c) the VH FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; and (d) the VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions.
58. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 56, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VH FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW1; (b) the VH FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW2; (c) the VH FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW3; and (d) the VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59G, or PC68-L31_59H VH FW4.
59. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 56, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH FW1, VH FW2, VH FW3 and VH FW4.
60. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 56, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein the VH FW1, VH FW2, VH FW3 and VH FW4 comprises the PC68-L31_54Q VH FW1, VH FW2, VH FW3 and VH FW4.
61. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 57 to 60, wherein the VH FW1, VH FW2, VH FW3 and VH FW4 are according to Table 2.
62. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 61, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VL FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW1 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; (b) the VL FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW2 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; (c) the VL FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW3 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions; and (d) the VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW4 comprising 0, 1, 2, 3, 4, or 5 substitutions, insertions or deletions.
63. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 61, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein (a) the VL FW1 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I; (b) the VL FW2 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW2; (c) the VL FW3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW3; and (d) the VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68- L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68- L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68- L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68- L31_59H, or PC68-L31_59I VL FW4.
64. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 61, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL FW1, VL FW2, VL FW3 and VL FW4.
65. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 27 to 61, wherein the VH comprises a VH FW1, VH FW2, VH FW3 and VH FW4 and the VL comprises a VL FW1, VL FW2, VL FW3 and VL FW4, and wherein the VL FW1, VL FW2, VL FW3 and VL FW4 comprises the PC68-L31_54Q VL FW1, VL FW2, VL FW3 and VL FW4.
66. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 57 to 65, wherein the VL FW1, VL FW2, VL FW3 and VL FW4 are according to Table 2.
67. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 27 to 66, wherein the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68- L31_59H VH.
68. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 27 to 67, wherein the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68- L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68- L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68- L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68- L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68- L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68- L31_59I VL.
69. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 27 to 66, wherein the VH and VL comprise the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH and VL.
70. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 27 to 69, wherein the VH and VL comprise the PC68-L31_54Q VH and VL.
71. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region (VH), wherein the VH comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH.
72. The isolated monoclonal antibody or antigen-binding fragment of claim 71, wherein the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3.
73. The isolated monoclonal antibody or antigen-binding fragment of claim 71, wherein the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3.
74. The isolated monoclonal antibody or antigen-binding fragment of claim 72 or claim 73, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Kabat.
75. The isolated monoclonal antibody or antigen-binding fragment of claim 72 or claim 73, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Table 1.
76. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 71 to 75 further comprising a light chain variable region (VL), wherein the VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68- L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68- L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68- L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68- L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68- L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68- L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL.
77. The isolated monoclonal antibody or antigen-binding fragment of claim 76, wherein the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2, and VL CDR3.
78. The isolated monoclonal antibody or antigen-binding fragment of claim 76, wherein the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3.
79. The isolated monoclonal antibody or antigen-binding fragment of claim 77 or claim 78, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Kabat.
80. The isolated monoclonal antibody or antigen-binding fragment of claim 77 or claim 78, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Table 1.
81. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises an amino acid sequence that is at least about 90%, 95%, 97%, 98%, 99% or 100% identical to the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68-L31_59H VH and VL.
82. The isolated monoclonal antibody or antigen-binding fragment of claim 81, wherein the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68- L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68- L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68- L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68- L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68- L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68- L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59G, or PC68-L31_59H VH CDR1, VH CDR2, and VH CDR3.
83. The isolated monoclonal antibody or antigen-binding fragment of claim 81, wherein the VH comprises a VH CDR1, VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprises the PC68-L31_54Q VH CDR1, VH CDR2, and VH CDR3.
84. The isolated monoclonal antibody or antigen-binding fragment of claim 82 or claim 83, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Kabat.
85. The isolated monoclonal antibody or antigen-binding fragment of claim 82 or claim 83, wherein the VH CDR1, VH CDR2, and VH CDR3 are according to Table 1.
86. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 81 to 85, wherein the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, PC68-L31_59H, or PC68-L31_59I VL CDR1, VL CDR2, and VL CDR3.
87. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 81 to 85, wherein the VL comprises a VL CDR1, VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprises the PC68-L31_54Q VL CDR1, VL CDR2, and VL CDR3.
88. The isolated monoclonal antibody or antigen-binding fragment of claim 86 or claim 87, wherein the VL CDR1, VL CDR2, and VL CDR3 are according to Kabat.
89. The isolated monoclonal antibody or antigen-binding fragment of claim 86 or claim 87, wherein the VL CDR1, VL CDR2, and VL CDR3 are according to Table 1.
90. An isolated monoclonal antibody or antigen-binding fragment thereof that is capable of binding an HIV Env trimer and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprises the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68- L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68- L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68- L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68- L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68- L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, or PC68- L31_59H VH and VL.
91. The isolated antibody of any one of claims 1 to 90, wherein the antibody is not the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68- L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68- L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68- L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68- L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68- L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68- L31_59E, PC68-L31_59F, or PC68-L31_59H antibody.
92. The monoclonal antibody or antigen-binding fragment of any one of claims 1 to 91, further comprising a heavy and/or light chain constant region.
93. The monoclonal antibody or antigen-binding fragment of any one of claims 1 to 91, further comprising a human heavy and/or light chain constant region.
94. The monoclonal antibody or antigen-binding fragment of claim 93, wherein the heavy chain constant region is selected from the group consisting of a human immunoglobulin IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2 constant region.
95. The monoclonal antibody or antigen-binding fragment of any one of claims 92 to 94, wherein the heavy chain constant region comprises a native amino acid sequence.
96. The monoclonal antibody or antigen-binding fragment of any one of claims 92 to 94, wherein the heavy chain constant region comprises a non-native variant amino acid sequence.
97. The isolated monoclonal antibody or antigen-binding fragment of any one of claims 1 to 96, wherein the antibody is a recombinant antibody, a chimeric antibody, a human antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody.
98. The isolated monoclonal antibody or antigen-binding fragment of claim 97, wherein the antibody fragment comprises a single-chain Fv (scFv), Fab fragment, F(ab’)2 fragment, or an isolated VH domain.
99. The antibody or antigen-binding fragment of any one of claims 1 to 98, wherein the antibody is a bispecific antibody.
100. The antibody or antigen-binding fragment of any one of claims 1 to 98, wherein the antibody is a trispecific antibody.
101. The antibody or antigen-binding fragment thereof of any one of claims 27 to 100, which competes with a reference antibody for binding to the HIV Env trimer, wherein the reference antibody is selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68- L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68- L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68- L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68- L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68- L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68- L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
102. The antibody or antigen-binding fragment of claim 101, wherein the reference antibody is the PC68-L31_54Q antibody.
103. The antibody or antigen-binding fragment thereof of any one of claims 27 to 100, which binds to the same epitope of the HIV Env trimer as a reference antibody selected from the group consisting of the PC68-L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68- L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68-L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68- L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68-L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68- L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68-L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68- L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68-L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68- L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68-L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68- L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody, optionally wherein the trimer is an SOSIP trimer, and optionally wherein the HIV Env is BG505 HIV Env.
104. The antibody or antigen-binding fragment of claim 103, wherein the reference antibody is the PC68-L31_54Q antibody.
105. The antibody or antigen-binding fragment thereof of any one of claims 1 to 104, wherein the HIV Env is BG505 HIV Env.
106. The antibody or antigen-binding fragment thereof of any one of claims 1 to 105, wherein the antibody is capable of neutralizing at least 6 HIV isolates in the 13-member indicator virus panel.
107. The antibody or antigen-binding fragment thereof of any one of claims 1 to 105, wherein the antibody is capable of neutralizing at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the HIV isolates in the 119-member indicator virus panel.
108. The antibody or antigen-binding fragment thereof of claim 106 or 107, wherein the antibody is capable of neutralizing the HIV isolates with a median IC50 equal to or less than about 1 µg/ml, about 0.8 µg/ml, 0.5 µg/ml, or 0.3 µg/ml.
109. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 108 and a pharmaceutically acceptable excipient.
110. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof of any one of claims 1 to 108.
111. The isolated polynucleotide of claim 110, which is a DNA.
112. The isolated polynucleotide of claim 110, which is an mRNA.
113. The isolated polynucleotide of claim 112, wherein the mRNA comprises a modified nucleotide.
114. A pharmaceutical composition comprising the isolated polynucleotide of any one of claims 110 to 113 and a pharmaceutically acceptable excipient.
115. An isolated vector comprising the polynucleotide of claim 110.
116. The isolated vector of claim 115, wherein the vector is a viral vector.
117. A recombinant virus comprising the polynucleotide of claim 110.
118. The recombinant virus of claim 117, which is a recombinant adeno-associated virus (AAV).
119. A pharmaceutical composition comprising the recombinant virus of claim 117 or claim 118 and a pharmaceutically acceptable excipient.
120. A host cell comprising the polynucleotide of claim 110 or the vector of claim 114.
121. The host cell of claim 118, which is E. coli, Pseudomonas, Bacillus, Streptomyces, yeast, CHO, YB/20, NS0, PER-C6, HEK-293T, NIH-3T3, HeLa, BHK, Hep G2, SP2/0, R1.1, B-W, L-M, COS 1, COS 7, BSC1, BSC40, BMT10 cell, plant cell, insect cell, or human cell in tissue culture.
122. A method of producing the antibody or antigen-binding fragment of any one of claims 1 to 108 comprising culturing the host cell of claim 118 or claim 119 so that the antibody or antigen-binding fragment is expressed and the antibody or antigen-binding fragment is produced.
123. A method of neutralizing an HIV virus comprising contacting the virus with a sufficient amount of the antibody or antigen-binding fragment of any one of claims 1 to 108.
124. A method of reducing the likelihood of HIV infection in a subject exposed to HIV comprising administering to the subject a therapeutically sufficient amount of the antibody or antigen-binding fragment of any one of claims 1 to 108.
125. A method of reducing the likelihood of HIV infection in a subject exposed to HIV comprising administering to the subject a therapeutically sufficient amount of the pharmaceutical composition of claim 114 or claim 119.
126. A method of treating HIV/AIDS comprising administering to a subject in need thereof a therapeutically sufficient amount of the antibody or antigen-binding fragment thereof of any one of claims 1 to 108.
127. A method of treating HIV/AIDS comprising administering to a subject in need thereof a therapeutically sufficient amount of the pharmaceutical composition of claim 114 or claim 119.
128. A method of reducing viral load comprising administering to a subject in need thereof a therapeutically sufficient amount of the antibody or antigen-binding fragment thereof of any one of claims 1 to 108.
129. A method of reducing viral load comprising administering to a subject in need thereof a therapeutically sufficient amount of the pharmaceutical composition of claim 114 or claim 119.
130. The method of claims 124 to 129, wherein the administering to the subject is by at least one mode selected from oral, parenteral, subcutaneous, intramuscular, intravenous, vaginal, rectal, buccal, sublingual, and transdermal.
131. The method of any one of claims 124 to 129, further comprising administering at least one additional therapeutic agent.
132. The method of claim 131, wherein the additional therapeutic agent is an antiretroviral agent, a reservoir activator, or a second antibody.
133. The method of claim 131, wherein the additional therapeutic agent comprises a broadly neutralizing antibody.
134. The method of claim 131, wherein the additional therapeutic agent comprises two broadly neutralizing antibodies.
135. The method of claim 131, wherein the additional therapeutic agent comprises three broadly neutralizing antibodies.
136. A method for detecting HIV in a sample comprising contacting the sample with the antibody of any one of claims 1 to 108.
137. A method of purifying HIV from a sample comprising contacting the sample with the antibody of any one of claims 1 to 108.
138. A kit comprising the antibody of any one of claims 1 to 108, or the pharmaceutical composition of claim 114 and a) a detection reagent, b) an HIV antigen, c) a notice that reflects approval for use or sale for human administration, or d) any combination thereof.
139. A kit comprising the pharmaceutical composition of claim 114 or claim 119 and a) a detection reagent, b) an HIV antigen, c) a notice that reflects approval for use or sale for human administration, or d) any combination thereof.
140. A method of producing an engineered variant of an antibody of any one of claims 1 to 108 comprising (a) substituting one or more amino acid residues of the VH; and/or substituting one or more amino acid residues of the VL to create an engineered variant antibody, and (b) producing the engineered variant antibody.
141. The method of claim 140 wherein the antibody is selected from the group consisting of the PC68- L31_32A, PC68-L31_32B, PC68-L31_32C, PC68-L31_32D, PC68-L31_32E, PC68-L31_32F, PC68-L31_32G, PC68-L31_32H, PC68-L31_32I, PC68-L31_32J, PC68-L31_32K, PC68- L31_38A, PC68-L31_38B, PC68-L31_38C, PC68-L31_38D, PC68-L31_38E, PC68-L31_43A, PC68-L31_43B, PC68-L31_43C, PC68-L31_43D, PC68-L31_43E, PC68-L31_43F, PC68- L31_43G, PC68-L31_43H, PC68-L31_43I, PC68-L31_43J, PC68-L31_43K, PC68-L31_43L, PC68-L31_43M, PC68-L31_43N, PC68-L31_43P, PC68-L31_43Q, PC68-L31_43R, PC68- L31_43S, PC68-L31_49A, PC68-L31_49B, PC68-L31_49C, PC68-L31_49D, PC68-L31_49E, PC68-L31_54A, PC68-L31_54B, PC68-L31_54C, PC68-L31_54D, PC68-L31_54E, PC68- L31_54F, PC68-L31_54G, PC68-L31_54H, PC68-L31_54I, PC68-L31_54J, PC68-L31_54K, PC68-L31_54L, PC68-L31_54M, PC68-L31_54N, PC68-L31_54P, PC68-L31_54Q, PC68- L31_54R, PC68-L31_54S, PC68-L31_59A, PC68-L31_59B, PC68-L31_59C, PC68-L31_59D, PC68-L31_59E, PC68-L31_59F, and PC68-L31_59H antibody.
142. The method of claim 140 wherein the antibody is the PC68-L31_54Q antibody.
PCT/US2024/044375 2023-08-31 2024-08-29 Human neutralizing antibodies against hiv env Pending WO2025049708A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363535669P 2023-08-31 2023-08-31
US63/535,669 2023-08-31

Publications (1)

Publication Number Publication Date
WO2025049708A1 true WO2025049708A1 (en) 2025-03-06

Family

ID=94820376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/044375 Pending WO2025049708A1 (en) 2023-08-31 2024-08-29 Human neutralizing antibodies against hiv env

Country Status (1)

Country Link
WO (1) WO2025049708A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200165324A1 (en) * 2017-07-14 2020-05-28 International Aids Vaccine Initiative Rapid elicitation of broadly neutralizing antibodies to hiv env
US20210155676A1 (en) * 2015-12-15 2021-05-27 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
US20210355197A1 (en) * 2018-10-22 2021-11-18 International Aids Vaccine Initiative Anti-hiv antibodies
US20230134571A1 (en) * 2019-10-29 2023-05-04 International Aids Vaccine Initiative Engineered antibodies to hiv env

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210155676A1 (en) * 2015-12-15 2021-05-27 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
US20200165324A1 (en) * 2017-07-14 2020-05-28 International Aids Vaccine Initiative Rapid elicitation of broadly neutralizing antibodies to hiv env
US20210355197A1 (en) * 2018-10-22 2021-11-18 International Aids Vaccine Initiative Anti-hiv antibodies
US20230134571A1 (en) * 2019-10-29 2023-05-04 International Aids Vaccine Initiative Engineered antibodies to hiv env

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUGGAN ET AL.: "SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41", VIROLOGY, vol. 96, no. 2, 26 January 2022 (2022-01-26), pages 1 - 15, XP093270538, DOI: 10.1128/JVI.01582-21 *

Similar Documents

Publication Publication Date Title
US20240109956A1 (en) Rapid elicitation of broadly neutralizing bovine antibodies to hiv env
US11760790B2 (en) Neutralizing antibodies to HIV-1 Env and their use
US20150044137A1 (en) Neutralizing antibodies to hiv-1 and their use
WO2015103549A1 (en) Neutralizing antibodies to hiv-1 env and their use
US20210292396A1 (en) Enginerred antibodies to hiv env
WO2017106346A2 (en) Human immunodeficiency virus neutralizing antibodies
US20250368722A1 (en) Multispecific antibodies targeting multiple epitopes on the hiv-1 envelope
US20210355197A1 (en) Anti-hiv antibodies
US20230265170A1 (en) Antibodies
US20230134571A1 (en) Engineered antibodies to hiv env
US20230272048A1 (en) Hiv-1 antibodies
US20240124560A1 (en) Human broadly neutralizing antibodies against the membrane-proximal external region of hiv env for vaccine design and intervention
US20250197483A1 (en) Neutralizing antibodies to hiv-1 env and their use
US20250197482A1 (en) Bispecific antibodies to hiv-1 env and their use
WO2025049708A1 (en) Human neutralizing antibodies against hiv env
US20240166728A1 (en) Antigen binding proteins
WO2024192203A2 (en) Multispecific anti-hiv antibodies
WO2025229018A1 (en) Neutralizing antibody constructs against hiv
JP2025541605A (en) antigen-binding proteins
WO2025184416A1 (en) Single-domain antibodies and bispecific antibodies against hiv-1 and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24861011

Country of ref document: EP

Kind code of ref document: A1